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The primary goal of this dissertation research was to investigate the effect of dehydroepiandrosterone 
(DHEA) administration on recovery from a GABA-agonist challenge in healthy young and older adults.  DHEA and 
its sulfate metabolite DHEA-S are natural steroid hormones that are produced primarily in the adrenal glands and 
act as precursors to other hormones (e.g., testosterone and estrogen) in the body.  Animal studies have 
demonstrated antagonistic effects of DHEA and DHEA-S at the GABA receptor complex.  When compared to young 
adults, the elderly have lower concentrations of DHEA and DHEA-S and recover more slowly from the CNS effects 
of benzodiazepines, the most commonly prescribed class of GABA-agonists.  To investigate the role of DHEA 
and/or DHEA-S as excitatory steroids in the human brain, a GABA-agonist challenge study was proposed.  
Secondary goals included evaluations of SEM variability over repeated same-day testing and assessing the 
influence of age and endogenous concentrations of DHEA and DHEA-S on SEMs. 
Both young (20 to 30 years) and older (60 to 79 years) men and women participated in this four-way 
crossover of placebo, DHEA, alprazolam plus placebo and alprazolam plus DHEA.  For the 12.5 hours after the 
drug or placebo was administered, responses mediated via the GABA-A receptor complex (saccadic eye 
movements (SEMs), sedation, memory, and psychomotor performance) were assessed and blood samples were 
collected for the purpose of determining DHEA, DHEA-S, and alprazolam concentrations.  
These data demonstrate that DHEA administration lessened alprazolam-induced impairment in young 
women, enhanced impairment in older men and women and did not alter impairment in young men.  DHEA 
administration did not accelerate recovery from GABA-agonist challenge in the older subjects.  In fact, the 
opposite effect was seen with the older men and women who demonstrated saccades with slower velocities and 
longer durations during the recovery phase of the DHEA/Alp treatment.  A surprising outcome of this report is the 
number of older subjects who experienced impairment at a level where they were unable to complete the SEM 
 iv 
tasks in both treatments.  The number of older subjects unable to perform the SEM tasks during the DHEA/Alp 
treatment was significantly greater than during the PL/Alp treatment.  
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Dehydroepiandrosterone (DHEA) and its sulfate metabolite DHEA-S, (the most abundant steroid in the 
human body), are natural steroid hormones produced from cholesterol primarily in the adrenal glands.  Often 
called the "mother hormone," DHEA acts as a precursor to other hormones in the body such as testosterone 
and estrogen.  Synthetic versions of DHEA are marketed for their ‘anti-aging’ performance and are widely 
available as over-the-counter nutritional supplements.  
DHEA was first isolated from human urine in the early 1930’s by Dr. Adolf Butenandt (Butenandt & 
Dannenbaum, 1934) and in human blood in 1954 by Migeon and Plager (Migeon & Plager, 1954).  The 
marked decrease in DHEA concentrations associated with aging was demonstrated as early as 1956 by the 
French biochemist, Max Fernand Jayle.  Other than being a step in the metabolic pathway to androgens and 
estrogens, the function of DHEA in humans was not understood.  Interestingly, the potential neuroactivity of 
DHEA was first explored in 1961 when Heuser and Eidelberg reported dose-dependent convulsions in mice 
after administration of DHEA (Heuser & Eidelberg, 1961).  Although often studied in laboratory animals in the 
ensuing years, it was not until 1986 when the New England Journal of Medicine published a longitudinal study 
by Barrett-Connor et al. associating high concentrations of DHEA with less cardiovascular disease in older men 
(Barrett-Connor, Khaw, & Yen, 1986), that DHEA function and its relation to aging in humans came to be a 
popular subject for investigation.  In fact, in 1990, Regelson et al. stated “DHEA modulates diabetes, obesity, 
carcinogenesis, tumor growth, neurite outgrowth, virus and bacterial infection, stress, pregnancy, hypertension, 
collagen and skin integrity, fatigue, depression, memory and immune responses.” (Regelson, Kalimi, & Loria, 
1990)  This surge in human research culminated in June, 1995, when the New York Academy of Sciences held 
a major conference entitled "DHEA and Aging" and presented data from many of the world’s renowned DHEA 
scientists.  Results presented at this meeting proposed that, in addition to their role as sex hormone 
precursors, DHEA and DHEA-S had various other functions.  Among these were protection of the circulatory 
system, enhancement of immune function, and increased insulin sensitivity.  Additionally, both DHEA and 
DHEA-S were reported to have neuroactive properties and to enhance cognition, brain development, and 
memory, effects characterized as ‘anti-aging.’  The wide media coverage given to this conference served to 
heighten not only scientific but also public interest in DHEA as a possible panacea to the consequences of 
aging.    
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Presently, reported physiologic roles of DHEA and DHEA-S continue to vary and are, at times, 
contradictory.  Several means of action of DHEA and DHEA-S, other than their role as sex hormone precursors, 
have been proposed.  Studies have suggested that DHEA and/or DHEA-S may modulate immunity (Ledochowski, 
Murr, Jager, et al.  2001; Khorram, Vu, & Yen, 1997), reduce the risk of heart disease in men (Barrett-Connor, 
Khaw, & Yen, 1986; Porsová-Dutoit, Sulcová, & Stárka, 2000), treat depressive symptoms (Wolkowitz, Reus, 
Keebler, et al.  1999), aid in erectile dysfunction (Reiter, Pycha, Schatzl, et al.  1999) and improve affect 
(Morales, Nolan, Nelson, et al.  1994; Hunt, Gurnell, Huppert, et al.  2000).  Furthermore, sex differences in 
response to oral administration of DHEA have been reported (Frye, Kroboth, Kroboth, et al.  2000; Morales, 
Haubrich, Hwand, et al.  1998). 
Of particular interest are the reports of DHEA and DHEA-S activity within the central nervous system 
(CNS), especially since it is now known that the brain, in addition to the adrenals, is a steroidogenic tissue 
producing its own neuroactive neurosteroids. Baulieu and colleagues completed an elegant series of animal 
studies in the 1980’s demonstrating that DHEA (and other steroids) were present in the CNS at concentrations 
higher than those of the periphery (Baulieu, Robel, Vatier, et al.  1987).  More importantly, he advanced the 
concept of the brain as steroidogenic when he proved these CNS concentrations remained long after 
gonadectomy and adrenalectomy.  Shortly thereafter, in agreement with the animal studies, DHEA was found 
throughout the human brain at concentrations 6.5 times that of plasma in deceased men and women aged 76 to 
93.  (Lacroix, Fiet, Benais, et al.  1987) 
Subsequent studies furthered the theory that neuroactive neurosteroids alter neuronal behavior via 
actions at various neurotransmitter receptors (Wilson, 1992; Pollock, Perel, & Reynolds, 1990). Specifically, 
electrophysiological and in vitro animal studies have demonstrated that both DHEA and DHEA-S are active at the 
gamma-aminobutyric acid receptor complex (GABA-RC).  The role of DHEA is more controversial with some 
researchers finding that DHEA does not bind to the GABA-RC (Sousa & Ticku, 1997) while others declare it an 
antagonist (Demirgören, Majewska, Spivak, et al.  1991; Majewska, 1992).  Studies in rats demonstrate that 
DHEA also selectively enhances the response of excitatory amino acids on the N-methyl-D-aspartate receptor 
(Debonnel, Bergeron, & de Montigny, 1996). However, information from human studies regarding the neuroactive 
role of steroids is limited (McAuley, Reynolds, Kroboth, et al.  1995; Friess, Trachsel, Guldner, et al.  1995).  
Specifically, there are no known reports of in vivo human research demonstrating that DHEA and/or DHEA-S have 




To investigate the role of DHEA and/or DHEA-S as neuroactive steroids with GABA-antagonist activity in 
the human brain, a GABA-agonist challenge study was proposed.  It is known that the elderly, who have 
concentrations of DHEA and DHEA-S that are less than that in the young, recover more slowly from the CNS 
effects of benzodiazepines, the most commonly prescribed class of GABA-agonists.  Previous research indicates 
that the concentration of DHEA may be related to the rate of recovery from such a challenge.  The purpose of this 
research was to determine the effect of DHEA and DHEA-S concentrations on recovery from GABA-agonist 
(benzodiazepine) challenge in young and older men and women.   
To test this, oral DHEA was administered to older adult volunteers between the ages of 65 and 79 to 
reproduce peak concentrations normally seen in the young between 20 and 30 years of age.  A full description of 
the methods can be found in Chapter 2.  Briefly, alprazolam, one of the top ten U.S prescriptions dispensed in 
2001 (RxIndex, The internet Drug Index, data furnished by NDC Health Retrieved February 26, 2003, from 
http://www.rxlist.com/top200.htm) was chosen as the GABA-agonist.  Both young and older subjects participated 
in this four-way crossover of placebo, DHEA, alprazolam plus placebo and alprazolam plus DHEA.  For the 12.5 
hours after the drug or placebo was administered, responses known to be mediated via the GABA-A receptor 
complex (saccadic eye movements, sedation, memory, and psychomotor performance) were assessed and blood 
samples were collected for the purpose of determining DHEA, DHEA-S and alprazolam concentrations.  
Background 
Metabolism of DHEA.  Figure 1.1 represents the synthesis and major metabolic pathways of DHEA and 
other steroids (Majewska, 1992; Sanger & Zivkovic, 1992; Robel & Baulieu, 1994; Orth & Kovacs, 1998; Wolf & 
Krischbaum, 1999). 
Pregnenolone, the immediate precursor of DHEA, is derived from cholesterol after side-chain cleavage 
by CYP11A1 (cytochrome P450 scc).  CYP17, a 17α-hydroxylase with 17,20-desmolase activity, catalyzes the 
synthesis of DHEA from pregnenolone (Robel & Baulieu, 1994; Stoffel-Wagner, 2001).  DHEA-S, quantitatively 
the most abundant steroid in humans (Nieschlag, Loriaux, Ruder, et al.  1973; Shealy, 1995) is metabolized 
from DHEA by hydroxysteroid sulfatransferase and can be converted back to DHEA by steroid sulfatase 
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(Kishimoto & Hoshi, 1972).  DHEA can also be metabolized to androstenedione, and in turn testosterone and 
estrogens in tissues with sulfatase activity. 
The adrenal cortex in humans and other primates secretes the greatest amounts of DHEA and DHEA-S.  
In men, the testes produce approximately 10-25% of DHEA and 5% of DHEA-S while in women the ovaries 
contribute only a minimal amount of both (Kroboth, Salek, Pittenger, et al.  1999).  DHEA and DHEA-S are 
precursors to nearly 50% of androgens in men and 75% of estrogens in premenopausal women.  After 
menopause, virtually all circulating estrogens are metabolized from DHEA (Baulieu, 1996). It is also known that 
DHEA and DHEA-S are produced de novo in the brain, hence their classification as neurosteroids (Baulieu, et al., 
1987; Baulieu, 1998). 
 
Figure 1.1.  The steroidogenic pathway of DHEA.  (CYP = Cytochrome P450; STS = Steroid sulfatase;  HSS = 
Hydrosteroid sulfatase;  HSD = Hydroxysteroid dehydrogenase.) 
 
Similar to cortisol, DHEA secretion demonstrates a circadian rhythm.  Unlike cortisol, this rhythm is age 







































status has also been associated with changes in the circadian rhythm of DHEA (Erb, Kadane, Tourney, et al.  
1981; Goodyer, Herbert, Altham, et al.  1996; Heuser, Deuschle, Luppa, et al.  1998).  The rhythmicity of DHEA-S 
is controversial with some researchers reporting systematic secretion (Montanini, Simoni, Chiossi, et al.  1988; 
Del Ponte, Di Monte, Graziani, et al.  1990; Liu, Laughlin, Fischer, et al.  1990) and others reporting none (Hall, 
Perry, & Spector, 1993; Moltz & Schwartz, 1986; Moltz & Schwartz, 1986; Kos-Kudla, Ostrowska, Marek, et al.  
2001). The lack of systematic variation in DHEA-S concentrations may be attributed to its extended half-life of 
approximately 10 to 20 hours, a substantial increase over the 0.5 to 3 hour half-life of DHEA.   
Age and Sex differences in DHEA.  Concentrations of DHEA and DHEA-S are known to vary with age.  
High concentrations are present in the human fetus and decrease to minimal levels shortly after birth where they 
remain until the advent of adrenarche at approximately 6 to 8 years of age.  At this point, adrenal production of 
DHEA and DHEA-S resumes and continues throughout life (Mesiano, Katz, Lee, et al.  1997).  Circulating 
concentrations of DHEA peak during the mid-twenties then steadily decline from the third decade onward 
(Orentreich, Brind, Vogelman, et al.  1992; Orentreich, Brind, Rizer, et al.  1984; Pavlov, Harman, Chrousos, et al.  
1986; Baulieu, Thomas, Legrain, et al.  2000).  DHEA levels tend to decrease at a rate of approximately 2% per 
year; concentrations in 70-year-old individuals are roughly 80% lower than those in young adults  
It is widely accepted that women have lower DHEA-S concentrations when compared to men (Carlström, 
Brody, Lunell, et al.  1988; Morales, et al., 1998).  It is unclear whether concentrations of DHEA in women differ 
from those in men; the literature reports both higher (Carlström, et al., 1988; Sulcová, Hill, Hampl, et al.  1997) 
and equivalent concentrations (Labrie, Bélanger, Cusan, et al.  1997; Frye, et al., 2000).   
DHEA and DHEA-S kinetics.  Reports of circulating concentrations of DHEA and DHEA-S after 
administration of DHEA are summarized in a review by Kroboth et al. (Kroboth, et al., 1999)  The 
concentration-time course of orally administered DHEA has been reported in young healthy women (Schmid, 
Sala, Bonanno, et al.  1998), young healthy men (Bosy, Moore, & Poklis, 1998), older men (Arlt, Haas, Callies, 
et al.  1999), and post-menopausal women (Buster, Casson, Straughn, et al.  1992).  However, all of these 
reports were after single dose administration of DHEA and most of them reported observations made at a 
single time point.  A recent report characterizing the pharmacokinetics of DHEA and DHEA-S over a 24-hour 
period after single and repeated oral doses of DHEA in older men and women has established the presence of 
sex-based differences (Frye, et al., 2000).   
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Frye and colleagues have reported that after a single 200 milligram dose of DHEA, concentrations of 
DHEA were 5 to 6-fold greater than endogenous concentrations in both men and women.  DHEA maximum 
concentration (Cmax) and area under the curve (AUC) were higher, and the apparent elimination half-life (t1/2) 
longer, in women compared to men.  Achieved DHEA-S concentrations represented a 21-fold increase from 
endogenous levels in women yet only a 5-fold increase in men, essentially eliminating the difference normally 
seen between the sexes.   DHEA-S Cmax, AUC, and t1/2 did not differ between men and women after a single 
dose.   
Pharmacokinetic parameters were also estimated after 8 and 15 doses of DHEA 200 mg. daily.  
Concentrations of DHEA and DHEA-S after the 15th dose were comparable to those seen after a single dose.  
DHEA Cmax and AUC were higher in women compared to men after both dose 8 and 15, and the t1/2 longer after 
dose 8. There was no sex-based difference in t1/2 after dose 15.  The DHEA AUC for women tended to decrease 
across time but in men it remained constant.  For DHEA-S, there was no difference between the women and 
men in either AUC or Cmax after continued dosing.  The difference in DHEA-S concentrations between men and 
women present before, but not after, oral administration of DHEA suggests a difference in the interconversion 
of DHEA and DHEA-S. 
Saccadic eye movements as a GABA-RC-mediated response.  Saccades are the brief, jerky 
movements the eye makes in order to refixate the fovea, i.e., to shift focus from one point to another in the 
visual field.  Saccadic eye movement (SEM) motor neurons and their neurochemical modulation have been 
precisely identified and can be traced progressively from the brainstem through to the cerebral cortex 
(O'driscoll, Wolff, Benkelfat, et al.  2000; Fuchs, Kaneko, & Scudder, 1985; Sparks & Mays, 1990; Law, Svarer, 
Holm, et al.  1997; Robinson, 2000; Quaia, Lefevre, & Optican, 1999; Hikosaka & Wurtz, 1989).  The central 
structures involved in the control of SEMs are the frontal cortex, basal ganglia, and cerebellum; the defined 
pathway consists of the frontal eye fields, caudate nucleus, substantia nigra, and superior colliculus.  
Inhibitory synaptic connections involving GABA in the mediation of SEMs have been extensively 
documented through anatomical, electrophysiological, and pharmacological methods (1989). Specifically, 
GABAergic projections from the substantia nigra tonically inhibit the superior colliculus in order to prevent 
involuntary eye movements away from objects of interest, thereby aiding fixation (Hikosaka & Wurtz, 1983; 
Hikosaka & Wurtz, 1985a; Hikosaka & Wurtz, 1985b; Hikosaka & Wurtz, 1985b; Hikosaka & Wurtz, 1985a).  
Subsequently, when a saccade is required to foveate a new target, signals from the striatum restrain the 
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substantia nigra, again via a GABAergic pathway, thus liberating the superior colliculus to facilitate saccade 
generation.    
Unlike psychomotor tests that require voluntary, conscious performance (Hindmarch, 1984; Hindmarch, 
1980), the basic mechanics of SEMs, once initiated, are under involuntary control.  This, coupled with the 
established role of GABA in the control of saccades (Sparks & Hartwich-Young, 1989), and the known 
benzodiazepine-induced drug effect on saccades (Bittencourt, Wade, Smith, et al.  1981; Kroboth, Folan, Bauer, 
et al.  1998; Tuk & Oberyé, 1997) make evaluation of SEMs an acceptable, and more sensitive (Williams & 
Bowie, 1999), indicator of drug response. 
Summary.  The full description of the design and methods of this research project can be found in 
Chapter 2.  The goal of the research presented in Chapter 3 is to assess the stability of SEMs during repeated 
same-day testing in young and older men and women.  Although SEM dynamics have shown little variability within 
a single testing session or when comparing single sessions between test days (Bollen, Bax, van Dijk, et al.  1993; 
Bollen, et al., 1993; van Steveninck, Verver, Schoemaker, et al.  1992), the influence of within-day repeated 
testing sessions over time in an older population has not been reported.  The scoring program used to generate 
the SEM data required a certain amount of subjectivity on the part of the scorer.  As such, Chapter 4 is dedicated 
to assessing the inter-rater reliability of the scoring program, which was created specifically for the purpose of 
measuring SEMs initiated while under the influence of a benzodiazepine.  The majority of studies involving SEM 
dynamics generally report the velocity, accuracy and reaction time of the saccade.  The purpose of the analysis 
presented in Chapter 5 is to evaluate the influence of age and endogenous concentrations of DHEA and DHEA-S 
on such saccade parameters.  The purpose of the overall dissertation research project, i.e., to determine the 
effect of DHEA administration on recovery from GABA-agonist challenge is addressed in Chapters 6 and 7.  
Chapter 6 is limited to analysis of the concentration-time data while Chapter 7 addresses the pharmacodynamic 
response to alprazolam challenge, specifically during the recovery phase. 
Collectively this work studying the effects of DHEA on recovery from alprazolam is of clinical significance 
in older men and women.  It has been demonstrated that aging affects both the pharmacokinetics and 
pharmacodynamics of alprazolam.  Previous studies have established that the aging are more sensitive to the 
effects of benzodiazepine and demonstrate decreased clearance (Greenblatt, Harmatz, & Shader, 1991; 
Greenblatt, Harmatz, Shapiro, et al.  1991; Bertz, Kroboth, Kroboth, et al.  1997; Smith, Divoll, Gillespie, et al.  
1983; Thompson, Moran, & Nies, 1983; Bertz, Reynolds, Kroboth, et al.  1995).  Compared to younger adults, 
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there is an increased use of benzodiazepines in the elderly (Miyamoto, Hirata, Miyamoto, et al.  2002; Tu, 
Mamdani, Hux, et al.  2001; Olfson & Pincus, 1994; Gleason, Schulz, Smith, et al.  1998).  Despite the known 
beneficial effects, the increased prevalence of benzodiazepine use in the aging population is of concern.  
Benzodiazepine use in the older population has been associated with falls, hip fractures, and motor vehicle 
accidents (Ray, Griffin, Schaffner, et al.  1987; Ray, Thapa, & Gideon, 2000; Ray, Griffin, & Downey, 1989).  The 































CS card sorting task 
DHEA dehydroepiandrosterone 
DHEA/Alp DHEA + Alprazolam treatment 
DHEA-S dehydroepiandrosterone-sulfate 
DSST digit symbol substitution test 
GCRC General Clinical Research Center 
HVLT Hopkins Verbal Learning Test 
NMDA N-methyl-D-aspartate 
NRSS Nurse rated sedation scale 
PL Placebo 
PL/Alp Placebo + Alprazolam treatment 
RMT Randt memory test 
SEM saccadic eye movements  
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Introduction 
 The research project detailed in this chapter produced all data used in subsequent analysis as 
presented in Chapters 3, 4, 5, and 6.  This chapter describes the overall study design, subject population, 
procedures, and process of data collection.    
Methods 
Study Design.  This study was completed at the General Clinical Research Center (GCRC) of the University of 
Pittsburgh Medical Center.  The protocol and consent forms were approved by the University of Pittsburgh 
Institutional Review Board. This randomized, double-blind, placebo-controlled, four-way crossover study was 
conducted in parallel in groups of young and older men and women.  The study was designed to include 16 men 
and 16 women in both the young and older groups with each group of 16 comprised of 12 Caucasian and four 
minority volunteers.  The study was divided into two phases and required four visits to the GCRC as indicated in 
Table 2A.  
 
Table 2A.  Treatment Assignment Scheme 
                 Phase I Treatment  Phase II Treatment 
      
  Visit 1 Visit 2 Visit 4 Visit 5 
Block A  PL DHEA Alp DHEA/Alp 
Block B  PL DHEA DHEA/Alp Alp 
Block C  DHEA PL DHEA/Alp Alp 
Block D  DHEA PL Alp DHEA/Alp 
      
Note. PL = placebo, DHEA = Dehydroepiandrosterone, Alp = alprazolam. 
 
 
Phase I was a placebo (PL) and DHEA crossover and Phase II was a PL plus alprazolam (PL/Alp) and a 
DHEA plus alprazolam (DHEA/Alp) crossover.  The unblinded investigational drug pharmacist of the University 
of Pittsburgh Medical Center randomized subject numbers to one of the four blocks in order to balance by age, 
sex, and minority status. Visits within a phase were separated by a minimum of one and a maximum of five 
weeks; phases were separated by a minimum of one and a maximum of thirty-nine weeks.   Alprazolam, DHEA 
and the placebo for DHEA were administered orally.    
The times and dose amounts of DHEA in Phase I were adjusted as data were accrued in order to 
maximize the probability of obtaining concentrations between 10 and 20 ng/ml for each study group.  As a 
result, the first five subjects recruited to the study received DHEA 150 mg at 0 hour and DHEA 50 mg at 6.5 
hours during Phase I.  Based on the concentration of DHEA noted in these subjects, the 0 hour DHEA dose for 
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Phase I was decreased to 50 mg for subsequent participants; the 6.5 hour dose remained the same.  In order 
to achieve DHEA concentrations between 10 and 20 ng/ml in Phase II, the dose and time of administration of 
DHEA was individualized for each subject based on their DHEA concentration-time profile from Phase I.  Tables 
2B and 2C detail the dose amounts and time of administration of DHEA (or placebo) for each subject in Phases 
I and II, respectively.  The majority of subjects received DHEA 50 mg at both 0 h and 6.5 h.  Exceptions are 
noted in the Tables 2B and 2C.  Identical doses of Alprazolam 2 mg were administered to all subjects at the 




Table 2B.  DHEA Dose Assignments for Phase I 
Subject 0 hour 6.5 hour Subject 0 hour 6.5 hour Subject 0 hour 6.5 hour 
1 50 mg 50 mg 
 
28 50 mg 50 mg 
 
54 50 mg 50 mg 
3 50 mg 50 mg 
 
29a 150 mg 50 mg 
 
55 50 mg 50 mg 
4 50 mg 50 mg 
 
30 50 mg 50 mg 
 
56 50 mg 50 mg 
5 50 mg 50 mg 
 
31 50 mg 50 mg 
 
57 50 mg 50 mg 
7 50 mg 50 mg 
 
33 50 mg 50 mg 
 
58 50 mg 50 mg 
8 50 mg 50 mg 
 
34 50 mg 50 mg 
 
59 50 mg 50 mg 
9 50 mg 50 mg 
 
35 50 mg 50 mg 
 
60 50 mg 50 mg 
10 50 mg 50 mg 
 
36 50 mg 50 mg 
 
61 50 mg 50 mg 
11 50 mg 50 mg 
 
37 50 mg 50 mg 
 
66 50 mg 50 mg 
12 50 mg 50 mg 
 
38 50 mg 50 mg 
 
102 50 mg 50 mg 
14 50 mg 50 mg 
 
39 50 mg 50 mg 
 
106 50 mg 50 mg 
15 50 mg 50 mg 
 
40 50 mg 50 mg 
 
111 50 mg 50 mg 
16 50 mg 50 mg 
 
41 50 mg 50 mg 
 
112 50 mg 50 mg 
17a 150 mg 50 mg 
 
42 50 mg 50 mg 
 
113 50 mg 50 mg 
18 50 mg 50 mg 
 
43 50 mg 50 mg 
 
114 50 mg 50 mg 
19 50 mg 50 mg 
 
44 50 mg 50 mg 
 
120 50 mg 50 mg 
20 50 mg 50 mg 
 
45 50 mg 50 mg 
 
140 50 mg 50 mg 
21 50 mg 50 mg 
 
46 50 mg 50 mg 
 
145 50 mg 50 mg 
22 50 mg 50 mg 
 
47 50 mg 50 mg 
 
146 50 mg 50 mg 
23 50 mg 50 mg 
 
48 50 mg 50 mg 
 
149 50 mg 50 mg 
24 50 mg 50 mg 
 
50a 150 mg 50 mg 
 
160 50 mg 50 mg 
25 50 mg 50 mg 
 
51a 150 mg 50 mg 
 
206 50 mg 50 mg 
26 50 mg 50 mg 
 
52 50 mg 50 mg 
 
213 50 mg 50 mg 
27 50 mg 50 mg 
 
53 50 mg 50 mg 
 
245 50 mg 50 mg 
           
Note.  The dose amounts indicate the dose on the DHEA treatment day of Phase I.  
aThe first five subjects enrolled in the study received an initial DHEA dose of 150 mg.  Subsequently, initial 
doses were decreased to 50 mg. 
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Table 2C.  DHEA Dose Assignments for Phase II 
Subject 0 hour 6.5 houra Subject 0 hour 6.5 houra Subject 0 hour 6.5 houra 
1 50 mg 50 mg 
 
28 100 mg 50 mg 
 
54 50 mg 100 mg 
3 50 mg 50 mg 
 
29 50 mg 100 mg 
 
55 50 mg 50 mg 
4 50 mg 50 mg 
 
30 50 mg 50 mg 
 
56 100 mg 50 mg 
5 50 mg 50 mg 
 
31 50 mg 50 mg 
 
57 100 mg 50 mg 
7 50 mg 50 mg 
 
33 150 mg 100 mg 
 
58 50 mg 50 mg 
8 50 mg 50 mg 
 
34 50 mg 50 mg 
 
59 50 mg 50 mg 
9 50 mg 50 mg 
 
35 50 mg 50 mg 
 
60 50 mg 50 mg 
10 50 mg 50 mg 
 
36 50 mg 50 mg 
 
61 50 mg 50 mg 
11 50 mg 50 mg 
 
37 50 mg 50 mg 
 
66 50 mg 50 mg 
12 50 mg 50 mg 
 
38 50 mg 50 mg 
 
102 50 mg 50 mg 
14 50 mg 50 mg 
 
39 50 mg 50 mg 
 
106 --    -- 
15 50 mg 50 mg 
 
40 --    -- 
 
111 50 mg 50 mg 
16 50 mg 50 mg 
 
41 50 mg 50 mg 
 
112 50 mg 100 mg 
17 50 mg 100 mg 
 
42 50 mg 50 mg 
 
113 50 mg 50 mg 
18 50 mg 50 mg 
 
43 50 mg 50 mg 
 
114 50 mg 50 mg 
19 50 mg 50 mg 
 
44 50 mg 50 mg 
 
120 100 mg 50 mg 
20 50 mg 50 mg 
 
45 50 mg 50 mg 
 
140 50 mg 50 mg 
21 50 mg 50 mg 
 
46 50 mg 50 mg 
 
145 50 mg 50 mg 
22 50 mg 50 mg 
 
47 50 mg 50 mg 
 
146 50 mg 50 mg 
23 50 mg 50 mg 
 
48 50 mg 50 mg 
 
149 100 mg 50 mg 
24 50 mg 50 mg 
 
50 50 mg 100 mg 
 
160 100 mg 50 mg 
25 50 mg 50 mg 
 
51 50 mg 100 mg 
 
206 50 mg 50 mg 
26 50 mg 50 mg 
 
52 100 mg 50 mg 
 
213 50 mg 50 mg 
27 50 mg 50 mg 
 
53 50 mg 100 mg 
 
245 50 mg 50 mg 
           
Note.  The dose amounts indicate the dose on the DHEA treatment day of Phase II.   A dash (--) indicates 
subjects who did not complete Phase II. 





 Subjects.  Table 2D summarizes demographic information and dates of participation for all subjects 
enrolled in the study. A total of 42 women (26 young and 16 older) and 35 men (20 young and 15 older) 
completed informed consent and were enrolled in the study.  Included in these 77 subjects were those who 
identified themselves as Black (n = 14), Hispanic (n = 2), Caucasian (n = 58), or Asian/Pacific Islander (n = 3).  
The young subjects were between the ages of 20 and 30 years; older subjects were between the ages of 66 and 
78 years.  Not all subjects completed all visits.  Subjects who did not complete all four treatments were 
replaced with new subjects who were assigned the same subject number plus 100.  Not all subjects were 
included in all analysis;  subsequent chapter will identify  those subjects used in each analyis. 
 All subjects were considered healthy by medical history and physical, and by laboratory screening.  
Screening took place within two weeks prior to participation in the study and included a routine and microscopic 
urinalysis, a complete blood count, a biochemical screening profile and a Structured Clinical Interview for 
Diagnosis of DSM IV Disorders, (SCID).  Specifics of the screening can be found in Appendix A.   Upon 
enrollment, a urine sample for drugs-of-abuse screening and a blood sample for blood alcohol determination was 
collected on each of the four visits.  For young women, urine was also collected for a pregnancy test. 
Excluded from the study were young women who had taken oral contraceptives and older women who 
had  taken hormone replacement therapy (estrogen or progesterone) within the six months prior to study 
enrollment.  Also excluded were volunteers known to have taken any enzyme-inducing (barbiturates, rifampin, etc.) 
or enzyme-inhibiting agents (e.g., erythromycin, ketoconazole) for a period of 30 days prior to the study day.  Men 
and women selected for this study should not have taken any chronic and/or over-the-counter medications for the 
seven days prior to each study.  Complete inclusion and exclusion criteria are included in Appendix A. 
Procedure 
Study Conditions.  On the afternoon before each of the four treatment days, subjects were admitted to 
the GCRC.  Subjects fasted from 10 p.m. on the evening of admission (water was permitted) until 7:30 a.m. the 
next day.  At this time, subjects received a light breakfast and an intravenous catheter was placed in a forearm 
vein for the purpose of obtaining multiple blood samples throughout the treatment day. 
To determine the concentrations of DHEA, DHEA-S, cortisol and alprazolam, blood samples were 




Table 2D.  Subject demographic data and visit dates.  






Visit 1 Visit 2 Visit 3 Visit 4 
1 Female Caucasian 20 63 153 11/15/97 11/22/97 12/06/97 12/13/97 
2 Female Caucasian 20 68 135 1/10/1998 -- -- -- 
3 Female Caucasian 30 68 169 05/20/98 05/27/98 06/03/98 06/10/98 
4 Female Caucasian 28 65 139 06/06/98 06/13/98 06/20/98 06/27/98 
5 Female Caucasian 24 61 121 07/11/98 07/18/98 07/25/98 08/01/98 
6 Female Caucasian 22 64 115 07/22/98 -- -- -- 
7 Female Caucasian 23 68 140 09/12/98 09/19/98 09/26/98 10/03/98 
8 Female Caucasian 20 64 137 10/10/98 10/17/98 10/24/98 10/31/98 
9 Female Caucasian 22 68 143 11/14/98 11/21/98 12/05/98 12/12/98 
10 Female Caucasian 21 66 170 02/06/99 02/13/99 02/20/99 02/27/99 
11 Female Caucasian 22 67 136 04/17/99 04/24/99 05/01/99 05/08/99 
12 Female Caucasian 22 68 127 05/19/99 05/26/99 06/02/99 06/09/99 
13 Female Hispanic 30 64 130 08/18/97 -- -- -- 
14 Female Black 23 63 110 01/24/98 01/31/98 10/31/98 11/07/98 
15 Female Black 27 66 125 02/14/98 02/21/98 02/28/98 03/07/98 
16 Female Black 22 70 144 10/17/98 10/24/98 01/23/99 01/30/99 
17 Female Caucasian 67 67 200 07/14/97 07/21/97 08/04/97 08/11/97 
18 Female Caucasian 68 59 192 11/18/97 11/25/97 12/02/97 12/09/97 
19 Female Caucasian 69 62 128 01/14/98 01/21/98 01/28/98 02/04/98 
20 Female Black 66 63 170 02/28/98 03/07/98 03/14/98 03/21/98 
21 Female Caucasian 67 63 170 04/22/98 04/29/98 05/06/98 05/13/98 
22 Female Caucasian 68 61 143 04/22/98 04/29/98 05/06/98 05/13/98 
23 Female Caucasian 72 63 126 06/17/98 06/24/98 07/01/98 07/08/98 
24 Female Caucasian 73 66 156 08/19/98 08/26/98 09/02/98 09/09/98 
25 Female Caucasian 75 62 142 01/24/00 01/31/00 02/07/00 02/14/00 
26 Female Caucasian 70 60 128 10/06/99 10/13/99 10/20/99 10/27/99 
27 Female Caucasian 68 63 154 09/06/00 09/13/00 09/20/00 09/27/00 
28 Female Caucasian 71 63 198 10/11/00 10/18/00 10/25/00 11/01/00 
29 Female Black 72 62 126 07/14/97 07/21/97 08/04/97 08/11/97 
30 Female Black 69 63 187 01/24/98 01/31/98 02/07/98 02/14/98 
31 Female Black 70 65 174 09/06/00 09/13/00 09/20/00 09/27/00 
33 Male Caucasian 22 69 133 09/27/97 10/04/97 10/18/97 10/25/97 
34 Male Caucasian 20 75 187 09/27/97 10/04/97 10/18/97 10/25/97 
35 Male Caucasian 21 69 187 09/27/97 10/04/97 10/18/97 10/25/97 
36 Male Caucasian 21 65 125 11/15/97 11/22/97 12/06/97 12/13/97 
37 Male Caucasian 25 74 186 07/29/98 08/05/98 08/12/98 08/19/98 
38 Male Caucasian 28 72 150 05/20/98 05/27/98 06/03/98 06/10/98 
39 Male Caucasian 29 68 154 08/05/98 08/12/98 08/19/98 08/26/98 
40 Male Caucasian 23 67 144 10/03/98 10/10/98 -- -- 
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Table 2D.  Subject demographic data and visit dates. (Cont’d) 






Visit 1 Visit 2 Visit 3 Visit 4 
41 Male Caucasian 28 71 170 11/14/98 11/21/98 12/05/98 12/12/98 
42 Male Caucasian 20 71 125 11/14/98 11/21/98 12/05/98 12/12/98 
43 Male Caucasian 21 68 179 01/09/99 01/16/99 01/23/99 01/30/99 
44 Male Caucasian 23 69 155 02/20/99 02/27/99 03/06/99 03/13/99 
45 Male Black 21 71 195 8/18/1997 8/25/1997 9/8/1997 9/15/1997 
46 Male Asian 29 70 149 09/27/97 10/04/97 10/18/97 10/25/97 
47 Male Hispanic 27 72 182 10/28/97 11/04/97 11/11/97 11/18/97 
48 Male Asian 21 67 146 06/06/98 06/13/98 06/20/98 06/27/98 
49 Male Caucasian 69 71 177 07/16/97 -- -- -- 
50 Male Caucasian 69 73 186 07/14/97 07/21/97 08/04/97 08/11/97 
51 Male Caucasian 75 73 204 07/14/97 07/21/97 08/04/97 08/11/97 
52 Male Caucasian 73 66 188 02/25/98 03/04/98 03/11/98 03/18/98 
53 Male Caucasian 72 67 166 02/25/98 03/04/98 03/11/98 03/18/98 
54 Male Caucasian 68 70 170 04/22/98 04/29/98 05/06/98 05/13/98 
55 Male Caucasian 71 65 154 04/22/98 04/29/98 05/06/98 05/13/98 
56 Male Caucasian 72 68 190 04/25/98 05/02/98 05/09/98 05/16/98 
57 Male Caucasian 67 71 215 12/02/98 12/09/98 06/03/98 06/10/98 
58 Male Caucasian 68 70 189 06/17/98 06/24/98 07/01/98 07/08/98 
59 Male Caucasian 68 70 180 08/12/98 08/19/98 08/26/98 09/09/98 
60 Male Caucasian 74 70 193 04/07/99 04/14/99 04/21/99 04/28/99 
61 Male Black 68 64 164 09/23/98 09/30/98 10/07/98 10/14/98 
66 Female Caucasian 27 66 156 04/25/98 05/02/98 05/09/98 05/16/98 
102 Female Caucasian 20 64 119 07/07/99 07/14/99 07/21/99 07/28/99 
106 Female Caucasian 26 64 113 08/07/99 08/14/99 -- -- 
111 Female Caucasian 29 63 157 02/19/00 02/26/00 03/10/00 03/18/00 
112 Female Caucasian 25 62 173 01/08/00 01/15/00 01/22/00 01/29/00 
113 Female Asian 20 65 117 11/14/98 11/21/98 01/09/99 01/16/99 
114 Female Black 21 67 156 04/08/00 04/29/00 05/06/00 05/20/00 
120 Female Caucasian 70 58 133 01/10/01 01/17/01 01/24/01 01/31/01 
140 Male Caucasian 24 75 173 02/27/99 03/06/99 03/20/99 03/27/99 
145 Male Black 26 67 259 01/20/01 01/27/01 02/03/01 02/10/01 
146 Male Black 26 70 177 06/19/99 06/26/99 07/10/99 07/17/99 
149 Male Caucasian 72 71 184 09/08/99 09/15/99 09/22/99 09/29/99 
160 Male Caucasian 78 65 163 06/21/00 06/28/00 07/12/00 07/19/00 
206 Female Caucasian 22 65 125 12/01/99 12/08/99 04/03/00 04/10/00 
213 Female Black 20 67 143 03/18/00 03/25/00 04/01/00 05/06/00 
245 Male Black 26 75 224 02/21/01 03/14/01 03/21/01 03/28/01 
          
Note. Subject numbers 32, 62, 63, 64, and 65 were not recruited.   A dash (--) indicates subject did not 
complete the visit.  
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20 and 23.5 h after dose administration.  Since alprazolam was administered only in Phase II, the blood 
volume for samples in Phase II was 7.0 ml, while in Phase I it was 4.5 ml.  Each blood sample was collected 
from the indwelling catheter in a forearm vein and placed in appropriately labeled vacuum tubes and 
centrifuged at 4ºC for 15 minutes at 3000g.  Serum was decanted and stored at -80oC. 
Pharmacodynamic Assessment.   During each of the four visits, response to the drug treatments was 
evaluated using a series of assessments that were conducted at multiple times throughout the treatment day 
as shown in Table 2E.   
 
Table 2E.  Schedule of Response Assessments 
Time of Assessment (h) 
Assessment 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23.5 
Blood x x x x x x x x x x x x x x x 
NRSS x x x x x x x x x x x x x x x 
DSST x  x  x x x  x x x x    
CS x  x  x x x  x x x x    
SEM x  x  x x x  x x x x    
RMT x    x x  x        
HVLT        x        
Note. Time 0 indicates baseline measurement.  All other times are relevant to time after administration of 
DHEA or placebo.  NRSS=Nurse Rated Sedation Score, DSST=digit symbol substitution, CS=card sorting, 
SEM=saccadic eye movements, RMT=Randt memory test, HVLT=Hopkins verbal learning test. 
 
The full battery of pharmacodynamic assessments required approximately 10 minutes to complete 
and was assessed in the same order at each testing time:  Nurse (observer) Rated Sedation scale (NRSS), Digit 
Symbol Substitution Test (DSST), card sorting (CS) task, memory test, (blood sample collection) and saccadic 
eye movement (SEM) task.  
To control for learning effects, during the screening session subjects were required to practice the DSST 
and CS to a plateau, i.e., no improvement in score on two consecutive trials, and to become familiar with the SEM 
task.  On the evening of admission to the GCRC for each of the four visits, subjects again practiced DSST, CS and 
SEMs.  A final practice for DSST and CS was done prior to the baseline evaluation on the treatment day. 
Sedation was assessed using the NRSS, a five point scale ranging from 0 (wide awake, alert) to 4 
(sleeping soundly, not able to perform testing session).  Psychomotor impairment was assessed using the DSST 
and CS task.  DSST was originally developed as part of the Wechsler Adult Intelligence Scale (Weschler, 1955).  
For this study, DSST consisted of a set of symbols associated with digits 0 through 9 in a key at the top of the 
paper.  Below the key were 120 digits with a corresponding blank space.  Subjects were instructed to use the 
key as a reference to draw the correct symbol in the blank space. The score was the number of symbols correctly 
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drawn within 90 seconds.   CS  required subjects to sort a deck of 52 playing cards by suits as quickly as possible 
with a maximum of 90 seconds allotted to complete the task; the score was the number of cards/sec.   
Memory  was assessed using the Hopkins Verbal Learning Test (HVLT) and a modified Randt Memory Test 
(RMT).  The HVLT measured both recall and recognition of word lists over a number of trials.  The HVLT required 
subjects to learn a list of 16 words from four different semantic categories over five trials and was assessed once 
during each treatment day.  RMT is a memory task in which a series of seven black and white line drawings of 
objects are presented at the rate of one per second.  Immediately thereafter, a series of 15 drawings that 
includes copies of the original 7, plus 8 distracters, is presented to subjects to test their immediate recognition 
of pictures just presented. There were 16 forms of the test used in this study, one for each testing session.  
Consequently, no pictures were repeated throughout the four visits.  
Saccadic eye movements (SEMs) were obtained using an infrared reflection technique (EyeTrac Model 
210, Applied Science Laboratories), digitized at 500 Hz by a DATAQ 12-bit A/D converter (DATAQ Instruments, 
Akron OH) and recorded to removable media for off-line analysis with custom software. The resultant resolution 
was sufficient to detect saccades of 0.25° of visual angle.  Visual presentations of targets for eye movements 
were presented on a computer screen using Micro Experimental Laboratory Software (Pittsburgh, PA: 
Psychology Software Tools). 
The saccade targets were presented on a 17-inch computer screen as a white cross on a black 
background circumscribed by a white circle.  Subjects were instructed to focus on the center of the cross and 
follow it as it changed positions.  For each subject for each testing session, eye movements were calibrated 
during a process where the targets were presented in the horizontal plane in the following order: center, 16° 
left, 8°left, center, 8° right and 16° right.  Subjects were instructed to fixate on each target as it appeared on 
the screen.  During the SEM testing session, 48 trials (saccade targets) were presented in a pseudo-random 
order.  In each trial, subjects began at center fixation and shifted their gaze to targets presented at one of the 
calibration target positions for 1.5 seconds, so that each target was presented 12 times.  After a target was 
presented to the right or left, the target returned to center to begin the next trial.  The timing and location of 
peripheral targets for saccades was unpredictable.  Eye movements were recorded from both eyes.  Data from 
only one eye were scored by choosing the eye with the most stable fixation data from the calibrated targets.  
The SEM data were scored using a computer algorithm to identify saccades.  Saccades were identified when 
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eye acceleration exceeded 1200°/sec2 and were defined as the time from that point until 25% of peak 
deceleration.  Each saccade was visually inspected and measurements on the basis of this algorithm were 
verified.  Saccades that occurred during blinks or that were not task-related were excluded.  Scoring of each 
saccade provided quantification of latency, duration, peak velocity, and accuracy.  Latency is the reaction time 
(msec) between target presentation and initiation of saccade, duration is the time (msec) required to complete 
the saccade, peak velocity (°/sec) is the maximum velocity achieved during the saccade, and accuracy is the 
percent of target step amplitude gained by the saccade. 
For each subject at each testing session, eye movements were separated according to the size of 
target amplitude (8° and 16°) and combined according to direction (left and right) allowing a maximum number 
of 24 scored trials per session per target amplitude.  The subject-specific mean for saccades to each target 
amplitude was used in all subsequent analysis. 
Drug treatment.  Although readily available as an over-the-counter dietary supplement, DHEA is not currently 
marketed under FDA approval in the United States.  However, the bioavailability of the DHEA formulation used in 
this study has been published (Buster, et al., 1992).  DHEA doses were prepared as described by Buster et al. 
(Buster, et al., 1992) and supplied by Belmar Pharmacy of Lakewood, CO.  Pharmacopoeia-grade DHEA 
(Diosynth Co., Chicago, IL) was micronized to <10 µm particles and mixed with a wax vegetable oil matrix and 
compressed with a silica-based excipient into tablets containing DHEA 50 mg.  Quality control assessment of 
the product is routinely done as described in our IND #48,123.  Placebos for DHEA were also supplied by 
Belmar Pharmacy.  Oral doses of alprazolam 2 mg were supplied by the Investigation Drug Pharmacy of the 
University of Pittsburgh Medical Center. 
Assays 
Alprazolam.  For alprazolam and the internal standard, triazolam, a gas chromatographic-electron 
capture detection method (GC) was developed from previously published methods;(Greenblatt et.al., 1981 and 
Coassolo, et. al., 1983.)  The assay was validated and used to determine serum alprazolam concentrations. 
After addition of the internal standard (triazolam 3 ng/0.5 ml), 0.5 ml aliquots of standards in blank serum, 
quality controls, and subject samples were extracted into 1.5% iso-amyl alcohol in toluene. The organic layer 
was dried under nitrogen and reconstituted samples were injected onto a 10 m x 0.32 mm x 0.25 µm capillary 
column (DB1701, J & W Scientific) in a Hewlett Packard 6890 gas chromatograph with helium as the carrier 
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gas and argon-methane (95:5) as the make-up gas. Alprazolam and triazolam were detected and quantified 
using a micro 63Ni electron capture detector (µECD). Data were acquired and analyzed using an HP 
ChemStation. For each analysis group standard curves (0.25 to 20 ng/0.5 ml blank serum) were prepared by 
plotting peak-height ratios of alprazolam:triazolam versus the alprazolam concentrations. Subject and quality 
control sample concentrations were determined from the standard curves. 
All standard concentrations were run in duplicate. Quality controls (0.3, 1.5, 3, 8 and 15 ng/0.5ml) 
were run in triplicate. Correlation coefficients were >0.99. Coefficients of variation for precision and accuracy 
of all standards and quality control samples were < 10%.  For alprazolam the lower limit of quantitation was 
0.25 ng/ml and the absolute recovery was 91%. 
Steroids.  The assays for steroid concentrations were done using 125I-radioimmunoassay techniques 
(Diagnostic Systems Lab Inc.).  Serum was assayed for DHEA, DHEA-S, and cortisol concentrations.  The detection 
range and lower limit of detection, respectively, for each assay were:  DHEA:  0.2 to 30 ng/ml and 0.009 ng/ml; 
DHEA-S:  50 to 8000 ng/ml and 17 ng/ml; cortisol:  0.5 to 60 µg/dl and 0.11 µg/dl.  The coefficient of variation for 
each was <10% throughout the range of the assay. 
Summary 
 A total of 77 young and older men and women participated in this four-way crossover study of placebo, 
DHEA, PL/Alp and DHEA/Alp administration.  During the 12.5 hours after dose administration, saccadic eye 
movements, psychomotor performance, memory, and sedation were assessed and blood samples were 
collected for determination of serum concentrations of DHEA, DHEA-S, cortisol and alprazolam.  Steroid 


















REPRODUCIBILITY OF SACCADIC EYE MOVEMENTS, CARD SORTING, AND DIGIT SYMBOL SUBSTITUTION TASKS 
IN YOUNG AND OLDER MEN AND WOMEN OVER 12.5 HOURS 
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Abbreviations: 
CS card sorting task 
DSST digit symbol substitution test 
GCRC General Clinical Research Center 
SEMs saccadic eye movements  
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Introduction 
Saccadic eye movements (SEMs), the rapid and intermittent jumps the eye makes when moving 
between points of focus, have been used to study neurological and psychiatric disorders, and to assess 
response to the effects of various drugs and alcohol (Cowley, Roy-Byrne, Radant, et al.  1994; Baloh, Sharma, 
Moskowitz, et al.  1979; Clementz, Farber, Lam, et al.  1996; Blekher, Beard, O'Connor, et al.  2002). In 
particular, SEMs have been identified as a measurable response to GABA-ergic drugs (Ball, Glue, Wilson, et al.  
1991; Glue, Wilson, Coupland, et al.  1995) and, as such, have been used to assess psychomotor impairment 
in response to benzodiazepine administration (Roy-Byrne, Fleishaker, Arnett, et al.  1993; Roy-Byrne, 
Wingerson, Radant, et al.  1996; Folan, Kroboth, Fabian, et al.  1999; Kroboth, et al., 1998). SEMs offer an 
advantage over other psychomotor tests (e.g., Digit Symbol Substitution Test, and Card Sorting) that are 
commonly used to determine dose-response relationships in pharmacodynamic studies.  Psychomotor tests 
are influenced by the subject’s degree of learning, alertness, fatigue, cooperation and motivation during each 
testing session (Hindmarch, 1984; Kroboth, Smith, & Erb, 1988).   Unlike psychomotor tests, SEMs are 
dependent only to a limited extent on subject motivation and are, for the most part, an involuntary response.  
For example, in order to improve saccade accuracy, a subject may willingly delay reaction time between 
presentation of a target and initiation of an eye movement.  However, once initiated, the velocity and duration 
of the eye movement cannot be voluntarily controlled.  Furthermore, saccades of less than 20-degrees 
amplitude demonstrate a linear relationship between both velocity and amplitude, and duration and amplitude 
(Bahill, Clark, & Stark, 1975; 1999).  Thus, any decrease in velocity is reflected in a decrease in amplitude.  
Although SEM dynamics have shown little variability within a single testing session, interindividual day-to-day 
differences, particularly in velocity, have been reported (Bollen, et al., 1993; Bollen, et al., 1993; van 
Steveninck, et al., 1992).  What is unclear is whether or not changes are evident in velocity and other SEM 
parameters during repeated testing throughout a day.  Repeated testing is necessary to fully characterize the 
concentration-effect and/or dose-response relationships of drugs. The objective of this study was to determine 
the reproducibility of specific SEM parameters (latency, velocity, duration and accuracy), Card Sorting (CS) 
scores, and Digit Symbol SubstitutionTest (DSST) scores during repeated same-day testing in healthy young 
and older men and women. 
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Methods 
Study design and subjects.  These data were collected from the placebo arm of the four-way crossover 
study that required subjects to complete four study visits at the General Clinical Research Center (GCRC) of the 
University of Pittsburgh Medical Center (see Chapter 2). Placebo was administered during either the first or 
second study visit.  SEM tests were administered to all subjects as part of the screening process in order to 
ascertain each individual’s ability to perform the test and to assist them in becoming familiar with the tasks 
that would be required on subsequent testing days.  CS tasks and DSST were also administered to subjects 
during the screening process.  To minimize learning effects, subjects were required to practice the CS and DSST 
to a plateau, i.e., no improvement in score on two consecutive trials, during screening.  All subjects were 
admitted to the GCRC by 7:00 p.m. the evening prior to the study day at which time they again practiced SEMs, 
CS, and DSST.  A final practice for CS and DSST was done in the morning prior to the baseline evaluation on each 
study day.  Baseline evaluations of SEMs, CS and DSST were conducted in the morning prior to administration of 
the placebo treatment. 
The 71 volunteers were medically and psychiatrically healthy women (22 young and 14 older) and men 
(18 young and 13 older).  The age range for young subjects was 20 to 30 years and for older subjects 66 to 78 
years.  Table 3A contains mean ages for the four groups.   
 
Table 3A.  Mean age for the four groups of participantsa 
















(67 – 78) 
aData are presented as mean, standard deviation, and range. 
 
 
All subjects were non-smoking (by self-report) and before participating in the study were screened by 
medical and psychiatric history, physical examination, Structured Clinical Interview for Diagnosis of DSM IV 
Disorders (SCID) (First, Spitzer, Gibbon, et al.  1995), biochemical and hematological laboratory screen, urine 
drug screen, and blood alcohol concentration.  
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Evaluation of saccadic eye movements.  The methods for SEM data collection, recording and scoring 
are detailed in Chapter 2.  Briefly, the SEM recordings were obtained using an infrared reflection technique 
(EyeTrac Model 210, Applied Science Laboratories).  The saccade targets were presented on a 17-inch 
computer screen as a white cross on a black background circumscribed by a white circle.  During the SEM 
testing session, 48 trials (saccade targets) were presented. In each trial, subjects began at center fixation and 
shifted their gaze to one of four target positions.  After a target was presented to the right or left, the target 
returned to center to begin the next trial.  The timing and location of peripheral targets for saccades was 
unpredictable.   
The SEM data were scored using a computer algorithm to identify saccades.  Each saccade was 
visually inspected and measurements on the basis of this algorithm were verified.  When multiple saccades 
were required to reach the target, only the initial, or primary saccade was scored.  Scoring of each saccade 
provided quantification of latency, duration, velocity, and accuracy.  For the purpose of this analysis latency is 
the reaction time (msec) between target presentation and initiation of saccade, duration is the time (msec) 
required to complete the saccade, velocity (degrees/sec) is the maximum or peak velocity achieved during the 
saccade, and accuracy is the percent of target step amplitude gained by the primary saccade. 
SEM testing was conducted at ten times throughout the testing day: immediately prior to 
administration of placebo (0 hour) and at 2, 3.5, 4.5, 5.5, 7, 8.5, 10, 11.5 and 12.5 hours after administration 
of placebo.  For each subject at each testing session eye movements were separated according to the target 
step amplitude (8-degrees  and 16-degrees) and combined according to direction (left and right) allowing a 
maximum number of 24 scored trials per session per target amplitude.  The subject-specific mean for 
saccades to each target amplitude was used in all subsequent analysis. 
Evaluation of Card Sorting and Digit Symbol Substitution.  CS required subjects to sort a deck of 52 
playing cards by suits as quickly as possible with a maximum of 90 seconds allotted to complete the task; the 
score was the number of cards/sec.  DSST,  originally developed as part of the Wechsler Adult Intelligence 
Scale112, required subjects to draw symbols corresponding to matching numbers.  The score is the number of 
symbols drawn in 90 seconds.  Both CS and DSST are described in more detail in Chapter 2.  CS and DSST were 
collected at the same ten time points as the SEMs.  
 Statistical analysis. Significant differences between group means were tested using a repeated 
measures mixed-model analysis of variance (ANOVA).  The four SEM parameters (latency, velocity, duration and 
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accuracy), CS score, and DSST score were used as the dependent variables.  This study was a crossover design 
and subjects could have received placebo on either one of two study visits.  Therefore, a term (order) was 
added to the model to determine if there was an effect due to order of placebo treatment, i.e., was there a 
difference in effect based on whether the placebo treatment was given the first study visit or the second study 
visit.   Age group (young or old), sex, time (0, 2, 3.5, 4.5, 5.5, 7, 8.5, 10, 11.5, 12.5), order (1 or 2), and the 
sex-by-time interaction term were considered as fixed effects.  Initial analysis demonstrated that the age 
groups differed from each other for each of the dependent variables tested.  The sex-by-time interaction was 
statistically significant for one of the models.  Subsequently,  the subjects were divided into four age/sex 
groups: young women, young men, older women and older men, and were analyzed separately.  Results were 
considered statistically significant if the observed p-value was less than or equal to a critical value of 0.05.  All 
plotting was performed using GraphPad Prism version 3.02 for Windows, GraphPad Software; San Diego, 
California USA; www.graphpad.com (Motulsky, 1999).  The ANOVA was performed using SAS Software (Cary, 
NC, version 8.02) (SAS Institute, 2000).  
Results 
Latency of saccades.  Figure 3.1 represents the individual and mean data for latency to the 8-degree 
saccade targets in the young and older men and women.  Data from the young groups and the older groups 
demonstrated no significant differences across time, (p ≥ 0.35 and p ≥ 0.12, respectively) for latency to the 8-
degree saccades.  For latency data from the 16-degree saccades, results (not shown) were similar in the young 
and older groups.  There were no significant differences in the latency data between the sexes in either the 
young or older groups for both the 8 and 16-degree saccades (p ≥ 0.09). 
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Figure 3.1.  For 8-degree saccades: line plots of latency vs. time for individual data (A = young women (?), B = 
young men (?), D = older women (?), E = older men (?)) and mean data with standard deviations (C = young 
women  and men; F = older women and men).  
 
 
Peak Velocity of saccades.  The individual and mean data for peak velocity of the 8-degree saccades 
in young and older men and women are shown in Figure 3.2. For mean peak velocity to the 8-degree saccades 
and the 16-degree saccades (not shown), there was no detectable time effect in the young women, the young 
men, and the older women, p ≥ 0.06;  for both targets there was a significant time-related difference in the 
older men’s group, p ≤ 0.02 with the greatest decrease from baseline (8.0%) occurring at the 5.5h time point.  
Similar to latency, there were no significant differences between data from the men and women in either the 
young or older groups (p ≥ 0.54).   




















































































































































































































































































Figure 3.2.  For 8-degree saccades: line plots of peak velocity vs. time for individual data (A = young women 
(?), B = young men (?), D = older women (?), E = older men (?)) and mean data with standard deviations (C 
= young women  and men; F = older women and men).  
 
 
Duration of saccades.  Figure 3.3 illustrates the individual and mean duration data for both groups for 
the 8-degree saccades. Similar to the latency and velocity data, there were no significant time differences in 
the duration data from either the young women or young, or the older women, group for either the 8 or the 16-
degree saccades (p ≥ 0.18 for all).  The older men displayed a significant time-related difference in the 
duration of both the 8 and 16-degree eye movements, (p = 0.02 and 0.006, respectively).  The longest 
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durations (i.e., a 16% increase from baseline measurements) were noted at  the 7 h and 8.5  h testing times.  
There were no significant sex-related differences (p ≥ 0.79) in duration for either the young or the older groups. 
  


























































































































Figure 3.3.  For 8-degree saccades: line plots of duration vs. time for individual data (A = young women (?), B 
= young men (?), D = older women (?), E = older men (?)) and mean data with standard deviations (C = young 
women  and men; F = older women and men).  
 
 
Accuracy of saccades.  The accuracy data for the 8-degree saccades are represented in Figure 3.4 
and include the individual and mean data for both young and older groups. There was a significant 
improvement over time in accuracy for the young women for the 16-degree saccades (greatest change from 
baseline = 4%; p = 0.006, not shown) but not for the 8-degree saccades (p = 0.08).  This was in contrast to the 
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stability or lack of change in latency, velocity, and duration of saccades.  Significant differences were also 
noted between the young men and women during the 16-degree saccade task, p = 0.01, but not the 8-degree 
task,  with the women demonstrating greater accuracy than the men.   For the older group there were no 
significant differences noted across time or between sexes for either the 8-degree or 16-degree saccade task 
(p ≥ 0.24 for all). 
 




















































































































Figure 3.4.  For 8-degree saccades: line plots of gain vs. time for individual data (A = young women (?), B = 
young men (?), D = older women (?), E = older men (?)) and mean data with standard deviations (C = young 





 Card Sorting.  The results of the CS task are represented in Figure 3.5.  The young women 
demonstrated significant improvement (10% change from baseline) over time for CS, p=0.04.  The young men 
showed no differences over time (p = 0.11) and were not different from the young women (p = 0.66).  In the 
older groups, both men and women were stable over time and there was not a sex-based difference (p ≥ 0.31 
for all comparisons).   
 
 




















































































































Figure 3.5.  Card Sorting: line plots of number of cards/sec vs. time for individual data (A = young women 
(?), B = young men (?), D = older women (?), E = older men (?)) and mean data with standard deviations 




Digit Symbol Substitution.  DSST results can be found in Figure 3.6.  The young women had higher 
DSST scores than the young men (p = 0.03) and did not demonstrate a time-related effect (p = 0.2).  The 
young men’s DSST scores tended to improve with time (p = 0.05); the maximum change from baseline was 5%.  
DSST scores were stable throughout the testing day for both older groups (p ≥ 0.38) and there were no 
differences between the older women and men, p = 0.69.   
 
 
Figure 3.6.  Digit Symbol Substitution: line plots of number of symbols vs. time for individual data (A = 
young women (?), B = young men (?), D = older women (?), E = older men (?)) and mean data with 
standard deviations (C = young women  and men; F = older women and men). 
 
 































































































































For clarity, Table 3B summarizes the significance of the statistical models for the SEM, DSST, and CS 
data for each of the age/sex groups.   
 
Table 3B.  Statistical analysis of reproducibility of SEM and Psychomotor Test Data 
  











 Latency -- -- -- -- 
 Velocity -- -- -- * 
 Duration -- -- -- * 
 Accuracy -- -- -- -- 
 
16-degree Saccades 
    
 Latency -- -- -- -- 
 Velocity -- -- -- * 
 Duration -- -- -- * 
 Accuracy * -- -- -- 
 
Psychomotor Tests 
-- -- -- -- 
 DSST -- -- -- -- 
 Card Sorting * -- -- -- 
Note:  DSST is Digit Symbol Substitution Test.  A dash (--) indicates no significant difference due to time 
within each age/sex group. 




Saccadic Eye Movements.  These results demonstrate that SEM dynamics and results from CS and DSST 
tests are relatively stable over time for ten repeated testing sessions during 12.5 hours in young and older men 
and women.  Although previous studies have examined repeated measurements of eye movements over time in 
young people under both drug and no-drug or placebo treatments (van Steveninck, et al., 1992; Glue, White, 
Wilson, et al.  1991; Ball, Glue, Wilson, & Nutt, 1991; Padoan, Korttila, Magnusson, et al.  1992),  little 
information is available regarding repeated same-day testing of SEMs in an older population.  A single report by 
Tuk et al., reported frequent testing (21 times over 8 hours) in a group of 21 patients whose ages ranged from 18 
to 78 years (Tuk & Oberyé, 1997).  However, there was no reference to breakdown of ages within this group and, 
more importantly, testing was done only after administration of an oral dose of either 10 or 20 mg of temazepam 
with no placebo control.   
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In the data reported here, latency, which is the reaction time (msec) between target presentation and 
initiation of eye movement, was the most stable of the SEM parameters across all four age/sex groups for both 
the 8-degree and 16-degree targets.  This is consistent with earlier reports of latency evaluation in young 
(Green, King, & Trimble, 2000; Ball, Glue, Wilson, & Nutt, 1991; Glue, et al., 1991; van Steveninck, 
Schoemaker, Peiters, et al.  1991).  However, in a study by van Steveninck et al., latency appeared to decrease 
with repeated testing (van Steveninck, et al., 1992) over an extended period of 33.5 h.  It’s important to note 
that van Steveninck’s testing paradigm was quite dense during the first 16 h (40 testing sessions) and sparse 
during the remaining 17.5 h (3 testing sessions).  Blekher and colleagues (Blekher, Ramchandani, Flury, et al.  
2002) recently reported  a decrease in latency when testing a group of adults three times within a 160 min. 
trial.  It has been reported that shorter latencies, i.e., ‘express saccades’ may be achieved when subjects 
expect the saccade, attributed to frequent testing, such as in the van Steveninck study.  The frequent testing 
results in a decreased tendency for target fixation (Fischer & Ramsperger, 1986) and thereby facilitates 
shorter reaction times.  Additionally, learning or practice effects may occur when  the target location is known, 
also resulting in decreased reaction times.  Van Steveninck and group employed only 30-degree saccade 
targets in their study and while Blekher et al. employed four targets (7.5 and 15 degrees to either the left or 
right), it appears subjects did not practice the tasks prior to collection of study data.  Hence, in these testing 
paradigms, learning may be occurring during the period of data collection.  In contrast, the data reported here 
are from participants who were required to practice the SEM tasks at screening and again upon admission to 
the GCRC the evening prior to data collection, limiting the possibility of learning during the study day. 
For peak saccade velocity, previous reports conflict concerning the stability over repeated testing 
times.  Ball et al., report no change in saccade velocity when tested seven times over 30 minutes (Ball, Glue, 
Wilson, & Nutt, 1991).  A recent study on the effect of sleep deprivation measured SEMs every 2 h for 40 h 
and found no variability in velocity for the first 22 h of testing (prior to sleep deprivation) (DeGennaro, Ferrara, 
Urbani, et al.  2000).  Conversely, van Steveninck’s group (van Steveninck, et al., 1992) reported a significant 
decrease in peak velocity within the first hour of testing (this included eight testing sessions).  The change from 
baseline ranged among subjects from 6.2% to 12.1% and remained statistically significant throughout 15 h of 
testing, over 40 testing sessions.  It is possible this decrease in velocity may be associated with fatigue 
attributed to the intensity of testing times and the large amplitude of the saccade target (30 degrees).  Larger 
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saccades of greater than 17 degrees have been reported to be more fatiguing than shorter saccades of 10 and 
15 degrees (Bahill & Stark, 1975).  
In contrast, saccade duration seems to display little variation over time (Roy-Byrne, Cowley, Radant, et 
al.  1993), though reports are limited.  In the data reported here, both mean peak velocity and duration of 
saccades remained stable throughout the testing day for both of the young groups and for the older women 
(for 8-degree and 16-degree targets).  Only the older men demonstrated a significant effect of time:  mean 
peak velocity decreased with an expected corresponding increase in duration of saccades, most notably 
between the 5.5 h and 8 h testing times for both target amplitudes.  Interestingly, the study protocol provided 
for subjects to be served a smoothie (a 12 oz. frozen drink consisting of non-dairy milk substitute, frozen 
sorbet and fruit punch) at 4.5 h and 7 h, possibly inducing a post-prandial effect within certain subjects.  For 
saccades to the 8-degree target, the overall impact of each observation within the group of older men was 
tested statistically using Cook’s distance (Cook, 1977).  Two subjects, (one at the 7 h testing session and one 
at time 8.5 h testing session) had the highest Cook’s distance measurement.  When data for these subjects 
from the identified time points were removed from the analysis, the model was no longer significant, thereby 
recognizing them as being influential to the model.   
The accuracy of saccades was consistently reproducible for all groups to both the 8-degree and 16-
degree targets with one exception.  For the 16-degree target, the young women differed from the young men and 
they significantly improved throughout the 12.5 h course of testing.  In a study of young men only, by DeGennaro 
et al., there were no changes in accuracy of saccades to targets stepped between 5 and 30 degrees of visual 
angle.  However, it was noted that, other than instructing the subjects to avoid moving their heads, no measures 
were taken to assure head immobility.  The combination of head and eye movements have a direct effect on 
accuracy of saccades (1999).  Blekher and group studied the accuracy of 7.5-, 15-, and 30-degree saccades at 
four different times in both young men and young women as part of the placebo control in an investigation of 
alcohol effects and did not report any placebo effects (Blekher, et al., 2002).  Although 38 of the 77 subjects in 
the alcohol arm of the study were young women, only a subset of the study population completed the placebo 
arm, precluding any sex-stratified analysis.  Additionally, the study design was somewhat weak in that the placebo 
session was always conducted after the alcohol session.   
Card Sorting and DSST.  For CS, only one group demonstrated a time-dependent difference:  the 
perfomance of the young women improved over time, in contrast to the stability of performance in the other three 
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groups.  Previous data in young and older men from this lab report no changes in CS over an 8.5 h testing session 
though significance was approached (p=0.057).  No significant placebo response within a day for CS when tested 
among 13 men and women aged 21 to 40 years on two occasions.  However, there was a significant 
improvement of 7% between the first and second occasions, which were separated by  21 days (Bertz, et al., 
1995).  
For both groups of women and for the older men, the DSST scores from this study support previous 
reports that indicate that both young and older subjects demonstrate no change in DSST scores over time 
(Nikaido, Ellinwood, Jr., Heatherly, et al.  1990; Greenblatt, et al., 1991; Nikaido, Ellinwood, Jr., Heatherly, & 
Gupta, 1990).  It’s important to note that the studies referenced here, in addition to our own,  provided for 
practice sessions in order to limit the amount of learning that might otherwise occur.  Since the young men in this 
study demonstrated variability across the time points and tended to improve during the day, it may be that young 
men require more practice to reach a plateau.  This is in contrast to a report by Nikaido and group who noted that 
young subjects (mean age approximately 26 years) required less practice than an older group (mean age 
approximately 67 years) before no substantial improvement was noted in task scores for a computerized digit 
substitution task .  When data from a single young man (who had the least number of symbols drawn at times 7 h 
and 8.5 h) was removed from the analysis, the model was no longer significant.  Although it appears he may be 
an outlier, subsequent analysis utilizing the Cook’s distance measure (Cook, 1977) did not identify this individual 
as influential.   
Overall, these data indicate that the SEM parameters are stable across testing in both young and older 
women and in young men.  Although the velocity and resultant duration of saccades were more variable in older 
men this could be attributed to two possible outliers or to the somewhat smaller number of subjects in this group 
as compared to the other groups.  Additonally, since the normal peak velocities to saccades of 8 and 16 degrees 
targets can range from 50 to 540 degress/second and 50 to 725 degress/second, respectively, it is improbable 
that the 8% magnitude of change in velocity noted in older men is of any clinical significance.  These results also 
indicate that healthy men and women between the ages of 66 and 78 years of age are capable of completing the 
SEM tasks on multiple occasions within a 12.5 h period.  To our knowledge, this is the first time that an older 
population has been tested on such a rigorous schedule similar to that required to characterize the time course 
of CNS-active drugs.   These data also confirm the need for ample practice of both the DSST and CS tasks in order 





















ICC intraclass correlation coefficient  




 Pharmsac, (Pharmacodynamic Research Center and Neurobehavioral Studies Program, University of 
Pittsburgh, Pittsburgh PA)  the program used to score the saccadic eye movements (SEMs) collected during 
this research study, is a modified version of a scoring program previously used in our laboratory.  Pharmsac 
was specifically designed for us in order to facilitate the quantitative analysis of saccades in volunteers who 
have been exposed to pharmacologic challenges with sedative-like effects, e.g., alprazolam.  The modifications 
made to the program allow the user (i.e., scorer) to manually mark and identify certain characteristics of the 
saccade that were previously controlled by a computerized algorithm.  As such, a certain degree of subjective 
interpretation was introduced into the scoring procedures.  To minimize this subjectivity and to standardize the 
scoring process, a Pharmsac scoring manual was created to guide users through proper scoring procedures 
and a process for training scorers was developed. 
Inter-rater reliability is used to evaluate the extent of consensus between two or more individuals (e.g., 
raters, judges, scorers) on the implementation of a rating system.   One form of inter-rater reliability is the 
intraclass correlation coefficient (ICC) which may be conceptualized as the ratio of between-groups variance to 
total variance.   ICC will approach 1.0 when there is perfect inter-rater reliability.  Intraclass correlations can be 
standardized as follows: 0.40 = poor, 0.40 to 0.59 = fair, 0.60 to 0.74 = good, and 0.75 to 1.00 = excellent 
(Viljoien, Roesch, & Zapf, 2002; Cicchetti, Showalter, & Tyrer, 1985).  The purpose of this research is to 
determine the ICC of two scorers in order to assess the reliability of the Pharmsac saccadic eye movement 
scoring program.  For each saccade parameter evaluated, a mean ICC greater than or equal to 0.60 (i.e., good 
or better), would be considered acceptable and, as such, validate the reliability of the Pharmsac software.   
Methods 
Study design and subjects.  These data were collected during the alprazolam administration visits (the 
third and fourth visits) of the four-way crossover study that is described in Chapter 2.  Subjects received 
alprazolam plus placebo on one visit and alprazolam plus DHEA on the alternate visit.  Saccadic eye 
movements were tested at 10 time points over a 12.5 hour period during each of the two visits.  Data from 
eight randomly chosen subjects (two from each of the age/sex groups:  young women, young men, older 
women, older men) were evaluated by the same two scorers.    Saccadic eye movement data from three time 
points during each of the two visits were scored.  The time points were chosen to represent eye movement 
performance prior to alprazolam administration (0 h), near to peak drug effect (3.5 h after alprazolam 
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ingestion) and during recovery from drug effect (9.5 h after alprazolam ingestion).  The scorers were blinded to 
treatment at the time of scoring.  Scorers were instructed to have the Pharmsac manual available during each 
scoring session. 
Rater Training.  Prior to doing any individual scoring, the raters were trained (one-on-one) in the use of 
the software by an instructor using the scoring manual as a guide.  The same instructor trained all raters.  
Additionally, group scoring sessions including several scorers and the instructor were held.  During these 
sessions, the group would collectively view and score eye movements as a means of insuring joint 
understanding of the scoring process and compliance with the scoring manual.  Finally, the rater scored data in 
the presence of the instructor before being judged ready to perform the task unsupervised.   
Statistical Analysis.  The specifics of the saccadic eye movement task and the scoring procedures are 
described in detail in Chapter 2.  Briefly, for each subject at each testing session, eye movements were 
separated according to the target step amplitude (8-degrees and 16-degrees) and combined according to 
direction (left and right) allowing a maximum number of 24 scored trials per session per target amplitude.  The 
subject-specific mean for saccades to each target amplitude was used in all subsequent analysis.  Saccade 
measurements from the 8-degree targets were analyzed separately from the 16-degree target measurements.  
The four SEM parameters (latency, velocity, duration and accuracy) were used as the dependent variables.  
Scorer was the fixed effect.  Based on the methods of Shrout and Fleiss (Shrout & Fleiss, 1979), scorers were 
conceived as a random selection of possible scorers, each of whom rated all eye movements from all randomly 
selected subjects such that each eye movement was evaluated by each scorer.  Using a one-way mixed effect 
ANOVA, the ICC was calculated as the ratio of the covariance parameter estimates; that is, the variance 
component for each random effect (SEM parameter) was divided by the sum of the residual error variance plus 
the random effect variance.   The ANOVA was performed using SAS Software (Cary, NC, version 8.02)(SAS 
Institute, 2000). 
Results 





Table 4A.  Intraclass Correlation Coefficients  
 
  8-degree Targets 16-degree Targets 
Visit Session (h) Duration Gain Latency Velocity Duration Gain Latency Velocity 
3 0 0.99 0.50 1.00 0.89 0.87 0.65 1.00 0.96 
3 5.5 0.87 0.91 0.96 0.96 0.93 0.77 0.99 0.96 
3 11.5 0.82 0.95 1.00 0.99 0.83 0.84 1.00 1.00 
4 0 0.92 0.61 1.00 0.99 0.97 0.84 1.00 0.99 
4 5.5 0.94 0.94 0.96 0.98 0.98 0.89 1.00 0.98 
4 11.5 0.79 0.91 1.00 0.99 0.82 0.91 1.00 0.99 





  These data suggest that the average inter-rater reliability of the Pharmsac saccadic eye movement 
scoring program is excellent (i.e., ICC ≥ 0.75)  (Viljoien, Roesch, & Zapf, 2002; Cicchetti, Showalter, & Tyrer, 
1985) for the duration, gain, latency, and velocity of saccades to both the 8-degree and 16-degree targets.  
Individually, the ICCs were excellent for all parameters at all time points except for gain to the 8-degree and 16-
degree saccades which can be classified as fair and good, respectively. 
The Pharmsac software allowed for subjective calibration of the individual saccades and for a 
combination of both subjective and programmed computation of the various saccade parameters.  Although 
parameters were derived from only one eye, movements from both eyes were recorded and the scorers were 
required to review both recordings before choosing which eye was to be scored, based on clarity of tracing and 
absence of noise in the signal.   Despite the opportunity for scorer bias, these data indicate that trained scorers 
with access to the Pharmsac scoring procedures manual produce reliable assessments of SEM data using 
Pharmsac software.   The scorers who participated in this research were trained in the use of the Pharmsac 







































CNS central nervous system 
DHEA dehydroepiandrosterone 
DHEA-S dehydroepiandrosterone-sulfate 
GABA gamma-aminobutyric acid 
GABA-RC GABA-benzodiazepine-receptor-complex 
NMDA N-methyl-d-aspartate 




 Saccadic eye movements (SEMs) are rapid, brief, jerk-like movements made by the eye when 
the focus of vision is shifted from one point to another in the visual field.  While the decision to initiate 
saccades is under volitional control, once initiated, the basic dynamics of these movements are not.  
For many reasons, saccades are ideal measures of central nervous system (CNS) activity for 
pharmacodynamic research.  They are quantitative, reliable, and reproducible, and are measured non-
invasively.  In addition, the CNS pathways involved in the control of these eye movements and their 
neurochemical modulation have been studied in detail (O'driscoll, et al., 2000; Wurtz & Hikosaka, 
1986; Fuchs, Kaneko, & Scudder, 1985; Sparks & Mays, 1990; Law, Svarer, Holm, & Paulson, 1997; 
Robinson, 2000; Quaia, Lefevre, & Optican, 1999).   
Electrophysiological, pharmacological, and anatomical findings have documented inhibitory 
synaptic connections involving gamma-aminobutyric acid (GABA) in the control of eye movements.  For 
example, the substantia nigra tonically inhibits (via GABAergic projections) the superior colliculus in 
order to prevent involuntary eye movements away from objects of interest (Hikosaka & Wurtz, 1983; 
Hikosaka & Wurtz, 1985b; Hikosaka & Wurtz, 1985a).  When a saccade is required to fixate a new 
target, signals from the striatum inhibit the substantia nigra via a GABAergic pathway thus releasing 
the superior colliculus to facilitate saccade generation.    
SEM dynamics have been studied extensively in young adults, and to a lesser extent in elderly 
individuals.  In 1980, Spooner et al. compared the three visually controlled eye tracking systems 
(saccadic, smooth pursuit, and optokinetic) in subjects of various ages and demonstrated age-related 
declines in all three systems (Spooner, Sakal, & Baloh, 1980).  While prolonged saccade latency has 
been associated with aging in the majority of studies, associations for saccade velocity and accuracy 
have not been as consistent.  Some studies have indicated that velocity does not change with age 
(Abel, Troost, & Dell'Osso, 1983; Hotson & Steinke, 1988; Munoz, Broughton, Goldring, et al.  1998), 
while other studies have shown a significant decrease in velocity with age, particularly for saccades at 
amplitudes greater than 10° (Spooner, Sakal, & Baloh, 1980; Warabi, Manabu, & Kato, 1984; Sharpe 
& Zackon, 1987; Sweeney, Rosano, Berman, et al.  2001; Moschner & Baloh, 1994). 
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Dehydroepiandrosterone (DHEA) and its sulfate metabolite, DHEA-S, are endogenous 
hormones secreted by the adrenal cortex (Nieschlag, et al., 1973).  Concentrations of both are age 
dependent, peaking in the third decade and decreasing thereafter (Sulcová, Hill, Hampl, & Stárka, 
1997; Pavlov, et al., 1986; Carlström, et al., 1988).  DHEA and DHEA-S are neurosteroids as they can 
be synthesized de novo in the brain (Majewska, Demirgören, Spivak, et al.  1990), where 
concentrations are considerably higher than in other organs (Corpechot, Robel, Axelson, et al.  1981).  
CNS concentrations appear to parallel those in the periphery (Robel & Baulieu, 1995; Lacroix, et al., 
1987; Guazzo, Kirkpatrick, Goodyer, et al.  1996).  On theoretical grounds, the overall effect of these 
neurosteroids in vivo should be excitatory based on in vitro activity at two receptors:  1) the GABA-
benzodiazepine-receptor-complex (GABA-RC) (Olsen & Delorey, 1998), to which GABA, the major CNS 
inhibitory neurotransmitter, binds, and 2) the N-methyl-d-aspartate (NMDA) receptor, a major receptor 
for excitatory amino acids (Dingledine & McBain, 1998).  In vitro, DHEA and DHEA-S act as 
noncompetitive negative modulators of the GABA-RC (Majewska, Demirgören, Spivak, & London, 
1990; Demirgören, Majewska, Spivak, & London, 1991) while DHEA demonstrates agonist activity at 
the NMDA receptor (Debonnel, Bergeron, & de Montigny, 1996).  
Despite the importance of endocrine modulations of the GABA-RC, and the role of GABA in the 
control of saccadic eye movements, little data are available regarding the possible relationship 
between SEM performance and concentrations of DHEA and DHEA-S.  The objective of this study was 
to determine whether there are age- and/or sex-related patterns of SEM dynamics (peak velocity, 
latency, duration, and accuracy) and whether these are associated with endogenous concentrations of 
DHEA and DHEA-S.  
Methods 
 
Study design and subjects.  The data used in this analysis were generated from a 
randomized, double-blind, placebo-controlled, four-way crossover study that required subjects to visit 
the GCRC on four separate occasions.  Analyses presented in this chapter include only data collected 
during the baseline evaluation during the first of these four visits, i.e., prior to administration of any 
drug or placebo.  Incorporated in the analysis are data from 68 medically and psychiatrically healthy 
volunteers.  Fifty-six of these subjects were women (19 young and 11 older) and men (15 young and 
11 older) who participated in the four-way crossover study described previously (see Chapter 2).  
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Twelve additional older subjects (six women and six men) participated in a separate study, but  were 
screened and evaluated in the same way and are included in the analysis.  The age range for young 
subjects was 20 to 30 years and for older subjects 66 to 78 years.  Included in the 68 subjects are 
individuals who identified themselves as Black (n=10), Hispanic (n=1), Caucasian (n=55), or 
Asian/Pacific Islander (n=2).  
Evaluation of saccadic eye movements.  Saccadic eye movement data were collected and 
assessed as described in Chapter 2.  For the purpose of this analysis, latency is the reaction time 
(msec) between target presentation and initiation of saccade, duration is the time (msec) required to 
complete the saccade, peak velocity (°/sec) is the maximum velocity achieved during the saccade, 
and accuracy is the percent of target step amplitude gained by the primary saccade. 
For each subject at each testing session eye movements were separated according to the size 
of target amplitude (8° and 16°) and combined according to direction (left and right) allowing a 
maximum number of 24 scored trials per session per target amplitude.  The subject-specific mean for 
saccades to each target amplitude was used in all subsequent analysis. 
Analysis 
Steroid concentration analysis.  The assays for steroid concentrations were done using 125I-
radioimmunoassay techniques (Diagnostic Systems Lab Inc., Webster, TX).  Serum was assayed for 
DHEA and DHEA-S concentrations.  The detection range and lower limit of detection, respectively, for 
each assay were:  DHEA:  0.2 to 30 ng/ml and 0.009 ng/ml; DHEA-S:  50 to 8000 ng/ml and 17 
ng/ml.  The coefficient of variation for each was <10% throughout the range of the assay.  Blood 
samples for DHEA and DHEA-S were collected from an indwelling catheter in a forearm vein and 
placed in appropriately labeled vacuum tubes and centrifuged.  Serum was decanted and stored at -
80oC. 
Data Analysis.  
Analysis included descriptive statistics of age, DHEA and DHEA-S concentrations, and SEM 
dynamics for the four groups of subjects: young women, young men, older women, and older men.  
SEM data are shown graphically using box and whisker plots.  The boxes extend from the 25th to the 
75th percentile with a line at the median, while the whiskers extend to the highest and lowest 
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observed values.  To determine whether hormone concentrations or saccade measures differed by 
age and/or sex, group means were compared using two-way analysis of variance (ANOVA).  The 
dependent variable was the SEM parameter (or steroid concentration) while the fixed effects were sex, 
age, and the sex-by-age interaction term.  The sex-by-age interaction term was not significant in 
preliminary analysis (p>0.07 for all analysis) and was subsequently dropped from the model.  Effects 
are reported as means and corresponding standard deviations (s.d.). 
Stepwise multiple linear regression was used to assess the influence of age, steroid 
concentration, race, and sex on SEM dynamics.  Results were considered statistically significant if the 
observed p-value was less than or equal to a critical value of 0.05.  All plotting was performed using 
GraphPad Prism version 3.02 for Windows, GraphPad Software; San Diego, California USA; 
www.graphpad.com (Motulsky, 1999).  All ANOVA and multiple linear regression analysis were 




 The number of subjects and mean age data per group are presented in Table 5A, along with 
DHEA and DHEA-S concentrations. 
 
 
Table 5A.  Mean age and morning DHEA and DHEA-S concentrations for the four groups of 
participantsa 




(20 – 30) 
14.1 (5.0) 
(2.6 - 21.4) 
1723.6 (924.3) 




(20 – 29) 
14.3 (3.7) 
(8.39 – 20.3) 
  2451.4 ( 804.4) 




(66 – 75) 
4.18 (2.9) 
(0.93 – 10.3) 
172.3 (112.4) 




(67 – 78) 
6.1 (4.9) 
(1.7 – 23.1) 
843.6 (654.1) 
(91.7 – 2011.4) 
Young vs. Olderb  __ p=0.0001 p=0.0001 
Men vs. Womenb  __ p=0.30 p=0.0001 
    
aData are presented as mean, standard deviation, and range.  





   Box plots of latency and duration of saccades to the 16° target for each group (i.e., young 
women,  young men, older women, and older men) are presented in Figure 4.1 (latency) and Figure 













Figure 5.1  Boxplots of mean saccade latency to response time for 16° targets for each age/sex group.  
The box defines the interquartile range and the middle line represents the median.  The whiskers 
extend to the highest and lowest values.  The filled squares represent data from minority subjects and 
the empty squares represent data from Caucasian subjects.  The latency in older subjects was 
















Figure 5.2.  Boxplots of mean duration of saccades or 16° targets for each age/sex group.  The box 
defines the interquartile range and the middle line represents the median.  The whiskers extend to the 
highest and lowest values.  The filled squares represent data from minority subjects and the empty 
squares represent data from Caucasian subjects.  The saccade duration for older subjects was 
significantly different from that of the young, p<0.04. 
 
 
Data in Table 5A demonstrate that mean DHEA and DHEA-S values differed significantly 
between the age groups with the young having higher concentrations of both hormones than the older 
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Mean = 72.4 msec Mean = 72.6 msec Mean = 78.1 msec Mean = 75.9 msec
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subjects (p = 0.0001).  The men had significantly higher DHEA-S concentrations than did the women 
(p = 0.0001).  No differences were noted between sexes for DHEA (p = 0.30). 
Latency (Fig. 5.1) differed by age (p = 0.0001) but not by sex, with the older subjects 
demonstrating longer latency to saccade initiation (mean =227.7msec; s.d. = 55.7) than the young 
(mean = 174.5; s.d. = 34.0).  Findings were similar for latency to saccades to the 8° targets.   
Similar to the results for latency, Figure 5.2 shows that the mean duration of the 16° 
saccades was longer (p = 0.041) in the older subjects (mean = 77.0msec; s.d. = 10.4) than in the 
young subjects (mean = 72.5msec; s.d. = 7.4 ), but was not significantly different between the sexes 
(p = 0.65).  The duration of saccades to the 8° targets did not differ significantly by either age or sex (p 
> 0.10 for each). 
In contrast to the results for latency and duration, the mean peak velocity for saccades to the 
16° target for the older group (387.6°/sec; s.d. = 63.1) did not differ significantly from that of the 
young group (405.3°/sec; s.d. = 55.3).  Peak velocity in men (397.6°/sec; s.d. = 61.5) did not differ 
from that in women (395.5°/sec; s.d. = 58.7); p > 0.22 for each comparison.  Similarly, no differences 
were observed between age or sex groups for mean peak velocity to targets of 8° (p > 0.16).  The 
average saccade gain (i.e., accuracy) to the 8° target did not differ by age (p = 0.29) but did differ 
significantly (p = 0.023) between men (0.92 s.d. = 0.07) and women (0.96; s.d. = 0.06).  No 
differences were observed between age or sex groups for accuracy of saccades to the 16° targets (p > 
0.11).  
For saccade latency, results of stepwise multiple linear regression analyses indicate that age 
is a significant predictor for both the 8° (r = 0.36, p = 0.002) and 16° targets (r = 0.51, p ≤ 0.0001).  
Addition of other variables (i.e., steroid concentration, race, or sex) did not improve the fit of the 
model. 
Conversely, significant predictors for duration of saccades to 8° and 16° targets included 
DHEA (r=0.27, p=0.023; r=0.30, p=0.014) and DHEA-S (r=0.26, p=0.033; r=0.30, p=0.012), 




Our results demonstrate significant age-related differences in saccade latency and duration, 
but not in the velocity or accuracy of saccades.  Several studies have shown that increased saccade 
latency, or reaction time, is associated with aging (Abel, Troost, & Dell'Osso, 1983; Sharpe & Zackon, 
1987; Abrams, Pratt, & Chasteen, 1998; Warabi, Manabu, & Kato, 1984; Whitaker, Shoptaugh, & 
Haywood, 1986; Sharpe & Zackon, 1987; Hotson & Steinke, 1988; Moschner & Baloh, 1994; Scialfa, 
Hamaluk, Skaloud, et al.  1999).  Our data corroborate these results with a significantly longer latency  
in older adults for saccades to both the 8° and 16° targets.  The increase in latency is consistent with 
age-related changes in motor function (Fozard, Vercruyssen, Reynolds, et al.  1994), possibly within 
the cortical eye fields or striatum or in their connections to brainstem saccade generators (Christakou, 
2001).  Although the 8° and 16°amplitudes of target steps used in our study are smaller than those 
used in some previous studies, they more closely emulate those seen in normal day-to-day eye 
movements (Bahill, Adler, & Stark, 1975).  Consistent with a previous report by Munoz et al. (Munoz, 
Broughton, Goldring, & Armstrong, 1998) the mean duration of the 16° saccades observed in the 
present study for older subjects  (mean=77.0msec; s.d.=10.4) was significantly longer than for the 
young (mean=72.5msec; s.d.=7.4).   
In contrast, the mean duration to the smaller 8° targets did not differ significantly between 
the young and older subjects (59 msec and 57 msec, respectively).  Likewise, no age-related 
differences in the peak saccade velocity to 8° and 16° targets were observed in this study, consistent 
with the results of some other studies (Abel, Troost, & Dell'Osso, 1983; Hotson & Steinke, 1988; 
Munoz, Broughton, Goldring, & Armstrong, 1998).  Moschner et al. has found a significant slowing in 
peak velocity as age increases, but only when the amplitude of the saccade was greater than 20° 
(Moschner & Baloh, 1994).  Others have drawn similar conclusions (Sweeney, Rosano, Berman, & 
Luna, 2001; Becker, 1989; Warabi, Manabu, & Kato, 1984), with Sharpe et al. noting a significant 
decrease in velocity when the amplitude of the saccade was 40°.  In addition to the size of the 
saccade, recording methods also influence velocity (Becker, 1989) making it difficult to compare 
different studies. 
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 DHEA concentrations in the multiple linear regression model explained a significant portion of 
variability in saccade duration.  There is good rationale to expect a relationship between SEMs and 
DHEA.  In vitro, DHEA is a non-competitive negative modulator of the GABA-RC and as such, should 
have an excitatory effect.  We hypothesized that the well-documented age-related decrease in the 
circulating concentrations of DHEA over time would have an effect similar to that of an increase in 
GABA-agonist activity, which decreases SEM performance (Glue, et al., 1995; Roy-Byrne, Cowley, 
Greenblatt, et al.  1990; Kroboth, et al., 1998; Cowley, Roy-Byrne, Radant, et al.  1995; Ball, Glue, 
Wilson, & Nutt, 1991).  Our results partially confirm this hypothesis.  Systemic GABA agonists are well 
known to affect both the latency of saccades as well as saccade metrics such as duration.  Our data 
indicate that DHEA and DHEA-S levels, which changed dramatically over the age span, were inversely 
related to saccade duration but not to well-established age-related changes in the latency of 
saccades.  This suggests that DHEA and DHEA-S may differentially modulate GABA systems in different 
brain regions.  The age-related changes in DHEA and DHEA-S observed in this study do not appear to 
alter activity in the cortical eye fields in a way that accounts for reductions in saccade latency shown 
by elderly individuals.  However, DHEA and DHEA-S levels do appear to modulate activity within the 
brainstem or cerebellum, or in direct GABAergic projections to those regions, which are known to 
regulate the duration of saccades.  One possibility is that this effect occurs by modulating GABA-
mediated inhibition of the superior colliculus by the substantia nigra, a modulator of the initiation and 
termination of saccades (Hikosaka & Wurtz, 1983; Hikosaka & Wurtz, 1985a).  DHEA and DHEA-S 
appear to modulate this pathway, or another GABAergic system intrinsic to the brainstem or 
cerebellum, to alter mechanisms that control the precise temporal synchronization of saccade onset 
and offset commands.  
 The relationship between eye movement activity and neuroendocrine levels seen in these 
data is correlational and, as such, the observed correlations of DHEA and /or DHEA-S with SEM 
dynamics must be viewed with caution.   Multiple changes within the brain occur during normal aging 
that may conceivably affect the observed relationships.  Studies in which steroid hormone 
concentrations are pharmacologically manipulated are needed to establish a direct linkage between 




 Changes in saccadic eye movements (SEMs) have been associated with aging.  With aging, 
there is also a decline in concentrations of the neurosteroids DHEA and DHEA-S, known to be 
noncompetitive negative modulators of the GABA-receptor complex.  GABA tone plays an important 
role in the execution of saccadic eye movements.  We evaluated the influence of age and endogenous 
concentrations of DHEA and DHEA-S on SEM dynamics in sixty-eight women and men (ages 20 to 78) 
who volunteered for the study.  Older adults had significantly longer latency and duration than young 
adults (p≤0.041); age had no effect on peak velocity.  Using stepwise multiple linear regression 
analysis, age was a significant predictor of latency (p≤0.002), which is consistent with age-related 
changes in corticofugal inputs from the cortical eye fields to the brainstem regulating saccade 
initiation.  This analysis also showed that DHEA and DHEA-S concentrations were significant predictors 
of duration (p≤0.023); this is likely explained by the GABAergic modulation of the connections from the 






















CONCENTRATION-TIME PROFILES  FOR ALPRAZOLAM, DHEA, DHEA-S AND CORTISOL AFTER ORAL 




AUC area under the concentration-time curve 
Cmax maximum observed concentration  
DHEA dehydroepiandrosterone 
DHEA/Alp  DHEA plus alprazolam treatment 
DHEA-S dehydroepiandrosterone-sulfate 
GABA gamma-aminobutyric acid 
PL/Alp placebo plus alprazolam treatment 
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Introduction 
It is expected that when a drug is administered, a response, or pharmacological event will 
result.  The potency and duration of this observed response is assumed to be related to the dose of 
drug administered.  However, the pharmacological effects, both therapeutic and undesirable, are 
often more closely associated with the concentration of drug in the body (Holford & Sheiner, 1981).  
Pharmacokinetics is the association of a drug’s concentration-time profile to dose, route of 
administration, absorption, distribution, elimination and metabolism .   Pharmacodynamics is the 
study of the pharmacological response relative to drug concentratation.  It is known there is 
interpatient variability in response to drugs.  Equivalent drug dosage does not always produce 
comparable concentrations, nor do comparable concentrations consistently result in equivalent 
effects among patients, or even within patients.  The source of variability can generally be attributed to 
variability in pharmacokinetics, pharmacodynamics, or even genetics.  This pharmacokinetic-
pharmacodynamic variability may be intra- or interindividual, may be associated with different 
populations based on, though not limited to, age, sex, ethnicity or disease process, or may be caused 
by concurrent drug use or even environmental factors (Marzo, 1997; Linder & Valdes, Jr., 2001; 
Johnson, 2001). 
The overall purpose of this dissertation research, as stated in Chapter 1, is to determine the 
effect of dehydroepiandrosterone (DHEA) concentration on recovery from gamma-aminobutyric acid 
(GABA)-agonist (benzodiazepine) challenge in young and older men and women.  To address this, both 
drug concentrations and drug responses were assessed in a design that required administration of both 
DHEA and the benzodiazepine, alprazolam.  The current chapter provides analysis of the concentration-
time data of alprazolam, DHEA, dehydroepiandrosterone-sulfate (DHEA-S), and cortisol during two visits:  
the DHEA plus alprazolam visit (DHEA/Alp) and the placebo plus alprazolam visit (PL/Alp).  The objective 
of this analysis is to describe the concentration-time profiles in four different age/sex groups (young 
women, young men, older women, and older men) and to determine whether age- and/or sex-based 
differences exist.   This analysis is a prerequisite to the subsequent research presented in Chapter 7, 




Study design and subjects.  The data used in this analysis were generated from a randomized, double-
blind, placebo-controlled, four-way crossover study that required subjects to be admitted to the 
General Clinical Research Center on four separate occasions.  Analyses in this chapter include only 
data collected during Phase II, i.e., the third and fourth visits.  Subjects received placebo plus 
alprazolam on one visit (PL/Alp)  and DHEA plus alprazolam on the alternate visit (DHEA/Alp).  In the 
afternoon before each of the visits, subjects were admitted to the GCRC and fasted from 10 p.m. on 
the evening of admission (water was permitted) until 7:30 a.m. the next day.  At this time, subjects 
received a light breakfast and an intravenous catheter was placed in a forearm vein for the purpose of 
obtaining multiple blood samples throughout the treatment day. 
 Based on the DHEA concentration-time profile from Phase I of the study, the times and dose 
amounts of DHEA administered during Phase II were individualized to achieve DHEA concentrations 
between 10 and 20 ng/ml.  The majority of subjects received DHEA 50 mg at both 0 h and 6.5 h.  
Exceptions are noted in Chapter 2, Tables 2.2 and 2.3.  Identical doses of Alp 2 mg were administered 
by mouth to all subjects at the same time (2.5 h) for both visits in Phase II.  To determine the 
concentrations of alprazolam, DHEA, DHEA-S, and cortisol blood samples were obtained at 0 h (prior to 
DHEA or placebo administration) and at 1, 2, 3, 3.5, 4.5, 5.5, 7, 8.5, 10, 11, 12.5, 16, 20 and 23.5 h 
after dose administration.  Blood samples for determination of steroid and alprazolam concentrations 
were collected from the indwelling catheter in a forearm vein and placed in appropriately labeled 
vacuum tubes and centrifuged.  Serum was decanted and stored at -80oC. 
Table 6A summarizes demographic information for the 36 women (20 young and 16 older) 
and 33 men (16 young and 14 older) whose data are included in this analysis.  
 
Table 6A.  Mean age and Body Mass Index (BMI) for the four groups of participantsa 




(20 - 30) 
23.32 (3.21) 




(20 - 29) 
23.30 (2.84) 




(66 – 75) 
28.40 (4.42) 




(67 - 78) 
27.02 (1.78) 
(24.39 - 30.34) 
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Alprazolam.  For alprazolam and the internal standard, triazolam, a gas chromatographic-
electron capture detection method (GC) was validated and used to determine serum alprazolam 
concentrations.   The assay is described in detail in Chapter 2.  Briefly, samples were injected onto a 
10 m x 0.32 mm x 0.25 µm capillary column (DB1701, J & W Scientific) in a Hewlett Packard 6890 
gas chromatograph with helium as the carrier gas and argon-methane (95:5) as the make-up gas. 
Alprazolam and triazolam were detected and quantified using a micro 63Ni electron capture detector 
(µECD). Data were acquired and analyzed using an HP ChemStation. 
Steroids.  The assays for steroid concentrations were done using 125I-radioimmunoassay 
techniques (Diagnostic Systems Lab Inc.).  Serum was assayed for DHEA, DHEA-S, and cortisol 
concentrations.  The detection range and lower limit of detection, respectively, for each assay were:  
DHEA:  0.2 to 30 ng/ml and 0.009 ng/ml; DHEA-S:  50 to 8000 ng/ml and 17 ng/ml; cortisol:  0.5 to 60 
µg/dl and 0.11 µg/dl.  The coefficient of variation for each was <10% throughout the range of the assay. 
Statistical Analysis.  The subjects were divided into four age/sex groups: young women, young 
men, older women and older men.  Concentration-time data were plotted for each subject for 
alprazolam and all steroid concentrations. Significant differences between groups were tested using a 
repeated measures mixed-model analysis of variance (ANOVA).  For the initial analysis, alprazolam, 
DHEA, DHEA-S and cortisol concentrations were used as the dependent variable.  Age/sex, treatment , 
time, and the age/sex-by-treatment interaction were considered as fixed effects.  The interaction term 
was dropped from the model when it was not significant. Subjects were treated as random effects and 
the variance/covariance matrix was modeled using compound symmetry.  
For alprazolam, the maximum observed concentration (Cmax) for each subject was identified.  
Area under the concentration-time curve was calculated for each subject  from 0 to 12.5 hours (AUC0-
12.5) and from 0 to 24 hours (AUC0-24) using the trapezoidal rule (Gibaldi & Perrier, 1982).  Significant 
differences between treatments and among age/sex groups were tested using a one-way ANOVA with 
AUC0-12.5, AUC0-24, and Cmax as the dependent variable and either treatment or age/sex as the main 
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effect.  To determine pairwise differences in AUC0-12.5, AUC0-24, and Cmax between groups, least 
squares means was used as the post hoc analysis. 
For DHEA, DHEA-S, and cortisol, mean maximum observed and mean concentrations from 0 
to 12.5 hours for each age/sex group were calculated for both the PL/Alp and DHEA/Alp treatments.  
Additionally, the change in steroid concentrations between the two treatments was determined for 
each subject, at each time point for the same time period.  Significant differences between treatments 
and among age/sex groups for both the mean steroid and change in steroid concentration were tested 
using a one-way ANOVA with either treatment or age/sex as the main effect.  To determine pairwise 
differences between groups, least squares means was used as the post hoc analysis.   
Results were considered statistically significant if the observed p-value was less than or equal 
to a critical value of 0.05.  All plotting was performed using GraphPad Prism version 3.02 for Windows, 
GraphPad Software; San Diego, California USA; www.graphpad.com (Motulsky, 1999).  The ANOVA was 
performed using SAS Software (Cary, NC, version 8.02) (SAS Institute, 2000).  
Results 
Alprazolam Concentrations.  Individual and mean concentration time profiles for the two 
treatments PL/Alp and DHEA/Alp are presented in Figures 6.1 (young subjects) and Figure 6.2 (older 
subjects).  None of the four age/sex groups demonstrated a difference in alprazolam concentrations 
between the two treatments, (p = 0.52).  The older women had significantly greater concentrations (p 





























































































































Figure 6.1.  Line plots of alprazolam concentration vs. time from the young subjects.  Individual 
alprazolam concentration data from the PL/Alp treatment are in panels A, young women (?), and B, 
young men (?).  Individual alprazolam concentration data from the DHEA/Alp treatment are in panels 
C, young women (?), and D, young men (?).  The mean data with standard deviations are in panels E 




























































































































Figure 6.2.  Line plots of alprazolam concentration vs. time from the older subjects.  Individual 
alprazolam concentration data from the PL/Alp treatment are in panels A, older women (?), and B, 
older men (?).  Individual alprazolam concentration data from the DHEA/Alp treatment are in panels 
C, older women (?), and D, older men (?).  The mean data with standard deviations are in panels E 




Table 6B contains the observed maximum alprazolam concentration values (Cmax) for both 
the PL/Alp and DHEA/Alp treatments.  Peak alprazolam concentrations in the young women did not 
differ from those in either the young or older men.  However, data from the older men revealed Cmax 
values significantly greater than those found in the young men and significantly less than those found 
in the older women.  The older women demonstrated significantly higher Cmax values than any of the 
other age/sex groups.   
 









Between treatment  
comparison 
Young women 
(n = 20) 
32.43 (6.52)AC 
(24.89 - 48.05) 
29.64 (7.99)A 
(5.89 - 41.06) p = 0.23 
Young men 
(n = 16) 
28.23 (4.99)A 
(14.25 - 34.61) 
32.35 (10.26)AB 
(16.45 - 51.05) p = 0.16 
Elderly women 
(n = 16) 
41.86 (10.36)B 
(24.70 - 61.43) 
37.45 (9.94 )B 
(27.02 - 60.24) p = 0.23 
Elderly  men 
(n = 14) 
34.42 (12.47)C 
(23.23 - 64.28) 
38.30 (10.94)B 
(27.43 - 60.13) p = 0.39 
Among group 
comparisonb p = 0.0005 p = 0.03  
    
aData are presented as mean, standard deviation and range. Superscripted uppercase 
letters indicate differences among the age/sex groups when the model was significant.  
Those with like letters were not different from each other. 





Table 6C includes the area under the alprazolam concentration-time curve (AUC) data for both 
treatments. Within each age/sex group there were no differences between the PL/Alp treatment and 
the DHEA/Alp treatment  for either AUC0-12.5 or AUC0-24, (p ≥ 0.13 for all). 


















(158.82 - 275.09) 
486.88 (131.63)A 
(105.60 - 755.77) 
200.08 (53.49)A 
(42.61 - 299.87) 
517.12 (72.92)A 




(111.26 - 239.17) 
498.87 (102.10)A 
(289.09 - 631.62) 
205.29 (44.80)A 
(115.76 - 270.07) 
493.08 (81.09)A 




(170.70 - 328.17) 
592.43 (98.79)B 
(458.23 - 778.99) 
236.97 (40.32)B 
(177.00 - 310.01) 
614.25 (96.76)B 
(429.14 - 814.24) 
Elderly  men 
(n=14) 
199.91 (32.37)A 
(114.34 - 252.51) 
514.70 (60.60)A 
(19.35 - 626.60) 
206.54 (22.54)A 
(171.77 - 252.20) 
500.76 (81.45)A 
(291.89 - 626.80) 
 
Among group 
Comparisonc p = 0.0004 p = 0.02 p = 0.07 p = 0.0003 
     
aData are presented as mean, standard deviation and range.  Superscripted uppercase letters indicate 
differences among the age/sex groups when the model was significant.  Those with like letters were 
not different from each other. 
bThe area under the time curves were calculated for two different time periods: from 0h to 12.5 h 
(AUC0-12.5) and from 0 h to 24 h (AUC0-24). 
cp-values were obtained by one-way ANOVA models. 
 
 
Steroid Concentration.  The individual and mean concentration-time plots for the steroid concentration 
data can be found in Figures 6.3 through 6.8.  Figures 6.3 and 6.4 contain the DHEA concentration 
data for the young and older subjects, respectively.  As expected, there was a statistically significant 
increase in DHEA concentration over time after administration of DHEA during the DHEA/Alp treatment 
for each of the age/sex groups, p < 0.001 for all.   For the PL/Alp treatment, overall concentrations did 
not differ between the sexes within each age group (p ≥ 0.32), but  were significantly higher in the 
young groups when compared to the older groups (p > 0.0001).  During the DH/Alp treatment there 
were again no differences between sexes within age groups (p ≥ 0.14);  older men differed from both 




































































































Figure 6.3.  Line plots of DHEA concentration vs. time from the young subjects.  Individual DHEA 
concentration data from the PL/Alp treatment are in panels A, young women (?), and B, young men 
(?).  Individual DHEA concentration data from the DHEA/Alp treatment are in panels C, young women 
(?), and D, young men (?).  The mean data with standard deviations are in panels E (young women) 
and F (young men). 
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Figure 6.4.  Line plots of DHEA concentration vs. time from the older subjects.  Individual DHEA 
concentration data from the PL/Alp treatment are in panels A, older women (?), and B, older men 
(?).  Individual DHEA concentration data from the DHEA/Alp treatment are in panels C, older women 
(?), and D, older men (?).  The mean data with standard deviations are in panels E (older women) 
and F (older men). 
 
 
The significant difference between treatments was also evident in the DHEA-S concentrations as 
presented in Figures 6.5 (young subjects) and 6.6 (older subjects).  Similar to DHEA, DHEA-S 
concentrations were significantly higher during the DH/Alp treatment (p < 0.0001).  All age/sex groups 
differed from each other during the Pl/Alp treatment (p < 0.0001) with the young men having the 
highest concentrations and older women the lowest.  The young women had higher concentrations 
than the older men.  During the DH/Alp treatment, the young men had higher concentrations when 




















































































































































































































Figure 6.5.  Line plots of DHEA-S concentration vs. time from the young subjects.  Individual DHEA-S 
concentration data from the PL/Alp treatment are in panels A, young women (?), and B, young men 
(?).  Individual DHEA-S concentration data from the DHEA/Alp treatment are in panels C, young 
women (?), and D, young men (?).  The mean data with standard deviations are in panels E (young 


















































































































Figure 6.6.  Line plots of DHEA-S concentration vs. time from the older subjects.  Individual DHEA-S 
concentration data from the PL/Alp treatment are in panels A, older women (?), and B, older men 
(?).  Individual DHEA concentration data from the DHEA/Alp treatment are in panels C, older women 
(?), and D, older men (?).  The mean data with standard deviations are in panels E (older women) 
and F (older men). 
 
The cortisol concentration-time data are illustrated in Figure 6.7 for the young subjects and Figure 6.8 
for the older subjects.  For each of the age/sex groups, the cortisol concentrations did not differ 
between the PL/Alp treatment and the DHEA/Alp treatment, nor were they different among the 
































































































































Figure 6.7.  Line plots of cortisol concentration vs. time from the young subjects.  Individual cortisol 
concentration data from the PL/Alp treatment are in panels A, young women (?), and B, young men 
(?).  Individual cortisol concentration data from the DHEA/Alp treatment are in panels C, young 
women (?), and D, young men (?).  The mean data with standard deviations are in panels E (young 
































































































































Figure 6.8.  Line plots of cortisol concentration vs. time from the older subjects.  Individual cortisol 
concentration data from the PL/Alp treatment are in panels A, older women (?), and B, older men 
(?).  Individual cortisol concentration data from the DHEA/Alp treatment are in panels C, older women 
(?), and D, older men (?).  The mean data with standard deviations are in panels E (older women) 
and F (older men). 
 
 
The mean DHEA, DHEA-S, and cortisol concentration data from the two treatments are presented in 
Table 6D (PL/Alp) and in Table 6E (DHEA/Alp).  During the PL/Alp treatment the mean DHEA and 
DHEA-S concentration data for both the young women and men were significantly higher than either 
the older women or older men.  There were no differences between the sexes in the either the young 
or older group for the DHEA mean data.  For mean DHEA-S concentration data, all age/sex groups 
differed from each other with the young men having the highest concentration and the older women 
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having the lowest; concentration data from the young women were greater than the older men.   There 
were no significant differences among the age/sex groups for mean cortisol concentrations. 
 
Table 6D.  Mean steroid concentration data from the first 12.5 h of the PL/Alp treatment daya. 
 
Group 
DHEA (ng/ml) during 
PL/Alp  
DHEA-S (ng/ml) during 
PL/Alp 





(0.58 - 22.46) 
1618.05 (819.25)A 
(99.42 - 4277.36) 
8.47 (7.26) 




(3.24 - 22.21) 
2435.62 (781.69)B 
(769.12 - 4536.96) 
9.62 (7.46) 




(0.61 - 10.90) 
209.20 (146.12)C 
(53.03 - 1146.66) 
9.10 (6.99) 




(0.68 - 10.81) 
732.38 (553.23)D 
(50.73 - 2140.81) 
8.14 (6.55) 
(0.39 - 31.15) 
Among group 
comparisonb p < 0.0001 p < 0.0001 p = 0.59 
    
aData are presented as mean, standard deviation and range. Superscripted uppercase letters 
indicate differences among the age/sex groups when the model was significant.  Those with like 
letters were not different from each other. 
bp-values were obtained by one-way ANOVA models. 
 
 
Table 6E.  Mean steroid concentration data from the first 12.5 h of the DHEA/Alp treatment daya. 
 
Group 
DHEA (ng/ml) during 
DHEA/Alp  
DHEA-S (ng/ml) during 
DHEA/Alp 





(1.72 - 24.12) 
4071.69 (1203.23)A 
(180.46 - 6206.49) 
8.12 (7.42) 




(6.02 - 22.54) 
4610.93 (999.66)B 
(1022.55 - 6603.58) 
9.96 (7.44) 




(1.00 - 25.77) 
3679.41 (1551.51)A 
(61.34 - 6004.13) 
9.09 (7.00) 




(1.18 - 23.29) 
3973.49 (1711.96)A 
(57.82 - 7939.09) 
8.34 (6.80) 
(0.56 - 34.79) 
Among group 
comparison p < 0.005 p < 0.001 p = 0.41 
    
aData are presented as mean, standard deviation and range. Superscripted uppercase letters 
indicate differences among the age/sex groups when the model was significant.  Those with like 
letters were not different from each other. 
bp-values were obtained by one-way ANOVA models. 
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 For the DHEA/Alp data, DHEA concentrations were higher in the young women and young men 
when compared to that of older men, but not the older women.  Within the older group, there was not 
a sex-associated difference for DHEA.  For the mean DHEA-S concentrations, the young men had 
significantly higher concentrations than any of the other age/sex groups whose data did not differ 
from each other.  There were no significant differences among the age/sex groups for the mean 
cortisol data. 
 Tables 6F, 6G and 6H present the mean observed maximum concentrations of DHEA, DHEA-S 
and cortisol (respectively) during the first 12.5 h for both the PL/Alp and DHEA/Alp treatments.   
 
Table 6F.  Mean observed maximum DHEA concentrations (0 – 12.5 h) for the two treatmentsa. 
 
Group 
PL/Alp Maximum  
DHEA (ng/ml)  







(3.07 - 22.46) 
18.23 (3.24) 




(7.84 - 22.21) 
18.73 (2.34) 




(1.15 - 10.90) 
17.33 (3.26) 




(1.74 - 10.81) 
17.41 (2.89) 
(13.42 - 23.29) p < 0.0001 
Among group 
comparisonb p < 0.0001 p = 0.49  
    
aData are presented as mean, standard deviation and range. Superscripted uppercase letters indicate 
differences among the age/sex groups when the model was significant.  Those with like letters were 
not different from each other. 




Table 6G.  Mean observed maximum DHEA-S concentrations (0 – 12.5 h) for the two treatmentsa. 
 
Group 
PL/Alp Maximum  
DHEA-S (ng/ml)  







(153.78 - 4277.36) 
5205.10 (595.24) 




(1074.02 - 4536.96) 
5487.58 (567.00) 




(74.70 - 1146.66) 
5190.49 (586.83) 




(62.32 - 2140.81) 
5615.82 (926.0) 
(4333.29 - 7939.09) p < 0.0001 
Among group 
comparisonb p < 0.0001 p = 0.21  
    
aData are presented as mean, standard deviation and range. Superscripted uppercase letters indicate 
differences among the age/sex groups when the model was significant.  Those with like letters were 
not different from each other. 
bp-values were obtained by one-way ANOVA models. 
 
 
Table 6H.  Mean observed maximum cortisol concentrations (0 – 12.5 h) for the two treatmentsa. 
 
Group 
PL/Alp Maximum  
CORTISOL (ng/ml)  







(7.18 - 36.16) 
20.75 (6.69) 




(12.54 - 43.97) 
25.31 (8.48) 




(16.97 - 34.80) 
24.86 (6.29) 




(5.65 - 31.15) 
23.63 (6.80) 
(9.36 - 34.79) p = 0.57 
Among group 
comparisonb p = 0.78 p = 0.21  
    
aData are presented as mean, standard deviation and range. Superscripted uppercase letters indicate 
differences among the age/sex groups when the model was significant.  Those with like letters were 
not different from each other. 
bp-values were obtained by one-way ANOVA models. 
 
During the PL/Alp treatment, DHEA Cmax for the young group was greater than that in the 
older groups (p < 0.0001), but did not differ between the sexes within each age group (p ≥ 0.87);  
DHEA-S Cmax also differed among the age/sex groups during the PL/ALP treatment with the highest in 
the young men and the lowest in the older women.  Cortisol Cmax did not differ among the groups 
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during the PL/ALP treatments.  There were no differences among the age/sex groups in mean 
observed maximum concentrations during the DH/Alp treatment for DHEA, DHEA-S or cortisol. 
 The mean change in steroid concentrations between the PL/Alp and the DHEA/Alp treatments 
can be seen in Table 6I. 
 
Table 6I.  Mean change in steroid concentrations between the PL/Alp and DHEA/Alp treatments 





Change in DHEA 
concentrations (ng/ml) 
 
Change in DHEA-S 
concentrations (ng/ml) 
 






(-9.12 - 16.35) 
2453.65 (1303.05)A 
(-747.36 - 5386.09) 
-0.35 (4.26) 





(-10.31 - 14.28) 
2175.31 (1005.62)A 
(-294.55 - 4358.39) 
 
0.34 (4.01) 





(-6.70 - 23.84) 
3470.21 (1550.84)B 
(-197.32 - 5946.27) 
 
0.00 (4.90) 





(-1.59 - 21.13) 
3233.65 (1783.71)B 
(-451.30 - 7176.19) 
 
0.20 (3.90) 





p < 0.0001 
 
p < 0.0001 
 
p = 0.68 
    
aData are presented as mean, standard deviation and range. Superscripted uppercase letters 
indicate differences among the age/sex groups when the model was significant.  Those with like 
letters were not different from each other. 
bp-values were obtained by one-way ANOVA models. 
 
 
The young women and men had smaller changes in DHEA concentration when compared to the older 
groups.  Overall, the greatest change was noted in the older women who were significantly higher than 
the other three age/sex groups, including the older men.  The change in DHEA-S did not demonstrate 
sex-based differences in either the young or older groups, but the older men and women had a 
significantly greater change than that seen in the young.  The change in cortisol concentrations was 
not different among the age/sex groups.  
Discussion 
This study describes the concentration-time profiles of alprazolam, DHEA, DHEA-S and cortisol 
after administration of PL/Alp or DHEA/Alp to healthy young and older adults.  These data 
demonstrate relatively little variability in alprazolam concentrations between the two treatment days 
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for each of the age/sex groups (the young women, young men, older women and older men).  It is 
interesting to note the greater alprazolam concentrations demonstrated in the older women when 
compared to the other three groups.  Previous studies, though not altogether consistent, suggest that 
differences in the pharmacokinetics of alprazolam between the young and elderly exist, but mostly in 
older men (Greenblatt, Divoll, Abernethy, et al.  1983; Kroboth, McAuley, & Smith, 1990; Dehlin, 
Kullingsjo, Liden, et al.  1991).  This is in contrast to the current data that indicate consistently higher 
AUC0-12.5, AUC0-24, and Cmax only in the older women.   Obesity is known to prolong alprazolam half-life 
(Abernethy, Greenblatt, Divoll, et al.  1984) and although the older women in this study had 
significantly greater BMIs than both of the young groups, they did not differ from the older men.    An 
age-related change in women but not men may indicate the influence of menopause on drug 
metabolism. When compared to young women, erythromycin and alfentanil, both substrates for 
CYP3A4, the enzyme responsible for metabolism of alprazolam, demonstrate decreased clearance in 
postmenopausal women (Harris, Benet, & Schwartz, 1999) without a corresponding decrease in older 
men.   The calculation of clearance and half-life was not done in this study since estimates of such 
parameters require that sampling continue for a minimum of 3 to 5 half-lives.  Alprazolam’s expected 
half-life is 12 to 15 h and, for these data, the final sample was collected at 21 h after administration 
of alprazolam. 
The age groups chosen for this study are representative of the ages when DHEA production is 
at its peak (20 to 30 years) or near its nadir (65 to 79 years) (Kroboth, et al., 1999).  The age related 
decrease in both DHEA and DHEA-S concentrations is well known and has been extensively reviewed 
(Barrou, Charru, & Lidy, 1997; Baulieu, et al., 2000; Baulieu, 1995; Kroboth, et al., 1999).  These data 
confirm that endogenous DHEA and DHEA-S concentrations are greater in the young groups when 
compared to the older men and women.   For DHEA, there were no differences between the sexes 
within each age group.  Although DHEA concentrations have been reported to be higher in women than 
in men (Sulcová, Hill, Hampl, & Stárka, 1997), not all studies are in agreement (Labrie, et al., 1997; 
Frye, Kroboth, Stone, et al.  1998).    For DHEA-S, the men had greater concentrations than the 
women, supporting previous data (Orentreich, Brind, Rizer, & Vogelman, 1984; Labrie, et al., 1997; 
Frye, et al., 1998).  Similarly,  the data presented here indicate that the older men’s DHEA-S 
concentrations were higher than in older women, though the order of magnitude differed. We report 
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older women’s DHEA-S concentrations to be 70% less than the older men,  in contrast to Labrie, et al, 
who report a 50% difference between older men and women.  In agreement with previous studies 
(Orentreich, Brind, Rizer, & Vogelman, 1984; Carlström, et al., 1988), the young women had DHEA-S 
concentrations approximately 35% less than the young men.  
Reports of the cortisol response to DHEA administration are not conclusive.  Cortisol 
concentrations have been reported to remain unchanged or to decrease after both single and 
repeated doses (Wolf, Köster, Kirschbaum, et al.  1997; Labrie, Bélanger, Cusan, et al.  1997).  
Previous data from our lab demonstrated significantly decreased cortisol concentrations after 
repeated administration of DHEA, and a trend toward a decrease after a single administration of 
DHEA(Kroboth, Amico, Stone, et al.  2003).  The data presented here indicate no differences in cortisol 
concentrations between treatments, or among the four age/sex groups.  This is in agreement with 
Labrie et al. who reported no change in cortisol concentrations after single and multiple percutaneous 
administration of DHEA to older men and women.  Although the cortisol response to stress may be 
altered in the elderly (Giordano, DiVito, Lanfranco, et al.  2001; Bergendahl, Iranmanesh, Mulligan, et 
al.  2000), studies agree that basal cortisol concentrations are similar between healthy young and 
older adults (Kudielka, Schmidt-Reinwald, Hellhammer, et al.  2000; Lupien, Lecours, Schwartz, et al.  
1995).   
 In order to test the hypothesis that DHEA concentration would impact recovery from GABA-
agonist challenge in young and older men and women, it was important to reproduce, in the elderly, 
the DHEA concentrations observed the young.  Collectively, these data indicate that two oral doses 
(separated by 6 h) of DHEA 50 mg duplicate DHEA and DHEA-S concentrations as seen in the young, 
maintain the concentrations over a 24 h period after, and do not alter cortisol concentrations.  
Additionally, alprazolam (2 mg, oral) administered to young and older men and women on two 






















In vitro animal studies have demonstrated that both dehydroepiandrosterone (DHEA) and its 
sulfated metabolite, DHEA-S are active at the gamma-amino butyric acid receptor complex (GABA-RC) 
(Demirgören, Majewska, Spivak, & London, 1991; Majewska, 1992; Sousa & Ticku, 1997), though 
information from human studies regarding neuroactive steroids is limited (McAuley, et al., 1995; 
Friess, et al., 1995).   The elderly have concentrations of DHEA and DHEA-S that are less than that in the 
young (Orentreich, et al., 1992; Orentreich, Brind, Rizer, & Vogelman, 1984; Pavlov, et al., 1986; 
Baulieu, et al., 2000).  It is known that the elderly are more sensitive to the CNS effects of GABA 
agonists such as benzodiazepines and may recover more slowly from such effects (Greenblatt, et al., 
1991; Bertz, et al., 1997; Thompson, Moran, & Nies, 1983).  Previous research indicates that the 
concentration of DHEA may be related to the rate of recovery from the GABA-agonist effects of such 
drugs (Kroboth, Salek, Stone, et al.  1999).  
Based on these data, we proposed the hypothesis that DHEA administered to older 
adults accelerates recovery from GABA-agonist challenge.  We used a classical pharmacological 
agonist-antagonist paradigm that called for administration of the GABA-agonist in one treatment 
and the GABA-agonist plus DHEA, the antagonist, in the other.  The benzodiazepine, alprazolam, 
was chosen as the probe GABA-agonist.  Alprazolam, an anxiolytic with known GABA agonist activity, 
has been successfully used in our lab to produce concentration-dependent decreases in saccade 
velocity and DSST scores (Kroboth, et al., 1998).  Because the concentrations of both DHEA and 
alprazolam can theoretically affect intensity of GABA response, concentrations of both were 
assessed.  The concentration-time data for alprazolam, DHEA, DHEA-S and cortisol is presented in 
Chapter 6.  Saccadic eye movement and psychomotor tasks were used as measures of intensity of 
response and recovery.  The current chapter provides analysis of the response versus time data for 
the saccadic eye movement tasks, Digit Symbol Substitution Test (DSST), and card sorting (CS) task 
in order to describe the recovery from alprazolam challenge in the presence and absence of an oral 




Study design and subjects.  The data were generated from a randomized, double-blind, 
placebo-controlled, four-way crossover study that required subjects to visit the General Clinical 
Research Center on four separate occasions.  Analyses in this chapter include only the response data 
collected during Phase II, i.e., the third and fourth visits.  Subjects received placebo plus alprazolam 
(PL/Alp) on one visit and DHEA plus alprazolam (DHEA/Alp) on the alternate visit.  During each of the 
visits, response to the drug treatments was evaluated using saccadic eye movement measurement 
(SEM), digit symbol substitution test (DSST) and card sorting (CS).  A series of assessments that were 
conducted at multiple times throughout the treatment day:  immediately prior to administration of 
placebo or DHEA (0 hour) and at 2, 3.5, 4.5, 5.5, 7, 8.5, 10, 11.5 and 12.5 hours thereafter.  Samples 
for the purpose of determining drug and steroid serum concentrations were also collected at these 
times.    The analysis of the concentration time data for alprazolam, DHEA, DHEA-S, and cortisol is 
reported in Chapter 6.  Complete details of the study design and subject inclusion/exclusion criteria 
are described in Chapter 2.   
During screening, SEM tests were administered to all subjects in order to ascertain each 
individual’s ability to perform the test and to assist them in becoming familiar with the tasks that 
would be required on subsequent testing days.  CS tasks and DSST were also administered to subjects 
during the screening process.  To minimize learning effects, subjects were required to practice the CS 
and DSST to a plateau, i.e., no improvement in score on two consecutive trials, during screening.  All 
subjects were admitted to the GCRC by 7:00 p.m. the evening prior to the study day at which time they 
again practiced SEMs, CS, and DSST.  A final practice for CS and DSST was done in the morning prior to 
the baseline evaluation on each study day. 
Table 7A summarizes demographic information for the 36 women (20 young and 16 older) 
and 33 men (16 young and 14 older) whose data are included in this analysis.  
 
Table 7A.  Mean age for the four groups of participantsa 

















(67 - 78) 
aData are presented as mean, standard deviation, and range 
 
Evaluation of saccadic eye movements.  The methods for SEM data collection, recording and 
scoring are detailed in Chapter 2.  Briefly, the SEM recordings were obtained using an infrared 
reflection technique (EyeTrac Model 210, Applied Science Laboratories).  The saccade targets were 
presented on a 17-inch computer screen as a white cross on a black background circumscribed by a 
white circle.  During the SEM testing session, 48 trials (saccade targets) were presented. In each trial, 
subjects began at center fixation and shifted their gaze to one of four target positions.  After a target 
was presented to the right or left, the target returned to center to begin the next trial.  The timing and 
location of peripheral targets for saccades was unpredictable.   
The SEM data were scored using a computer algorithm to identify saccades.  Each saccade 
was visually inspected and measurements on the basis of this algorithm were verified.  When multiple 
saccades were required to reach the target, only the initial, or primary saccade was scored.  Scoring of 
each saccade provided quantification of velocity (VEL), latency (LAT), duration (DUR), and accuracy 
(ACC).  For the purpose of this analysis velocity (degrees/sec) is the maximum or peak velocity 
achieved during the saccade, latency is the reaction time (msec) between target presentation and 
initiation of saccade, duration is the time (msec) required to complete the saccade, and accuracy is 
the percent of target step amplitude gained by the primary saccade. 
SEM testing was conducted at ten times throughout the testing day.  For each subject at each 
testing session eye movements were separated according to the target step amplitude (8 degrees and 
16 degrees) and combined according to direction (left and right) allowing a maximum number of 24 
scored trials per session per target amplitude.  The subject-specific mean for saccades to each target 
amplitude was used in all subsequent analysis.  In this chapter, only saccades to the 8-degree target 
are presented. 
Evaluation of DSST and CS.  DSST, originally developed as part of the Wechsler Adult 
Intelligence Scale (Vogel, Barker, Gibbons, et al.  1976), required subjects to draw symbols 
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corresponding to matching numbers.  The score is the number of symbols drawn in 90 seconds.  CS 
required subjects to sort a deck of 52 playing cards by suits as quickly as possible with a maximum of 
90 seconds allotted to complete the task; the score was the number of cards/sec.  Both CS and DSST 
are described in more detail in Chapter 2.  CS and DSST were collected at the same ten time points as 
the SEMs. 
Statistical Analysis.  The subjects were divided into four age/sex groups: young women, young 
men, older women and older men and these groups were used for all subsequent analysis.   
The numbers of subjects unable to perform the SEM tasks were calculated at each time point 
for the two treatments.  A Mantel-Haenszel chi-square was computed to determine whether the 
number of subjects unable to perform the SEM tasks differed between the two treatments within each 
age/sex group.  The statistical model used in the analysis included all time points from 0 h to 12.5 h.   
The percent change in effect from baseline was calculated for the 12.5 h time point for VEL, 
LAT, DUR, ACC, DSST and CS for each subject for both treatments.  Data are presented graphically in a 
scatter plot with a horizontal line indicating the 10% threshold.  Data less than or equal to 10% were 
considered to be equivalent to baseline evaluations.     
Differences between treatments at each time point were determined for the four SEM 
parameters.  Specifically, the value of the SEM parameter during the PL/Alp treatment was subtracted 
from that of the DHEA/Alp treatment.  Age/sex groups means were calculated and plotted on an x-y 
graph with a horizontal line drawn at zero (the center of the y-axis) indicating no change in value 
between the two treatments.  If the value of the SEM parameter increases as performance improves, 
as it would with velocity, data above the horizontal line specifies greater improvement in performance 
during the DHEA/Alp treatment and data below the line indicates impairment.   Plots for SEM data that 
demonstrate a decrease in value with improved performance, e.g., latency, are represented in the 
opposite direction. 
Effect versus time data were plotted for each subject for the four SEM parameters (VEL, LAT, 
DUR, and ACC), DSST, and CS.  In keeping with the hypothesis that DHEA would accelerate the 
recovery from a GABA-agonist challenge, only data collected during the 7 h to 12.5 h time period was 
used.  This time period begins 4.5 h after alprazolam administration and occurs subsequent to the 
maximum alprazolam concentrations in most subjects.  Also, the greatest number of subjects unable 
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to complete the SEM tasks due to the effects of alprazolam occurred prior to the 7 h time point, 
limiting the amount of data available for analysis. Including data only from the 7 h to 12.5 h time 
period provided data from the greatest number of subjects.   
Initial analysis of the recovery time period used a data set that excluded observations from 
those subjects who could not complete the SEM tasks during a visit.  Significant differences between 
groups were tested using a repeated measures mixed-model analysis of variance (ANOVA).  VEL, LAT, 
DUR, ACC, DSST, and CS were used as the dependent variable.  Treatment, time, and the treatment-
by-time interaction were considered as fixed effects.  Subjects were treated as random effects and the 
variance/covariance matrix was modeled using compound symmetry.  The interaction term was 
dropped from the model when it was not significant. 
A subsequent analysis of recovery data was conducted for the SEM parameters using censored 
data.  Specifically, data missing due to the effects of alprazolam were assigned a minimum (for VEL and 
ACC) or maximum (for LAT and DUR) value and a censored regression model was executed.  Tobit 
analysis (Long, 1997) was performed using the PROC LIFEREG procedure in SAS (SAS Institute, 2000) 
with the SEM parameter as the dependent variable and treatment, time and the treatment-by-time 
interaction as the independent variable.   The interaction term was not significant and was subsequently 
dropped from the model.  For VEL and ACC, data were left-censored at the assigned minimum values.  
For LAT and DUR, data were right-censored at the assigned maximum values.   
The mean maximum observed effects for VEL, LAT, DUR, ACC, DSST and CS for each subject 
for both treatments were identified.  Significant differences between treatments and among age/sex 
groups were tested using a one-way ANOVA with the maximum observed effect as the dependent 
variable and either treatment or age/sex as the main effect.  To determine pair-wise differences in 
maximum observed effect between groups, least squares means was used as the post hoc analysis. 
Results were considered statistically significant if the observed p-value was less than or equal 
to a critical value of 0.05.  All plotting was performed using GraphPad Prism version 3.02 for Windows, 
GraphPad Software; San Diego, California USA; www.graphpad.com (Motulsky, 1999).  The ANOVA and 
Tobit analyses were performed using SAS Software (Cary, NC, version 8.02) (SAS Institute, 2000).  
Results 
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Table 7B displays the number of subjects in each treatment who were unable to complete the 
SEM tasks due to the sedating effects of alprazolam.  When all time points were included in the 
statistical model, the number of young subjects able to complete the SEM task did not differ between 
the two treatments.  The number of older women and older men who were able to complete the SEM 
task during the PL/ALP treatment was greater than the number able to complete the tasks during the 
DHEA/ALP treatment, (p ≤ 0.0006 for both).     
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Table7B.  Subjects unable to complete SEM tasks during Pl/Alp and DHEA/Alp treatments 
 TIME (hours) 
Age/Sex 
Group  0 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
           
PL/Alp -- -- -- -- -- -- -- -- -- Young 
Women 
n = 20 DHEA/Alp -- -- 1 -- -- -- -- -- -- 
           
PL/Alp -- 1 2 1 -- -- -- -- -- Young 
Men 
n = 16 DHEA/Alp -- 1 1 1 -- -- -- -- -- 
           
PL/Alp -- 10 5 3 4 2 1 -- -- Older 
Women 
n = 16 DHEA/Alp -- 9 8 7 7 2 1 1 -- 
           
PL/Alp -- 4 2 2 1 -- -- -- -- Older 
Men 
n = 14 DHEA/Alp -- 6 4 3 3 -- -- -- -- 
(--) indicates all subjects were able to complete the SEM task. 
 
 
Figures 7.1 and 7.2 contain composite scatter plots of all SEM parameters and DSST and CS 
scores for the 12.5 h assessment represented as percent change from baseline values.  The symbols 
below the horizontal line identify those values that are less than or equal to baseline values indicating no 
impairment.  The majority of young subjects are no longer impaired at the 12.5 h assessment time 
whereas the majority of older subjects continue to have values greater than 10% of baseline. 
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Figure 7.1.  Scatter plots of percent change in performance from baseline at the 12.5 h time point for 
the young women (panels A and B), and young men (panels C and D). The SEM variables, VEL 
(velocity), LAT (latency), DUR (duration), and ACC (accuracy) are from saccades to the 8 degree target.  
DSST= digit symbol substitution test and CS = card sorting.  The horizontal line indicates the 10% 
threshold.  Values are considered to be equivalent to baseline if they are ≤ 10% of baseline values.  




















































































Figure 7.2.  Scatter plots of percent change in performance from baseline at the 12.5 h time point for 
the young women (panels A and B), and young men (panels C and D). The SEM variables, VEL 
(velocity), LAT (latency), DUR (duration), and ACC (accuracy) are from saccades to the 8 degree target.  
DSST= digit symbol substitution test and CS = card sorting.  The horizontal line indicates the 10% 
threshold.  Values are considered to be equivalent to baseline if they are ≤ 10% of baseline values.  
Hollow symbols indicate PL/ALP treatment, filled symbols indicate DHEA/ALP treatment. 
 
 
SEM parameters.  Individual and mean velocity (8 degree) versus time profiles for the two 
treatments PL/Alp and DHEA/Alp are found in Figures 7.3 (young subjects) and Figure 7.4 (older 
subjects).  Results from the ANOVA analysis indicate that during the recovery phase, velocity to the 8 
degree saccades in the young women was significantly higher in the DHEA/Alp treatment, (p = .0002), 
indicating that DHEA enhanced recovery.  In contrast, velocity for the older men was significantly lower 
in the DHEA/Alp treatment during recovery, (p = 0.02).  Data from the older women indicated a trend 
towards a decrease (p = 0.06) similar to the older men.  There was no difference in velocity between 


















































































































































Figure 7.3.  Line plots of velocity vs. time for the 8-degree saccades for the young subjects.  Individual 
velocity data from the PL/ALP treatment are in panels A, young women (?), and B, young men (?).  
Individual velocity data from the DHEA/ALP treatment are in panels C, young women (?), and D, young 
men (?).  The mean data with standard deviations are in panels E (young women) and F (young men). 
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Figure 7.4.  Line plots of velocity vs. time for the 8-degree saccades for the older subjects.  Individual 
velocity data from the PL/Alp treatment are in panels A, older women (?), and B, older men (?).  
Individual velocity data from the DHEA/Alp treatment are in panels C, older women (?), and D, older 
men (?).  The mean data with standard deviations are in panels E (older women) and F (older men). 
 
 
Figure 7.5  illustrates the change in velocity between the PL/Alp and DHEA/Alp treatments.  
The velocity during the PL/Alp treatment was subtracted from that of the DHEA/Alp treatment.  Since 
velocity decreases with impairment, points below the horizontal line indicate greater impairment 
during the DHEA/Alp  treatment while points above indicate an improvement.   The majority of data 
points for the young women are above the line representing improved performance in the DHEA/Alp 















































































































































treatment.  Data points for the young men are close to zero demonstrating little change in velocity 
between the two treatments.  Data from the older men and women are below the line signifying poorer 
performance in the DHEA/Alp treatment. 
 
 




























































Figure 7.5.  Line plots of change in velocity between the two treatments (DHEA/Alp – 
PL/Alp) for the young women (?), young men (?) older women (?), older men.  Points 
above the horizontal line represent improvement during the DHEA/Alp treatment.  




The individual and mean latency (8 degree) versus time plots for both treatments can be 
found in Appendix F.  Figure 7.6 is the change in latency between the PL/Alp and DHEA/Alp 
treatments for the four age/sex groups.  Latency increases with impairment, hence, points above the 
horizontal line indicate greater impairment during the DHEA/Alp  treatment while points below indicate 
an improvement.   Latency during the recovery phase did not differ between treatments in any of the 
age/sex groups, (p ≥ 0.24).  The Tobit analysis was in agreement with these results from the mixed 






























































Figure 7.6.  Line plots of change in latency between the two treatments (DHEA/Alp – 
PL/Alp)  for young women (?), young men (?), older women (?), older men. Points 
above the horizontal line indicate greater impairment during the DHEA/Alp treatment. 




For duration, the individual and mean response  versus time plots for both treatments can be 
found in Appendix F.  Figure 7.7 is the change in duration between the PL/Alp and DHEA/Alp 
treatments.  Duration increases with age so that  points above the horizontal line indicate greater 
impairment during the DHEA/Alp  treatment while points below indicate an improvement.   As 
expected, results of duration are consistent with those of velocity.  In the young women, the duration 
of saccades to the 8 degree targets during the recovery phase was significantly shorter (p = 0.007) for 
the PL/Alp treatment  when compared to the DHEA/Alp treatment.  An opposite effect was noted in 
older women (p = 0.03) with the DHEA/Alp treatment producing longer durations.  There were no 
significant differences in duration during this time period for either the young or older men (p ≥ 0.23).  
For the Tobit analysis, results were similar except for data from the older women, which no longer 
demonstrated a difference between the two treatments (p = 0.38). 
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Figure 7.7.  Line plots of change in duration between the two treatments (DHEA/Alp – 
PL/Alp)  for young women (?), young men (?) older women (?), older men. Points 
above the horizontal line indicate greater impairment during the DHEA/Alp treatment. 




Individual and mean effect versus time data for accuracy of saccades to the 8 degree targets 
are in Appendix F.  Figure 7.8  shows the change in accuracy between the PL/Alp and DHEA/Alp 
treatments.  Since accuracy decreases with impairment, points below the horizontal line indicate 
greater impairment during the DHEA/Alp  treatment while points above indicate an improvement.   
Results from the ANOVA model indicate that accuracy of saccades did not differ between treatments 
for any of the groups, though the older men indicated a trend (p = 0.06) towards a decrease in 
accuracy in the DHEA/Alp treatment compared to the PL/Alp treatment.  For all other groups, p 0 ≥ 
0.16.  The results from the Tobit analysis confirm a treatment difference for the older men, (p = 0.02) 




























































Figure 7.8.  Line plots of change in accuracy between the two treatments (DHEA/Alp – 
PL/Alp) for the young women (?), young men (?) older women (?), older men. Points 
above the horizontal line represent improvement during the DHEA/Alp treatment. 
Points below the horizontal line indicate greater impairment during the DHEA/Alp 
treatment. 
 
Table 7C contains the observed minimum velocity (due to the effects of alprazolam) for the 
four age/sex groups during both treatments.  The minimum velocity (i.e., the maximum drug effect) 
was not different between the PL/Alp and DHEA/Alp treatments for any of the groups.  Within the 
PL/Alp treatment, there were no differences among the groups.  Minimum velocity during the 
DHEA/PL treatment differed among the age/sex groups with the older women having the slowest 
velocity and the young men the highest velocity.  Minimum velocity did not differ between the older 
men and young women.  
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Table 7C.  Mean maximum effect for velocity (degrees/sec) from 0 h to 12.5 h to the 8 degree 









Between treatment  
p valueb 
Young women 
(n = 20) 
133.79 (36.60) 
(69.15 - 203.00) 
152.00 (41.54)AB 
(97.99 - 274.23) 0.16 
Young men 
(n = 16) 
154.59 (63.18) 
(66.99 - 272.25) 
164.03 (54.83)B 
(77.18 - 243.88) 0.65 
Elderly women 
(n = 16) 
120.16 (40.75) 
(64.83 - 207.10) 
118.04 (49.83)C 
(52.21 - 245.99) 0.89 
Elderly  men 
(n = 14) 
117.70 (27.60) 
(73.12 - 171.83) 
125.62 (40.46)AC 
(62.61 - 191.56) 0.56 
Among group 
comparisonb 0.09 0.02  
aData are presented as mean, standard deviation and range. Superscripted uppercase letters 
indicate differences among the age/sex groups when the model was significant.  Those with like 
letters were not different from each other. 
bp-values were obtained by one-way ANOVA models. 
 
Table 7D contains the data for maximum latency values for the PL/Alp and DHEA/Alp 
treatments.  The maximum latency (i.e., the maximum drug effect) was not different between the 
PL/Alp and DHEA/Alp treatments for any of the groups.  Within the PL/Alp treatment, the older men 
and women demonstrated significantly longer latencies when compared to the young.  For the 
DHEA/PL treatment, maximum latency in the older women differed significantly from both of the young 
groups, but not from the older men.  The older men did not differ from the either the young women or 




Table 7D.  Mean maximum effect for latency (msec) to the 8 degree saccades from 0 h to 12.5 h for 









Between treatment  
comparisonb 
Young women 
(n = 20) 
230.68 (39.20)A 
(177 – 322) 
220.20 (31.57)A 
(187 – 306) p = 0.36 
Young men 
(n = 16) 
207.50 (53.61)A 
(140 – 350) 
205.88 (44.90)A 
(144 – 289) p = 0.92 
Elderly women 
(n = 16) 
286.53 (98.26)B 
(221 – 646) 
298.38 (113.78)B 
(178 – 660) p = 0.75 
Elderly  men 
(n = 14) 
291.07 (122.81)B 
(168 – 553) 
259.85 (86.45)AB 
(158 – 490) p = 0.46 
Among group 
comparisonb p = 0.008 p = 0.003  
aData are presented as mean, standard deviation and range. Superscripted uppercase letters 
indicate differences among the age/sex groups when the model was significant.  Those with like 
letters were not different from each other. 
bp-values were obtained by one-way ANOVA models. 
 
The maximum duration data from both treatments for the four age/sex groups are in Table 7E.  The 
maximum duration of saccades to the 8 degree targets did not differ between treatments for any of 
the age/sex groups.  Within the PL/Alp treatment duration among the young and older men and 
women were similar.  This was also true for the duration data during the DHEA/ALP treatment. 
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Table 7E.  Mean maximum effect for duration (msec) of the 8 degree saccades from 0 h to 12.5 h for 









Between treatment  
comparisonb 
Young women 
(n = 20) 
132.05 (39.92) 
(77 – 223) 
112.65 (34.57) 
(56 – 191) p =0.11 
Young men 
(n = 16) 
119.13 (47.40) 
(58 – 191) 
117.06 (61.16) 
(58 - 233) p =0.91 
Elderly women 
(n = 16) 
141.81 (51.89) 
(69 – 263) 
140.56 (61.07) 
(79 - 284) p =0.95 
Elderly  men 
(n = 14) 
118.85 (43.33) 
(59 – 193) 
118.38 (65.60) 
(62 – 284) p =0.98 
Among group 
comparisonb p = 0.44 p = 0.47  
aData are presented as mean, standard deviation and range. Superscripted uppercase letters 
indicate differences among the age/sex groups when the model was significant.  Those with like 
letters were not different from each other. 
bp-values were obtained by one-way ANOVA models. 
 
 
Data describing the maximum impairment in accuracy from both treatments for the four 
age/sex groups are in Table 7F.  The minimum accuracy of saccades did not differ between 
treatments for any of the age/sex groups.  Within the PL/Alp treatment, the elderly men demonstrated 
significantly less accuracy when compared to the young men and women, but not the older women, 
who were not different from either of the young groups.   During the DHEA/Alp treatment, saccades in 
the young were more accurate than those in the elderly.  There were no sex-based differences 
demonstrated within the age groups. 
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Between treatment  
comparisonb 
Young women 
(n = 20) 
0.74 (0.11)A 
(0.52 - 0.93) 
0.77 (0.12)A 
(0.58 - 0.94) 0.32 
Young men 
(n = 16) 
0.74 (0.15)A 
(0.43 - 0.98) 
0.73 (0.09)A 
(0.47 - 0.86) 0.86 
Elderly women 
(n = 16) 
0.66 (0.14)AB 
(0.45 - 0.91) 
0.63 (0.15)B 
(0.33 - 0.85) 0.56 
Elderly  men 
(n = 14) 
0.62 (0.13)B 
(0.44 - 0.83) 
0.60 (0.11)B 
(0.38 - 0.75) 0.76 
 
Among group 
comparisonb 0.03 0.0003  
aData are presented as mean, standard deviation and range. Superscripted uppercase letters 
indicate differences among the age/sex groups when the model was significant.  Those with like 
letters were not different from each other. 
bp-values were obtained by one-way ANOVA models. 
 
 
DSST and CS.  Individual response versus time data for the DSST and CS tests are contained in 
Appendix F.   Mean data are presented in Figures 7.9 (DSST) and 7.10 (CS).  When compared to the 
PL/Alp treatment during the recovery phase, DSST scores were significantly higher for the DHEA/Alp 
treatment in young women (p = 0.05).  The difference in DSST scores between treatments was not 
significant in any of the other age/sex groups (p ≥ 0.13).  For CS, there were no differences between 
the PL/Alp and the DHEA/Alp treatments for any of the age/sex groups.      
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Figure 7.9.  Line plots of mean DSST score vs. time for the young women (panel A), young men (panel 
B), older women (panel C) and older men (panel D).  Empty symbols denote data from the PL/Alp 
treatment, filled  symbols denote data from the DHEA/Alp treatment.   













































































Figure 7.10.  Line plots of mean CS score vs. time for the young women (panel A), young men (panel 
B), older women (panel C) and older men (panel D).  Empty symbols denote data from the PL/Alp 
treatment, filled  symbols denote data from the DHEA/Alp treatment.  
 
 
 Table 7G includes the mean minimum (maximum drug effect) DSST scores for the four 
age/sex groups for both treatments.  Minimum DSST scores were different between the treatments in 
the young women, but not in any of the other groups.  Analysis of data from both treatments showed  
differences among the age/sex groups with the older women having the lowest score and the young 
women the highest.  Data from the older men were lower than that of the young men.   
 
 




















































































































































Between treatment  
comparisonb 
Young women 
(n = 20) 
34.90 (11.08)A 
(11 - 59) 
39.90 (15.84)A 
(7 - 70) p = 0.0003 
Young men 
(n = 16) 
29.75 (17.60)B 
(5 - 67) 
31.19 (17.72)B 
(3 - 61) p = 0.47 
Elderly women 
(n = 16) 
12.44 (8.34)C 
(1 - 31) 
13.38 (7.86)C 
(4 - 33) p = 0.30 
Elderly  men 
(n = 14) 
17.00 (8.96)D 
(3 - 36) 
16.50 (11.38)C 
(2 – 42) p = 0.68 
Among group 
comparisonb p < 0.0001 p < 0.0001  
aData are presented as mean, standard deviation and range. Superscripted uppercase letters 
indicate differences among the age/sex groups when the model was significant.  Those with like 
letters were not different from each other. 
bp-values were obtained by one-way ANOVA models. 
 
 
The data in Table 7H include the minimum number of cards per second for all groups during 
both treatments.  The young men sorted significantly fewer cards per second during the PL/Alp 
treatment than in the DHEA/Alp treatment.  There were no differences in CS between treatments for 
the other groups.  During both treatments, the age/sex groups differed from one another.  Overall, the 
older women had the lowest CS scores and the young men has the highest.  The older men had lower 
CS scores than the young women. 
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PL/ALP Minimum CS DHEA/ALP Minimum 
CS 
Between treatment  
comparisonb 
Young women 
(n = 20) 
0.76 (0.21)A 
(0.33 - 1.13) 
0.79 (0.21)A 
(0.41 - 1.18) p = 0.14 
Young men 
(n = 16) 
0.83 (0.29)B 
(0.30 - 1.33) 
0.91 (0.27)B 
(0.50 - 1.27) p = 0.007 
Elderly women 
(n = 16) 
0.40 (0.23)C 
(0.08 - 0.87) 
0.42 (0.15)C 
(0.20 - 0.76) p = 0.41 
Elderly  men 
(n = 14) 
0.52 (0.20)D 
(0.16 - 0.95) 
0.52 (0.23)D 
(0.26 - 0.93) p = 0.94 
Among group 
comparisonb p < 0.0001 p < 0.0001  
aData are presented as mean, standard deviation and range. Superscripted uppercase letters 
indicate differences among the age/sex groups when the model was significant.  Those with like 
letters were not different from each other. 





This study describes the pharmacological response to alprazolam in the presence and absence 
of orally administered DHEA as measured by SEMs, DSST and CS.  To our knowledge, the data presented 
here are unique in that both men and women in two age groups with disparate endogenous DHEA and 
DHEA-S concentrations were assessed, allowing for age- and sex-specific analysis.  These data 
demonstrate that DHEA administration enhanced alprazolam-induced impairment in older men and 
women.  Conversely, in the DHEA/ALP treatment, the young women experienced less impairment.  In the 
young men, there was no difference in impairment between the two treatments.  Thus, contrary to our 
hypothesis, DHEA administration did not accelerate recovery from GABA-agonist challenge in the older 
subjects.  In fact, the opposite effect was seen with the older men and women whose saccades showed 
slower velocities and longer durations during the recovery phase of the DHEA/Alp treatment.  A 
surprising outcome of this report is the number of older subjects who experienced impairment at a level 
where they were unable to complete the SEM tasks in both treatments.  Remarkably, and in direct 
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contrast to our hypothesis, the number of older subjects unable to perform the SEM tasks during the 
DHEA/Alp treatment was significantly greater than during the PL/Alp treatment.   
There are three possible explanations for the results observed in the older subjects.  First, the 
oral administration of DHEA may have disrupted the body’s normal secretory rhythm.  Second, DHEA 
administration resulted in very high concentrations of both DHEA and DHEA-S, allowing for increased 
concentrations of androstenedione, a precursor of the GABA-agonist, androsterone.  And finally, the 
expected action of DHEA at the superior colliculus may have been confounded by its simultaneous action 
at the substantia nigra; both structures are crucial to initiation of SEMs.  A discussion of these 
explanations ensues.   
In the older men and women, the single oral doses of DHEA in this study achieved the targeted 
range of 10 to 20 ng/ml over an approximately 12 hour period of time, which differs from the normal 
physiological rhythm of DHEA secretion.  Similar to cortisol, DHEA secretion demonstrates a circadian 
rhythm with the highest concentrations occurring in the morning hours.  Unlike cortisol, this rhythm is age 
dependent as noted by a decrease in pulse amplitude, though not pulse frequency, with increasing age.  
The sustained high concentrations achieved after oral doses of DHEA may have altered the normal 
pulsatile frequency, possibly interrupting a neuroendocrine-based homeostasis.  
An alternative explanation for the results found in the older subjects may be related to the 
concentrations of DHEA and/or DHEA-S in the brain.  The design used in this study is based on 
assumptions that peripheral concentrations of DHEA and DHEA-S parallel those in the brain.  This is 
based on evidence that changes in blood concentrations reflect those changes in CSF (Guazzo, et al., 
1996; Lacroix, et al., 1987), and theoretically, the brain.  Therefore, if the serum concentrations 
achieved in these older adults were indeed mirrored in the brain, it can be theorized that such 
supraphysiologic concentrations were high enough and sustained over a time period long enough to 
induce a desensitization of the DHEA excitatory response at the GABA-RC. 
Previous data from our lab indicated that older men with lower concentrations of DHEA were 
more sensitive to the psychomotor impairing effects of alprazolam (Kroboth, et al., 1999), leading us to 
hypothesize that increasing the concentrations of DHEA would create a GABA-antagonist effect.  The data 
presented here contrast with such a hypothesis and suggest the possibility of a u-shaped response 
curve.  This can be explained by the potential metabolism of DHEA to androsterone, a hormone with 
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GABA-agonist activity (Kroboth, et al., 1999; Majewska, 1992), by way of androstenedione.   Relative to 
endogenous concentrations, the amount of DHEA and DHEA-S available to the metabolic pathway for 
such a conversion was substantially greater in the older subjects than in the young.  DHEA 
concentrations were increased by approximately 50% in the young subjects, while the older subjects 
demonstrated an increase of 500%.  The changes in DHEA-S concentrations were even more prominent 
with the older women and men exhibiting increases of approximately 17- and 7-fold, respectively.  In 
contrast, the young women and men demonstrated an approximate 2.5-fold increase in DHEA-S 
concentrations. 
Finally, the greater SEM impairment noted in the older subjects during the DHEA/Alp treatment 
may be attributed to the complicated, yet well described, inhibitory synaptic connections involving GABA 
pathways during the mediation of SEMs.   Specifically, the superior colliculus is tonically inhibited via a 
GABA-ergic pathway from the substantia nigra, which is itself inhibited by GABA.  A GABA-agonist at the 
substantia nigra has the same effect as a GABA-antagonist at the superior colliculus; both result in 
irrepressible saccades and inability to fixate (Hikosaka and Wurtz, 1989).  The anticipated GABA-
antagonistic effect of DHEA was not specific to a particular brain region and, as such, may have been 
confounded by its simultaneous actions at multiple brain regions, particularly the substantia nigra and 
superior colliculus.   
These explanations however, do not address those results noted in the young women and men.  
Specifically, data from the young women demonstrated a decrease in alprazolam-induced impairment 
during the DHEA/ALP treatment, while data from the young men indicate no difference in impairment 
between the two treatments.  Potentially, the decrease in alprazolam-induced impairment noted in the 
younger women during the DHEA/Alp treatment, as compared to the PL/Alp treatment, may be attributed 
to the difference in alprazolam concentrations between the two treatments.  Although not statistically 
significant, the alprazolam concentrations (presented graphically in Chapter Six) in the young women 
during the DHEA/Alp treatment were lower than during the PL/Alp treatment throughout the study day.  
These lower concentrations would correspond with less impairment.  However, the alprazolam 
concentration-time profiles for the two treatments in the young men, who showed no change in 
impairment, were virtually superimposable.  It would seem, therefore, that DHEA administration does not 
alter alprazolam-induced impairment in the young subjects.  
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Since the current data are not sufficient to determine actual brain concentrations, it must also 
be speculated that concentrations of DHEA achieved in the brain may have been too low to elicit the 
GABA-antagonist effect.  Though unlikely, inadequate concentrations of DHEA in the brain would suggest 
that the effects of DHEA at the level of the GABA-RC might be bi-modal, following the same pattern of the 
neurosteroid, pregnenolone sulfate, which has recently been shown to be anxiolytic at low doses and 
anxiogenic at high doses (Majewska, 1992).    (Le Mellédo & Baker, 2002) 
In agreement with previous data (Kroboth, et al., 1998), the present data indicate that SEMs are 
a more sensitive measure of GABA-agonist effects than global measures such as DSST and CS.  After 
administration of alprazolam, a number of subjects were unable to perform the SEM tasks, yet were still 
capable of doing the DSST and CS tests.  This was true especially in the older men and women, 50% of 
who were unable to perform the SEM tasks at one hour after administration of alprazolam during both 
treatment days.  Yet, at the same time point, all of the older men and women were capable of completing 
the CS tests while 85% of them completed the DSST tests.  Therefore, whereas testing SEMs is labor-
intensive and requires more time and greater expense, it is worth the effort involved. 
Although reasons for the variability in response among the age/sex groups presented here are 
unclear and may be the result of interindividual differences it is interesting to speculate on whether a 
change in study design may have provided a different outcome.  Attaining a DHEA target concentration 
for a short duration rather than a sustained plateau may have resulted in a different conclusion.  
Additionally, future explorations may want to target relative change in DHEA concentrations, rather than 
















The primary goal of this dissertation research was to investigate the effect of DHEA 
administration on recovery from a GABA-agonist challenge in healthy young and older adults.  
Additionally, secondary goals included evaluations of SEM variability over repeated same-day testing, 
determining the inter-rater reliability of a software program modified to evaluate SEMs initiated while 
under the influence of a benzodiazepine, and assessing the influence of age and endogenous 
concentrations of DHEA and DHEA-S on SEMs. 
Results indicate that after administration of an oral dose of DHEA, response to alprazolam was 
diminished in young women, enhanced in older men and women, and remained unchanged in young 
men.  The study also determined that SEM measurements are stable within a testing day in both young 
and older men and women, use of the Pharmsac software by trained scorers produce reliable 
assessments of SEMs, that there are age-related differences in saccade latency and duration, and that 
DHEA and DHEA-S concentrations predict saccade duration.   
 Given these results and the design of this four-way crossover study, there are multiple 
opportunities for further investigation.    Future considerations could be given to expanding the 
evaluation of the effects of DHEA administration on the time-specific SEM parameters.  A comparison 
between the placebo alone and DHEA alone treatments would address the question of whether oral 
administration of DHEA affect SEMs and whether or not the relationship is altered by age, sex, and/or 
concentration.  Evaluation of the association between endogenous DHEA and SEM parameters 
reported here were assessed at only one time point.   The placebo treatment offers the opportunity to 
study the 24-hour DHEA diurnal profile in relation to SEMs with age and/or sex as covariates. 
 The data presented in this dissertation investigated the concentration-time data separately 
from the effect-time data.   A direct comparison of the relationship between alprazolam concentration 
and effect for the PL/Alp and DHEA/Alp treatments for individual subjects would assess true 
differences in sensitivity, if any, due to DHEA administration.  Drug impairment associated with 
alprazolam, corrected for DHEA concentration, may further explain the differences noted here.  Also, 
the older subjects in this study experienced greater alprazolam-induced impairment than the young, 
especially during the eye movement tasks.  As a result missing data was generated and proved 
difficult to handle in the analysis.  Since the data was missing as a direct result of drug impairment, it 
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would be advantageous to develop a model that could take these data into account.  Although not 
reported here, memory and sedation data were also collected during this study.  Future analysis would 
include these parameters.   
The sum total of this dissertation research was a statistical analysis of differences among 
age/sex groups in response to DHEA administration.  The data presented here is from an extremely 
rich data set that has yet to be mined to its full capacity.  In order to truly understand the influence of 
DHEA on GABA-agonist sensitivity, future directions should include studying the data from individuals 
and choosing optimal sampling times to include in the analysis.  Methods to consider would be 
individual concentration-effect modeling and possibly a population 
pharmacokinetic/pharmacodynamic approach.   Additionally, genetic variation that depends on factors 
besides age and sex, such as the environment and various inherent determinants, should not be 
overlooked.  Pharmacokinetic studies have already identified allelic variants that influence drug 
response and drug-metabolizing enzymes.  Studying genetic variants may be a reasonable approach to 
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TITLE  Dehydroepiandrosterone (DHEA) and GABA-Receptor Mediated Responses in Aged Adults 
 
 
INTRODUCTION AND BACKGROUND  
DHEA and DHEA-S.  DHEA and DHEA-S have been widely publicized in both the lay press1,2 and in the scientific 
literature3-5 for their anti-aging effects.  Electrophysiological studies have demonstrated that DHEA, a hormone 
secreted by the adrenal cortex in response to adrenocorticotrophin (ACTH),6 has GABA-antagonist effects.7 
DHEA is metabolized to dehydroepiandrosterone-sulfate (DHEA-S), which also has GABA-antagonist effects.7  
Despite the importance of the GABA receptor complex (GABA-RC) to the normal functioning of the central 
nervous system, information from human studies that describe the role of DHEA, DHEA-S, and other 
neurosteroid modulators of the GABA-RC is limited.8,9 
 
The GABA-RC and the Relevance of DHEA and DHEA-S.  GABA, the major inhibitory neurotransmitter in the 
central nervous system, binds to the GABA-RC, a  macromolecular, ligand-gated chloride ion channel complex 
that has distinct binding domains for GABA, benzodiazepines, barbiturates, and convulsants.10-12 Naturally 
occurring agonists of the GABA-RC include tetrahydroxydeoxycorticosterone (THDOC), tetrahydroprogesterone 
(THP), and androsterone.  These steroids enhance binding of GABA and benzodiazepines to their respective 
sites on the GABA-RC.12-16 These neurosteroids modulate synaptic events as well, leading Majewska to propose 
that neurosteroids may have a vital role in neuronal plasticity.12  Naturally occurring noncompetitive 
antagonists of the GABA-RC include DHEA and DHEA-S.7,17  Critical to their role as modulators of the GABA-RC, 
both DHEA-S and pregnenolone sulfate can be desulfated and metabolized to antagonist steroids. 
 
Influence of Age and Gender on DHEA and DHEA-S Concentrations.  Unlike ACTH and cortisol in humans, 
plasma concentrations of DHEA and DHEA-S are age and gender dependent, with concentrations rising during 
puberty, peaking in the early 20's, and declining from the third decade onward.18-20  Many have suggested that 
changes in adrenal secretion of DHEA with age may be explained by a decrease in 17,20-desmolase activity in 
the adrenal cortex.21,22 
 
Carlström et al. evaluated the influence of age and gender on DHEA and DHEA-S concentrations in a study of 
590 women and 60 men and reported that women have a higher DHEA:DHEA-S ratio than men at ages 20 to 
29, 30 to 39, 40 to 49 and 60 to 69.23  While both DHEA and DHEA-S correlated negatively with age, the 
DHEA:DHEA-S ratio was unrelated to age. Women tended to have higher DHEA concentrations and lower DHEA-
S concentrations.  At age 20 to 29, mean DHEA concentrations for women and men, respectively, were 21.7 
and 14.3 nM, while for ages 60 to 69, mean DHEA concentrations were 8.6 (women) and 7.4 (men) nM.  
DHEA-S concentrations for 20 to 29 year old women and men were 4191 and 6155 nM, respectively and for 
ages 60 to 69 were 1656 (women) to 2318 (men) nM.   
 
To our knowledge, changes of this magnitude in concentrations of other neurosteroids have not been 
documented with aging.  The decline in DHEA and DHEA-S concentrations with age are well documented; both 
have GABA-antagonist effects.  Unless a proportionate decrease in GABA-agonist neurosteroids occurs, the loss 
of GABA-antagonist tone with age could cause an imbalance in the positive and negative modulation of the 
GABA-RC and reduce plasticity. 
 
Human aging and the GABA-RC:  Sensitivity to benzodiazepines. Benzodiazepines are the most commonly 
prescribed class of GABA-agonists, with women taking benzodiazepines more frequently than men.24  In 1993, 
alprazolam (Xanax) was the ninth most commonly prescribed drug in the United States.25 There is clear 
evidence that the elderly respond differently than young adults to similar doses of benzodiazepines.26  
Diazepam,27-29 triazolam,30 and alprazolam31 have been shown to produce more sedation and to impair 
memory and psychomotor performance to a greater extent in the elderly, who also have higher plasma 
concentrations than young adults.  In addition, the duration of psychomotor impairment is longer in elderly 
than in the young.31 
 
SPECIFIC AIMS 
In this study, to evaluate the importance of DHEA as a modulator of GABAA-receptor complex (GABA-RC) 
mediated responses, we have three specific aims: 
  
1. To determine whether DHEA administered to elderly adults accelerates recovery from GABA-agonist 
challenge.  
2. To test the effect of acute DHEA administration on neurobehavioral function in young and elderly 
adults. 





Study Design. This is a randomized, double-blind, placebo-controlled, 4-way crossover study that will be 
conducted in parallel in groups of young and elderly men and women.  The study is divided into two phases as 
indicated below:  a placebo (PL) and DHEA crossover in Phase I and an alprazolam (AL) and DHEA+AL 
crossover in Phase II.  The unblinded investigational drug pharmacist of the University of Pittsburgh Medical 
Center will randomize subject numbers to groups that will be balanced by age, gender, and minority status. 
Subjects who do not complete all four treatments will be replaced with new subjects who will be assigned the 
same numbers plus 100.  Treatment days within a phase are separated by one week; phases will be separated 
by one or two weeks to allow for DHEA analysis between phases.  The times and dose amounts of DHEA in 
Phase I will be adjusted as data is accrued to maximize the probability of obtaining concentrations between 10 
and 20 ng/ml for each study group.  Based on the DHEA concentration from Phase I, the dose of DHEA for 
Phase II will be individualized to achieve DHEA concentrations between 10 and 20 ng/ml.  Details of drug 
administration, blood sampling and psychomotor testing are found in Appendix B. 
 
               Phase I            Phase II 
      
  Week 1 Week 2 Week  4 Week 5 
Group A  PL DHEA AL DHEA+AL 
Group B  PL DHEA DHEA+AL AL 
Group C  DHEA PL DHEA+AL AL 
Group D  DHEA PL AL DHEA+AL 
 
The design preserves blinding because the treatment arms paired in each phase are relatively equivalent in 
the expected level of sedation.  The treatment pairing in the phases is legitimate since the major contrasts are 
between the two treatments within each phase, which are balanced for order (AL and DHEA+AL; placebo and 
DHEA). 
 
The times and dose amounts of drug and/or placebo administration are approximate and dependent on 
concentrations achieved in Phase I.  Times and doses are indicated below; treatments include a placebo for 
DHEA.  Both alprazolam and DHEA will be administered by mouth.  We have an approved IND (#48,123) for 
DHEA administration. 
 
Phase I Treatment 8:30 a.m. 11:00 a.m. 3:00 p.m. 
Placebo (PL) Placebo for DHEA ---- Placebo for DHEA 
DHEA DHEA ≤150 mg ---- DHEA ≤150 mg 
    
Phase II Treatment    
Alprazolam (AL) Placebo for DHEA Alprazolam 2 mg Placebo for DHEA 
DHEA+AL DHEA 150 mg* Alprazolam 2 mg DHEA 50 mg* 
* DHEA dose in Phase II will be determined based on the concentrations observed in Phase I.  The 
maximum 
 DHEA dose will not exceed 400 mg in either Phase.  
 
  
Population Description.  A sufficient number of subjects will be recruited for participation in this study so as to 
result in a total of 64 subjects who complete this four-way crossover study. 
 
Age Group Age (years) Men           Women  Age Group Total 
Young 20 to 30  16  16   32  
Elderly  65 to 79  16  16   32  
       TOTAL  64  
Twelve subjects in each group will be Caucasian and four will be minority subjects.  The number of minority 
subjects  (25% per group) is greater than the representation in the local community and provides balance for order 
of treatment in groups A-D.   
 
In the screening process, it is anticipated that some subjects will be identified who do not meet all of the 
inclusion criteria (e.g., abnormal SCID).  For pilot study purposes, these volunteers may be studied in this 
protocol, but will not be included in the analysis of 64 subjects.  Also for pilot purposes, subjects of ages 20 to 
79 who do not meet inclusion criteria for healthy volunteers may be specifically recruited to participate in this 
study (e.g., stable patients with adrenal insufficiency, women taking hormone replacement therapy, patients 
with diabetes, obsessive compulsive disorder, etc.).  For pilot study subjects, age- and gender-matched healthy 
volunteers will be recruited and evaluated.  Up to 24 additional subjects will be evaluated in the pilot studies.  
The pilot study patients and their matched control volunteers will not be included in the analysis with the 64 
healthy volunteers.  
 
Inclusion/Exclusion Criteria   A complete list of laboratory screenings and exclusion criteria is found in 
Appendix A.  The subjects will sign an informed consent prior to laboratory screening, medical history, and 
physical examination.  This will be performed free of charge to patients or third party payers.  Vital signs and 
laboratory parameters listed in Appendix A will be evaluated.  Subjects will be considered healthy if they have 
screening labs and vital signs within the normal reference range as defined by the clinical laboratory or judged 
clinically insignificant by the study investigators.  The urine drug screen and blood alcohol concentration 
collected during screening must be negative.  Age, height, weight, and alcohol consumption will be recorded in 
a demographic record.   
 
Young or elderly women who have taken estrogen or progesterone as contraceptive or hormone replacement 
therapy during the three months prior to participation in the study will not be eligible to participate in the study 
of 64 healthy volunteers. Young women must not be pregnant.  Subjects should not have received any known 
enzyme inducing (e.g., barbiturates, rifampin) or enzyme inhibiting agents (e.g., cimetidine, erythromycin) for 
30 days prior to the study day.  Men and women selected for this study will not have taken any chronic and/or 
over-the-counter medications for seven days prior to the first study day. 
 
Study Conditions Informed consent procedures and screening for laboratory and psychiatric eligibility for the 
study occurs within 3 months prior to the first treatment day.  Screening for medical eligibility occurs at the 
General Clinical Research Center (GCRC) of the University Pittsburgh Medical Center within 1 month prior to 
the first treatment day of Phase I.  On the afternoon before each of the four treatment days, subjects will report 
to the GCRC. Young women will provide urine for pregnancy tests.  Subjects will fast from 10 pm (water is 
allowed) until 7:30 am on the treatment day.  At this time, subjects will receive a light breakfast and an 
intravenous catheter will be placed in a forearm vein for the purpose of obtaining multiple blood samples.  In 
order to provide for subject safety in Phase II, subjects will remain in the study chair from time 2.5 to 8.5 h; 
after each test session from 8.5 to 12 h, subjects may ambulate with supervision for 15 min.  The schedule of 
events can be found in Appendix B.  
 
Pharmacokinetic Assessment  For the purpose of determining the concentrations of alprazolam, and the 
steroids on each of the four treatment days, blood samples of either 4.5 ml (Phase I) or 7 ml (Phase II) each 
will be obtained at times indicated in Appendix B.  Urine will be obtained in 12 hour intervals from 0 to 12 h 
and 12 to 23 h in each phase of the study.  In addition, 3 ml samples will be obtained a total of 10 times 
during the entire study for testing lymphocyte function (Dr. Lotze's laboratory). The total volume of blood drawn 
for each subject including laboratory and alcohol screening will be approximately 395 ml.  Each blood sample 
will be collected from an indwelling catheter in a forearm vein. 
 
  
Pharmacodynamic Assessment Saccadic eye movements (SEMs), the very brief and rapid movements the eye 
makes when shifting from one point to another in the visual field, will be used as an assessment of response.  
Previous studies have demonstrated that changes in the velocity, latency, and accuracy of saccades are useful 
measures of the time course of effect of benzodiazepines.32-34  Other response assessments include digit 
symbol substitution (DSST), card sorting (CS), Randt Memory (RMT), Hopkins Verbal Learning (HVLT) and Nurse 
(observer) Rated Sedation (NRSS).  At the time of the screening session to determine eligibility for the study 
(within three months prior to the first treatment), subjects will practice digit symbol substitution and card 
sorting to a plateau, i.e., no improvement in score on two consecutive trials, in order to minimize learning 
during this study.  At this time subjects will also be familiarized with the saccade tasks.  One additional practice 
session of digit symbol substitution and card sorting will be done prior to the baseline evaluation on each of 
the four treatment days. 
 
Analytical Technique  Blood samples will be collected in appropriately labeled vacutainers and centrifuged.  
Plasma or serum will be decanted, transferred to appropriately labeled polypropylene tubes and stored at -
80oC.  Alprazolam concentrations will be analyzed using an established gas chromatography method at the 
Pharmacodynamic Research Center.  Plasma for DHEA, DHEA-S, and cortisol concentrations and serum for 
progesterone concentrations will be assayed using 125I-radioimmunoassay techniques (Diagnostic Systems Lab 
Inc.). 
 
Data Analysis Most of the responses and corresponding drug concentrations are directly measured at each 
observation time. Summary measures will be used for Specific Aim #1.  For Specific Aim #1 the primary 
response is the recovery from GABA-agonist challenge; this will be quantified by the slope of the SEM velocity vs. 
alprazolam concentration in the recovery phase, defined as all observations after the time of peak effect.  Each 
subject and treatment-specific slope will be estimated using linear regression, if appropriate; otherwise non-linear 
curve fitting will be done, and the appropriate parameters compared.  Other summary measures include DHEA 
area under the plasma concentration-time curve (DHEA-AUC) calculated by the linear trapezoidal rule.  Appropriate 
graphical and numerical descriptives will be used to summarize the data for each subject (by treatment) and 
for each treatment group. Race-, gender- and age-specific plots include: 
• concentration vs. time for DHEA, DHEA-S, and cortisol (four treatments), and alprazolam, (two treatments); 
• response vs. time (four treatments) for digit symbol substitution, card sorting, memory, sedation and SEM 
variables:  peak velocity, gain, duration:amplitude ratio and number of fractionated saccades. 
• response vs. DHEA concentration (four treatments) and response vs. alprazolam concentration (two 
treatments) for digit symbol substitution, card sorting, memory, sedation and SEM variables: gain, peak 
velocity, duration:amplitude ratio and number of fractionated saccades. 
 
Statistical Comparison of Treatments  For each of the specific aims, the analysis assesses the influence of age, 
gender, and race on the corresponding outcome. A subgroup analysis of Caucasian subjects is planned as a 
check that the statistical adjustments for minority are adequate. For those response measures that follow a 
normal distribution, the analysis will be within the framework of a mixed-effects linear model.35 When the 
normality assumption is suspect, a comparable analysis will be done within the Generalized Estimating 
Equation framework.36  All plots and statistical comparisons will performed on a Digital Equipment Corporation 
VAX cluster using SAS37 software.  A p ≤ 0.05 will be considered the critical level of significance.   
 
SIGNIFICANCE 
DHEA and DHEA-S have considerable physiologic significance and clinical relevance as indicated in recent 
workshops sponsored by NIMH, FDA and NIA.  Despite the abundance of information addressing DHEA effects 
on immunity and glucose metabolism, there is a lack of information about neurobehavioral effects.  We will 
assess the role of DHEA as a modulator of GABA-RC responses.  Although age and gender appear not to affect 
the GABA-RC directly, age and gender do influence response to GABA-RC agonists.  For example, the elderly, 
who have greater impairment and slower rate of recovery than the young after benzodiazepine challenge are 
more prone to falls, a serious consequence of lingering benzodiazepine effects.  This study will test the 
hypothesis whether the lower DHEA concentrations in the elderly explain the slower offset of psychomotor and 




The risks involved include the discomfort and inconvenience of having an I.V. catheter placed and blood 
samples collected with potential for pain, bruising, bleeding and infection.  Potential side effects of alprazolam 
include drowsiness, headache, dizziness, dry mouth, and hiccoughs.  Subjects will most likely experience 
drowsiness or sedation, expected effects, after alprazolam administration. Subjects will not be discharged from 
the GCRC until approximately 21 h after alprazolam administration and will be instructed not to drink alcohol or 
take sedatives the day they are discharged.  Long term adverse reactions with DHEA are limited to rare reports. 
One time administration of DHEA has not produced any side effects. After oral administration of DHEA 1600 
mg/day for 28 days, Welle et. al.38 reported that one subject experienced increased lactate dehydrogenase 
and aspartate aminotransferase levels that returned to normal after discontinuing the DHEA.  For the purpose 
of evaluating liver enzymes, a blood sample will be obtained at the end of each of the two Phases.  A phone 
call will be made to each subject during the week after each treatment day for follow-up assessment.  Other 
than payment for participation and their contribution to our knowledge of drug action and measurement of 
drug effect, there is no benefit to the subjects.  
 
COSTS AND PAYMENTS 
The procedures and medications involved in the study will not be charged to the subjects.  The total payment 
for participating in the study will be $600.00.  There will be partial payment depending on the extent of the 
subject's involvement if the investigators require withdrawal from the study prior to completion or if the subject 
decides to withdraw from the study.   
 
QUALIFICATION OF INVESTIGATORS 
Patricia D. Kroboth, Ph.D. is Professor and Chairman of Pharmaceutical Sciences.  Since 1980, when she 
joined the faculty at the University of Pittsburgh, she has conducted numerous clinical research studies; most 
have dealt with the question of how disease state, aging and hormones/other drugs modulate sensitivity to 
benzodiazepines. 
 
Reginald Frye, Pharm.D., Ph.D. is Assistant Professor of Pharmacy and Therapeutics and has conducted many 
research studies.  He has expertise in in vitro and in vivo assessment of drug metabolism as well as 
pharmacokinetics and has recently developed probes and analytical methodology for cytochrome P4503A4. 
 
M. Margaret Folan, B.S.N., R.N. has been a research nurse in the Pharmacodynamic Research Center since 
1988 and is currently a graduate student in the Clinical Scientist Ph.D. program in the School of Pharmacy.  
She has conducted pharmacodynamic studies, analyzed the resulting data and published the results. 
 
John A. Sweeney, Ph.D. is Associate Professor of Psychiatry and Neurology and Director for the 
Neurobehavioral Studies Program at the Laboratories of Neuropsychopharmacology.  He has been conducting 
studies of eye movements and their relationship to mental health since 1975. 
 
Bruce G. Pollock, M.D., Ph.D. is Associate Professor of Psychiatry and Pharmacology, Director of the Geriatric 
Psychopharmacology Program and Principal Investigator of the Geriatric Psychopharmacology Core of the 
Mental Health Clinical Research Center for Late Life Mood Disorders(MH52247).  He is well known for his 
contributions to psychopharmacology in general and drug metabolism in particular.   
 
Gretchen Haas, Ph.D. is Associate Professor and Director of the Family and Psychosocial Studies Program in 
the Department of Psychiatry.  Having been trained by the developers of the SCID diagnostic procedures for 
DSM-III-R/DSM-IV, she is highly familiar with the nuances of utilizing structured clinical diagnostic procedures 
in the assessment of both community control subjects and acutely ill psychiatric inpatients. 
 
Frank J. Kroboth III, M.D. is Professor of Medicine at the University of Pittsburgh and Assistant Chief of 
Medicine, Presbyterian University Hospital.  He is Director of the Internal Medicine House Staff Training 
Program, and Medical Director of the Pharmacodynamic Research Center.  He has been involved in numerous 
clinical studies during his 16 years on the faculty.   
 
  
Roslyn Stone, Ph.D. is Assistant Professor of Biostatistics at the Graduate School of Public Health.  She has 
extensive experience in development and implementation of statistical methods in research studies.  
 
Michael T. Lotze, M.D. is Professor of Surgery, Molecular Genetics, and Biochemistry.  He is also Co-Director of 
the Biological Therapeutics at University of Pittsburgh Cancer Institute.   
 
Janet A. Amico, M.D. is Professor of Medicine in the Division of Endocrinology.  She is active in both clinical and 




LISTING OF LABORATORY TESTS FOR SCREENING SUBJECTS 
 
Biochemical Profile: BUN, creatinine, sodium, potassium, chloride, glucose, phosphorus, calcium, uric 
acid, cholesterol, triglycerides, total protein, albumin, total and direct bilirubin, 
LDH, AST, ALT and alkaline phosphatase, cortisol 
 
Complete Blood Count: hemoglobin, hematocrit, RBC count, RBC index (MCV, MCH, MCHC), platelets and 
WBC 
 
Urinalysis:   Routine and Microscopic 
 




Excluded will be those subjects who have:  
1. Drug or alcohol dependence, or who abuse or consume, on average, more than 2 alcoholic beverages per 
day. 
2. Seizure disorder reported in the medical history (i.e., seizure disorders that required chronic treatment into 
adolescence and adulthood). 
3. A score of less than 25 on the MiniMental State Exam,39 or history of any major psychiatric illness, or 
abnormal psychiatric examination as assessed by the  Structured Clinical Interview for DSM-IV Diagnosis 
(SCID).40 
4. Renal, hepatic, collagen, vascular, or pulmonary disease; GI disturbances or history of malabsorption. 
5. Endocrine diseases such as diabetes mellitus, Cushing's disease, Addison's disease, or thyroid conditions. 
6. Cardiovascular disease that is symptomatic or clotting abnormalities. 
7. Known hypersensitivity/allergy to alprazolam, other benzodiazepines or steroids. 
8. History of benzodiazepine ingestion in the previous 6 months or chronic benzodiazepine use (greater than 
one week) within the last year, steroid ingestion in the previous 3 months or chronic steroid use (greater 
than one week) within the last year, participation as a blood donor in the past 2 months, or participation in 
a drug study in the past 6 months. 
9. Saccade dysmetria, strabismus or nystagmus (assessed during SEM screening). 
 
Elderly women who have taken hormone replacement therapy (estrogen or progesterone) during the three 
months prior to participation in the study will not be eligible.  Young women must not be pregnant and must not 
have taken oral contraceptives for at least three months.  Subjects should not have received any known 
enzyme inducing agents (barbiturates, rifampin, etc.) or any known enzyme inhibiting agents (cimetidine, 
erythromycin, etc.) for a period of 30 days prior to the study day. 
  
APPENDIX B 
Schematic of Study Participation for Each Subject 
 
Within 3 months prior to the first week of study: Informed consent; laboratory, saccadic eye movement, 
and psychiatric screening for eligibility and psychomotor 
practice to plateau performance. 
Within 1 month prior to the first week of study: Medical screening. 
 
 
Schematic of study events for each of  the four treatment days. 
 
 












































X   x   x x x  x x x x x    
Dose (drug or 
placebo)¶ 
 x   x     x         
DHEA conc & 
Sedation 
X  x x  x x x x  x x x x x x x x 
Alprazolam conc 
Phase II 
X     x x x x  x x x x x x x x 
DHEA-S X  x x  x  x    x x x x   x 
Cortisol X   x        x   x   x 
Other 
assessments 
*†§   §    † †  † ‡      § 
 
¶Dose administration schedule in Phase I: DHEA ≤150 mg at 0h (8:30am), DHEA ≤150 mg at 6.5h (3pm)—  
times are approximate. 
  Dose administration schedule in Phase II: DHEA at 0 h and at 6.5 h, an individualized dose not to exceed a  
      total of 400 mg.; Alprazolam 2 mg at 2.5 h. 
 *Blood sample for progesterone 
 § Blood sample for immunologic testing  
 †Randt Memory Test Administration 
 ‡Hopkins Verbal Learning Test 
 
Subjects will be discharged after the 23 h sample in Phases I and II.  In the week after discharge, subjects will 
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SOURCE OF SUPPORT: NIMH, NIH General Clinical Research Center, and The  
Pharmacodynamic Research Center 
 
DESCRIPTION:  The purpose of this study is to determine if the hormone dehydroepiandrosterone (DHEA) 
hastens recovery from the sedative effects (sleepiness, slowing of response time) that occur after taking the 
drug alprazolam (Xanax®).  At least sixty-four healthy young and elderly men and women will complete all four 
treatments in this study.  The treatment that I receive on each of the four days will be unknown to me.  Each of 
the treatment days will require two overnight stays at the General Clinical Research Center at Montefiore 
University Hospital.  I am being asked to participate in all four treatment days.  I am being asked to participate 
in this study because I am between the ages of 20 and 79 years old and (investigator circle one) am healthy or 
have a stable medical or psychiatric condition. 
 
This study is divided into Phase I and Phase II.   
Phase I: This phase consists of two treatments given on two separate days with one week between each day.  
On one of the days I will receive two doses of a placebo and on the other day I will receive two doses of DHEA 
for a total dose of no greater than 300 mg.  Neither I nor the investigators will know which treatment I receive 
  
on each day until the study is completed.  A sealed record of the treatment that I receive will be kept at the 
study site in the event that it is necessary to determine whether I have received the drug or a placebo. 
I will begin Phase II one or two weeks after the second treatment day of Phase I. 
Phase II:  This phase consists of two treatments given on two separate days with one week between each day.  
On one of the days I will receive two doses of a placebo and a single dose of alprazolam (Xanax®, 2 mg).  On 
the other day I will receive DHEA and alprazolam. The total DHEA dose will be no greater than 400 mg. Neither 
I, nor the investigators, will know which treatment I receive on each day until the study is completed. 
 
DHEA is a naturally occurring steroid hormone that is being investigated for treatment of different conditions 
such as obesity, memory loss, and immune deficiencies.  I understand that the DHEA tablet that I will receive is 
not yet approved by the FDA for general use.  I will receive no more than 400 mg of DHEA in one day.  DHEA 
has been given safely to patients in doses up to 2250 mg each day. Alprazolam tablets have been approved by 
the FDA and are available by prescription to treat anxiety disorders. I will receive 2 mg of alprazolam in one 
day.  The maximum recommended daily dose used to treat anxiety or nervousness is 4 mg. Both DHEA and 
alprazolam will be given to me by mouth. 
 
This study will require me to complete several tests and tasks throughout each treatment day. These tests 
include a card sorting task and a pen and paper test where I must draw symbols to match numbers and 
memory tests where I will be asked to remember some pictures and a series of words. Also, in order to 
measure my eye movements, I must wear a special pair of glasses with infrared sensors on them and follow a 
moving dot on a computer screen.  In addition, small electrodes will be placed on the middle of my forehead, 
and above and below one of my eyes. 
 
If I agree to participate, I understand that I will be expected to do the following: 
 
• I will be required to have a physical exam and give information about my past medical, psychiatric and 
medication history.  Psychologists from Western Psychiatric Institute and Clinic will conduct my 
psychiatric screening interview and a physician will perform my medical history, physical examination 
and laboratory screening at no cost to me or my third party payers.   
• If I am determined to be suffering from psychological distress, a referral for treatment will be offered 
to me. 
• My  eyes will also be tested to determine if I have a condition, which might prevent me from properly 
responding to the eye movement test. These examinations and screenings will require several hours of 
my time and are not designed for the purpose of my personal health care, but only for qualification to 
enter the study.  I will also complete some questionnaires and practice the tests described in the 
previous paragraph. 
• I will be tested for drugs of abuse and alcohol at the time of screening and may be tested at other 
times. 
• I will not take any over-the-counter and/or prescription medications for one week prior to the start of 
each treatment day or during the treatment day without knowledge of the study investigators. 
• I will not have any beverages that contain alcohol or caffeine for 48 hours before each treatment day.  
Examples of caffeine containing beverages include coffee, tea, colas (e.g. Pepsi and Coke), and 
Mountain Dew. 
• I will be admitted to the General Clinical Research Center at Montefiore Hospital in the afternoon 
before the treatment day, practice the manual tasks and other tests and be in bed by 11:00 p.m. 
• I will not eat or drink anything other than water after 10:00 p.m. on the night prior to each treatment 
day. 
• Before each treatment day, I will go to bed so that I obtain 8 hours or a normal night of sleep. 
 
For each treatment day: 
 
• I will arise by 7:00 a.m. and eat the light breakfast provided for me on the morning of the treatment 
day.  An intravenous catheter will be placed in my forearm to be used for blood sampling. 
• For Phase I:  At approximately 8:30 a.m. on the treatment day, I will receive either placebo or DHEA  (in 
a dose no greater than 150 mg). I will be given a second dose of either placebo or DHEA (in a dose no 
greater than 150 mg) at approximately 3:00 p.m.  The total dose of DHEA that I will receive during 
  
Phase I is 300 mg or less. I will receive all treatments by mouth.  The treatment that I receive on each 
day will be unknown to me. During each treatment day of Phase I, 85.5ml ( 3 ounces, about 1/3 cup) 
of blood will be taken from the catheter in my arm.  All of my urine will be collected from the time of 
the morning dose until the next morning.     
• For Phase II:  At approximately 8:30 a.m. on the treatment day, I will receive either placebo or DHEA.  
Approximately  2½ hours later, I will receive alprazolam (2 mg).  At approximately 3:00 p.m. I will 
receive a second dose of either placebo or DHEA.  The dose of DHEA that I receive during Phase II will 
not exceed 400 mg. I will receive all treatments by mouth.  The treatment that I receive on each day 
will be unknown to me. During each treatment day of Phase II, 123 ml (4 ounces, about 1/2 cup) of 
blood will be taken from the catheter in my arm. All of my urine will be collected from the time of the 
morning dose until the next morning.     
• After breakfast, I will be required to fast throughout the morning with only water permitted.  I will be 
given a glass of juice or a liquid meal several times throughout the day at approximately 10:30 a.m., 
12:30 p.m., and 2:30 p.m. Dinner will be served at approximately 5:30 p.m.  Also, a snack will be 
served before I go to bed. 
• On several occasions during the each of the four treatment days I will be requested to complete some 
manual tasks (for example, a pen and paper test), memory tests (for example, remembering words 
and pictures), and eye movement tests. 
• I will remain in the study chair until 6 hours after the alprazolam dose (until about 5:00 p.m.); after 
this time, I will be able to walk around with supervision for 15 minutes. 
• Breakfast will be provided on the morning after the treatment day and I will be discharged after the 
last blood sample (approximately 8:00 a.m.). 
• The total amount of blood withdrawn for all four treatment days, including the screening labs will be 
approximately 395 ml (about 13 ounces or 1 and 1/2 cups).   The amount of blood withdrawn when 
someone donates a unit of blood is approximately 480 ml (16 ounces or 2 cups). 
• After each of the treatment days, prior to being discharged, I understand I must answer the question, 
“Since you received the study medication, have you noticed anything unusual?”  During the week after 
each of the treatment days, I will receive a phone call from one of the study investigators and the 
same question will be asked. 
 
RISK AND BENEFITS:  I understand that I will not experience any personal benefits to my health as a result of 
my participation in these studies.  The risks of participating in these studies include the discomfort and 
inconvenience of having an intravenous catheter placed in my arm and light-headedness from having blood 
samples collected.  I understand that arm pain, swelling, bruising and/or infection may result from having the 
catheter placed and blood withdrawn.   
 
I understand that I may feel drowsy or sleepy for a few hours after alprazolam is administered.  Other side 
effects for alprazolam include:  hiccups, dizziness, confusion, headache, inability to remember events that 
occur within 8 hours after drug administration, slowing of response time and interference when operating 
automobiles or other machinery, dry mouth, light-headedness, nausea, double vision, loss of coordination, and 
slurred speech.  Studies have shown that oral administration of DHEA 50 to 2,250 mg each day over a long 
period (1 to 4 months) is well tolerated. One subject in a past study received DHEA 1600 mg each day for 28 
days and experienced an elevation in liver enzymes.  Liver enzymes returned to normal levels after the subject 
stopped taking DHEA.  I will have a blood sample drawn prior to discharge after each of the two phases  for the 
purpose of evaluating my liver enzymes. 
 
In Phase II of the study, I will abstain from drinking alcohol or taking any sedatives the day I am discharged. 
 
NEW INFORMATION:  New information, whether good or bad, which comes to the attention of the investigators 
during the course of the research and which relate to my willingness to participate will be provided to me or my 
legal representative. 
 
COSTS AND PAYMENTS:  If I agree to participate, all procedures necessary for the completion of this study will 
be performed at no cost to me.  Upon successful completion of all that is required for the four treatment 
periods I will be paid a total of $600.00.  There will be a partial payment of $125.00 if I decide to withdraw 
from the study after the first treatment period, a total of $250.00 if I decide to withdraw from the study after 
  
the second treatment period, and a total of $400.00 if I decide to withdraw from the study after the third 
treatment period.  There will be partial payment dependent on the extent of my involvement in the study if the 
investigators require me to withdraw from the study prior to its completion. 
 
CONFIDENTIALITY:  I understand that any information about me obtained from this research, including answers 
to questionnaires, history, laboratory data, or test results will be kept confidential.  It is now University policy 
that all research records be kept for a period of at least five years post termination.  When the study results are 
published, they will be anonymous and/or my identity will not be revealed.  I understand that my research 
records, just like hospital records, may be subpoenaed by court order, or reviewed by federal investigatory 
agents.  The FDA may also need to have access to my medical records.  With these exceptions, any research 
data released or published will not identify me by name.  Therefore, I consent to such publication for scientific 
purposes. 
 
RIGHT TO WITHDRAW:  I understand that I am free to refuse to participate in this study or to withdraw at any 
time.  My decision will not adversely affect my care at this institution or cause a loss of benefits to which I 
might otherwise be entitled.  I also understand that the investigators may ask that I withdraw from the study if 
it is felt that the risks to my health outweigh the benefits to continue to be enrolled in this study. 
 
COMPENSATION FOR ILLNESS OR INJURY:  University of Pittsburgh investigators and their associates who 
provide services at the UPMC Health System (UPMC HS) recognize the important of your voluntary participation 
to their research studies.  These individuals and their staffs will make reasonable efforts to minimize, control, 
and treat any injuries that may arise as a result of this research.  
 
If you believe that you are injured as the result of the research procedures being performed, please contact 
immediately the Principal Investigator listed on the cover sheet of this form or the University of Pittsburgh 
Institutional Review board (412-692-4376).  Emergency medical treatment for injured solely and directly 
relating to your participation in this research will be provided to you by hospitals of the UPMC HS may bill your 
insurance provider for the costs of this emergency treatment, but none of these costs will be charged directly 
to you.  If your research-related injury requires medical care beyond this emergency treatment, you will be 
responsible for the costs of this follow-up care unless otherwise specifically stated below.  You will not receive 
monetary payment for, or associated with, any injury that you suffer in relation to this research.   
 
VOLUNTARY CONSENT:  I certify that I have read the preceding or it has been read to me, and I understand its 
contents.  Any questions I have pertaining to the research have been, and will continue to be answered by Dr. 
Patricia Kroboth (648-8430) or her associates.  Any questions I have concerning my rights as a research 
subject will be answered by the Human Subjects Protection Advocate at the University of Pittsburgh IRB Office 
(412-692-4376).  A copy of this consent form will be given to me.  My signature below means that I have freely 
agreed to participate in this project. 
 
 
_____________   ____________________________________________ 
Date Subject Signature 
    
 
  ____________________________________________  
   Witness 
 
******************************************************************************* 
I certify that I have explained to the above individual the nature and purpose, the potential benefits, and the 
possible risks associated with participating in this research study, have answered any questions that have 
been raised, and have witnessed the above signature. 
 
_____________ ____________________________________________ 
Date   Investigator Signature 
  
 
INITIAL AND RECORD ACTUAL TIME IN ALL BLANK AREAS 
























SEM Vital Signs Meals other 
assessments 












Administer  oral dose of DHEA _____mg or PLACEBO   Administered by__________  Time of 
administration________    
                                                                                               Begin Urine Collection #1 (0h-
12h) 
1.0h      4.5ml redtop    
2.0h      4.5ml redtop 3ml greentop   Juice 
3.0h      4.5ml redtop    
3.5h      4.5ml redtop    
4.5h      4.5ml redtop   POMS, Liquid lunch 
5.5h      4.5ml redtop    
6.5h  
Administer  oral dose of DHEA ____mg or PLACEBO   Administered by__________  Time of 
administration_________  
7.0h      4.5ml redtop   Liquid Lunch 
8.5h      4.5ml redtop   POMS, Hopkins 
10.0h      4.5ml redtop   Dinner 
11.5h 
     4.5ml redtop   
End  #1 urine 
collect Begin 
#2 (12h-23h) 
12.5h      4.5ml redtop   POMS 
16.0h      4.5ml redtop    
20.0h      4.5ml redtop    
23.0h 





* Activity:  
 **Split redtop sample per orders,  greentop goes in tube labelled ‘LOTZE’                                   SIGNATURES 
AND INITIALS 
  Nurse Rated Sedation Score 
0 Wide Awake; Alert 3 Sleeping; Awakened by Name 
1 Awake; Lethargic 4 Sleeping; Responds to Strong Stimuli 
2 Eyes closed; Responds to Name AND/OR Unable to do Psychomotor Performance Tests 
  
 
INITIAL AND RECORD ACTUAL TIME IN ALL BLANK AREAS 





























-1.0h         Breakfast; Collect baseline urine 




Administer oral dose of DHEA _____mg or PLACEBO   Administered by________  Time of 
administration_______  
Begin Urine Collection #1 (0h-12h) 
1.0h      7ml redtop    
2.0h      7ml redtop 3ml greentop   Juice 
2.5h  
Administer oral dose of Alprazolam 2mg   Administered by_________  Time of 
administration__________    
3.0h      7ml redtop    
3.5h      7ml redtop    
4.5h      7ml redtop   POMS, Liquid lunch 
5.5h      7ml redtop    
6.5h  
Administer oral dose of DHEA _____mg or PLACEBO   Administered by__________ Time of 
administration__________ 
7.0h      7ml redtop   Liquid Lunch 
8.5h      7ml redtop   POMS, Hopkins 
10.0
h      7ml redtop   Dinner 
11.5
h      7ml redtop   
End  #1 urine 
collect Begin #2 
(12h-23h) 
12.5
h      7ml redtop   POMS 
16.0
h      7ml redtop    
20.0
h      7ml redtop    
23.0
h      7ml redtop 3ml greentop   
Discharge subject 
End urine collect 
#2 
* Activity:  
 **Split redtop sample per orders,  greentop goes in tube labelled ‘LOTZE’                                   SIGNATURES 
AND INITIALS 
  Nurse Rated Sedation Score 
0 Wide Awake; Alert 3 Sleeping; Awakened by Name 
1 Awake; Lethargic 4 Sleeping; Responds to Strong Stimuli 





Saccadic Eye Movement Parameters 




Table B1.  Velocity (msec) to 8 degree targets for young women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 349.02 348.58 362.78 365.75 366.12 368.72 351.72 354.80 377.92 360.42 
     3 276.22 274.08 285.71 285.92 273.84 274.72 272.65 283.68 262.07 258.58 
     4 298.14 311.97 282.68 267.74 288.44 294.13 312.24 275.33 284.18 274.02 
     5 283.78 308.12 291.60 261.64 250.96 239.16 256.03 269.99 248.28 272.20 
     7 236.93 241.05 239.01 257.94 260.42 252.70 245.70 255.48 257.23 244.41 
     8 246.06 245.22 235.31 247.48 245.13 235.22 230.86 257.68 275.01 260.33 
     9 309.36 283.26 281.99 295.58 308.14 298.41 269.94 295.86 283.73 319.46 
   10 284.14 274.43 276.83 247.04 259.50 245.01 252.32 245.89 255.44 241.82 
   12 269.45 214.14 236.45 258.55 251.09 261.23 259.78 258.11 273.50 268.78 
     14* 318.83 302.45 310.65 289.97 320.01 349.39 318.58 287.93 341.79 313.80 
    15* 247.04 237.55 215.49 233.44 225.29 236.50 229.48 230.48 243.48 241.42 
    16* 283.09 283.76 294.19 270.06 268.86 276.18 292.08 282.54 251.29 277.67 
102 259.51 289.92 295.26 291.96 268.97 271.54 287.03 299.83 271.63 270.78 
111 307.41 297.95 271.26 264.92 280.38 269.27 282.23 274.15 279.17 282.00 
112 321.27 328.43 335.42 316.19 306.10 334.10 311.49 315.01 303.17 325.69 
  114* 263.52 252.46 268.21 260.77 268.10 252.45 302.69 268.79 287.06 280.52 
206 335.75 323.39 306.21 331.27 297.19 315.35 338.26 296.57 305.47 339.79 
  213* 293.92 313.34 339.11 294.77 313.54 309.51 296.84 320.72 327.01 307.81 
Mean 287.97 285.01 284.90 280.06 280.67 282.42 283.88 281.82 284.86 285.53 
St. Dev. 31.65 36.01 38.49 32.96 33.51 39.88 35.01 29.60 35.32 34.67 
           
*Minority Subjects 
  
Table B2.  Velocity (msec) to 8 degree targets for young men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 289.57 306.14 304.50 302.74 300.66 308.65 287.19 314.06 326.21 303.65 
  34 203.34 185.73 287.65 320.48 300.47 318.37 274.17 297.65 293.64 285.78 
  35 341.17 310.43 316.19 342.87 325.19 325.37 343.10 319.58 332.14 316.72 
  36 314.80 308.85 308.40 289.27 289.85 263.48 310.99 320.38 314.33 312.16 
  37 301.75 297.69 300.59 297.83 308.29 335.14 309.17 326.87 299.93 355.74 
  38 307.85 296.79 302.63 295.87 300.04 301.05 321.88 297.32 302.90 291.13 
  39 324.45 275.30 237.58 319.15 290.87 275.59 268.99 318.49 310.20 319.80 
  41 307.85 305.31 324.58 293.75 322.64 307.84 293.39 308.64 312.97 299.00 
  42 296.06 262.98 303.29 288.69 282.67 289.20 302.68 297.60 295.61 301.27 
  43 308.87 313.41 327.50 321.06 317.35 317.54 310.02 300.60 290.10 314.41 
  44 269.23 272.63 275.65 262.55 279.02 278.53 291.20 297.24 286.96 301.98 
     47* 330.08 295.95 320.33 289.81 310.88 292.52 314.28 293.48 298.31 302.85 
     48* 256.28 223.70 252.48 261.46 263.82 259.63 254.41 269.15 273.54 233.47 
 140 282.41 275.33 292.39 257.73 267.16 289.61 269.54 263.24 282.49 271.62 
  146* 249.83 239.80 259.12 241.04 257.11 245.13 218.89 247.58 253.90 258.81 
  245* 243.67 228.85 240.38 255.65 240.10 231.29 255.84 256.69 245.48 252.45 
Mean 289.20 274.93 290.83 290.00 291.01 289.93 289.11 295.54 294.92 295.05 
St. Dev. 36.59 37.69 29.42 28.28 24.61 29.52 30.99 24.24 23.42 29.71 
           
*Minority Subjects 
  
Table B3.  Velocity (msec) to 8 degree targets for older women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 238.42 254.16 221.81 232.47 235.77 234.66 279.62 280.72 279.99 257.17 
    18 262.62 252.84 284.23 270.27 269.85 312.09 265.14 277.43 278.45 282.57 
    19 271.10 273.18 270.32 240.55 220.68 244.39 261.46 275.58 219.12 252.88 
      20* 235.60 245.28 218.90 233.77 251.87 244.63 228.50 256.35 216.84 249.44 
   21 276.92 270.97 253.12 235.44 246.34 327.34 270.50 252.75 236.76 278.28 
   22 268.77 267.01 258.07 267.79 260.82 258.14 261.82 274.85 255.56 251.75 
   23 271.45 238.53 291.79 269.38 233.27 249.48 221.95 223.16 249.17 230.99 
   24 326.95 294.41 309.32 294.70 151.81 319.48 315.92 287.36 331.64 287.02 
   25 289.35 282.69 267.22 301.90 295.54 275.58 282.23 271.30 307.79 278.76 
   26 219.04 196.45 204.35 221.34 189.09 203.98 247.98 221.17 249.33 235.21 
   27 252.01 301.40 250.76 253.81 276.73 256.43 277.96 252.79 265.49 259.89 
   28 291.07 287.71 273.03 277.23 280.73 265.20 277.49 255.21 267.52 270.71 
     29* 276.52 264.50 285.55 241.71 -- 291.00 252.57 230.59 226.95 323.68 
     30* 276.01 230.53 242.26 270.21 259.19 274.16 268.36 258.45 258.04 235.00 
     31* -- 212.99 174.34 277.95 184.27 241.16 222.42 -- 235.20 205.42 
120 330.94 293.05 285.87 296.11 276.57 309.62 282.24 279.46 273.00 301.72 
Mean 272.45 260.36 255.68 261.54 242.17 269.21 263.51 259.81 259.43 262.53 
St. Dev. 30.44 30.02 35.98 25.16 40.66 34.70 24.76 21.25 31.03 29.48 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B4.  Velocity (msec) to 8 degree targets for older men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 257.99 220.74 231.91 221.95 193.18 172.63 278.46 219.15 268.67 252.61 
  51 310.72 262.71 255.13 281.53 285.13 278.59 272.70 261.74 258.54 253.02 
  52 259.70 236.46 260.52 286.07 276.18 255.58 195.15 249.11 260.50 248.94 
  53 272.59 248.67 250.38 273.43 243.32 261.99 237.10 238.59 281.15 285.47 
  54 208.20 228.89 206.56 197.38 203.10 210.13 162.40 243.91 256.25 235.11 
  55 231.03 239.49 239.56 246.48 242.37 219.73 238.51 237.99 241.52 247.74 
  56 294.24 294.18 324.82 311.23 290.01 303.80 296.54 272.94 317.65 313.03 
  57 353.71 352.82 337.71 348.45 324.82 343.13 337.86 316.30 357.21 340.31 
  58 230.14 227.12 241.41 229.24 236.77 224.18 254.24 247.42 241.32 245.11 
  59 290.79 254.42 281.33 272.94 254.09 245.75 275.58 290.20 281.05 262.14 
     61* -- 281.84 273.62 299.01 284.39 289.14 303.42 286.18 287.58 297.25 
149 284.45 313.83 289.52 330.13 292.61 272.94 286.71 298.43 298.79 307.78 
160 313.22 305.16 273.52 236.21 241.81 230.08 194.74 277.36 264.26 298.67 
Mean 275.57 266.64 266.61 271.85 259.06 254.44 256.42 264.56 278.04 275.94 
St. Dev. 41.09 40.16 36.39 44.36 37.46 44.66 49.65 28.27 32.27 32.91 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B5.  Velocity (msec) to 8 degree targets for young women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 349.43 296.67 349.10 252.11 341.20 358.20 357.53 358.45 290.92 344.88 
     3 237.01 245.39 260.89 287.06 271.58 277.17 292.76 298.94 282.84 266.98 
     4 300.52 276.76 274.24 285.11 290.89 278.01 273.50 284.92 295.38 281.32 
     5 291.83 272.16 288.09 256.81 256.40 274.17 293.52 273.18 281.82 266.53 
     7 269.90 256.34 258.75 228.35 245.24 251.14 249.40 258.41 267.51 239.41 
     8 237.46 265.07 260.06 263.24 263.78 257.64 265.54 268.03 271.91 278.47 
     9 301.65 295.93 321.39 301.74 283.37 269.88 267.55 287.43 302.51 299.60 
   10 311.55 290.34 260.72 252.13 248.48 299.19 253.39 261.44 256.61 276.21 
   12 276.59 239.36 231.48 262.50 229.84 251.81 269.72 253.76 274.51 245.81 
     14* 315.90 297.21 296.26 322.20 282.87 292.29 327.41 300.12 339.67 275.20 
    15* 242.08 256.36 225.14 232.33 215.41 212.31 251.95 248.88 257.94 227.09 
    16* 318.41 304.55 262.97 266.24 279.06 284.00 268.47 292.97 311.69 271.62 
102 262.51 253.88 263.56 264.98 281.39 276.48 280.17 262.28 269.72 267.36 
111 271.20 287.48 266.96 267.34 260.50 268.01 255.88 290.05 265.29 270.06 
112 342.57 337.28 316.07 341.50 320.79 342.59 340.24 353.37 355.17 344.39 
  114* 260.42 259.42 262.17 272.01 260.96 278.54 277.95 243.03 267.82 262.48 
206 314.25 302.47 303.04 306.56 -- 311.76 306.86 329.03 309.37 328.39 
  213* -- -- 298.83 266.85 -- 304.41 326.56 296.50 326.39 296.83 
Mean 288.43 278.63 277.76 273.84 270.74 282.64 286.58 286.71 290.39 280.15 
St. Dev. 34.88 25.88 31.57 29.27 31.31 33.49 32.54 33.30 28.61 32.55 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B6.  Velocity (msec) to 8 degree targets for young men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 299.13 305.77 299.76 299.21 311.78 303.50 296.29 298.68 309.77 299.52 
  34 294.35 289.84 296.15 310.61 283.60 290.74 283.91 297.66 279.01 318.86 
  35 196.67 339.71 296.29 331.52 329.63 333.97 321.06 334.58 309.42 325.26 
  36 293.25 291.67 318.28 299.62 293.15 312.97 310.08 307.64 307.94 299.81 
  37 330.25 303.41 279.64 272.77 291.35 316.77 290.47 276.70 298.74 319.67 
  38 287.74 325.39 309.84 297.04 309.76 296.54 313.49 300.06 314.17 278.44 
  39 329.20 304.07 341.95 276.33 270.43 291.14 289.48 274.58 338.62 345.29 
  41 292.67 290.40 291.42 300.08 298.66 319.37 310.46 295.69 318.51 326.38 
  42 318.52 321.66 303.86 326.84 319.52 307.35 301.64 298.05 316.76 309.59 
  43 309.36 309.07 309.40 288.58 338.21 319.63 305.63 320.33 320.51 325.90 
  44 282.09 273.90 294.40 296.10 290.67 278.52 284.30 270.19 298.80 296.79 
     47* 314.09 307.35 318.80 296.54 306.16 318.28 330.43 318.82 292.70 308.78 
     48* 239.30 247.35 232.59 232.31 277.94 231.89 278.63 270.29 244.87 272.24 
 140 271.27 254.18 276.75 269.56 268.40 277.89 271.33 293.22 287.09 271.47 
  146* 232.64 223.50 238.03 253.41 244.92 215.26 243.74 238.93 225.57 231.84 
  245* 256.28 250.13 263.59 251.52 221.44 233.67 231.25 250.51 240.13 238.42 
Mean 284.18 289.84 291.92 287.63 290.98 290.47 291.39 290.37 293.91 298.02 
St. Dev. 37.08 32.03 28.75 26.93 30.26 35.27 26.46 25.50 31.85 32.04 
           
*Minority Subjects 
  
Table B7.  Velocity (msec) to 8 degree targets for older women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 269.26 249.33 239.11 231.37 184.18 262.29 283.04 230.87 247.22 260.48 
    18 256.18 290.11 251.58 283.06 290.41 322.02 305.24 273.35 273.49 304.82 
    19 274.08 270.17 248.79 270.39 232.29 256.39 289.72 261.86 265.87 257.52 
      20* 214.41 221.77 214.75 226.60 217.08 230.04 245.33 272.83 204.04 218.14 
   21 265.40 264.51 280.39 296.14 253.13 277.46 281.48 264.06 282.95 276.44 
   22 292.85 269.26 287.65 274.10 270.27 282.50 283.97 298.31 279.64 302.70 
   23 227.83 236.24 269.34 226.93 233.10 265.29 269.27 259.98 241.48 225.42 
   24 285.62 287.42 318.81 274.57 319.45 324.53 326.28 320.13 294.17 294.82 
   25 285.09 251.78 290.94 300.37 284.23 270.98 277.81 269.75 256.57 302.68 
   26 203.52 180.43 235.29 216.42 212.85 178.76 205.45 205.04 237.98 196.80 
   27 -- 297.90 288.68 248.43 281.85 237.62 238.11 255.94 238.99 223.87 
   28 288.26 277.43 272.69 270.64 268.03 291.01 271.47 258.81 274.37 299.77 
     29* 278.32 254.40 305.07 282.87 327.38 276.13 294.49 297.79 313.13 264.28 
     30* 251.27 231.25 303.83 284.97 232.20 259.14 229.10 315.48 268.72 284.71 
     31* -- -- -- 200.73 -- -- -- 188.45 -- 190.23 
120 293.13 260.43 303.17 295.25 281.00 256.91 268.98 278.20 271.11 282.12 
Mean 263.23 256.16 274.01 261.43 259.16 266.07 271.32 265.68 263.32 261.55 
St. Dev. 29.30 30.22 30.27 31.66 40.35 35.52 30.94 35.47 26.64 39.09 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B8.  Velocity (msec) to 8 degree targets for older men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 250.85 269.18 258.65 299.32 272.14 245.77 265.57 246.51 268.49 259.51 
  51 258.05 271.54 246.02 273.29 248.37 286.13 312.14 250.39 295.30 259.14 
  52 270.38 270.64 283.38 240.23 270.71 262.73 194.45 270.92 250.00 231.35 
  53 271.73 260.86 251.18 275.12 231.82 278.66 287.34 229.14 218.71 256.79 
  54 176.35 208.64 198.54 197.68 192.11 190.14 171.80 196.38 240.23 214.08 
  55 243.88 240.96 233.08 231.00 248.12 227.49 251.21 243.63 248.92 233.79 
  56 284.88 257.60 315.89 289.50 298.95 299.95 353.27 352.90 293.60 299.60 
  57 346.01 315.61 358.24 325.57 346.51 329.62 338.23 349.81 357.93 354.79 
  58 233.39 245.44 235.24 236.56 253.48 246.95 250.54 248.68 247.28 238.27 
  59 259.12 306.92 251.56 283.26 310.07 291.06 306.05 276.30 271.44 246.21 
     61* 233.07 238.69 270.21 242.93 283.20 258.78 310.95 278.60 277.03 292.73 
149 308.17 327.38 279.28 275.24 295.45 317.86 288.35 286.74 309.92 311.22 
160 272.23 214.08 236.41 287.03 170.17 234.11 260.54 275.71 230.63 253.31 
Mean 262.16 263.66 262.90 265.90 263.16 266.87 276.19 269.67 269.96 265.45 
St. Dev. 40.26 36.25 40.52 34.31 47.63 38.90 52.18 43.63 37.64 38.94 
           
*Minority Subjects 
  
Table B9.  Velocity (msec) to 8 degree targets for young women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 350.06 257.75 158.68 136.62 143.71 144.58 188.93 198.09 179.86 313.39 
     3 249.94 245.68 160.87 167.01 166.57 210.69 190.88 207.45 253.41 264.69 
     4 282.14 285.19 194.97 111.64 210.44 157.23 230.97 235.29 256.83 233.47 
     5 259.42 249.53 85.16 164.66 127.02 141.26 250.72 247.04 271.23 269.54 
     7 234.49 223.35 160.07 141.43 161.28 192.57 213.05 197.26 199.77 197.83 
     8 216.20 254.14 126.79 128.64 69.15 169.66 131.75 217.74 209.89 245.64 
     9 286.50 281.40 246.19 151.32 136.72 223.50 246.04 256.76 253.29 272.79 
   10 242.96 252.95 250.94 183.04 211.21 212.86 239.14 220.47 224.93 238.72 
   11 296.69 285.87 178.05 106.57 167.21 188.54 236.39 298.97 304.64 287.67 
   12 260.36 259.72 213.02 123.94 154.06 158.57 97.26 224.69 215.34 215.66 
     14* 314.33 319.82 262.99 163.47 168.75 218.23 283.35 271.93 240.72 309.60 
    15* 234.60 244.02 139.44 90.51 117.86 185.50 194.51 219.52 216.84 222.88 
    16* 276.14 239.13 242.87 232.81 203.00 215.44 220.49 248.48 248.68 267.56 
102 267.06 260.97 151.93 102.42 132.86 175.61 213.45 252.74 227.16 263.66 
111 257.20 284.97 231.08 120.84 124.26 180.41 224.14 238.41 226.96 253.12 
112 348.96 314.11 191.33 200.71 167.14 238.64 211.99 263.08 295.26 297.49 
  114* 222.68 221.55 153.77 163.06 141.98 154.85 214.38 198.13 196.69 210.78 
206 322.95 317.16 226.68 157.22 149.95 162.76 212.03 228.74 253.53 277.57 
  213* 279.97 283.04 174.24 184.80 186.79 220.59 239.31 238.32 279.48 279.97 
Mean 273.82 267.39 186.79 148.98 154.73 186.92 212.57 234.90 239.71 259.05 
St. Dev. 39.13 29.41 48.19 36.53 34.83 29.68 41.70 27.06 33.65 32.97 
           
*Minority Subjects 
  
Table B10.  Velocity (msec) to 8 degree targets for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 293.84 310.99 156.23 162.83 182.08 228.52 209.52 275.08 309.30 299.43 
  34 299.26 284.11 114.93 143.54 252.46 236.62 263.33 260.68 304.17 292.39 
  35 281.75 328.93 -- 272.25 282.30 300.13 296.11 302.64 316.31 306.29 
  36 303.90 307.80 267.79 243.56 239.15 257.30 280.10 284.52 274.83 290.77 
  37 288.08 291.15 226.09 203.74 212.82 293.27 301.96 305.30 309.89 314.37 
  38 320.73 330.82 174.39 88.32 192.23 213.04 289.54 289.80 280.18 286.51 
  39 314.39 335.35 102.76 128.06 170.33 144.29 208.80 294.82 296.92 320.28 
  41 295.81 307.90 281.77 264.85 285.73 287.30 282.59 282.41 310.82 297.16 
  42 -- 277.31 172.06 136.88 179.12 185.79 241.37 240.73 255.86 274.45 
  43 320.44 297.08 216.43 154.85 141.48 231.46 254.68 288.37 289.46 288.55 
  44 288.49 281.73 219.85 107.05 124.03 148.73 -- 212.55 265.55 282.66 
     47* 325.01 297.57 184.61 195.94 218.55 203.78 212.95 278.36 261.46 239.09 
     48* 287.13 240.51 170.75 -- 113.42 183.03 192.24 238.99 212.95 234.78 
 140 263.06 253.93 66.99 106.85 140.60 186.14 193.50 254.33 236.42 270.32 
  146* 243.98 232.43 156.63 141.06 106.91 169.84 161.60 208.89 221.85 238.56 
  245* 235.44 238.10 -- -- -- 173.85 197.01 183.89 249.84 209.27 
Mean 290.75 288.48 179.38 167.84 189.41 215.19 239.02 262.59 274.74 277.81 
St. Dev. 26.61 33.08 60.37 59.42 58.44 49.85 45.26 36.37 33.05 31.67 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B11.  Velocity (msec) to 8 degree targets for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 225.81 238.36 142.04 95.21 109.41 150.99 181.74 64.83 132.66 104.83 
    18 312.24 290.98 99.42 109.83 91.48 142.73 183.94 232.17 250.04 228.60 
    19 274.71 292.87 -- -- 106.34 -- 131.14 118.52 209.22 200.39 
      20* 262.67 246.74 215.87 155.76 129.21 129.80 122.97 161.30 152.27 174.33 
   21 289.99 266.46 -- 94.78 139.54 208.95 219.65 238.52 252.01 263.91 
   22 234.17 271.03 171.98 65.58 94.60 88.88 92.28 171.23 176.08 194.31 
   23 -- 236.81 -- 151.74 162.06 189.32 172.92 199.18 231.79 185.57 
   24 321.34 312.97 192.18 138.40 178.46 251.57 274.70 259.65 303.78 -- 
   25 279.23 312.56 229.95 137.79 145.76 263.23 231.65 222.06 232.80 263.17 
   26 231.54 212.76 -- -- 129.51 140.09 103.68 141.87 95.07 143.69 
   27 287.64 306.05 -- -- -- -- -- -- 192.72 179.07 
   28 293.26 282.38 -- 174.88 129.01 -- -- 178.18 240.79 197.46 
     29* 273.32 322.44 -- 67.26 169.04 102.26 187.66 197.50 210.00 123.17 
     30* 225.08 280.06 -- -- 185.50 118.98 267.99 189.91 236.26 273.47 
     31* 232.11 206.40 -- -- -- -- -- -- 152.14 173.19 
120 304.07 274.81 -- -- -- -- 207.10 222.45 247.99 242.83 
Mean 269.81 272.11 175.24 119.12 136.15 162.44 182.88 185.53 207.23 196.53 
St. Dev. 32.92 35.46 48.56 38.07 31.03 58.30 58.35 52.13 53.81 50.81 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B12.  Velocity (msec) to 8 degree targets for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 238.76 267.08 96.65 73.12 161.02 181.00 136.29 201.37 203.28 217.79 
  51 284.48 261.60 103.58 150.44 101.30 193.91 199.00 205.38 242.38 236.76 
  52 259.60 191.89 -- -- -- -- 152.61 123.15 195.20 180.31 
  53 298.71 266.33 145.73 143.22 193.62 124.40 190.85 243.39 260.20 228.58 
  54 196.75 217.62 116.34 111.76 93.92 91.14 159.03 202.94 154.99 191.34 
  55 260.16 198.17 198.17 146.60 202.91 184.28 195.42 233.11 236.21 238.34 
  56 339.21 290.24 -- 116.12 120.25 169.96 198.29 252.89 289.30 197.34 
  57 322.89 325.93 194.71 212.50 152.84 217.20 280.01 268.70 317.24 325.51 
  58 233.38 246.22 194.86 188.48 171.83 201.89 211.93 201.70 206.72 226.65 
  59 275.37 291.98 -- 108.26 151.81 240.17 250.31 215.77 243.10 203.09 
     61* 288.23 326.51 92.04 175.99 220.08 253.59 272.99 283.16 317.16 320.52 
149 306.94 -- 101.63 123.36 126.70 124.45 165.89 239.92 234.20 224.75 
160 259.41 262.18 -- -- -- 127.67 148.47 132.89 154.92 148.32 
Mean 274.15 262.15 138.19 140.90 154.21 175.81 197.01 215.72 234.99 226.10 
St. Dev. 38.86 43.90 46.00 40.23 41.20 50.28 46.72 46.99 52.78 49.87 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B13.  Velocity (msec) to 8 degree targets for young women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 344.47 282.96 152.83 145.35 225.17 204.92 228.24 263.93 316.00 318.99 
     3 270.85 288.93 170.95 175.85 151.57 184.84 207.13 270.75 246.22 275.56 
     4 295.54 275.28 183.55 127.69 154.17 174.32 232.44 267.06 245.63 249.07 
     5 264.70 262.13 97.99 139.39 123.49 185.91 229.37 245.52 226.51 265.01 
     7 243.43 235.22 146.76 141.39 136.44 172.42 161.29 200.68 213.46 205.10 
     8 264.68 257.64 239.82 143.58 160.37 178.43 169.73 209.84 214.15 246.48 
     9 319.21 265.51 240.52 205.22 179.23 217.03 224.62 268.19 275.65 289.92 
   10 262.10 269.12 173.12 217.58 164.44 226.40 235.13 251.20 269.65 262.14 
   11 310.04 279.90 223.21 176.14 171.74 244.37 271.87 258.46 285.27 314.48 
   12 268.85 236.72 163.18 135.84 146.59 166.35 209.97 243.38 223.68 212.83 
     14* 332.73 326.73 287.55 318.39 315.40 298.79 274.23 326.18 319.68 322.31 
    15* 222.73 233.11 152.56 101.64 118.39 131.80 192.75 200.31 212.88 189.74 
    16* 271.68 292.54 203.62 249.86 253.93 238.15 275.58 253.04 270.71 248.80 
102 263.62 257.47 227.93 198.56 172.96 190.99 246.98 192.90 251.87 230.64 
111 263.56 240.51 163.54 108.92 135.63 179.46 164.01 230.81 257.30 226.52 
112 292.45 327.10 164.52 260.66 205.67 248.98 271.71 266.74 297.29 306.90 
  114* 250.98 262.11 198.21 145.44 197.24 209.84 248.66 238.55 226.32 234.30 
206 309.07 333.66 234.93 -- 164.21 174.68 189.89 257.67 266.55 285.16 
  213* 265.34 298.55 98.54 200.13 205.88 255.70 227.62 259.22 287.45 257.75 
Mean 279.79 275.01 185.44 177.31 178.03 204.39 224.27 247.60 258.22 260.09 
St. Dev. 31.53 30.76 49.00 57.38 48.21 39.91 36.70 31.43 33.71 39.14 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B14.  Velocity (msec) to 8 degree targets for young men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 319.89 312.36 185.09 89.43 142.83 265.66 247.95 315.69 300.19 299.73 
  34 350.42 324.53 163.15 199.20 242.85 243.36 282.22 257.41 267.01 294.61 
  35 293.41 297.43 258.34 243.88 254.88 260.55 257.09 267.15 308.96 321.91 
  36 293.30 308.48 248.73 238.19 241.22 261.42 266.11 268.45 299.33 277.13 
  37 294.97 284.25 220.34 243.52 246.16 274.06 295.55 299.53 292.19 310.04 
  38 299.76 296.13 147.59 77.18 150.93 254.87 245.85 277.33 285.40 305.67 
  39 320.78 313.06 136.55 128.33 155.42 118.82 255.80 266.93 250.12 322.05 
  41 -- 290.33 214.03 256.48 239.93 238.47 281.42 301.78 299.62 285.94 
  42 286.15 285.71 249.36 215.69 170.22 178.03 255.23 262.67 277.40 274.42 
  43 323.26 324.40 204.71 189.76 213.59 254.04 223.96 286.40 299.16 320.10 
  44 297.21 291.68 205.02 171.66 199.31 191.36 234.66 246.56 258.69 287.50 
     47* 302.92 309.72 195.39 204.56 207.23 217.39 265.49 273.99 285.40 265.87 
     48* 257.02 232.53 166.43 164.03 92.09 110.09 134.55 180.09 214.32 200.22 
 140 251.59 272.14 145.64 122.60 95.38 172.03 177.16 221.02 230.31 262.89 
  146* 240.61 247.66 217.46 176.34 154.79 216.83 265.06 252.16 252.06 259.42 
  245* 237.49 240.01 -- -- -- 194.56 190.13 209.20 209.94 210.49 
Mean 291.25 289.40 197.19 181.39 187.12 215.72 242.39 261.65 270.63 281.12 
St. Dev. 32.41 28.51 39.20 56.53 54.25 51.12 42.56 35.09 31.80 36.07 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B15.  Velocity (msec) to 8 degree targets for older women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 246.05 242.22 -- -- -- -- 187.95 178.05 189.17 163.77 
    18 269.42 301.03 131.59 140.64 97.94 158.72 138.45 177.29 237.40 217.61 
    19 275.09 270.44 -- -- -- -- 136.24 182.06 173.94 185.73 
      20* 239.29 223.17 99.24 106.01 104.09 125.09 77.87 173.28 173.05 125.79 
   21 280.55 261.36 95.92 83.09 145.84 191.50 185.20 186.99 201.18 199.68 
   22 260.48 252.05 79.55 77.22 108.50 160.48 146.18 184.13 182.30 239.06 
   23 231.82 267.39 -- 101.45 146.83 178.70 235.46 203.03 238.61 229.93 
   24 313.57 332.02 129.23 234.05 123.81 222.05 287.19 274.90 278.77 302.98 
   25 374.44 285.81 220.10 106.11 82.02 150.87 202.69 199.79 185.38 186.90 
   26 198.50 210.78 -- -- -- 62.64 52.21 70.40 99.40 209.70 
   27 289.10 296.24 -- -- -- -- -- 157.49 241.67 214.66 
   28 292.72 287.61 112.22 -- 156.19 -- 212.68 206.39 -- 230.36 
     29* 252.26 270.52 -- -- -- -- -- -- 259.40 245.99 
     30* 238.40 258.01 -- 120.48 183.31 179.44 67.62 198.02 201.28 210.03 
     31* 235.10 242.68 -- -- -- -- -- 174.47 219.16 208.75 
120 297.55 282.29 -- -- -- 170.38 135.15 195.18 233.67 237.54 
Mean 268.40 267.73 123.98 121.13 127.61 159.99 158.84 184.10 207.63 213.03 
St. Dev. 41.03 30.43 46.25 49.78 32.62 42.77 68.68 41.06 44.05 38.94 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B16.  Velocity (msec) to 8 degree targets for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 252.95 257.76 -- -- -- -- 198.92 194.86 141.36 198.42 
  51 256.48 268.65 -- -- -- -- 197.07 216.87 240.38 191.56 
  52 245.77 218.25 -- -- 130.25 65.91 65.64 113.30 141.48 62.61 
  53 251.86 160.68 242.53 157.09 125.68 150.77 178.14 212.98 162.38 206.81 
  54 148.52 214.05 76.34 70.94 80.05 111.92 118.34 164.83 182.79 199.07 
  55 252.02 235.71 157.05 190.71 211.27 187.47 196.04 204.67 208.07 216.75 
  56 314.67 330.29 164.55 198.55 167.79 189.35 122.28 167.87 207.67 237.05 
  57 341.24 325.23 170.72 162.37 221.69 247.90 253.54 281.62 321.46 295.31 
  58 235.61 245.13 150.55 130.01 185.56 166.84 202.09 224.92 231.46 212.75 
  59 260.37 252.15 -- 167.51 117.40 214.95 224.98 245.90 218.86 167.88 
     61* 287.85 270.63 188.93 233.67 -- 175.98 208.64 236.78 282.57 314.55 
149 293.23 282.48 -- 99.54 122.07 176.01 149.96 217.43 230.08 230.97 
160 276.52 245.64 -- -- -- -- 96.61 122.24 83.57 76.28 
Mean 262.85 254.36 164.38 156.71 151.31 168.71 170.17 200.33 204.01 200.77 
St. Dev. 45.69 44.98 49.58 50.39 47.67 51.00 55.12 47.77 62.91 70.89 
           
*Minority Subjects 
(--) Velocity not obtained 
 
  
Table B17.  Velocity (msec) to 16 degree targets for young women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 564.74 526.62 555.22 583.40 590.82 552.95 517.08 541.34 574.42 569.38 
     3 391.14 396.01 428.17 426.39 425.33 403.64 396.87 406.08 376.34 370.96 
     4 418.67 402.42 370.41 407.54 349.79 403.53 412.92 371.35 404.60 410.71 
     5 342.22 395.14 378.52 337.55 367.14 335.17 361.78 352.93 325.05 368.81 
     7 330.53 343.53 329.41 319.82 325.66 356.52 324.12 335.26 322.59 321.63 
     8 361.85 365.44 409.39 392.53 368.94 362.45 356.26 387.17 393.57 376.71 
     9 429.42 405.26 413.49 441.40 452.55 408.66 423.07 422.50 426.70 446.80 
   10 403.41 415.94 406.82 363.94 369.51 380.59 366.34 367.79 365.81 344.92 
   12 373.05 381.11 345.04 368.54 370.33 382.48 409.81 414.73 399.03 346.33 
     14* 421.56 415.57 416.22 458.67 445.65 402.29 450.81 344.40 431.52 463.50 
    15* 303.94 320.82 318.14 338.06 413.55 315.06 336.36 323.91 352.21 337.61 
    16* 385.69 385.77 411.16 371.43 380.70 395.43 401.81 383.73 377.75 388.06 
102 329.97 359.32 351.22 346.27 340.89 459.39 320.55 337.56 341.27 351.12 
111 440.85 490.80 374.00 358.94 345.87 379.86 396.91 352.91 381.41 373.04 
112 450.96 422.14 433.84 422.93 440.47 453.35 439.81 455.11 451.18 477.54 
  114* 360.61 397.96 416.29 386.73 398.75 395.79 446.71 398.45 423.41 409.71 
206 441.05 441.19 435.14 450.35 411.18 429.51 453.45 396.44 434.75 442.59 
  213* 419.79 429.02 460.97 396.59 435.11 433.27 414.59 426.45 454.99 420.91 
Mean 398.30 405.23 402.97 398.39 401.79 402.77 401.63 389.90 402.03 401.13 
St. Dev. 60.11 48.66 54.71 61.67 61.22 52.89 51.18 52.21 59.13 61.80 
           
*Minority Subjects 
  
Table B18.  Velocity (msec) to 16 degree targets for young men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 467.18 429.00 458.17 439.66 417.10 415.09 398.74 442.53 419.14 427.26 
  34 323.68 307.87 479.91 417.81 456.49 438.37 435.22 464.15 437.24 427.26 
  35 506.04 459.38 447.08 440.71 462.39 446.47 463.85 436.56 419.12 434.89 
  36 449.68 436.08 430.80 429.90 395.14 412.36 456.02 446.76 453.78 428.47 
  37 408.61 403.53 381.05 419.01 449.16 434.91 393.11 404.51 412.77 437.34 
  38 424.18 420.89 428.13 431.13 408.35 418.62 415.06 421.17 434.29 420.41 
  39 475.97 435.19 385.53 462.59 430.73 420.31 391.62 435.25 466.87 421.39 
  41 492.13 440.33 465.37 422.52 434.76 439.56 446.74 435.09 461.67 417.14 
  42 363.64 357.47 364.54 355.95 346.79 354.54 418.61 434.58 487.26 408.94 
  43 446.98 438.38 431.99 445.91 382.49 389.13 444.29 425.84 436.66 442.59 
  44 347.07 323.75 370.25 380.40 376.69 389.34 391.43 396.50 387.99 395.76 
     47* 487.48 462.06 418.40 444.03 431.85 419.50 414.83 431.62 453.00 443.38 
     48* 381.11 392.74 437.89 335.05 394.48 388.86 403.50 392.98 317.88 323.87 
 140 347.24 342.67 306.90 330.03 350.81 339.10 353.58 349.29 360.04 346.37 
  146* 368.37 338.76 365.63 341.05 385.54 375.99 382.24 383.74 341.45 365.48 
  245* 341.69 321.52 332.81 334.50 356.37 342.62 369.95 355.11 352.76 334.61 
Mean 414.44 394.35 406.53 401.89 404.95 401.55 411.17 415.98 415.12 404.70 
St. Dev. 61.73 53.64 49.79 47.18 37.33 34.54 31.60 32.74 49.58 39.71 
           
*Minority Subjects 
  
Table B19.  Velocity (msec) to 16 degree targets for older women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 420.69 396.43 324.81 356.90 359.46 396.24 380.36 357.29 381.01 370.86 
    18 458.85 426.94 458.27 449.55 430.33 386.83 369.34 399.20 406.01 438.69 
    19 385.00 480.24 335.61 391.66 347.84 365.82 343.07 346.46 367.90 383.93 
      20* 345.78 400.55 305.89 382.30 453.02 395.57 431.79 391.18 407.25 360.58 
   21 423.61 411.94 364.93 352.21 316.33 369.45 355.11 353.97 348.15 329.47 
   22 398.94 372.65 352.43 372.86 331.91 355.88 382.79 370.30 340.68 361.29 
   23 405.13 388.68 398.54 402.08 364.03 339.26 331.09 342.73 335.16 355.30 
   24 435.61 500.93 396.59 627.76 212.18 405.27 379.86 362.75 377.04 424.99 
   25 388.73 346.11 368.62 444.27 425.35 405.13 429.40 444.15 430.87 410.33 
   26 283.34 245.60 255.04 346.52 251.36 277.69 317.16 273.14 274.24 289.27 
   27 364.67 510.45 411.09 435.90 344.43 365.66 394.91 358.64 376.74 376.95 
   28 502.24 374.55 402.31 361.74 372.09 361.86 381.15 394.75 382.97 403.27 
     29* 314.97 438.68 361.80 313.26 -- 384.78 422.91 314.79 353.66 524.23 
     30* 286.67 280.35 318.11 316.68 313.46 457.62 320.81 343.34 296.86 294.52 
     31* -- 297.29 302.16 386.30 354.47 406.46 314.51 -- 344.63 264.48 
120 423.30 413.30 377.24 395.20 373.24 377.82 438.56 399.09 372.10 420.37 
Mean 389.17 392.79 358.34 395.95 349.97 378.21 374.55 363.45 362.20 375.53 
St. Dev. 61.65 74.69 50.45 73.75 63.04 38.37 41.94 40.23 39.83 64.25 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B20.  Velocity (msec) to 16 degree targets for older men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 386.65 390.02 338.18 350.36 383.50 343.22 336.28 -- 394.22 464.05 
  51 378.87 358.28 362.86 362.65 342.66 361.84 351.34 355.71 366.99 379.87 
  52 353.95 389.07 403.82 414.81 361.66 341.25 274.79 337.24 403.15 323.80 
  53 390.60 336.47 347.17 322.04 350.16 348.07 331.29 356.16 338.87 305.52 
  54 260.29 308.72 238.79 246.74 261.96 267.21 199.96 309.15 285.23 332.16 
  55 292.99 332.49 319.86 325.84 323.58 306.24 313.53 303.82 310.66 338.11 
  56 472.24 419.81 470.82 487.48 485.50 451.92 437.39 434.13 423.14 503.81 
  57 465.02 504.79 456.36 473.28 447.41 455.65 455.88 449.63 467.01 448.93 
  58 331.69 334.56 312.97 310.14 303.87 290.82 305.26 300.10 311.97 312.91 
  59 498.12 335.72 398.31 303.02 385.38 351.55 372.72 390.69 420.43 370.80 
     61* -- 445.46 444.81 392.41 448.41 411.36 432.08 438.50 458.53 464.41 
149 458.46 422.47 412.60 449.14 425.09 405.53 425.62 438.01 435.08 428.22 
160 378.03 350.00 344.61 339.65 304.80 310.96 281.50 363.81 369.34 365.38 
Mean 388.91 379.07 373.17 367.50 371.08 357.36 347.51 373.08 383.43 387.54 
St. Dev. 73.84 56.31 65.87 71.90 66.20 58.99 75.54 56.05 58.63 66.71 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B21.  Velocity (msec) to 16 degree targets for young women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 516.48 491.57 531.85 465.94 528.71 511.91 555.47 544.45 495.57 510.63 
     3 347.43 361.09 386.59 411.06 394.63 389.73 428.15 387.36 400.76 422.84 
     4 407.88 396.88 370.72 391.03 379.08 387.27 366.14 356.44 395.33 371.73 
     5 392.23 332.37 371.16 370.23 352.17 363.74 432.62 339.47 424.49 357.93 
     7 356.77 333.84 344.69 320.03 354.46 354.64 338.66 353.75 358.94 329.82 
     8 395.50 386.53 385.88 403.94 380.94 384.95 380.02 375.71 408.59 400.37 
     9 435.09 414.83 422.23 414.39 413.65 400.83 405.67 428.90 428.36 432.18 
   10 427.77 423.72 401.75 359.04 381.67 407.94 384.98 393.49 385.60 405.26 
   12 373.82 371.63 385.06 387.37 354.69 409.36 410.25 364.30 397.39 397.73 
     14* 398.05 385.99 407.76 516.27 518.21 370.91 380.94 382.08 388.08 375.80 
    15* 333.28 348.46 341.16 326.19 339.77 318.41 347.38 352.80 344.53 328.78 
    16* 425.36 423.58 389.59 381.53 404.73 388.52 370.10 367.15 443.72 375.23 
102 343.81 301.87 318.71 274.57 450.28 385.89 356.67 312.42 308.02 347.15 
111 362.80 392.24 351.76 348.55 361.02 365.60 347.64 362.17 368.46 356.56 
112 486.17 456.13 495.41 498.42 446.63 478.44 476.14 490.95 484.36 438.73 
  114* 364.51 359.90 369.69 379.25 418.65 363.27 373.66 391.80 398.82 404.35 
206 429.22 427.86 421.81 425.10 -- 423.40 408.96 432.88 434.37 430.83 
  213* -- -- 392.79 383.86 -- 434.54 413.40 458.45 432.99 422.95 
Mean 399.77 388.73 393.81 392.04 404.96 396.63 398.71 394.14 405.47 394.94 
St. Dev. 50.13 48.16 51.82 60.12 56.65 45.11 52.62 57.61 46.00 45.25 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B22.  Velocity (msec) to 16 degree targets for young men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 426.10 398.95 408.72 444.57 416.53 425.06 401.15 434.09 416.17 421.95 
  34 465.46 466.42 455.71 442.78 442.69 423.74 440.00 455.71 418.99 373.66 
  35 327.40 466.78 436.92 454.74 460.74 447.67 417.27 424.95 388.36 435.37 
  36 421.55 404.73 403.85 421.47 394.38 441.44 422.09 416.54 432.75 448.61 
  37 424.69 424.84 393.08 405.94 396.45 399.09 383.90 389.88 411.04 388.61 
  38 447.32 435.92 372.11 418.60 449.14 438.55 426.21 422.77 441.99 436.01 
  39 478.07 387.75 438.86 422.24 408.63 420.08 352.15 395.02 457.73 484.41 
  41 472.02 430.03 439.70 425.09 448.94 476.72 443.25 482.26 444.47 470.15 
  42 443.39 475.58 371.24 452.84 419.34 374.22 418.91 400.02 416.99 421.94 
  43 450.78 432.69 420.83 417.66 450.72 424.89 447.27 453.58 466.34 442.02 
  44 386.54 375.83 376.21 385.06 375.49 384.56 388.96 400.35 395.08 377.96 
     47* 449.30 432.99 432.27 449.96 442.73 449.98 451.72 467.07 428.02 453.61 
     48* 424.34 452.87 380.65 495.61 429.06 463.77 474.00 447.59 385.63 453.95 
 140 307.46 343.04 338.62 345.82 326.78 320.77 355.94 335.52 346.96 321.68 
  146* 354.28 367.78 366.92 419.13 373.45 316.03 375.39 336.60 329.44 349.18 
  245* 374.57 353.63 358.54 367.07 316.46 342.76 325.27 354.21 337.70 354.79 
Mean 415.83 415.61 399.64 423.04 409.47 409.33 407.72 413.51 407.35 414.62 
St. Dev. 51.50 41.34 34.92 36.18 43.62 49.16 41.26 44.39 41.26 47.69 




Table B23.  Velocity (msec) to 16 degree targets for older women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 386.42 368.12 353.62 286.69 285.89 367.45 406.35 343.36 374.54 386.66 
    18 438.26 575.51 457.09 474.77 477.81 409.82 444.31 445.41 401.29 396.75 
    19 313.37 382.92 319.08 349.78 350.54 346.32 319.43 435.89 327.69 371.01 
      20* 408.14 324.20 425.22 410.77 349.73 382.08 389.60 468.30 384.44 339.61 
   21 388.12 374.78 351.05 341.22 355.91 381.31 372.09 396.86 349.14 350.23 
   22 427.90 384.74 399.62 372.99 396.27 389.88 376.67 386.31 382.16 378.36 
   23 411.65 445.53 386.91 419.75 392.08 344.60 376.53 407.51 374.93 326.96 
   24 443.09 379.96 419.12 447.15 377.92 416.61 560.33 353.20 646.88 432.35 
   25 411.92 386.08 438.56 442.11 378.71 389.16 375.27 396.21 360.93 401.17 
   26 273.56 277.30 273.72 308.69 247.33 254.05 260.61 259.88 336.72 253.46 
   27 -- 476.03 498.32 343.76 488.73 328.89 347.63 329.56 315.47 286.62 
   28 426.60 416.25 433.14 375.40 389.31 388.29 408.72 369.11 399.01 388.30 
     29* 374.04 372.37 317.90 366.40 449.28 356.21 436.05 342.36 343.81 389.50 
     30* 314.05 318.03 465.89 329.83 324.57 334.25 273.29 338.61 312.58 311.13 
     31* -- -- -- 284.61 -- -- -- 401.75 -- 218.17 
120 377.63 353.37 386.83 442.10 398.25 348.56 378.41 398.77 394.63 379.91 
Mean 385.34 389.01 395.07 374.75 377.49 362.50 381.69 379.57 380.28 350.64 
St. Dev. 51.53 70.88 62.46 59.26 64.82 40.14 71.63 51.41 79.41 58.28 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B24.  Velocity (msec) to 16 degree targets for older men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 367.74 389.86 390.32 409.98 412.40 473.70 380.29 399.24 337.45 369.20 
  51 369.69 365.92 350.15 335.72 361.11 322.77 388.66 371.34 389.13 454.40 
  52 435.89 353.37 441.26 382.44 372.81 343.54 293.34 392.19 367.29 366.69 
  53 358.12 367.02 351.00 356.17 354.53 363.00 358.89 444.09 339.67 294.41 
  54 211.94 248.04 253.72 233.84 230.47 254.73 202.19 239.93 274.87 234.09 
  55 322.61 360.35 322.25 322.94 315.59 306.97 315.46 330.37 362.29 329.20 
  56 442.57 439.98 397.47 387.32 418.55 418.06 421.76 477.57 412.29 403.33 
  57 452.96 491.20 473.39 468.58 483.55 440.95 473.20 455.12 534.15 494.83 
  58 315.54 326.12 310.87 311.41 346.59 312.57 320.90 312.97 311.18 309.80 
  59 343.88 390.60 440.59 443.39 350.34 356.44 385.45 337.88 345.77 375.17 
     61* 407.13 414.81 389.30 433.76 452.59 420.37 448.10 488.83 443.81 422.42 
149 416.50 436.88 416.58 429.21 375.66 450.39 419.32 398.65 401.69 392.14 
160 340.94 292.00 275.37 405.66 347.60 286.14 345.09 329.98 314.93 317.81 
Mean 368.12 375.09 370.17 378.49 370.91 365.36 365.59 382.94 371.89 366.42 
St. Dev. 65.73 64.44 66.75 64.95 63.30 69.26 72.15 72.34 66.88 70.19 




Table B25.  Velocity (msec) to 16 degree targets for young women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 511.62 500.37 322.35 245.59 307.12 284.35 290.55 385.11 311.26 439.45 
     3 372.08 378.89 308.19 271.04 252.07 323.84 323.67 329.88 387.41 399.32 
     4 401.77 380.11 313.27 170.33 271.74 273.19 357.07 352.83 376.62 357.25 
     5 315.63 348.74 178.08 219.76 204.34 191.15 338.82 336.26 384.55 360.09 
     7 311.93 337.66 200.71 224.04 230.11 246.60 274.94 290.27 307.46 275.76 
     8 338.29 403.36 278.33 255.43 170.29 314.27 272.05 312.40 315.48 327.05 
     9 391.09 392.61 381.43 266.47 256.08 378.84 381.56 362.12 361.39 338.83 
   10 377.32 376.64 364.28 315.08 309.02 361.22 345.93 337.63 360.96 337.31 
   11 431.68 409.98 286.51 234.71 265.54 286.10 357.59 401.97 415.63 396.81 
   12 400.00 385.55 357.06 238.33 264.63 261.71 217.85 352.93 355.20 352.93 
     14* 431.22 464.92 352.66 219.85 236.73 272.27 282.94 334.41 353.46 435.85 
    15* 336.54 333.99 180.06 156.80 196.68 254.83 248.04 287.52 291.13 290.30 
    16* 367.74 388.06 307.65 305.27 342.60 361.50 309.36 355.34 318.95 355.55 
102 292.87 337.46 266.48 203.81 205.18 233.30 299.28 324.69 307.22 320.28 
111 352.37 344.17 292.44 186.56 165.93 233.58 313.31 309.84 313.42 331.06 
112 482.40 456.48 299.15 316.47 306.71 300.49 334.75 374.07 403.14 427.77 
  114* 324.92 363.94 255.33 254.28 225.49 280.55 293.47 302.98 308.02 306.01 
206 454.42 426.80 287.25 197.57 158.57 301.68 230.46 310.18 338.77 360.77 
  213* 384.06 394.17 300.74 284.64 312.60 333.95 332.46 348.55 408.28 366.51 
Mean 383.05 390.73 291.16 240.32 246.39 289.13 305.48 337.31 348.33 356.78 
St. Dev. 59.39 45.77 57.35 46.38 54.30 48.76 44.39 31.25 39.48 46.44 
           
*Minority Subjects 
  
Table B26.  Velocity (msec) to 16 degree targets for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 410.34 437.39 242.10 291.40 318.15 373.87 315.41 411.57 432.33 448.76 
  34 457.12 443.39 102.93 219.96 316.16 363.81 423.56 408.58 446.49 425.41 
  35 392.37 439.94 -- 332.64 374.50 369.91 419.68 424.96 438.32 425.96 
  36 429.75 423.72 363.48 327.28 355.35 380.22 424.16 405.51 368.70 410.61 
  37 393.49 367.84 326.88 286.59 317.05 368.35 387.38 399.28 422.77 434.63 
  38 442.16 455.88 241.86 149.94 253.62 293.74 364.02 391.50 360.34 393.46 
  39 449.78 504.05 238.68 216.40 227.08 253.37 271.28 443.29 448.01 460.85 
  41 472.34 436.29 402.27 404.63 439.72 403.08 380.91 390.97 456.40 446.77 
  42 -- 372.65 202.23 209.49 208.53 272.14 315.58 337.07 330.11 370.33 
  43 433.22 414.66 257.49 278.33 306.28 302.17 360.22 376.38 389.80 403.16 
  44 399.22 366.43 311.30 203.18 182.74 304.94 -- 337.10 391.39 389.94 
     47* 423.23 407.08 314.98 322.05 294.15 329.76 400.24 429.68 372.49 345.86 
     48* 435.34 296.82 276.09 -- 163.68 418.95 321.72 330.09 287.90 328.55 
 140 323.46 364.17 111.46 352.65 211.08 237.67 226.02 323.57 334.71 333.55 
  146* 399.76 350.44 236.27 253.05 191.90 243.03 286.42 320.69 318.93 335.45 
  245* 326.56 331.60 -- -- -- 230.25 280.57 274.51 303.09 302.51 
Mean 412.54 400.77 259.14 274.83 277.33 321.58 345.14 375.30 381.36 390.99 
St. Dev. 42.79 53.50 84.61 69.92 79.80 62.58 62.22 48.48 55.55 49.50 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B27.  Velocity (msec) to 16 degree targets for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 406.86 351.30 198.87 150.89 147.28 214.56 315.52 184.86 248.45 216.81 
    18 467.52 412.65 154.01 150.48 196.52 209.02 244.54 335.76 328.79 308.35 
    19 383.42 379.82 -- -- 173.78 -- 182.54 187.09 240.00 279.12 
      20* 479.89 394.19 403.65 230.32 202.57 167.54 197.72 227.41 384.47 294.81 
   21 377.22 344.49 -- 170.26 198.42 266.58 270.19 305.72 334.26 305.53 
   22 357.93 380.47 208.52 132.47 123.95 199.80 177.67 232.35 273.41 297.98 
   23 -- 362.39 -- 193.06 212.09 303.50 312.06 358.33 380.40 263.62 
   24 559.64 404.70 239.22 284.94 228.13 327.54 337.73 361.92 366.57 417.92 
   25 421.82 440.33 249.56 160.18 161.92 262.84 308.65 291.20 283.33 351.01 
   26 300.23 296.64 -- -- 200.45 174.96 122.89 159.59 189.53 197.24 
   27 404.66 417.88 -- -- -- -- -- -- 297.36 300.32 
   28 494.40 376.16 -- 190.09 195.33 -- -- 278.83 307.29 292.43 
     29* 299.54 437.05 -- 205.44 224.67 261.13 308.24 351.68 334.04 194.18 
     30* 291.68 355.96 -- -- 320.84 180.86 394.27 298.80 422.78 380.52 
     31* 298.70 302.84 -- -- -- -- -- -- 315.94 256.91 
120 385.98 379.79 -- -- -- -- 304.10 282.66 369.10 306.60 
Mean 395.30 377.29 242.31 186.81 198.92 233.48 267.39 275.44 317.23 291.46 
St. Dev. 80.34 41.62 85.93 45.30 47.33 53.95 77.24 67.47 61.13 60.19 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B28.  Velocity (msec) to 16 degree targets for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 405.53 357.51 171.06 182.60 251.91 292.15 263.43 312.49 310.14 383.37 
  51 373.61 338.90 180.26 179.73 205.72 298.04 257.88 329.18 316.25 333.06 
  52 366.49 309.12 -- -- -- -- 252.94 209.87 253.47 272.21 
  53 366.21 346.65 237.61 261.31 244.18 185.09 275.70 309.54 324.78 321.65 
  54 300.91 254.16 155.76 197.03 178.94 124.00 159.23 264.32 184.03 239.37 
  55 368.34 272.34 272.34 192.60 250.25 263.07 272.24 281.24 309.85 317.76 
  56 558.07 458.71 -- 221.61 230.25 327.20 282.45 321.67 439.40 370.95 
  57 467.67 451.41 238.98 292.43 228.74 336.14 382.33 381.83 448.05 456.62 
  58 328.43 328.43 219.19 232.55 229.59 263.50 298.81 260.88 316.58 307.91 
  59 348.36 355.49 -- 181.91 212.18 360.74 290.86 408.02 303.89 315.48 
     61* 472.68 502.02 166.14 275.92 337.29 337.93 446.97 442.88 412.06 418.55 
149 444.36 -- 174.12 153.34 141.39 226.87 308.14 363.46 330.93 329.97 
160 354.27 369.43 -- -- -- 205.58 223.80 178.70 237.14 246.36 
Mean 396.53 362.01 201.72 215.55 228.22 268.36 285.75 312.62 322.04 331.79 
St. Dev. 70.92 74.73 41.09 44.96 48.92 71.58 69.83 75.44 76.09 63.14 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B29.  Velocity (msec) to 16 degree targets for young women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 553.13 503.97 255.50 311.72 368.50 292.56 411.24 387.99 507.29 502.27 
     3 435.82 412.56 282.71 193.75 147.10 276.74 317.47 359.60 414.44 400.62 
     4 394.70 379.53 273.42 258.80 225.28 237.82 325.80 336.48 339.64 307.24 
     5 369.80 356.99 194.63 215.76 208.78 275.51 325.41 330.73 361.33 339.49 
     7 341.37 327.96 227.10 219.02 269.66 245.71 268.27 281.96 299.33 281.79 
     8 290.46 362.56 274.41 280.06 286.75 279.84 281.28 345.22 324.49 353.70 
     9 451.64 417.53 367.20 370.03 326.02 360.66 373.94 348.36 364.78 378.95 
   10 365.70 389.13 363.89 270.03 243.78 319.25 343.50 372.82 379.77 383.63 
   11 469.50 433.95 265.46 292.13 312.69 409.31 413.76 369.70 390.52 472.62 
   12 363.29 335.81 247.29 183.69 251.74 279.28 326.81 328.33 356.86 358.16 
     14* 422.88 436.26 418.05 424.37 506.58 419.86 420.17 451.86 517.97 391.15 
    15* 330.99 324.00 198.67 150.01 176.00 174.14 258.73 292.92 301.08 274.97 
    16* 370.86 418.49 318.83 362.40 325.40 346.97 340.52 353.99 389.71 380.92 
102 347.19 333.13 280.10 247.34 285.02 247.99 290.58 287.87 294.83 294.86 
111 342.43 346.67 190.48 207.09 198.65 238.33 245.59 293.66 337.24 315.75 
112 421.82 437.52 327.78 341.77 307.73 397.73 401.15 409.26 422.88 415.66 
  114* 388.55 387.61 338.75 227.85 299.75 299.51 327.32 355.99 337.07 310.87 
206 447.75 432.58 320.92 -- 220.28 367.28 229.74 322.38 333.26 373.94 
  213* 369.75 417.52 160.98 334.01 337.94 364.87 340.52 351.90 373.79 353.11 
Mean 393.56 392.30 279.27 271.66 278.82 307.02 328.52 346.37 370.86 362.62 
St. Dev. 60.73 48.35 68.09 74.15 80.94 67.13 57.40 42.73 61.73 60.24 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B30.  Velocity (msec) to 16 degree targets for young men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 455.05 458.28 265.15 244.48 249.76 410.90 346.67 427.21 416.08 420.18 
  34 523.94 535.61 218.08 317.40 386.83 358.41 420.47 371.42 395.38 402.59 
  35 422.22 431.48 365.35 328.94 384.29 383.85 441.50 368.40 448.36 430.15 
  36 383.05 420.40 370.25 336.31 344.76 352.36 397.64 364.76 405.67 375.88 
  37 395.92 385.45 304.50 317.53 332.53 377.90 372.27 394.11 408.09 408.12 
  38 427.13 416.30 174.65 143.99 236.82 378.67 407.69 382.10 454.45 409.77 
  39 459.30 472.45 191.71 247.69 212.74 205.44 430.39 366.84 403.76 443.70 
  41 -- 445.91 323.44 380.69 360.86 380.26 416.98 419.51 422.87 447.06 
  42 389.70 403.61 307.35 258.83 252.79 273.61 379.48 374.77 374.89 433.43 
  43 418.64 449.76 260.69 294.09 333.10 362.28 347.60 374.28 414.47 415.15 
  44 408.21 389.31 309.53 324.09 334.02 341.52 322.43 383.74 387.35 362.00 
     47* 426.80 380.24 240.31 279.88 297.54 315.98 350.84 364.51 408.53 361.11 
     48* 319.51 306.45 261.14 209.96 94.22 244.81 242.82 302.87 271.09 270.70 
 140 347.48 350.23 241.32 183.78 165.37 275.86 250.25 308.19 331.40 326.68 
  146* 362.45 358.62 326.82 285.90 282.09 337.30 377.67 399.24 350.00 373.06 
  245* 356.17 368.67 -- -- -- 257.30 267.16 287.31 308.35 302.61 
Mean 406.37 410.80 277.35 276.90 284.51 328.53 360.74 368.08 387.55 386.39 
St. Dev. 51.16 55.42 58.78 63.22 83.33 59.72 62.85 38.91 49.69 51.53 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B31.  Velocity (msec) to 16 degree targets for older women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 345.11 408.41 -- -- -- -- 324.13 360.36 399.73 425.17 
    18 425.05 445.59 227.28 165.59 205.15 251.16 231.67 305.04 321.27 342.57 
    19 364.76 338.11 -- -- -- -- 245.91 348.50 321.65 321.88 
      20* 413.66 329.89 149.17 181.13 119.02 158.85 201.50 262.13 265.17 217.42 
   21 345.33 365.80 133.71 167.88 247.96 221.48 325.78 270.95 250.01 286.41 
   22 365.51 336.41 104.36 108.40 128.23 213.95 226.70 253.94 286.87 329.59 
   23 457.61 398.83 -- 185.90 270.20 259.99 315.00 298.88 375.77 346.42 
   24 443.01 430.47 209.98 291.69 229.58 339.20 363.72 369.46 360.51 331.78 
   25 758.66 489.64 240.22 119.72 191.07 240.43 229.07 288.26 290.98 229.07 
   26 247.99 303.93 -- -- -- 78.48 162.09 169.24 176.47 225.55 
   27 442.05 466.03 -- -- -- -- -- 264.00 326.97 321.33 
   28 367.73 408.18 210.87 -- 234.51 -- 313.42 293.07 -- 267.74 
     29* 446.58 491.21 -- -- -- -- -- -- 415.97 348.96 
     30* 329.32 351.50 -- 155.79 250.83 326.53 136.66 270.22 253.84 231.80 
     31* 393.98 302.91 -- -- -- -- -- 190.92 331.31 426.74 
120 410.43 421.01 -- -- -- 251.68 274.95 326.35 348.38 334.11 
Mean 409.80 393.00 182.23 172.01 208.51 234.18 257.74 284.75 314.99 311.66 
St. Dev. 107.93 62.44 52.43 55.68 53.67 75.53 68.63 55.95 63.11 64.90 
           
*Minority Subjects 
(--) Velocity not obtained 
  
Table B32.  Velocity (msec) to 16 degree targets for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 365.52 371.15 -- -- -- -- 301.29 347.00 219.18 317.04 
  51 345.03 336.64 -- -- -- -- 272.06 320.83 323.02 275.13 
  52 389.45 332.38 -- -- 213.29 143.66 172.79 159.76 202.04 136.70 
  53 356.11 209.07 339.80 236.03 241.11 197.08 239.80 255.83 279.56 277.79 
  54 224.61 273.31 85.08 139.33 109.73 147.73 156.03 231.21 219.05 251.35 
  55 323.80 321.15 217.67 308.53 275.16 257.22 264.09 293.79 298.69 297.03 
  56 560.25 401.09 278.23 291.95 230.87 276.48 334.76 250.22 303.45 429.20 
  57 466.54 451.60 250.20 298.47 315.10 344.30 325.64 382.36 417.04 503.82 
  58 326.57 324.26 170.80 182.76 263.53 257.50 273.75 299.27 309.68 301.37 
  59 352.43 390.32 -- 141.94 204.45 364.26 372.17 334.44 347.23 252.25 
     61* 439.00 503.40 216.20 320.16 -- 351.03 340.59 408.84 411.45 415.60 
149 403.22 416.02 -- 341.31 232.66 314.85 229.61 313.44 358.08 391.82 
160 306.76 380.13 -- -- -- -- 128.12 172.56 302.00 143.81 
Mean 373.79 362.35 222.57 251.16 231.77 265.41 262.36 289.97 306.96 307.15 
St. Dev. 82.60 76.13 80.88 78.60 56.91 81.21 75.33 74.41 67.60 106.65 
           
*Minority Subjects 






Saccadic Eye Movement Parameters 




Table C1.  Latency (msec) to 8 degree targets for young women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 141 149 143 148 129 145 144 152 147 148 
     3 180 168 144 163 164 218 238 206 210 227 
     4 208 212 210 215 221 201 223 213 201 199 
     5 148 144 145 141 142 140 159 145 158 151 
     7 142 167 135 152 156 126 130 140 136 149 
     8 126 144 135 142 155 134 142 141 175 163 
     9 181 181 179 173 173 183 178 174 189 184 
   10 295 327 290 261 270 252 323 236 265 270 
   12 188 310 168 171 178 174 173 167 163 155 
     14* 156 159 149 149 165 149 158 153 154 165 
    15* 159 160 189 150 162 156 163 151 157 163 
    16* 162 171 164 173 165 157 150 156 169 158 
102 143 146 153 147 173 140 150 167 161 158 
111 185 210 198 223 196 203 173 179 172 168 
112 128 125 127 128 134 124 131 131 134 139 
  114* 247 160 195 165 153 143 146 147 155 155 
206 178 166 168 157 160 164 183 159 170 189 
  213* 144 143 147 153 150 149 150 162 156 163 
Mean 172.83 180.11 168.83 167.28 169.22 164.33 173 165.50 170.67 172.44 
St. Dev. 42.90 54.97 38.70 33.52 32.96 34.70 47.03 27.68 30.75 32.27 
           
*Minority Subjects 
  
Table C2.  Latency (msec) to 8 degree targets for young men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 162 186 170 167 163 147 174 162 157 162 
  34 157 166 160 165 151 161 154 157 162 165 
  35 133 132 143 126 126 130 124 134 125 124 
  36 139 134 137 131 127 132 135 139 132 131 
  37 216 214 229 246 227 226 233 229 251 238 
  38 157 157 152 156 153 154 155 154 151 143 
  39 169 157 147 146 160 175 165 164 162 169 
  41 172 165 166 154 165 177 174 169 172 166 
  42 152 168 152 157 150 157 171 155 147 163 
  43 169 158 173 185 198 189 194 177 171 178 
  44 136 144 135 133 127 141 126 124 123 124 
     47* 143 150 162 152 155 154 150 147 153 152 
     48* 161 192 150 161 220 146 152 149 149 144 
 140 117 130 120 109 112 121 117 138 116 116 
  146* 131 137 129 138 136 133 136 127 129 128 
  245* 146 158 156 148 164 157 148 155 162 164 
Mean 153.75 159.25 155.06 154.63 158.38 156.25 156.75 155 153.88 154.19 
St. Dev. 22.84 23.10 24.63 30.45 32.67 26.12 29.13 24.66 31.26 29.48 
           
*Minority Subjects 
  
Table C3.  Latency (msec) to 8 degree targets for older women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 185 215 250 207 218 207 181 223 194 188 
    18 197 172 179 211 184 191 228 210 220 193 
    19 176 170 185 186 170 166 170 158 171 160 
      20* 497 499 547 558 592 546 537 582 553 530 
   21 193 184 212 178 191 200 194 194 190 194 
   22 160 186 193 191 211 199 184 199 195 171 
   23 232 254 241 247 234 236 246 233 243 237 
   24 228 176 178 164 320 176 186 179 186 170 
   25 228 227 225 227 223 227 227 228 217 226 
   26 169 184 182 173 158 180 167 166 181 181 
   27 195 191 209 193 194 209 212 204 198 209 
   28 199 176 180 179 184 171 180 184 172 185 
     29* 164 181 181 176 -- 193 171 185 166 176 
     30* 172 190 188 177 165 172 176 179 175 175 
     31* -- 171 208 223 246 195 175 -- 173 201 
120 195 200 219 194 196 203 202 191 200 209 
Mean 212.67 211 223.56 217.75 232.40 216.94 214.75 221 214.63 212.81 
St. Dev. 81.92 80.11 89.22 93.52 107.27 89.89 89.12 102.20 92.59 87.12 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C4.  Latency (msec) to 8 degree targets for older men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 132 170 158 150 134 146 148 132 136 133 
  51 158 149 162 165 165 166 169 175 177 178 
  52 158 160 185 179 158 174 183 152 159 167 
  53 223 232 236 227 248 222 217 216 211 221 
  54 388 356 328 363 409 393 367 449 343 391 
  55 136 139 137 137 136 141 135 130 146 137 
  56 152 169 162 160 182 176 175 183 158 172 
  57 171 160 162 157 166 161 157 150 150 157 
  58 184 183 175 158 148 172 168 159 159 179 
  59 193 205 182 181 180 195 186 180 162 186 
     61* -- 138 132 134 144 152 151 134 141 154 
149 147 181 170 170 185 175 172 175 174 173 
160 188 214 207 203 186 205 213 189 181 197 
Mean 185.83 188.92 184.31 183.38 187.77 190.62 187.77 186.46 176.69 188.08 
St. Dev. 68.83 57.64 51.06 59.64 72.81 64.99 58.78 82.81 53.73 65.34 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C5.  Latency (msec) to 8 degree targets for young women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 159 162 166 140 164 152 148 149 155 149 
     3 212 203 173 156 162 169 175 156 170 177 
     4 199 202 201 234 220 226 201 217 198 198 
     5 148 139 132 150 148 150 149 138 148 159 
     7 131 152 147 137 141 143 163 146 176 162 
     8 125 141 131 129 140 136 173 180 182 173 
     9 177 166 169 180 193 177 176 167 170 172 
   10 226 242 290 347 254 199 254 245 291 233 
   12 169 187 214 193 196 183 173 179 158 164 
     14* 160 160 154 150 152 154 150 157 157 148 
    15* 174 189 160 164 189 157 157 153 159 162 
    16* 166 159 187 188 184 176 163 162 178 174 
102 156 165 166 159 162 158 158 149 160 145 
111 168 152 156 173 164 169 162 167 166 164 
112 146 141 118 122 130 128 129 129 128 130 
  114* 183 175 184 170 151 157 155 165 163 159 
206 167 156 155 166 -- 147 160 156 168 147 
  213* -- -- 176 163 -- 152 148 157 146 149 
Mean 168.59 170.06 171.06 173.39 171.88 162.94 166.33 165.11 170.72 164.72 
St. Dev. 26.21 27.14 38.21 50.51 32.63 23.39 26.73 27.52 33.70 22.87 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C6.  Latency (msec) to 8 degree targets for young men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 192 181 210 195 191 180 203 175 171 178 
  34 157 158 154 159 157 163 154 156 151 146 
  35 135 135 133 123 127 131 136 139 167 135 
  36 137 128 124 138 136 136 137 130 121 126 
  37 236 242 234 234 234 230 213 220 218 229 
  38 156 165 146 150 151 169 169 172 157 158 
  39 168 176 167 157 166 162 157 162 158 158 
  41 152 156 164 160 161 150 156 155 154 162 
  42 154 178 173 178 160 168 166 163 158 155 
  43 176 161 158 181 169 182 188 159 160 170 
  44 129 120 125 134 136 132 139 151 129 130 
     47* 149 135 143 148 144 149 145 149 145 153 
     48* 188 195 162 194 176 171 173 173 173 163 
 140 111 139 123 110 124 114 119 121 115 122 
  146* 131 125 130 127 122 131 129 129 127 122 
  245* 160 168 145 161 175 176 157 151 163 161 
Mean 158.19 160.13 155.69 159.31 158.06 159 158.81 156.56 154.19 154.25 
St. Dev. 29.95 31.22 30.75 31.61 28.64 27.91 26.06 23.25 24.67 26.48 
           
*Minority Subjects 
  
Table C7.  Latency (msec) to 8 degree targets for older women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 178 195 180 219 211 198 188 203 193 187 
    18 233 222 204 212 211 207 237 189 196 205 
    19 185 183 175 187 202 209 212 193 181 170 
      20* 625 603 593 608 639 645 612 549 586 570 
   21 209 192 189 193 188 173 200 178 194 179 
   22 179 173 197 185 188 190 213 189 177 198 
   23 197 193 203 200 204 206 192 189 196 211 
   24 232 229 208 213 212 211 207 224 230 218 
   25 232 218 223 210 224 215 236 225 227 230 
   26 163 189 164 172 172 154 178 177 179 181 
   27 -- 207 202 220 198 206 201 211 205 222 
   28 181 170 166 170 163 161 166 167 163 168 
     29* 155 156 165 154 164 165 165 164 154 172 
     30* 170 182 179 166 176 168 178 161 157 168 
     31* -- -- -- 252 -- -- -- 219 -- 257 
120 195 188 171 189 209 229 189 202 183 191 
Mean 223.86 220 214.60 221.88 224.07 222.47 224.93 215 214.73 220.44 
St. Dev. 118.23 107.80 106.23 105.89 116.32 119.09 109.26 91.37 105.04 96.65 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C8.  Latency (msec) to 8 degree targets for older men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 177 150 150 147 162 143 153 146 145 140 
  51 149 154 164 149 157 157 150 154 148 152 
  52 154 157 157 170 169 161 169 164 164 163 
  53 205 233 221 210 237 233 210 223 238 208 
  54 388 419 425 436 397 368 370 404 365 375 
  55 140 132 125 131 132 136 142 137 132 143 
  56 151 177 157 167 165 161 164 163 170 172 
  57 192 188 175 176 176 178 169 168 171 166 
  58 154 243 242 206 173 200 178 192 182 183 
  59 183 184 189 193 169 222 175 187 184 196 
     61* 147 156 159 150 148 148 145 159 156 145 
149 189 184 174 182 182 183 191 206 182 191 
160 191 200 204 197 185 190 194 189 191 172 
Mean 186.15 198.23 195.54 193.38 188.62 190.77 185.38 191.69 186.77 185.08 
St. Dev. 64.29 73.64 75.72 76.86 67.15 60.90 59 68.32 59.65 60.86 
           
*Minority Subjects 
  
Table C9.  Latency (msec) to 8 degree targets for young women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 134 139 199 200 204 162 179 152 163 167 
     3 212 195 287 276 253 261 238 199 171 181 
     4 237 239 218 292 270 225 192 218 204 214 
     5 139 153 175 193 183 167 168 146 146 145 
     7 122 118 183 238 250 210 168 148 154 159 
     8 132 133 208 240 322 248 225 168 168 132 
     9 167 175 178 193 180 185 174 179 179 177 
   10 247 229 215 207 223 234 230 223 208 191 
   11 150 149 193 241 190 181 169 162 149 150 
   12 176 174 177 173 173 169 172 171 170 171 
     14* 176 165 227 231 239 202 200 182 183 179 
    15* 155 151 182 189 184 154 159 153 165 154 
    16* 166 169 249 210 191 199 213 172 181 164 
102 156 158 196 230 202 205 172 152 150 140 
111 159 153 167 226 238 218 170 179 169 184 
112 131 129 193 196 188 190 174 139 132 124 
  114* 141 145 193 189 211 172 173 171 162 157 
206 162 171 232 214 227 219 215 220 192 195 
  213* 173 185 191 180 190 192 193 187 180 179 
Mean 165 164.74 203.32 216.74 216.74 199.63 188.63 174.79 169.79 166.47 
St. Dev. 34.31 31.18 29.54 31.63 38.18 29.59 24.38 25.44 19.46 22.82 
           
*Minority Subjects 
  
Table C10.  Latency (msec) to 8 degree targets for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 166 198 206 210 210 184 186 197 166 151 
  34 152 156 292 196 173 162 161 154 148 151 
  35 127 129 -- 137 140 133 137 140 131 127 
  36 136 142 148 135 144 138 144 153 136 145 
  37 241 228 204 225 205 223 228 215 216 218 
  38 155 138 147 161 150 174 142 158 154 150 
  39 150 151 180 187 188 179 165 168 157 164 
  41 167 163 174 175 167 165 161 164 159 162 
  42 -- 185 182 169 196 169 170 167 178 207 
  43 171 158 250 223 217 190 178 177 172 172 
  44 127 135 189 169 167 156 -- 169 134 130 
     47* 146 146 204 245 224 183 150 192 141 159 
     48* 128 125 350 -- 289 160 154 151 141 147 
 140 116 124 162 181 207 196 210 168 156 153 
  146* 127 129 157 162 163 136 139 137 140 143 
  245* 153 176 -- -- -- 198 183 169 180 165 
Mean 150.80 155.19 203.21 183.93 189.33 171.63 167.20 167.44 156.81 159 
St. Dev. 30.16 29.17 57.99 32.72 38.66 24.53 26.31 20.45 22.06 24.12 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C11.  Latency (msec) to 8 degree targets for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 179 185 254 240 280 257 287 248 235 231 
    18 194 197 307 289 241 244 252 226 212 232 
    19 170 167 -- -- 264 -- 227 228 191 190 
      20* 530 574 600 521 312 646 630 597 602 641 
   21 165 180 -- 231 205 209 216 207 207 222 
   22 180 191 302 292 333 264 242 213 209 205 
   23 -- 195 -- 276 238 250 231 239 215 218 
   24 167 170 258 228 210 191 189 190 174 -- 
   25 200 192 258 242 218 257 274 230 239 284 
   26 157 170 -- -- 304 255 247 244 218 201 
   27 183 183 -- -- -- -- -- -- 226 223 
   28 163 160 -- 260 247 -- -- 214 203 202 
     29* 149 157 -- 252 279 222 201 182 184 195 
     30* 161 162 -- -- 223 188 189 180 191 183 
     31* 172 193 -- -- -- -- -- -- 221 210 
120 188 176 -- -- -- -- 236 236 206 208 
Mean 197.20 203.25 329.83 283.10 258 271.18 263.15 245.29 233.31 243 
St. Dev. 93.13 99.74 134.43 86.64 41.20 127.29 114.11 103.61 99.89 112.67 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C12.  Latency (msec) to 8 degree targets for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 132 138 223 213 185 166 168 174 168 192 
  51 150 149 219 244 238 210 179 178 179 168 
  52 167 155 -- -- -- -- 206 207 167 178 
  53 215 225 276 217 228 218 224 207 206 230 
  54 430 484 553 401 487 435 553 411 418 433 
  55 131 161 161 168 154 153 153 145 146 145 
  56 144 147 -- 238 224 168 185 199 177 210 
  57 172 172 211 201 183 178 167 183 183 167 
  58 145 152 176 179 182 173 165 174 166 166 
  59 197 199 -- 372 320 205 231 199 194 222 
     61* 130 139 316 208 216 214 169 168 175 171 
149 174 -- 258 263 261 238 203 221 194 203 
160 175 208 -- -- -- 249 269 234 213 225 
Mean 181.69 194.08 265.89 245.82 243.45 217.25 220.92 207.69 198.92 208.46 
St. Dev. 79 95.60 117.92 74.99 92.59 74.92 105.05 65.59 68.22 72.55 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C13.  Latency (msec) to 8 degree targets for young women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 131 139 196 189 154 153 155 157 184 181 
     3 199 177 306 270 265 285 232 223 168 169 
     4 213 209 227 249 282 278 193 200 204 189 
     5 164 149 169 173 232 170 156 146 150 152 
     7 131 138 218 240 237 222 215 159 178 167 
     8 128 169 222 233 210 187 168 193 204 149 
     9 168 170 170 175 187 185 182 152 173 176 
   10 226 243 218 224 198 196 200 219 181 188 
   11 161 158 231 212 195 177 183 173 155 156 
   12 172 204 191 196 192 182 182 173 174 180 
     14* 150 161 149 176 155 187 154 169 164 161 
    15* 163 156 174 194 202 182 161 157 156 160 
    16* 163 166 217 197 216 174 178 170 159 164 
102 148 155 145 190 211 198 169 185 150 148 
111 160 162 190 216 202 189 187 180 170 165 
112 131 128 199 133 162 137 132 135 137 137 
  114* 146 150 170 201 167 161 167 155 153 151 
206 143 149 208 -- 209 237 229 181 185 170 
  213* 167 164 189 176 189 180 190 190 184 186 
Mean 161.26 165.63 199.42 202.44 203.42 193.68 180.68 174.58 169.95 165.74 
St. Dev. 27.10 27.37 36.35 32.66 33.95 37.98 25.86 23.47 18.10 14.91 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C14.  Latency (msec) to 8 degree targets for young men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 157 180 210 195 195 169 177 168 171 167 
  34 156 161 243 166 153 148 146 145 141 147 
  35 124 124 131 139 145 140 137 133 130 125 
  36 134 134 139 139 138 135 137 144 138 129 
  37 232 214 204 212 215 213 202 190 219 206 
  38 170 142 150 162 146 150 158 159 157 147 
  39 151 152 205 214 188 204 165 167 173 159 
  41 -- 156 177 168 168 156 166 168 154 150 
  42 150 168 175 186 180 194 197 172 155 177 
  43 164 153 219 221 197 213 207 154 148 150 
  44 122 122 160 167 151 146 147 129 134 141 
     47* 140 142 253 185 157 176 150 152 140 141 
     48* 153 146 189 201 279 241 194 176 143 148 
 140 125 118 230 281 289 178 173 173 143 140 
  146* 134 128 137 154 162 139 140 141 139 129 
  245* 150 164 -- -- -- 186 191 183 179 184 
Mean 150.80 150.25 188.13 186 184.20 174.25 167.94 159.63 154 152.50 
St. Dev. 26.86 24.57 39.44 36.96 46.24 31.92 24.35 17.90 22.52 21.73 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C15.  Latency (msec) to 8 degree targets for older women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 160 170 -- -- -- -- 222 193 196 194 
    18 205 196 256 265 261 211 253 212 207 218 
    19 161 188 -- -- -- -- 205 190 174 170 
      20* 616 660 551 501 574 606 523 570 612 515 
   21 171 182 211 252 206 209 220 215 224 216 
   22 189 188 349 354 268 208 206 195 194 190 
   23 192 190 -- 383 244 220 206 212 204 214 
   24 182 168 345 221 308 194 207 181 184 175 
   25 228 204 296 257 282 274 274 267 222 262 
   26 158 161 -- -- -- 356 301 267 220 206 
   27 177 194 -- -- -- -- -- 291 218 220 
   28 160 167 255 -- 219 -- 202 228 -- 220 
     29* 153 152 -- -- -- -- -- -- 177 178 
     30* 168 167 -- 200 198 202 220 198 182 185 
     31* 179 185 -- -- -- -- -- 216 197 194 
120 199 191 -- -- -- 231 276 258 222 206 
Mean 206.13 210.19 323.29 304.13 284.44 271.10 255 246.20 228.87 222.69 
St. Dev. 111.15 120.82 112.20 101.20 114.44 127.26 86.94 95.47 107.38 81.19 
           
*Minority Subjects 
(--) Latency not obtained 
  
TableC16.  Latency (msec) to 8 degree targets for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 132 130 -- -- -- -- 158 158 165 152 
  51 142 150 -- -- -- -- 187 190 188 188 
  52 170 151 -- -- 197 264 287 270 196 290 
  53 201 278 218 245 264 241 235 219 230 230 
  54 330 440 307 340 490 365 380 413 349 420 
  55 126 141 142 138 147 158 149 147 148 152 
  56 149 168 196 198 178 221 202 208 178 196 
  57 164 156 259 224 190 172 174 172 165 173 
  58 132 160 201 177 162 175 162 155 164 168 
  59 211 204 -- 305 269 192 205 204 217 212 
     61* 122 128 303 229 -- 322 225 142 156 159 
149 169 181 -- 258 252 222 178 230 205 201 
160 204 220 -- -- -- -- 233 241 233 233 
Mean 173.23 192.85 232.29 234.89 238.78 233.20 213.46 211.46 199.54 213.38 
St. Dev. 56.02 85.06 60.48 62.10 104.27 67.52 63.06 72.13 52.86 73.32 
           
*Minority Subjects 
(--) Latency not obtained 
 
  
Table C17.  Mean Latency (sec) to 16 degree targets for young women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 145 154 157 148 147 164 148 162 156 153 
     3 186 165 143 164 143 233 235 211 203 231 
     4 209 230 211 227 232 230 232 217 216 218 
     5 147 146 144 156 149 156 156 151 164 149 
     7 161 173 152 152 149 153 137 151 150 154 
     8 137 146 147 166 166 162 154 151 160 157 
     9 175 172 178 168 170 174 172 174 186 179 
   10 335 356 307 286 302 262 322 263 271 295 
   12 171 252 165 177 180 168 175 178 178 166 
     14* 176 185 173 172 172 191 172 188 199 193 
    15* 164 164 195 169 169 162 162 161 159 171 
    16* 184 185 179 189 195 161 151 169 171 170 
102 158 158 156 177 170 164 166 167 166 176 
111 205 243 229 242 223 216 198 195 196 191 
112 133 139 136 141 136 134 142 140 133 140 
  114* 307 149 210 159 144 146 141 143 160 147 
206 178 166 171 172 164 173 185 171 194 200 
  213* 143 137 142 137 143 140 140 153 152 158 
Mean 184.11 184.44 177.50 177.89 175.22 177.17 177.11 174.72 178.56 180.44 
St. Dev. 54.41 54.81 41.93 37.84 41.35 35.34 46.21 30.99 31.78 37.90 
           
*Minority Subjects 
  
Table C18.  Mean Latency (sec) to 16 degree targets for young men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 190 197 193 188 209 166 192 194 180 168 
  34 169 166 166 179 154 165 165 155 171 164 
  35 132 126 134 128 127 127 126 128 131 135 
  36 143 145 139 140 144 137 139 145 132 137 
  37 202 201 229 245 225 235 227 218 257 233 
  38 154 152 156 158 159 178 152 148 165 158 
  39 170 156 188 155 167 160 162 165 173 171 
  41 174 173 166 168 160 176 171 171 159 158 
  42 169 184 163 177 171 176 179 180 167 195 
  43 184 167 180 202 228 201 201 185 175 180 
  44 160 166 159 162 150 165 157 142 151 135 
     47* 150 159 169 146 150 145 155 152 162 156 
     48* 175 171 184 178 234 161 166 155 155 161 
 140 117 138 135 120 118 136 125 141 121 115 
  146* 138 143 144 141 145 141 144 132 129 148 
  245* 164 167 170 162 172 168 162 169 172 185 
Mean 161.94 163.19 167.19 165.56 169.56 164.81 163.94 161.25 162.50 162.44 
St. Dev. 22.24 20.26 24.58 30.48 35.73 26.71 26.67 24.12 31.26 27.88 
           
*Minority Subjects 
  
Table C19.  Mean Latency (sec) to 16 degree targets for older women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 193 225 262 228 226 233 212 211 221 202 
    18 229 224 210 246 224 227 303 235 276 258 
    19 202 207 189 200 210 183 201 188 195 182 
      20* 542 548 569 577 627 577 551 579 545 509 
   21 215 226 231 212 238 229 223 218 218 215 
   22 203 231 235 241 253 237 251 234 219 229 
   23 277 282 266 263 250 235 261 225 251 243 
   24 229 228 201 206 383 223 217 221 229 209 
   25 278 261 310 250 263 278 246 281 261 273 
   26 211 234 220 224 218 200 221 227 213 252 
   27 207 211 209 221 202 211 201 222 205 203 
   28 180 178 194 191 180 195 200 192 182 185 
     29* 200 206 216 211 -- 222 220 243 245 227 
     30* 219 228 210 209 196 197 228 199 246 205 
     31* -- 214 232 240 361 212 235 -- 215 215 
120 207 222 214 218 228 226 231 252 216 238 
Mean 239.47 245.31 248 246.06 270.60 242.81 250.06 248.47 246.06 240.31 
St. Dev. 88.06 83.92 90.96 90.42 113.57 91.80 84.43 94.43 83.39 76.10 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C20.  Mean Latency (sec) to 16 degree targets for older men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 160 210 183 167 177 172 198 -- 169 166 
  51 196 188 187 185 184 184 195 223 204 209 
  52 195 188 195 173 175 201 223 195 186 188 
  53 231 243 248 251 303 274 236 252 235 267 
  54 459 393 358 454 456 494 389 463 442 454 
  55 153 148 151 153 161 175 155 162 157 168 
  56 156 199 187 177 186 175 174 194 182 164 
  57 169 175 168 185 176 170 165 178 165 157 
  58 210 203 191 184 179 193 198 190 178 196 
  59 177 219 202 225 208 202 204 191 184 193 
     61* -- 191 183 188 205 205 178 197 185 169 
149 184 195 196 203 198 193 199 209 203 197 
160 207 223 214 225 206 214 214 199 196 231 
Mean 208.08 213.46 204.85 213.08 216.46 219.38 209.85 221.08 206.62 212.23 
St. Dev. 82.54 58.78 51.34 77.22 80.05 86.86 58.41 79.39 73.47 78.85 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C21.  Mean Latency (sec) to 16 degree targets for young women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 173 178 171 154 168 163 168 153 171 163 
     3 221 202 175 159 142 162 174 157 159 164 
     4 229 210 211 250 238 232 250 241 210 220 
     5 145 143 146 146 163 161 145 146 157 160 
     7 156 153 163 159 150 164 184 157 183 181 
     8 140 153 142 137 148 143 166 183 166 158 
     9 173 164 163 160 181 166 168 162 168 166 
   10 235 304 339 315 270 250 264 290 317 227 
   12 170 212 197 186 180 178 184 191 172 172 
     14* 201 209 180 177 188 200 172 215 200 166 
    15* 163 167 178 166 166 149 148 153 158 154 
    16* 191 167 204 207 186 174 168 195 175 191 
102 170 197 171 191 163 178 188 178 155 160 
111 176 168 176 186 178 186 182 178 177 180 
112 154 150 121 133 135 139 138 140 135 136 
  114* 172 159 172 159 156 158 152 172 156 150 
206 175 176 168 181 -- 162 170 167 160 176 
  213* -- -- 157 154 -- 156 133 142 140 130 
Mean 179.06 183.06 179.67 178.89 175.75 173.39 175.22 178.89 175.50 169.67 
St. Dev. 27.86 38.47 45.18 43.74 34.80 28.82 33.85 38.09 39.79 24.64 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C22.  Mean Latency (sec) to 16 degree targets for young men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 215 209 236 202 199 200 242 187 201 183 
  34 167 162 163 165 160 162 162 156 154 156 
  35 140 131 133 136 136 133 131 136 183 137 
  36 136 143 134 137 145 143 142 139 131 137 
  37 230 257 254 243 235 249 203 201 211 230 
  38 164 160 145 164 150 155 163 174 162 156 
  39 170 169 159 164 161 169 156 160 164 152 
  41 166 160 172 169 181 158 174 160 148 160 
  42 174 190 215 195 185 187 183 167 170 173 
  43 180 174 170 172 178 205 191 162 166 178 
  44 129 133 128 131 130 142 147 169 148 141 
     47* 150 146 151 148 160 161 145 142 154 157 
     48* 195 196 164 188 176 185 172 183 200 178 
 140 127 137 145 134 134 121 126 120 141 112 
  146* 136 138 136 137 133 140 141 136 130 127 
  245* 176 173 160 167 177 172 175 171 172 173 
Mean 165.94 167.38 166.56 165.75 165 167.63 165.81 160.19 164.69 159.38 
St. Dev. 29.82 33.32 37.20 30.29 28.15 32.14 29.66 21.48 24.25 27.48 




TableC23.  Mean Latency (sec) to 16 degree targets for older women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 205 206 197 213 248 190 184 192 195 203 
    18 255 290 238 226 210 236 262 210 240 282 
    19 231 224 238 223 246 230 226 207 215 239 
      20* 623 621 631 627 661 656 611 570 643 645 
   21 235 210 215 227 198 207 210 196 217 202 
   22 226 232 255 233 263 239 247 261 255 210 
   23 241 241 218 218 224 202 228 221 236 222 
   24 266 257 251 247 227 224 223 247 223 228 
   25 264 251 257 261 296 279 283 273 300 275 
   26 222 261 232 243 236 229 217 215 229 243 
   27 -- 226 202 234 200 201 201 215 219 242 
   28 193 175 186 169 165 185 163 169 173 187 
     29* 187 191 189 201 187 204 207 226 221 224 
     30* 211 218 227 190 210 193 204 185 194 187 
     31* -- -- -- 290 -- -- -- 245 -- 331 
120 201 224 212 199 213 276 235 228 210 209 
Mean 254.29 255.13 249.87 250.06 252.27 250.07 246.73 241.25 251.33 258.06 
St. Dev. 109.03 105.23 107.90 104.51 117.57 115.86 105.02 91.91 112.19 109.88 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C24.  Mean Latency (sec) to 16 degree targets for older men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 236 191 179 159 169 187 194 194 182 194 
  51 176 171 183 174 183 163 180 173 160 161 
  52 167 174 182 173 186 189 194 176 168 175 
  53 237 305 243 261 285 269 221 246 231 257 
  54 409 481 484 479 442 405 432 482 423 439 
  55 164 155 157 155 147 157 157 166 160 164 
  56 174 172 176 174 168 163 187 181 175 176 
  57 194 188 187 197 187 199 182 178 174 182 
  58 210 266 270 238 196 238 216 230 224 224 
  59 207 197 210 190 212 227 189 240 225 221 
     61* 191 189 166 204 222 243 188 201 224 182 
149 215 227 216 208 215 207 222 223 214 223 
160 208 206 198 225 228 196 206 185 206 193 
Mean 214.46 224.77 219.31 218.23 218.46 218.69 212.92 221.15 212.77 214.69 
St. Dev. 63.13 87.47 85.50 84.30 75.53 65.33 68.28 82.88 68.57 72.95 




Table C25.  Mean Latency (sec) to 16 degree targets for young women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 157 149 210 202 176 182 171 181 168 158 
     3 208 186 264 284 231 226 221 191 159 172 
     4 262 272 225 296 252 241 203 215 230 223 
     5 150 150 218 200 190 190 177 142 139 159 
     7 144 150 186 225 213 188 167 164 157 168 
     8 161 142 211 208 241 235 205 181 175 146 
     9 167 168 169 179 180 174 161 159 164 162 
   10 303 290 253 215 212 272 208 216 225 185 
   11 163 161 249 244 214 197 180 172 162 161 
   12 168 166 178 180 178 178 176 188 165 167 
     14* 201 197 234 285 299 233 225 209 233 227 
    15* 137 145 193 214 195 151 153 150 160 146 
    16* 171 187 242 233 199 210 215 166 190 175 
102 159 163 193 205 205 180 172 165 153 146 
111 169 166 185 235 221 224 194 185 184 196 
112 142 144 166 173 165 163 161 147 141 137 
  114* 148 150 189 179 169 170 160 173 157 153 
206 167 166 233 245 214 212 210 200 185 188 
  213* 156 168 179 168 178 177 199 171 163 159 
Mean 175.42 174.74 209.32 219.47 206.95 200.16 187.26 177.63 174.21 169.89 
St. Dev. 42.21 40.53 30.29 38.54 33.05 31.63 22.99 21.87 27.82 24.68 
           
*Minority Subjects 
  
Table C26.  Mean Latency (sec) to 16 degree targets for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 193 215 209 227 201 185 192 209 180 170 
  34 154 156 247 202 182 161 164 155 148 152 
  35 140 132 -- 140 135 127 139 139 123 134 
  36 143 147 141 146 144 133 144 151 142 151 
  37 245 222 203 209 215 207 222 217 209 212 
  38 151 142 148 158 146 163 148 149 153 149 
  39 153 156 182 243 216 187 182 162 167 162 
  41 170 171 175 172 178 166 157 165 161 162 
  42 -- 211 181 175 234 194 199 179 209 225 
  43 155 173 240 213 197 189 170 171 182 167 
  44 139 139 189 166 166 164 -- 148 136 146 
     47* 136 153 197 253 195 164 173 202 148 186 
     48* 146 144 150 -- 230 163 161 158 177 152 
 140 121 124 246 204 195 204 187 147 161 131 
  146* 133 141 158 156 160 148 148 146 158 148 
  245* 167 191 -- -- -- 227 209 182 209 177 
Mean 156.40 163.56 190.43 190.29 186.27 173.88 173 167.50 166.44 164 
St. Dev. 30.01 30.80 35.76 36.29 31.18 27.02 25 24.07 26.30 25.80 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C27.  Mean Latency (sec) to 16 degree targets for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 177 191 268 262 259 243 301 315 233 242 
    18 202 224 306 357 256 279 323 249 276 251 
    19 194 194 -- -- 348 -- 311 280 207 198 
      20* 561 595 631 558 378 709 691 689 621 651 
   21 198 209 -- 273 231 233 232 221 222 235 
   22 214 231 348 382 384 349 284 289 267 259 
   23 -- 208 -- 420 282 313 266 258 225 213 
   24 204 194 295 270 238 212 235 241 203 328 
   25 236 244 305 332 279 277 326 281 312 309 
   26 204 206 -- -- 453 344 298 289 254 249 
   27 190 187 -- -- -- -- -- -- 212 220 
   28 162 172 -- 253 250 -- -- 210 202 215 
     29* 178 184 -- 247 258 216 208 202 218 230 
     30* 193 187 -- -- 290 241 224 219 223 225 
     31* 215 210 -- -- -- -- -- -- 254 269 
120 228 193 -- -- -- -- 309 273 234 245 
Mean 223.73 226.81 358.83 335.40 300.46 310.55 308.31 286.86 260.19 271.19 
St. Dev. 95.26 99.95 135.80 98.61 68.44 140.55 121.76 120.64 100.78 106.82 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C28.  Mean Latency (sec) to 16 degree targets for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 152 171 255 256 236 186 199 185 188 335 
  51 177 170 278 291 258 228 216 205 202 197 
  52 197 185 -- -- -- -- 224 233 203 185 
  53 224 280 248 264 254 218 258 215 255 236 
  54 480 515 523 469 536 553 567 459 522 459 
  55 144 173 173 185 164 166 159 168 163 165 
  56 150 161 -- 292 246 202 220 201 197 227 
  57 182 168 256 222 200 202 180 192 190 191 
  58 186 173 222 202 210 199 187 207 194 193 
  59 219 211 -- 301 383 213 207 206 223 228 
     61* 159 164 349 234 193 211 190 178 175 177 
149 189 -- 276 292 317 256 236 215 222 219 
160 224 221 -- -- -- 315 303 218 227 225 
Mean 206.38 216 286.67 273.45 272.45 245.75 242 221.69 227.77 233.62 
St. Dev. 86.69 100.17 100.29 75.84 106.52 103.84 104.35 73.45 91.62 79.86 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C29.  Mean Latency (sec) to 16 degree targets for young women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 152 162 217 171 206 215 158 158 166 180 
     3 162 166 241 302 239 230 189 195 156 152 
     4 241 237 229 248 235 279 233 203 235 206 
     5 165 159 195 203 208 169 166 151 167 153 
     7 152 144 213 209 219 214 207 161 169 168 
     8 144 152 225 206 214 210 176 172 199 145 
     9 156 163 165 169 171 173 173 175 176 173 
   10 241 260 228 244 195 194 202 192 190 206 
   11 178 176 208 212 207 199 182 180 174 164 
   12 161 190 199 175 189 191 181 168 171 171 
     14* 195 181 180 200 179 250 191 192 191 199 
    15* 153 158 185 198 219 208 155 156 160 166 
    16* 176 158 255 192 196 180 172 176 156 165 
102 160 153 154 170 189 171 167 175 159 158 
111 185 173 210 205 215 197 198 192 181 183 
112 136 137 202 135 157 150 136 145 148 141 
  114* 142 149 165 208 183 154 151 151 149 180 
206 154 163 231 -- 211 208 209 186 195 168 
  213* 156 158 191 170 170 171 177 171 165 171 
Mean 168.89 170.47 204.89 200.94 200.11 198.05 180.16 173.63 174.05 171 
St. Dev. 29.33 30.46 27.27 37.19 22.06 32.26 23.31 16.89 21.06 18.41 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C30.  Mean Latency (sec) to 16 degree targets for young men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 171 206 217 216 170 179 198 170 175 181 
  34 154 160 231 175 156 157 151 151 147 155 
  35 124 131 129 143 142 142 136 136 129 134 
  36 141 137 142 149 141 146 143 140 144 139 
  37 222 239 199 210 196 203 197 185 209 193 
  38 166 154 165 168 164 153 159 156 147 148 
  39 156 153 189 177 210 197 171 163 170 158 
  41 -- 163 182 162 169 163 156 165 161 158 
  42 169 195 191 197 202 227 219 193 166 192 
  43 161 156 228 212 196 191 192 163 151 157 
  44 137 136 144 141 136 131 138 143 132 143 
     47* 145 152 244 173 166 169 150 152 144 142 
     48* 167 157 209 215 246 211 186 165 152 145 
 140 135 126 223 287 251 167 157 158 142 131 
  146* 142 135 146 152 159 145 140 140 141 142 
  245* 164 171 -- -- -- 184 189 183 199 181 
Mean 156.93 160.69 189.27 185.13 180.27 172.81 167.63 160.19 156.81 156.19 
St. Dev. 23.02 30.12 36.90 38.71 35.74 27.52 25.80 16.81 22.43 20.11 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C31.  Mean Latency (sec) to 16 degree targets for older women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 166 193 -- -- -- -- 205 198 196 217 
    18 257 213 341 334 303 237 321 304 248 238 
    19 183 212 -- -- -- -- 223 215 188 193 
      20* 657 644 636 713 669 491 662 673 752 704 
   21 203 206 260 264 265 241 243 242 231 249 
   22 218 204 274 354 397 304 245 251 247 237 
   23 204 204 -- 363 259 230 250 221 202 209 
   24 207 235 324 261 260 210 200 219 202 198 
   25 256 273 296 265 350 276 311 302 290 328 
   26 212 207 -- -- -- 480 292 257 261 235 
   27 175 197 -- -- -- -- -- 290 218 213 
   28 166 177 240 -- 216 -- 198 221 -- 217 
     29* 168 193 -- -- -- -- -- -- 192 224 
     30* 193 185 -- 246 232 234 253 220 222 217 
     31* 201 206 -- -- -- -- -- 261 222 217 
120 233 214 -- -- -- 247 291 288 268 225 
Mean 231.19 235.19 338.71 350 327.89 295 284.15 277.47 262.60 257.56 
St. Dev. 117.08 111.18 135.74 153.79 140.21 103.73 120.70 114.64 138.71 122.88 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table C32.  Mean Latency (sec) to 16 degree targets for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 175 183 -- -- -- -- 188 184 240 174 
  51 162 173 -- -- -- -- 220 224 212 224 
  52 186 180 -- -- 230 274 291 260 213 380 
  53 214 263 224 266 249 238 252 257 258 223 
  54 395 483 424 375 522 492 432 457 425 462 
  55 146 143 158 160 159 179 163 164 169 156 
  56 166 175 224 209 221 280 254 208 192 201 
  57 192 186 405 225 199 183 184 180 193 190 
  58 165 186 211 199 184 190 199 182 183 187 
  59 207 225 -- 296 254 205 243 219 210 231 
     61* 151 165 274 216 -- 306 219 170 187 194 
149 197 195 -- 289 274 249 231 225 228 218 
160 206 207 -- -- -- -- 301 247 297 257 
Mean 197.08 212.62 274.29 248.33 254.67 259.60 244.38 229 231.31 238.23 
St. Dev. 63.40 86.41 101.72 64.86 106.57 92.83 69.32 75.82 67.69 86.89 
           
*Minority Subjects 

















Saccadic Eye Movement Parameters 
Duration:  8 degree & 16 degree 
  
Table D1.  Duration (msec) to 8 degree targets for young women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 50.00 51.00 49.00 49.00 49.00 50.00 49.00 49.00 48.00 49.00 
     3 57.00 58.00 56.00 58.00 58.00 60.00 60.00 59.00 58.00 61.00 
     4 54.00 55.00 56.00 58.00 57.00 57.00 57.00 56.00 58.00 56.00 
     5 57.00 55.00 57.00 59.00 61.00 62.00 59.00 58.00 62.00 60.00 
     7 64.00 64.00 66.00 61.00 61.00 63.00 63.00 63.00 63.00 64.00 
     8 61.00 61.00 61.00 62.00 60.00 61.00 59.00 62.00 59.00 59.00 
     9 61.00 65.00 57.00 61.00 59.00 58.00 63.00 56.00 54.00 53.00 
   10 57.00 64.00 65.00 64.00 69.00 68.00 66.00 66.00 64.00 63.00 
   12 56.00 62.00 60.00 61.00 63.00 62.00 61.00 60.00 61.00 60.00 
     14* 50.00 53.00 53.00 54.00 55.00 54.00 53.00 54.00 53.00 51.00 
    15* 57.00 59.00 62.00 60.00 61.00 62.00 60.00 60.00 59.00 59.00 
    16* 56.00 58.00 56.00 56.00 57.00 57.00 58.00 57.00 60.00 57.00 
102 56.00 54.00 59.00 55.00 60.00 58.00 57.00 57.00 59.00 57.00 
111 57.00 58.00 58.00 61.00 57.00 57.00 55.00 57.00 57.00 57.00 
112 52.00 51.00 53.00 52.00 52.00 53.00 52.00 53.00 53.00 51.00 
  114* 67.00 60.00 61.00 62.00 61.00 64.00 58.00 60.00 62.00 61.00 
206 51.00 53.00 54.00 53.00 53.00 54.00 52.00 53.00 53.00 51.00 
  213* 55.00 57.00 54.00 56.00 56.00 55.00 55.00 55.00 54.00 54.00 
Mean 56.56 57.67 57.61 57.89 58.28 58.61 57.61 57.50 57.61 56.83 
St. Dev. 4.55 4.42 4.38 4.09 4.52 4.53 4.39 4.06 4.30 4.48 
           
*Minority Subjects 
  
Table D2.  Duration (msec) to 8 degree targets for young men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 55.00 55.00 55.00 54.00 55.00 55.00 57.00 54.00 53.00 56.00 
  34 71.00 74.00 55.00 54.00 62.00 56.00 58.00 54.00 57.00 55.00 
  35 54.00 54.00 53.00 52.00 53.00 52.00 53.00 54.00 52.00 53.00 
  36 54.00 51.00 50.00 51.00 56.00 59.00 52.00 52.00 53.00 52.00 
  37 57.00 55.00 59.00 58.00 54.00 57.00 55.00 55.00 58.00 54.00 
  38 61.00 64.00 59.00 69.00 57.00 61.00 57.00 59.00 58.00 62.00 
  39 50.00 60.00 81.00 56.00 59.00 63.00 75.00 57.00 53.00 50.00 
  41 53.00 56.00 55.00 57.00 55.00 55.00 56.00 53.00 56.00 55.00 
  42 54.00 59.00 53.00 54.00 55.00 54.00 55.00 52.00 54.00 54.00 
  43 56.00 53.00 52.00 53.00 54.00 52.00 52.00 54.00 53.00 52.00 
  44 55.00 56.00 60.00 58.00 58.00 56.00 53.00 55.00 56.00 58.00 
     47* 53.00 56.00 55.00 56.00 55.00 57.00 55.00 55.00 59.00 56.00 
     48* 62.00 61.00 60.00 59.00 57.00 60.00 59.00 60.00 58.00 61.00 
 140 53.00 56.00 54.00 54.00 54.00 54.00 54.00 56.00 54.00 54.00 
  146* 60.00 60.00 64.00 62.00 63.00 64.00 65.00 63.00 64.00 62.00 
  245* 60.00 62.00 61.00 62.00 71.00 62.00 61.00 59.00 61.00 62.00 
Mean 56.75 58.25 57.88 56.81 57.38 57.31 57.31 55.75 56.19 56.00 
St. Dev. 5.08 5.47 7.24 4.58 4.62 3.79 5.84 3.09 3.37 3.90 
           
*Minority Subjects 
  
TableD3.  Duration (msec) to 8 degree targets for older women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 60.00 61.00 61.00 65.00 60.00 60.00 58.00 58.00 58.00 61.00 
    18 52.00 60.00 77.00 63.00 61.00 56.00 57.00 57.00 62.00 55.00 
    19 59.00 62.00 61.00 65.00 69.00 60.00 59.00 61.00 62.00 59.00 
      20* 56.00 59.00 60.00 60.00 62.00 64.00 68.00 63.00 62.00 61.00 
   21 57.00 57.00 58.00 59.00 58.00 60.00 58.00 58.00 61.00 58.00 
   22 56.00 58.00 59.00 57.00 59.00 58.00 60.00 56.00 57.00 59.00 
   23 59.00 62.00 59.00 60.00 64.00 64.00 64.00 63.00 62.00 64.00 
   24 52.00 57.00 50.00 52.00 57.00 50.00 52.00 53.00 50.00 51.00 
   25 57.00 58.00 58.00 57.00 58.00 58.00 58.00 58.00 55.00 60.00 
   26 68.00 67.00 65.00 64.00 66.00 68.00 62.00 62.00 63.00 62.00 
   27 71.00 65.00 83.00 75.00 64.00 63.00 75.00 73.00 87.00 75.00 
   28 76.00 62.00 61.00 61.00 62.00 60.00 63.00 64.00 62.00 62.00 
     29* 50.00 65.00 58.00 58.00 -- 66.00 56.00 53.00 55.00 52.00 
     30* 70.00 68.00 70.00 64.00 67.00 68.00 64.00 65.00 66.00 70.00 
     31* -- 64.00 76.00 61.00 68.00 63.00 63.00 -- 62.00 62.00 
120 58.00 57.00 58.00 57.00 58.00 56.00 58.00 60.00 58.00 58.00 
Mean 60.07 61.38 63.38 61.13 62.20 60.88 60.94 60.27 61.38 60.56 
St. Dev. 7.68 3.63 8.71 5.12 3.97 4.77 5.38 5.12 7.90 5.94 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D4.  Duration (msec) to 8 degree targets for older men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 66.00 73.00 65.00 74.00 86.00 124.00 60.00 60.00 58.00 60.00 
  51 56.00 57.00 58.00 57.00 57.00 57.00 58.00 57.00 57.00 58.00 
  52 56.00 58.00 81.00 58.00 57.00 63.00 92.00 66.00 59.00 62.00 
  53 58.00 64.00 72.00 66.00 63.00 63.00 72.00 72.00 59.00 60.00 
  54 86.00 71.00 72.00 71.00 80.00 81.00 106.00 61.00 62.00 83.00 
  55 63.00 66.00 66.00 64.00 64.00 68.00 64.00 66.00 70.00 61.00 
  56 54.00 56.00 56.00 60.00 63.00 59.00 60.00 62.00 58.00 55.00 
  57 49.00 48.00 50.00 50.00 49.00 50.00 49.00 50.00 48.00 48.00 
  58 61.00 62.00 62.00 60.00 62.00 63.00 61.00 60.00 60.00 61.00 
  59 49.00 70.00 52.00 57.00 57.00 56.00 52.00 51.00 49.00 53.00 
     61* -- 56.00 51.00 53.00 54.00 53.00 57.00 58.00 55.00 57.00 
149 54.00 58.00 54.00 54.00 55.00 54.00 56.00 55.00 53.00 53.00 
160 57.00 56.00 58.00 74.00 76.00 92.00 90.00 64.00 59.00 56.00 
Mean 59.08 61.15 61.31 61.38 63.31 67.92 67.46 60.15 57.46 59.00 
St. Dev. 9.87 7.29 9.47 7.89 10.94 20.51 17.54 6.16 5.62 8.26 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D5.  Duration (msec) to 8 degree targets for young women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 47.00 52.00 50.00 64.00 50.00 51.00 47.00 48.00 62.00 48.00 
     3 59.00 62.00 63.00 57.00 59.00 58.00 57.00 55.00 58.00 57.00 
     4 55.00 56.00 58.00 56.00 58.00 59.00 56.00 57.00 56.00 57.00 
     5 54.00 55.00 57.00 56.00 63.00 58.00 56.00 57.00 57.00 60.00 
     7 59.00 62.00 63.00 62.00 63.00 62.00 62.00 60.00 60.00 64.00 
     8 59.00 61.00 60.00 60.00 60.00 60.00 61.00 61.00 61.00 60.00 
     9 57.00 55.00 56.00 59.00 59.00 60.00 59.00 60.00 58.00 57.00 
   10 55.00 58.00 66.00 67.00 65.00 59.00 65.00 60.00 65.00 59.00 
   12 56.00 58.00 64.00 63.00 67.00 63.00 60.00 60.00 59.00 65.00 
     14* 52.00 54.00 53.00 53.00 55.00 52.00 52.00 53.00 53.00 54.00 
    15* 61.00 63.00 65.00 60.00 61.00 60.00 60.00 58.00 60.00 61.00 
    16* 54.00 55.00 60.00 52.00 75.00 55.00 54.00 55.00 54.00 57.00 
102 55.00 57.00 58.00 58.00 57.00 54.00 57.00 59.00 58.00 58.00 
111 57.00 56.00 57.00 57.00 58.00 57.00 57.00 58.00 58.00 57.00 
112 50.00 50.00 50.00 51.00 52.00 51.00 50.00 50.00 50.00 50.00 
  114* 61.00 58.00 61.00 60.00 57.00 58.00 58.00 58.00 61.00 60.00 
206 52.00 53.00 53.00 53.00 -- 54.00 56.00 54.00 52.00 52.00 
  213* -- -- 56.00 59.00 -- 56.00 55.00 56.00 54.00 55.00 
Mean 55.47 56.76 58.33 58.17 59.94 57.06 56.78 56.61 57.56 57.28 
St. Dev. 3.83 3.68 4.86 4.31 5.97 3.59 4.32 3.60 3.84 4.39 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D6.  Duration (msec) to 8 degree targets for young men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 57.00 56.00 56.00 55.00 55.00 56.00 55.00 55.00 55.00 55.00 
  34 71.00 58.00 58.00 66.00 55.00 59.00 57.00 61.00 62.00 58.00 
  35 70.00 51.00 53.00 53.00 52.00 52.00 52.00 53.00 53.00 52.00 
  36 56.00 54.00 52.00 52.00 52.00 52.00 52.00 52.00 50.00 52.00 
  37 56.00 55.00 57.00 56.00 56.00 58.00 58.00 57.00 55.00 55.00 
  38 55.00 56.00 63.00 56.00 56.00 58.00 60.00 57.00 59.00 62.00 
  39 50.00 54.00 54.00 65.00 67.00 57.00 59.00 66.00 54.00 52.00 
  41 54.00 54.00 55.00 55.00 55.00 55.00 56.00 55.00 55.00 54.00 
  42 54.00 51.00 52.00 53.00 52.00 54.00 52.00 53.00 53.00 54.00 
  43 53.00 53.00 54.00 57.00 53.00 52.00 54.00 53.00 50.00 51.00 
  44 52.00 53.00 55.00 54.00 54.00 56.00 55.00 59.00 54.00 54.00 
     47* 55.00 56.00 56.00 56.00 56.00 53.00 56.00 57.00 56.00 56.00 
     48* 59.00 64.00 58.00 64.00 57.00 59.00 64.00 59.00 62.00 59.00 
 140 52.00 56.00 56.00 52.00 62.00 54.00 53.00 53.00 54.00 53.00 
  146* 63.00 63.00 69.00 63.00 63.00 66.00 61.00 63.00 68.00 62.00 
  245* 60.00 63.00 60.00 63.00 66.00 67.00 64.00 63.00 63.00 63.00 
Mean 57.31 56.06 56.75 57.50 56.94 56.75 56.75 57.25 56.44 55.75 
St. Dev. 6.09 4.06 4.36 4.93 4.88 4.51 3.97 4.27 5.01 3.91 
           
*Minority Subjects 
  
Table D7.  Duration (msec) to 8 degree targets for older women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 61.00 61.00 61.00 71.00 79.00 60.00 57.00 62.00 59.00 59.00 
    18 61.00 76.00 78.00 77.00 59.00 56.00 56.00 61.00 55.00 54.00 
    19 60.00 58.00 61.00 57.00 66.00 63.00 57.00 62.00 61.00 58.00 
      20* 63.00 60.00 66.00 64.00 78.00 67.00 69.00 61.00 65.00 76.00 
   21 58.00 57.00 57.00 59.00 61.00 59.00 60.00 59.00 63.00 59.00 
   22 59.00 55.00 57.00 55.00 58.00 64.00 60.00 63.00 58.00 57.00 
   23 76.00 91.00 69.00 67.00 63.00 66.00 60.00 59.00 62.00 69.00 
   24 54.00 54.00 50.00 53.00 51.00 51.00 53.00 51.00 53.00 52.00 
   25 58.00 57.00 58.00 59.00 57.00 58.00 56.00 59.00 56.00 55.00 
   26 63.00 66.00 67.00 70.00 72.00 71.00 63.00 67.00 62.00 65.00 
   27 -- 67.00 66.00 63.00 57.00 62.00 63.00 76.00 66.00 84.00 
   28 62.00 60.00 60.00 62.00 61.00 66.00 60.00 61.00 61.00 60.00 
     29* 54.00 54.00 54.00 53.00 49.00 58.00 57.00 58.00 54.00 54.00 
     30* 65.00 71.00 69.00 65.00 66.00 75.00 69.00 60.00 68.00 59.00 
     31* -- -- -- 69.00 -- -- -- 73.00 -- 70.00 
120 57.00 58.00 58.00 58.00 57.00 62.00 59.00 58.00 58.00 58.00 
Mean 60.79 63.00 62.07 62.63 62.27 62.53 59.93 61.88 60.07 61.81 
St. Dev. 5.45 10.04 7.11 6.94 8.74 6.03 4.54 5.94 4.46 8.82 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D8.  Duration (msec) to 8 degree targets for older men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 56.00 60.00 59.00 55.00 62.00 56.00 58.00 60.00 58.00 56.00 
  51 57.00 57.00 67.00 60.00 62.00 57.00 58.00 59.00 58.00 62.00 
  52 61.00 56.00 60.00 59.00 58.00 63.00 79.00 58.00 58.00 58.00 
  53 58.00 64.00 64.00 64.00 65.00 63.00 62.00 79.00 72.00 60.00 
  54 90.00 75.00 77.00 79.00 90.00 92.00 96.00 81.00 63.00 66.00 
  55 75.00 66.00 69.00 71.00 67.00 65.00 69.00 63.00 67.00 63.00 
  56 59.00 57.00 55.00 58.00 55.00 57.00 57.00 53.00 53.00 54.00 
  57 48.00 50.00 54.00 54.00 48.00 51.00 51.00 49.00 48.00 48.00 
  58 59.00 62.00 63.00 61.00 62.00 60.00 59.00 60.00 61.00 60.00 
  59 55.00 48.00 54.00 56.00 51.00 51.00 53.00 48.00 50.00 49.00 
     61* 53.00 55.00 52.00 53.00 54.00 49.00 53.00 53.00 54.00 52.00 
149 56.00 67.00 59.00 54.00 65.00 80.00 70.00 54.00 52.00 51.00 
160 72.00 89.00 88.00 55.00 103.00 87.00 61.00 56.00 95.00 81.00 
Mean 61.46 62.00 63.15 59.92 64.77 63.92 63.54 59.46 60.69 58.46 
St. Dev. 11.21 10.89 10.25 7.59 15.42 13.88 12.51 10.11 12.34 8.78 
           
*Minority Subjects 
  
Table D9.  Duration (msec) to 8 degree targets for young women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 51.00 64.00 157.00 169.00 190.00 131.00 118.00 103.00 166.00 63.00 
     3 57.00 60.00 74.00 77.00 59.00 62.00 66.00 65.00 59.00 63.00 
     4 55.00 56.00 79.00 136.00 72.00 75.00 63.00 63.00 61.00 61.00 
     5 63.00 60.00 149.00 146.00 138.00 124.00 71.00 60.00 60.00 58.00 
     7 58.00 63.00 106.00 108.00 133.00 87.00 73.00 73.00 74.00 81.00 
     8 65.00 65.00 73.00 109.00 119.00 82.00 141.00 65.00 67.00 66.00 
     9 57.00 57.00 67.00 100.00 109.00 82.00 71.00 67.00 67.00 65.00 
   10 65.00 62.00 70.00 88.00 87.00 76.00 73.00 69.00 67.00 65.00 
   11 55.00 60.00 126.00 121.00 104.00 95.00 72.00 57.00 58.00 59.00 
   12 61.00 62.00 63.00 175.00 150.00 114.00 223.00 69.00 65.00 79.00 
     14* 55.00 55.00 60.00 84.00 80.00 58.00 57.00 60.00 59.00 58.00 
    15* 58.00 59.00 102.00 158.00 155.00 68.00 68.00 66.00 66.00 64.00 
    16* 58.00 64.00 71.00 86.00 80.00 107.00 82.00 61.00 60.00 63.00 
102 57.00 60.00 94.00 194.00 130.00 85.00 69.00 63.00 61.00 61.00 
111 57.00 57.00 61.00 127.00 148.00 83.00 67.00 64.00 63.00 62.00 
112 51.00 52.00 88.00 82.00 110.00 78.00 83.00 57.00 55.00 53.00 
  114* 65.00 70.00 92.00 102.00 113.00 102.00 73.00 74.00 76.00 65.00 
206 53.00 54.00 67.00 109.00 126.00 141.00 92.00 66.00 72.00 58.00 
  213* 56.00 57.00 80.00 82.00 75.00 69.00 65.00 61.00 58.00 58.00 
Mean 57.74 59.84 88.37 118.58 114.63 90.47 85.63 66.47 69.16 63.26 
St. Dev. 4.33 4.36 28.57 35.44 33.96 23.54 38.88 10.01 24.14 6.77 
           
*Minority Subjects 
  
Table D10.  Duration (msec) to 8 degree targets for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 54.00 55.00 92.00 102.00 96.00 61.00 86.00 57.00 56.00 54.00 
  34 66.00 56.00 162.00 165.00 132.00 87.00 86.00 67.00 58.00 59.00 
  35 56.00 50.00 -- 55.00 58.00 55.00 52.00 53.00 55.00 53.00 
  36 51.00 52.00 53.00 56.00 56.00 59.00 63.00 56.00 59.00 55.00 
  37 58.00 56.00 74.00 65.00 81.00 59.00 57.00 57.00 56.00 55.00 
  38 57.00 57.00 100.00 191.00 87.00 83.00 61.00 57.00 57.00 55.00 
  39 52.00 53.00 158.00 152.00 97.00 140.00 81.00 62.00 61.00 57.00 
  41 54.00 55.00 59.00 67.00 60.00 61.00 62.00 58.00 57.00 56.00 
  42 -- 59.00 88.00 111.00 77.00 70.00 61.00 60.00 57.00 55.00 
  43 53.00 54.00 97.00 116.00 117.00 61.00 62.00 59.00 57.00 56.00 
  44 54.00 53.00 63.00 171.00 188.00 120.00 -- 72.00 60.00 56.00 
     47* 54.00 55.00 75.00 70.00 76.00 61.00 62.00 61.00 60.00 60.00 
     48* 55.00 59.00 109.00 -- 143.00 68.00 68.00 63.00 66.00 66.00 
 140 54.00 58.00 96.00 128.00 108.00 102.00 82.00 62.00 59.00 59.00 
  146* 63.00 67.00 98.00 109.00 184.00 92.00 92.00 68.00 66.00 64.00 
  245* 61.00 64.00 -- -- -- 74.00 63.00 64.00 65.00 67.00 
Mean 56.13 56.44 94.57 111.29 104.00 78.31 69.20 61.00 59.31 57.94 
St. Dev. 4.22 4.34 32.43 45.48 42.04 24.59 12.54 4.98 3.55 4.30 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D11.  Duration (msec) to 8 degree targets for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 61.00 64.00 118.00 169.00 163.00 129.00 99.00 263.00 129.00 223.00 
    18 56.00 56.00 136.00 112.00 105.00 138.00 82.00 60.00 58.00 63.00 
    19 60.00 60.00 -- -- 182.00 -- 120.00 113.00 93.00 92.00 
      20* 56.00 58.00 71.00 109.00 87.00 144.00 118.00 89.00 128.00 96.00 
   21 55.00 56.00 -- 146.00 126.00 70.00 69.00 60.00 60.00 62.00 
   22 57.00 57.00 178.00 145.00 220.00 124.00 127.00 68.00 71.00 64.00 
   23 -- 62.00 -- 163.00 153.00 57.00 96.00 94.00 65.00 67.00 
   24 49.00 53.00 76.00 112.00 76.00 53.00 58.00 60.00 52.00 -- 
   25 59.00 57.00 59.00 157.00 133.00 65.00 64.00 64.00 63.00 67.00 
   26 63.00 65.00 -- -- 64.00 81.00 76.00 65.00 125.00 62.00 
   27 73.00 64.00 -- -- -- -- -- -- 76.00 77.00 
   28 60.00 59.00 -- 83.00 73.00 -- -- 93.00 66.00 76.00 
     29* 58.00 53.00 -- 161.00 117.00 135.00 76.00 91.00 66.00 139.00 
     30* 71.00 62.00 -- -- 107.00 139.00 95.00 92.00 103.00 86.00 
     31* 65.00 64.00 -- -- -- -- -- -- 68.00 69.00 
120 58.00 58.00 -- -- -- -- 80.00 78.00 68.00 61.00 
Mean 60.07 59.25 106.33 135.70 123.54 103.18 89.23 92.14 80.69 86.93 
St. Dev. 6.10 3.91 45.96 29.35 46.19 37.38 22.14 51.93 26.31 42.83 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D12.  Duration (msec) to 8 degree targets for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 65.00 55.00 151.00 172.00 68.00 60.00 70.00 63.00 66.00 75.00 
  51 56.00 58.00 91.00 74.00 100.00 58.00 60.00 57.00 62.00 61.00 
  52 59.00 69.00 -- -- -- -- 77.00 95.00 68.00 72.00 
  53 59.00 64.00 91.00 74.00 74.00 93.00 62.00 62.00 63.00 61.00 
  54 78.00 73.00 118.00 135.00 126.00 147.00 193.00 65.00 92.00 86.00 
  55 64.00 76.00 76.00 90.00 74.00 71.00 73.00 68.00 66.00 69.00 
  56 58.00 55.00 -- 168.00 126.00 83.00 77.00 79.00 65.00 81.00 
  57 51.00 51.00 51.00 53.00 59.00 55.00 53.00 53.00 51.00 52.00 
  58 62.00 60.00 74.00 73.00 76.00 69.00 65.00 66.00 64.00 65.00 
  59 48.00 50.00 -- 107.00 57.00 54.00 54.00 56.00 54.00 52.00 
     61* 53.00 54.00 85.00 60.00 62.00 59.00 57.00 54.00 55.00 56.00 
149 52.00 -- 120.00 132.00 142.00 130.00 109.00 58.00 73.00 59.00 
160 59.00 79.00 -- -- -- 165.00 128.00 138.00 141.00 133.00 
Mean 58.77 62.00 95.22 103.45 87.64 87.00 82.92 70.31 70.77 70.92 
St. Dev. 7.69 10.03 29.92 42.38 30.60 38.88 39.64 23.35 23.41 21.44 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D13.  Duration (msec) to 8 degree targets for young women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 49.00 56.00 121.00 149.00 114.00 151.00 77.00 67.00 51.00 52.00 
     3 59.00 58.00 87.00 69.00 113.00 74.00 71.00 64.00 61.00 59.00 
     4 56.00 56.00 69.00 84.00 74.00 68.00 64.00 61.00 61.00 63.00 
     5 61.00 58.00 138.00 130.00 142.00 81.00 69.00 65.00 74.00 65.00 
     7 59.00 63.00 119.00 133.00 121.00 94.00 87.00 73.00 70.00 71.00 
     8 59.00 62.00 69.00 86.00 79.00 78.00 74.00 69.00 68.00 62.00 
     9 57.00 63.00 66.00 80.00 104.00 86.00 72.00 58.00 63.00 61.00 
   10 60.00 62.00 84.00 101.00 105.00 68.00 66.00 67.00 62.00 62.00 
   11 55.00 57.00 92.00 114.00 104.00 63.00 66.00 60.00 57.00 56.00 
   12 60.00 71.00 147.00 191.00 164.00 125.00 77.00 68.00 65.00 68.00 
     14* 52.00 53.00 55.00 56.00 54.00 54.00 56.00 53.00 53.00 53.00 
    15* 60.00 60.00 69.00 97.00 147.00 111.00 67.00 69.00 69.00 73.00 
    16* 59.00 55.00 99.00 67.00 92.00 66.00 65.00 59.00 59.00 58.00 
102 58.00 59.00 61.00 70.00 84.00 86.00 62.00 69.00 60.00 61.00 
111 56.00 58.00 90.00 132.00 133.00 74.00 105.00 63.00 58.00 59.00 
112 52.00 50.00 78.00 58.00 64.00 55.00 53.00 56.00 53.00 54.00 
  114* 60.00 59.00 93.00 121.00 77.00 74.00 66.00 63.00 67.00 63.00 
206 53.00 55.00 66.00 -- 99.00 87.00 79.00 57.00 61.00 57.00 
  213* 56.00 55.00 155.00 84.00 67.00 66.00 64.00 60.00 57.00 58.00 
Mean 56.89 58.42 92.53 101.22 101.95 82.16 70.53 63.21 61.53 60.79 
St. Dev. 3.38 4.59 30.08 36.03 30.20 24.31 11.58 5.36 6.19 5.67 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D14.  Duration (msec) to 8 degree targets for young men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 54.00 55.00 104.00 205.00 118.00 58.00 72.00 55.00 56.00 56.00 
  34 63.00 61.00 105.00 119.00 94.00 74.00 66.00 72.00 62.00 60.00 
  35 53.00 52.00 54.00 54.00 58.00 54.00 56.00 55.00 55.00 52.00 
  36 56.00 53.00 53.00 55.00 58.00 58.00 57.00 56.00 60.00 56.00 
  37 57.00 56.00 66.00 68.00 70.00 59.00 58.00 56.00 58.00 56.00 
  38 57.00 57.00 115.00 199.00 97.00 64.00 65.00 55.00 57.00 56.00 
  39 50.00 55.00 65.00 106.00 106.00 219.00 68.00 62.00 67.00 66.00 
  41 -- 56.00 67.00 62.00 69.00 65.00 61.00 58.00 57.00 57.00 
  42 54.00 55.00 55.00 69.00 78.00 70.00 59.00 58.00 58.00 57.00 
  43 54.00 52.00 79.00 114.00 88.00 67.00 74.00 58.00 54.00 55.00 
  44 59.00 55.00 70.00 81.00 74.00 60.00 81.00 63.00 57.00 58.00 
     47* 55.00 55.00 66.00 67.00 61.00 61.00 60.00 61.00 59.00 58.00 
     48* 59.00 63.00 90.00 90.00 140.00 151.00 115.00 73.00 69.00 70.00 
 140 54.00 55.00 125.00 233.00 162.00 97.00 95.00 76.00 78.00 58.00 
  146* 61.00 64.00 69.00 91.00 119.00 76.00 66.00 66.00 68.00 64.00 
  245* 62.00 62.00 -- -- -- 66.00 65.00 65.00 67.00 66.00 
Mean 56.53 56.63 78.87 107.53 92.80 81.19 69.88 61.81 61.38 59.06 
St. Dev. 3.66 3.79 23.25 58.22 31.22 43.57 15.68 6.88 6.60 4.88 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D15.  Duration (msec) to 8 degree targets for older women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 74.00 62.00 -- -- -- -- 91.00 88.00 112.00 93.00 
    18 59.00 58.00 96.00 100.00 117.00 82.00 91.00 83.00 63.00 76.00 
    19 57.00 61.00 -- -- -- -- 98.00 117.00 80.00 75.00 
      20* 65.00 64.00 120.00 99.00 151.00 125.00 153.00 110.00 110.00 164.00 
   21 58.00 57.00 143.00 164.00 113.00 80.00 73.00 72.00 73.00 67.00 
   22 56.00 57.00 127.00 177.00 169.00 73.00 74.00 66.00 67.00 64.00 
   23 58.00 59.00 -- 69.00 87.00 85.00 65.00 71.00 71.00 63.00 
   24 51.00 51.00 92.00 61.00 98.00 55.00 69.00 53.00 55.00 53.00 
   25 72.00 57.00 64.00 194.00 226.00 139.00 79.00 74.00 132.00 110.00 
   26 66.00 62.00 -- -- -- 210.00 284.00 147.00 232.00 60.00 
   27 59.00 90.00 -- -- -- -- -- 79.00 70.00 83.00 
   28 60.00 60.00 93.00 -- 88.00 -- 77.00 88.00 -- 79.00 
     29* 69.00 79.00 -- -- -- -- -- -- 69.00 54.00 
     30* 67.00 63.00 -- 125.00 92.00 103.00 222.00 83.00 79.00 83.00 
     31* 63.00 68.00 -- -- -- -- -- 79.00 65.00 70.00 
120 57.00 58.00 -- -- -- 81.00 140.00 87.00 63.00 72.00 
Mean 61.94 62.88 105.00 123.63 126.78 103.30 116.62 86.47 89.40 79.13 
St. Dev. 6.35 9.46 26.55 50.01 46.94 44.98 67.26 23.04 45.00 26.90 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D16.  Duration (msec) to 8 degree targets for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 58.00 60.00 -- -- -- -- 64.00 65.00 83.00 70.00 
  51 58.00 58.00 -- -- -- -- 59.00 62.00 60.00 60.00 
  52 57.00 69.00 -- -- 127.00 106.00 101.00 106.00 103.00 130.00 
  53 58.00 88.00 62.00 89.00 94.00 80.00 70.00 65.00 66.00 62.00 
  54 91.00 70.00 181.00 181.00 284.00 212.00 244.00 110.00 88.00 73.00 
  55 67.00 69.00 83.00 69.00 66.00 77.00 66.00 69.00 67.00 64.00 
  56 56.00 55.00 94.00 77.00 101.00 104.00 106.00 90.00 77.00 70.00 
  57 50.00 50.00 54.00 60.00 72.00 65.00 53.00 54.00 53.00 48.00 
  58 60.00 61.00 71.00 81.00 72.00 74.00 66.00 66.00 66.00 66.00 
  59 51.00 52.00 -- 68.00 72.00 54.00 54.00 50.00 61.00 84.00 
     61* 51.00 54.00 76.00 73.00 -- 86.00 78.00 59.00 57.00 58.00 
149 54.00 54.00 -- 146.00 152.00 74.00 101.00 69.00 65.00 74.00 
160 68.00 71.00 -- -- -- -- 199.00 173.00 209.00 222.00 
Mean 59.92 62.38 88.71 93.78 115.56 93.20 97.00 79.85 81.15 83.15 
St. Dev. 10.84 10.64 42.76 41.31 69.51 44.66 58.78 33.61 40.87 46.12 
           
*Minority Subjects 
(--) Duration not obtained 
 
  
Table D17.  Duration (msec) to 16 degree targets for young women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 57.00 59.00 60.00 65.00 62.00 62.00 59.00 59.00 65.00 58.00 
     3 76.00 72.00 70.00 71.00 73.00 76.00 78.00 73.00 77.00 79.00 
     4 71.00 74.00 75.00 76.00 81.00 73.00 75.00 76.00 70.00 73.00 
     5 74.00 71.00 72.00 72.00 74.00 79.00 72.00 75.00 77.00 75.00 
     7 81.00 79.00 84.00 80.00 82.00 83.00 88.00 84.00 85.00 85.00 
     8 76.00 75.00 75.00 78.00 75.00 75.00 74.00 76.00 84.00 76.00 
     9 79.00 81.00 71.00 72.00 74.00 74.00 79.00 81.00 70.00 69.00 
   10 73.00 83.00 81.00 78.00 79.00 78.00 79.00 81.00 82.00 85.00 
   12 72.00 72.00 80.00 76.00 77.00 78.00 73.00 76.00 69.00 78.00 
     14* 63.00 65.00 64.00 67.00 67.00 66.00 67.00 68.00 69.00 64.00 
    15* 73.00 68.00 78.00 75.00 69.00 72.00 72.00 71.00 75.00 74.00 
    16* 71.00 74.00 73.00 73.00 72.00 70.00 71.00 71.00 76.00 71.00 
102 77.00 77.00 77.00 81.00 79.00 76.00 79.00 79.00 80.00 78.00 
111 72.00 71.00 74.00 80.00 78.00 74.00 73.00 74.00 74.00 73.00 
112 64.00 66.00 65.00 68.00 66.00 64.00 65.00 65.00 66.00 64.00 
  114* 87.00 73.00 75.00 77.00 76.00 83.00 78.00 74.00 73.00 73.00 
206 66.00 68.00 69.00 68.00 69.00 69.00 67.00 70.00 66.00 72.00 
  213* 68.00 67.00 66.00 68.00 69.00 69.00 71.00 68.00 68.00 69.00 
Mean 72.22 71.94 72.72 73.61 73.44 73.39 73.33 73.39 73.67 73.11 
St. Dev. 7.03 5.98 6.32 5.00 5.55 5.94 6.54 6.15 6.28 6.91 
           
*Minority Subjects 
  
Table D18.  Duration (msec) to 16 degree targets for young men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 68.00 71.00 70.00 68.00 75.00 74.00 74.00 71.00 69.00 71.00 
  34 84.00 84.00 70.00 69.00 73.00 69.00 71.00 71.00 71.00 68.00 
  35 66.00 66.00 67.00 66.00 68.00 67.00 67.00 67.00 66.00 69.00 
  36 64.00 66.00 66.00 64.00 73.00 71.00 65.00 67.00 70.00 68.00 
  37 76.00 71.00 78.00 79.00 76.00 76.00 74.00 77.00 76.00 73.00 
  38 73.00 72.00 77.00 73.00 72.00 71.00 69.00 69.00 75.00 71.00 
  39 63.00 72.00 77.00 71.00 67.00 70.00 78.00 71.00 66.00 69.00 
  41 71.00 76.00 73.00 74.00 74.00 74.00 71.00 70.00 70.00 71.00 
  42 73.00 74.00 71.00 73.00 78.00 73.00 74.00 72.00 65.00 69.00 
  43 67.00 69.00 66.00 65.00 70.00 68.00 68.00 69.00 67.00 66.00 
  44 77.00 77.00 86.00 82.00 75.00 74.00 71.00 76.00 76.00 73.00 
     47* 69.00 68.00 67.00 68.00 70.00 70.00 67.00 67.00 71.00 67.00 
     48* 75.00 79.00 80.00 79.00 77.00 78.00 82.00 81.00 81.00 87.00 
 140 66.00 71.00 72.00 84.00 67.00 81.00 72.00 71.00 67.00 73.00 
  146* 73.00 76.00 79.00 76.00 77.00 79.00 85.00 76.00 86.00 77.00 
  245* 73.00 74.00 75.00 77.00 79.00 75.00 77.00 76.00 77.00 76.00 
Mean 71.13 72.88 73.38 73.00 73.19 73.13 72.81 71.94 72.06 71.75 
St. Dev. 5.50 4.80 5.81 6.13 3.89 4.03 5.53 4.12 5.96 5.11 
           
*Minority Subjects 
  
Table D19.  Duration (msec) to 16 degree targets for older women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 76.00 77.00 77.00 79.00 76.00 74.00 77.00 73.00 72.00 77.00 
    18 65.00 69.00 62.00 75.00 68.00 65.00 78.00 66.00 74.00 71.00 
    19 74.00 79.00 78.00 80.00 85.00 76.00 79.00 76.00 74.00 78.00 
      20* 74.00 75.00 78.00 74.00 80.00 78.00 81.00 78.00 79.00 83.00 
   21 84.00 80.00 77.00 87.00 81.00 93.00 81.00 80.00 81.00 84.00 
   22 87.00 72.00 77.00 75.00 85.00 86.00 81.00 75.00 78.00 76.00 
   23 78.00 79.00 74.00 76.00 79.00 84.00 83.00 84.00 79.00 84.00 
   24 68.00 65.00 64.00 60.00 67.00 70.00 68.00 65.00 61.00 67.00 
   25 81.00 73.00 72.00 72.00 67.00 76.00 79.00 77.00 69.00 73.00 
   26 101.00 113.00 109.00 96.00 108.00 98.00 97.00 98.00 97.00 91.00 
   27 113.00 83.00 81.00 70.00 90.00 109.00 84.00 89.00 75.00 87.00 
   28 75.00 73.00 71.00 73.00 76.00 77.00 77.00 82.00 76.00 78.00 
     29* 68.00 73.00 77.00 76.00 -- 81.00 70.00 66.00 65.00 65.00 
     30* 79.00 99.00 105.00 84.00 102.00 85.00 89.00 102.00 95.00 95.00 
     31* -- 84.00 119.00 85.00 108.00 75.00 83.00 -- 79.00 80.00 
120 73.00 74.00 77.00 74.00 75.00 75.00 97.00 75.00 79.00 80.00 
Mean 79.73 79.25 81.13 77.25 83.13 81.38 81.50 79.07 77.06 79.31 
St. Dev. 12.75 11.82 15.88 8.14 13.62 11.07 7.87 10.83 9.20 8.11 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D20.  Duration (msec) to 16 degree targets for older men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 80.00 109.00 88.00 86.00 85.00 92.00 79.00 -- 77.00 82.00 
  51 72.00 73.00 75.00 76.00 72.00 71.00 73.00 74.00 71.00 69.00 
  52 76.00 84.00 82.00 71.00 71.00 72.00 134.00 82.00 71.00 79.00 
  53 91.00 95.00 93.00 89.00 81.00 87.00 93.00 92.00 79.00 86.00 
  54 120.00 108.00 110.00 116.00 118.00 122.00 161.00 87.00 95.00 114.00 
  55 79.00 85.00 83.00 86.00 83.00 83.00 82.00 89.00 84.00 86.00 
  56 74.00 74.00 84.00 67.00 69.00 79.00 79.00 81.00 71.00 64.00 
  57 58.00 59.00 61.00 67.00 66.00 64.00 63.00 64.00 58.00 62.00 
  58 82.00 87.00 82.00 83.00 80.00 86.00 80.00 84.00 79.00 81.00 
  59 58.00 83.00 70.00 61.00 68.00 75.00 65.00 65.00 59.00 72.00 
     61* -- 68.00 66.00 68.00 68.00 73.00 70.00 70.00 64.00 67.00 
149 67.00 69.00 69.00 67.00 72.00 69.00 68.00 68.00 70.00 67.00 
160 81.00 87.00 80.00 91.00 102.00 102.00 104.00 87.00 79.00 90.00 
Mean 78.17 83.15 80.23 79.08 79.62 82.69 88.54 78.58 73.62 78.38 
St. Dev. 16.35 14.89 12.81 14.94 15.21 15.78 28.99 9.91 10.19 14.15 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D21.  Duration (msec) to 16 degree targets for young women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 56.00 61.00 58.00 66.00 63.00 59.00 58.00 58.00 70.00 59.00 
     3 78.00 82.00 78.00 74.00 74.00 74.00 72.00 74.00 73.00 72.00 
     4 73.00 75.00 75.00 74.00 78.00 76.00 77.00 76.00 72.00 74.00 
     5 68.00 69.00 73.00 69.00 70.00 76.00 62.00 72.00 69.00 75.00 
     7 78.00 81.00 88.00 83.00 83.00 82.00 83.00 81.00 82.00 82.00 
     8 74.00 75.00 75.00 79.00 75.00 79.00 77.00 78.00 76.00 76.00 
     9 73.00 73.00 70.00 75.00 72.00 74.00 72.00 76.00 70.00 70.00 
   10 69.00 74.00 74.00 79.00 78.00 74.00 78.00 76.00 81.00 75.00 
   12 75.00 74.00 78.00 74.00 76.00 73.00 72.00 75.00 74.00 75.00 
     14* 65.00 72.00 70.00 67.00 68.00 69.00 68.00 66.00 68.00 67.00 
    15* 72.00 75.00 69.00 77.00 78.00 76.00 77.00 71.00 79.00 79.00 
    16* 70.00 67.00 73.00 58.00 74.00 70.00 70.00 72.00 68.00 69.00 
102 75.00 80.00 80.00 81.00 78.00 79.00 75.00 84.00 80.00 78.00 
111 75.00 73.00 74.00 74.00 76.00 74.00 75.00 75.00 76.00 76.00 
112 61.00 64.00 59.00 64.00 66.00 64.00 63.00 64.00 64.00 64.00 
  114* 74.00 76.00 79.00 72.00 72.00 73.00 73.00 72.00 73.00 76.00 
206 71.00 70.00 68.00 71.00 -- 70.00 78.00 70.00 67.00 67.00 
  213* -- -- 67.00 66.00 -- 69.00 63.00 66.00 66.00 65.00 
Mean 71.00 73.00 72.67 72.39 73.81 72.83 71.83 72.56 72.67 72.17 
St. Dev. 5.85 5.61 7.21 6.48 5.15 5.48 6.71 6.24 5.41 5.98 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D22.  Duration (msec) to 16 degree targets for young men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 73.00 75.00 77.00 70.00 70.00 70.00 76.00 69.00 68.00 68.00 
  34 76.00 68.00 72.00 77.00 72.00 77.00 74.00 89.00 92.00 79.00 
  35 82.00 68.00 67.00 67.00 68.00 68.00 68.00 69.00 68.00 67.00 
  36 67.00 69.00 67.00 69.00 64.00 64.00 66.00 66.00 70.00 65.00 
  37 73.00 72.00 75.00 74.00 81.00 77.00 79.00 74.00 75.00 75.00 
  38 69.00 71.00 87.00 69.00 69.00 79.00 74.00 72.00 72.00 79.00 
  39 62.00 70.00 68.00 74.00 77.00 75.00 80.00 77.00 67.00 65.00 
  41 66.00 67.00 72.00 69.00 75.00 69.00 72.00 70.00 69.00 70.00 
  42 66.00 67.00 69.00 66.00 66.00 70.00 71.00 71.00 67.00 70.00 
  43 65.00 67.00 68.00 71.00 67.00 68.00 67.00 66.00 64.00 66.00 
  44 74.00 77.00 78.00 73.00 80.00 73.00 73.00 72.00 70.00 72.00 
     47* 67.00 69.00 72.00 67.00 67.00 64.00 68.00 65.00 67.00 68.00 
     48* 80.00 72.00 78.00 71.00 78.00 73.00 77.00 76.00 80.00 70.00 
 140 69.00 70.00 72.00 79.00 74.00 77.00 68.00 67.00 67.00 62.00 
  146* 81.00 77.00 78.00 80.00 76.00 85.00 78.00 83.00 84.00 84.00 
  245* 73.00 76.00 77.00 77.00 97.00 79.00 78.00 75.00 77.00 77.00 
Mean 71.44 70.94 73.56 72.06 73.81 73.00 73.06 72.56 72.31 71.06 
St. Dev. 6.07 3.57 5.44 4.40 8.11 5.85 4.67 6.47 7.54 6.14 
           
*Minority Subjects 
  
Table D23.  Duration (msec) to 16 degree targets for older women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 74.00 75.00 81.00 95.00 93.00 77.00 73.00 73.00 75.00 76.00 
    18 85.00 72.00 82.00 88.00 69.00 71.00 75.00 76.00 72.00 74.00 
    19 79.00 74.00 78.00 75.00 89.00 78.00 78.00 81.00 86.00 77.00 
      20* 89.00 85.00 86.00 83.00 87.00 88.00 81.00 79.00 85.00 85.00 
   21 84.00 92.00 83.00 85.00 82.00 85.00 83.00 80.00 84.00 78.00 
   22 78.00 73.00 78.00 77.00 77.00 76.00 82.00 77.00 83.00 88.00 
   23 89.00 84.00 97.00 92.00 82.00 84.00 84.00 80.00 83.00 86.00 
   24 69.00 69.00 69.00 67.00 72.00 67.00 66.00 74.00 71.00 64.00 
   25 71.00 73.00 70.00 68.00 68.00 70.00 70.00 73.00 76.00 71.00 
   26 106.00 99.00 103.00 123.00 133.00 117.00 109.00 101.00 90.00 107.00 
   27 -- 71.00 70.00 85.00 70.00 85.00 85.00 84.00 92.00 134.00 
   28 72.00 71.00 76.00 77.00 75.00 81.00 76.00 76.00 75.00 76.00 
     29* 64.00 65.00 66.00 74.00 62.00 68.00 70.00 72.00 67.00 72.00 
     30* 86.00 98.00 87.00 88.00 100.00 96.00 99.00 88.00 96.00 87.00 
     31* -- -- -- 88.00 -- -- -- 83.00 -- 88.00 
120 73.00 77.00 75.00 76.00 77.00 87.00 77.00 75.00 80.00 76.00 
Mean 79.93 78.53 80.07 83.81 82.40 82.00 80.53 79.50 81.00 83.69 
St. Dev. 10.84 10.62 10.29 13.28 17.37 12.73 11.19 7.27 8.28 16.66 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D24.  Duration (msec) to 16 degree targets for older men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 76.00 74.00 84.00 70.00 73.00 76.00 72.00 75.00 76.00 73.00 
  51 71.00 73.00 80.00 76.00 81.00 79.00 73.00 81.00 74.00 69.00 
  52 76.00 75.00 73.00 81.00 80.00 92.00 107.00 77.00 74.00 76.00 
  53 78.00 83.00 80.00 83.00 87.00 94.00 83.00 83.00 89.00 93.00 
  54 141.00 110.00 112.00 124.00 117.00 121.00 142.00 121.00 97.00 114.00 
  55 86.00 84.00 83.00 90.00 83.00 80.00 88.00 82.00 80.00 86.00 
  56 74.00 74.00 71.00 70.00 71.00 72.00 71.00 73.00 74.00 73.00 
  57 62.00 59.00 64.00 69.00 59.00 75.00 62.00 60.00 56.00 59.00 
  58 81.00 83.00 84.00 83.00 77.00 81.00 82.00 82.00 82.00 82.00 
  59 72.00 70.00 69.00 69.00 69.00 65.00 63.00 58.00 59.00 61.00 
     61* 68.00 62.00 59.00 64.00 66.00 70.00 63.00 69.00 67.00 68.00 
149 69.00 75.00 73.00 70.00 70.00 72.00 71.00 72.00 73.00 63.00 
160 100.00 122.00 140.00 87.00 96.00 132.00 82.00 97.00 114.00 106.00 
Mean 81.08 80.31 82.46 79.69 79.15 85.31 81.46 79.23 78.08 78.69 
St. Dev. 20.31 17.64 21.57 15.59 14.92 20.11 21.99 16.16 15.39 17.05 
           
*Minority Subjects 
  
Table D25.  Duration (msec) to 16 degree targets for young women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 60.00 72.00 130.00 134.00 94.00 92.00 108.00 117.00 159.00 98.00 
     3 76.00 76.00 109.00 114.00 124.00 86.00 89.00 83.00 76.00 82.00 
     4 75.00 75.00 94.00 201.00 91.00 100.00 83.00 83.00 81.00 83.00 
     5 82.00 75.00 141.00 126.00 154.00 174.00 93.00 81.00 77.00 82.00 
     7 80.00 80.00 151.00 164.00 149.00 108.00 102.00 96.00 96.00 98.00 
     8 80.00 76.00 102.00 110.00 164.00 107.00 114.00 86.00 93.00 87.00 
     9 77.00 72.00 87.00 116.00 109.00 99.00 86.00 82.00 84.00 79.00 
   10 78.00 78.00 81.00 100.00 117.00 90.00 94.00 85.00 84.00 81.00 
   11 67.00 74.00 154.00 185.00 121.00 109.00 95.00 78.00 78.00 76.00 
   12 74.00 76.00 81.00 171.00 155.00 143.00 203.00 78.00 81.00 104.00 
     14* 72.00 75.00 80.00 109.00 125.00 92.00 86.00 89.00 86.00 84.00 
    15* 73.00 74.00 131.00 150.00 159.00 89.00 86.00 83.00 83.00 81.00 
    16* 73.00 70.00 96.00 82.00 121.00 102.00 125.00 84.00 83.00 74.00 
102 86.00 84.00 94.00 135.00 138.00 121.00 105.00 84.00 84.00 85.00 
111 75.00 74.00 87.00 157.00 183.00 127.00 89.00 91.00 86.00 84.00 
112 64.00 64.00 96.00 102.00 109.00 113.00 88.00 80.00 76.00 79.00 
  114* 86.00 91.00 114.00 118.00 140.00 105.00 101.00 91.00 90.00 86.00 
206 68.00 70.00 107.00 220.00 141.00 136.00 135.00 106.00 101.00 80.00 
  213* 69.00 71.00 94.00 107.00 95.00 89.00 83.00 76.00 71.00 73.00 
Mean 74.47 75.11 106.79 136.89 131.00 109.58 103.42 87.00 87.84 84.00 
St. Dev. 6.92 5.69 23.70 37.45 25.77 22.49 28.08 10.12 18.72 8.11 
           
*Minority Subjects 
  
Table D26.  Duration (msec) to 16 degree targets for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 73.00 71.00 120.00 108.00 98.00 92.00 107.00 77.00 71.00 69.00 
  34 87.00 77.00 309.00 175.00 132.00 140.00 113.00 91.00 74.00 82.00 
  35 69.00 66.00 -- 82.00 78.00 75.00 85.00 72.00 73.00 70.00 
  36 64.00 65.00 78.00 88.00 77.00 77.00 81.00 71.00 77.00 69.00 
  37 78.00 82.00 93.00 104.00 99.00 90.00 81.00 81.00 79.00 75.00 
  38 70.00 71.00 131.00 193.00 136.00 118.00 93.00 72.00 80.00 71.00 
  39 65.00 61.00 159.00 182.00 156.00 168.00 140.00 79.00 83.00 68.00 
  41 69.00 70.00 79.00 80.00 80.00 80.00 80.00 76.00 70.00 72.00 
  42 -- 81.00 159.00 144.00 156.00 139.00 91.00 91.00 80.00 79.00 
  43 66.00 68.00 135.00 116.00 105.00 88.00 79.00 71.00 74.00 70.00 
  44 69.00 80.00 92.00 187.00 208.00 132.00 -- 97.00 77.00 76.00 
     47* 65.00 73.00 86.00 90.00 89.00 81.00 81.00 79.00 76.00 86.00 
     48* 71.00 80.00 116.00 -- 184.00 90.00 92.00 82.00 93.00 86.00 
 140 66.00 69.00 251.00 118.00 159.00 118.00 119.00 77.00 86.00 82.00 
  146* 74.00 80.00 123.00 136.00 172.00 141.00 103.00 88.00 89.00 86.00 
  245* 74.00 77.00 -- -- -- 84.00 82.00 83.00 83.00 84.00 
Mean 70.67 73.19 137.93 128.79 128.60 107.06 95.13 80.44 79.06 76.56 
St. Dev. 6.03 6.52 66.74 40.97 42.49 29.30 17.93 7.88 6.46 6.91 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D27.  Duration (msec) to 16 degree targets for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 73.00 82.00 162.00 196.00 215.00 159.00 145.00 181.00 142.00 181.00 
    18 65.00 69.00 200.00 188.00 177.00 197.00 139.00 97.00 93.00 98.00 
    19 76.00 77.00 -- -- 164.00 -- 168.00 134.00 131.00 140.00 
      20* 72.00 83.00 88.00 110.00 114.00 162.00 142.00 134.00 132.00 125.00 
   21 71.00 74.00 -- 156.00 165.00 100.00 94.00 93.00 93.00 101.00 
   22 77.00 74.00 80.00 157.00 185.00 125.00 165.00 98.00 105.00 91.00 
   23 -- 81.00 -- 121.00 136.00 131.00 115.00 121.00 91.00 92.00 
   24 62.00 69.00 94.00 105.00 121.00 71.00 74.00 88.00 74.00 70.00 
   25 82.00 82.00 101.00 179.00 207.00 121.00 97.00 99.00 111.00 103.00 
   26 90.00 100.00 -- -- 141.00 147.00 214.00 154.00 177.00 141.00 
   27 79.00 72.00 -- -- -- -- -- -- 87.00 92.00 
   28 74.00 76.00 -- 171.00 140.00 -- -- 123.00 103.00 108.00 
     29* 77.00 67.00 -- 130.00 159.00 169.00 150.00 99.00 99.00 165.00 
     30* 97.00 88.00 -- -- 137.00 226.00 140.00 138.00 116.00 135.00 
     31* 94.00 84.00 -- -- -- -- -- -- 95.00 104.00 
120 77.00 82.00 -- -- -- -- 102.00 122.00 81.00 96.00 
Mean 77.73 78.75 120.83 151.30 158.54 146.18 134.23 120.07 108.13 115.13 
St. Dev. 9.76 8.36 48.62 32.96 31.18 43.57 37.61 26.68 26.39 29.97 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D28.  Duration (msec) to 16 degree targets for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 79.00 76.00 112.00 126.00 127.00 97.00 119.00 88.00 90.00 85.00 
  51 75.00 79.00 124.00 118.00 105.00 81.00 81.00 79.00 80.00 79.00 
  52 74.00 82.00 -- -- -- -- 117.00 130.00 105.00 111.00 
  53 82.00 84.00 112.00 111.00 118.00 154.00 96.00 87.00 91.00 88.00 
  54 103.00 114.00 177.00 147.00 185.00 247.00 126.00 106.00 133.00 136.00 
  55 81.00 103.00 103.00 112.00 96.00 92.00 94.00 96.00 88.00 94.00 
  56 68.00 68.00 -- 122.00 139.00 103.00 100.00 94.00 77.00 100.00 
  57 61.00 64.00 99.00 76.00 72.00 74.00 63.00 63.00 65.00 62.00 
  58 80.00 76.00 94.00 88.00 93.00 90.00 83.00 92.00 81.00 83.00 
  59 61.00 61.00 -- 145.00 67.00 67.00 72.00 70.00 66.00 68.00 
     61* 65.00 70.00 119.00 85.00 79.00 89.00 73.00 75.00 72.00 72.00 
149 64.00 -- 157.00 236.00 188.00 130.00 103.00 85.00 94.00 81.00 
160 85.00 94.00 -- -- -- 171.00 150.00 195.00 162.00 146.00 
Mean 75.23 80.92 121.89 124.18 115.36 116.25 98.23 96.92 92.62 92.69 
St. Dev. 11.81 15.91 27.70 43.58 41.65 51.98 24.80 33.94 27.48 25.14 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D29.  Duration (msec) to 16 degree targets for young women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 57.00 65.00 209.00 90.00 84.00 122.00 89.00 91.00 61.00 62.00 
     3 72.00 70.00 105.00 151.00 223.00 105.00 94.00 87.00 74.00 76.00 
     4 75.00 75.00 110.00 119.00 116.00 112.00 83.00 83.00 82.00 88.00 
     5 78.00 76.00 139.00 134.00 156.00 111.00 90.00 87.00 89.00 91.00 
     7 82.00 83.00 131.00 169.00 128.00 124.00 114.00 98.00 93.00 97.00 
     8 73.00 75.00 86.00 97.00 95.00 86.00 104.00 88.00 88.00 81.00 
     9 71.00 74.00 80.00 91.00 110.00 96.00 89.00 77.00 81.00 78.00 
   10 77.00 75.00 99.00 117.00 119.00 87.00 82.00 84.00 78.00 78.00 
   11 66.00 71.00 136.00 132.00 110.00 79.00 76.00 78.00 73.00 69.00 
   12 75.00 76.00 165.00 231.00 182.00 142.00 95.00 109.00 99.00 94.00 
     14* 70.00 69.00 75.00 73.00 70.00 72.00 71.00 72.00 72.00 76.00 
    15* 74.00 77.00 85.00 119.00 182.00 147.00 90.00 90.00 85.00 91.00 
    16* 72.00 67.00 120.00 84.00 120.00 79.00 78.00 73.00 72.00 71.00 
102 78.00 81.00 92.00 111.00 111.00 100.00 92.00 92.00 85.00 83.00 
111 75.00 75.00 154.00 147.00 146.00 111.00 108.00 86.00 81.00 84.00 
112 65.00 64.00 96.00 83.00 91.00 72.00 85.00 77.00 77.00 81.00 
  114* 70.00 72.00 105.00 140.00 99.00 90.00 85.00 78.00 80.00 80.00 
206 68.00 70.00 95.00 -- 124.00 92.00 150.00 98.00 90.00 80.00 
  213* 70.00 70.00 191.00 112.00 87.00 85.00 82.00 78.00 76.00 77.00 
Mean 72.00 72.89 119.63 122.22 123.84 100.63 92.47 85.58 80.84 80.89 
St. Dev. 5.62 4.97 37.90 37.86 38.84 21.93 17.57 9.51 8.88 8.75 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D30.  Duration (msec) to 16 degree targets for young men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 69.00 69.00 139.00 144.00 117.00 73.00 95.00 71.00 72.00 73.00 
  34 69.00 66.00 170.00 145.00 138.00 118.00 119.00 91.00 90.00 90.00 
  35 66.00 67.00 80.00 97.00 112.00 95.00 79.00 97.00 71.00 71.00 
  36 68.00 69.00 72.00 87.00 84.00 85.00 76.00 86.00 81.00 70.00 
  37 74.00 74.00 105.00 92.00 97.00 80.00 78.00 74.00 74.00 82.00 
  38 69.00 73.00 186.00 254.00 157.00 83.00 87.00 78.00 75.00 75.00 
  39 65.00 68.00 107.00 132.00 213.00 227.00 81.00 93.00 86.00 73.00 
  41 -- 72.00 90.00 86.00 88.00 85.00 81.00 75.00 74.00 71.00 
  42 74.00 75.00 93.00 114.00 128.00 102.00 85.00 86.00 87.00 84.00 
  43 67.00 66.00 110.00 124.00 100.00 94.00 84.00 76.00 74.00 72.00 
  44 76.00 72.00 113.00 101.00 90.00 96.00 104.00 84.00 85.00 79.00 
     47* 64.00 66.00 95.00 110.00 95.00 86.00 86.00 84.00 78.00 76.00 
     48* 84.00 80.00 126.00 124.00 247.00 149.00 114.00 93.00 92.00 97.00 
 140 72.00 72.00 158.00 158.00 200.00 113.00 146.00 87.00 79.00 78.00 
  146* 74.00 79.00 88.00 103.00 129.00 91.00 82.00 80.00 85.00 81.00 
  245* 73.00 78.00 -- -- -- 81.00 80.00 80.00 82.00 81.00 
Mean 70.93 71.63 115.47 124.73 133.00 103.63 92.31 83.44 80.31 78.31 
St. Dev. 5.16 4.67 33.93 42.08 50.23 37.77 19.26 7.63 6.66 7.46 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D31.  Duration (msec) to 16 degree targets for older women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 80.00 77.00 -- -- -- -- 104.00 88.00 101.00 110.00 
    18 69.00 75.00 179.00 200.00 207.00 107.00 154.00 107.00 108.00 91.00 
    19 73.00 84.00 -- -- -- -- 136.00 109.00 114.00 102.00 
      20* 81.00 86.00 151.00 141.00 124.00 136.00 158.00 115.00 142.00 161.00 
   21 71.00 74.00 172.00 179.00 124.00 128.00 106.00 98.00 112.00 96.00 
   22 77.00 77.00 128.00 218.00 207.00 108.00 112.00 100.00 103.00 88.00 
   23 76.00 76.00 -- 135.00 110.00 102.00 96.00 96.00 82.00 88.00 
   24 66.00 65.00 94.00 74.00 101.00 78.00 89.00 75.00 74.00 86.00 
   25 99.00 75.00 95.00 223.00 218.00 160.00 139.00 106.00 133.00 179.00 
   26 98.00 94.00 -- -- -- 205.00 156.00 242.00 190.00 126.00 
   27 98.00 80.00 -- -- -- -- -- 101.00 85.00 93.00 
   28 73.00 75.00 144.00 -- 149.00 -- 106.00 130.00 -- 106.00 
     29* 101.00 74.00 -- -- -- -- -- -- 98.00 89.00 
     30* 87.00 85.00 -- 189.00 162.00 151.00 212.00 119.00 109.00 112.00 
     31* 74.00 89.00 -- -- -- -- -- 112.00 102.00 86.00 
120 74.00 77.00 -- -- -- 116.00 126.00 118.00 99.00 92.00 
Mean 81.06 78.94 137.57 169.88 155.78 129.10 130.31 114.40 110.13 106.56 
St. Dev. 11.76 7.08 33.97 50.34 45.17 36.05 34.01 37.76 28.21 27.38 
           
*Minority Subjects 
(--) Duration not obtained 
  
Table D32.  Duration (msec) to 16 degree targets for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 81.00 88.00 -- -- -- -- 88.00 95.00 127.00 97.00 
  51 76.00 78.00 -- -- -- -- 80.00 85.00 81.00 85.00 
  52 74.00 83.00 -- -- 128.00 142.00 109.00 163.00 119.00 182.00 
  53 81.00 121.00 90.00 98.00 141.00 116.00 102.00 100.00 84.00 102.00 
  54 115.00 101.00 327.00 272.00 217.00 269.00 249.00 142.00 117.00 110.00 
  55 85.00 89.00 104.00 89.00 83.00 107.00 93.00 95.00 92.00 87.00 
  56 68.00 75.00 121.00 100.00 138.00 123.00 122.00 112.00 104.00 86.00 
  57 62.00 65.00 79.00 66.00 81.00 77.00 79.00 63.00 66.00 53.00 
  58 78.00 80.00 95.00 104.00 92.00 94.00 91.00 85.00 85.00 86.00 
  59 70.00 65.00 -- 128.00 134.00 66.00 58.00 68.00 77.00 90.00 
     61* 65.00 62.00 119.00 106.00 -- 109.00 100.00 74.00 72.00 69.00 
149 68.00 68.00 -- 87.00 121.00 97.00 148.00 91.00 86.00 78.00 
160 101.00 96.00 -- -- -- -- 205.00 222.00 182.00 198.00 
Mean 78.77 82.38 133.57 116.67 126.11 120.00 117.23 107.31 99.38 101.77 
St. Dev. 14.91 16.85 86.63 60.59 41.49 56.74 54.10 44.46 31.21 41.77 
           
*Minority Subjects 


















Saccadic Eye Movement Parameters 




Table E1.  Accuracy (msec) to 8 degree targets for young women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 101.70 103.90 100.90 105.00 100.90 103.50 101.40 99.20 105.40 99.70 
     3 94.20 95.30 96.00 98.60 97.10 99.30 98.40 101.60 95.70 96.70 
     4 101.60 102.40 98.60 95.00 99.60 101.50 102.30 97.60 100.00 96.00 
     5 95.40 102.40 99.90 93.80 94.40 94.40 98.90 96.60 97.10 99.50 
     7 89.90 91.80 95.20 96.50 97.80 97.80 93.90 97.30 98.60 97.00 
     8 91.50 93.10 92.60 96.10 91.10 89.90 95.20 96.70 96.10 94.90 
     9 97.60 99.70 97.40 103.10 105.70 101.70 100.80 100.70 98.90 106.90 
   10 97.20 96.80 103.40 96.60 101.30 101.00 98.50 97.50 97.90 94.70 
   12 93.20 92.40 88.10 95.90 97.70 93.50 94.00 92.40 97.90 96.80 
     14* 94.30 93.00 96.50 92.40 97.60 100.10 99.60 92.40 104.50 94.90 
    15* 89.40 90.00 85.50 93.10 86.00 90.00 88.50 90.60 92.00 89.60 
    16* 93.60 96.20 101.00 91.70 94.20 95.40 102.50 95.50 94.30 97.20 
102 88.10 91.90 99.80 96.20 96.40 94.70 97.50 98.70 95.70 95.40 
111 104.50 101.90 99.50 100.30 99.30 96.70 96.60 94.10 97.70 97.00 
112 97.90 103.30 102.60 97.30 94.70 104.50 97.20 97.10 94.10 96.00 
  114* 98.90 92.80 97.50 100.20 97.90 92.00 103.80 96.50 104.10 100.90 
206 99.50 99.20 96.30 100.70 92.80 100.40 101.30 92.80 96.30 101.30 
  213* 96.40 104.50 105.70 97.80 104.30 100.10 99.20 103.30 106.50 98.00 
Mean 95.83 97.26 97.58 97.24 97.16 97.58 98.31 96.70 98.49 97.36 
St. Dev. 4.39 4.79 4.91 3.50 4.54 4.34 3.65 3.28 4.02 3.48 
           
*Minority Subjects 
  
Table E2.  Accuracy (msec) to 8 degree targets for young men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 95.60 99.00 96.30 100.90 97.60 99.30 97.90 99.40 99.20 98.60 
  34 87.30 85.00 91.60 98.10 96.90 97.30 90.70 94.00 94.80 88.10 
  35 100.50 98.20 96.70 100.20 100.10 97.30 103.20 100.00 98.30 96.60 
  36 93.60 91.60 92.60 90.50 93.50 91.30 94.00 96.30 97.70 92.80 
  37 94.40 96.90 97.80 102.10 97.80 108.50 98.40 103.60 102.10 109.70 
  38 91.50 91.90 95.70 96.00 94.50 94.80 101.70 95.90 95.60 96.20 
  39 95.60 96.60 88.20 96.90 94.50 90.80 92.70 98.10 94.30 93.60 
  41 98.30 99.10 107.00 95.00 108.20 101.10 98.20 98.20 103.30 97.70 
  42 92.10 90.00 92.70 92.60 91.50 93.30 94.80 89.80 95.10 94.10 
  43 97.60 98.80 97.70 100.50 101.50 97.20 94.80 94.90 91.70 96.30 
  44 88.00 89.20 93.90 93.70 92.50 95.60 93.50 98.10 95.20 97.50 
     47* 103.50 101.80 103.60 97.40 100.10 93.70 100.80 95.20 95.80 101.60 
     48* 92.80 85.40 95.50 95.80 95.20 96.00 93.10 98.70 96.90 89.30 
 140 90.60 91.30 93.90 85.00 86.00 94.90 87.30 87.30 90.90 87.30 
  146* 89.90 87.40 97.00 91.00 99.40 94.30 89.60 96.70 96.70 95.30 
  245* 92.00 88.20 93.50 98.40 100.00 91.40 97.20 94.80 93.70 96.00 
Mean 93.96 93.15 95.86 95.88 96.83 96.05 95.49 96.31 96.33 95.67 
St. Dev. 4.43 5.45 4.50 4.52 5.03 4.37 4.44 3.89 3.31 5.37 
           
*Minority Subjects 
  
Table E3.  Accuracy (msec) to 8 degree targets for older women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 92.00 95.50 85.20 91.30 90.40 88.00 96.20 101.30 98.20 94.60 
    18 84.70 78.60 93.30 96.80 93.80 99.00 88.80 90.00 92.50 93.30 
    19 89.90 98.50 94.20 86.80 89.10 90.40 96.10 95.90 82.90 89.20 
      20* 83.90 89.70 82.20 86.60 91.40 94.30 89.30 94.00 85.30 92.40 
   21 92.10 92.90 91.80 91.60 89.80 94.30 91.90 90.30 91.50 98.00 
   22 89.50 95.80 94.10 91.80 93.60 92.60 91.80 94.50 90.00 90.80 
   23 94.60 96.50 101.70 97.90 91.60 98.90 90.90 92.50 97.30 92.70 
   24 97.70 91.00 92.00 100.40 60.70 94.10 93.80 88.10 91.10 96.70 
   25 102.20 98.40 97.60 105.70 106.30 103.10 101.50 103.70 110.90 107.40 
   26 86.30 81.60 86.10 86.20 82.40 86.60 90.30 86.40 95.10 87.60 
   27 93.10 95.40 93.30 92.00 101.90 96.60 97.10 91.40 91.60 95.30 
   28 100.00 102.30 98.70 97.60 101.20 93.30 103.40 98.10 100.00 98.70 
     29* 83.00 93.00 95.80 92.80 -- 94.70 88.90 82.80 84.80 110.00 
     30* 100.00 91.40 92.80 99.70 95.90 96.00 98.80 95.20 92.60 96.20 
     31* -- 87.10 85.40 93.20 77.50 94.10 89.60 -- 90.90 86.10 
120 113.90 101.10 101.40 101.10 98.50 101.10 100.50 101.80 96.10 101.40 
Mean 93.53 93.05 92.85 94.47 90.94 94.82 94.31 93.73 93.18 95.65 
St. Dev. 8.28 6.50 5.75 5.68 11.12 4.39 4.86 5.89 6.73 6.53 
           
*Minority Subjects 
(--) Accuracy not obtained 
  
Table E4.  Accuracy (msec) to 8 degree targets for older men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 83.30 83.90 79.60 83.50 87.40 83.80 96.10 76.30 91.10 92.20 
  51 98.10 92.50 92.60 97.80 97.60 95.10 94.10 91.00 91.80 90.90 
  52 88.70 84.10 94.40 95.70 95.90 94.20 96.30 91.70 87.70 91.30 
  53 97.90 96.10 99.20 100.70 92.60 96.40 92.90 94.70 96.80 102.20 
  54 95.10 95.30 91.00 85.10 90.40 92.20 88.40 92.40 93.40 102.40 
  55 89.50 88.70 92.70 94.30 93.90 86.20 95.40 92.70 92.30 91.00 
  56 99.50 100.90 106.60 108.00 99.80 101.50 102.70 98.70 98.30 102.60 
  57 98.40 102.60 97.10 100.50 94.00 100.90 95.60 93.40 103.80 95.70 
  58 87.50 89.00 93.60 86.80 94.20 90.70 95.90 92.90 91.20 92.40 
  59 82.80 84.10 85.60 82.70 81.00 78.80 84.30 88.80 83.70 82.10 
     61* -- 90.80 82.40 91.80 91.40 91.80 96.80 91.70 89.50 92.20 
149 91.10 100.10 93.20 103.40 95.50 91.30 96.40 94.00 95.30 93.30 
160 95.20 97.40 91.80 85.80 90.40 97.80 84.20 92.90 96.30 90.90 
Mean 92.26 92.73 92.29 93.55 92.62 92.36 93.78 91.63 93.17 93.78 
St. Dev. 5.93 6.58 7.00 8.30 4.79 6.54 5.24 5.14 5.09 5.78 
           
*Minority Subjects 
(--) Accuracy not obtained 
  
Table E5.  Accuracy (msec) to 8 degree targets for young women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 93.60 85.00 102.90 86.80 101.10 104.80 98.40 99.20 106.10 95.60 
     3 86.30 96.60 96.10 100.40 96.20 96.60 99.20 99.80 96.10 94.50 
     4 99.80 94.50 98.40 98.40 102.10 98.90 96.70 96.70 99.40 96.80 
     5 93.90 91.90 98.00 91.10 97.90 95.90 93.80 95.90 98.40 100.80 
     7 95.00 94.90 99.30 88.10 94.50 94.50 93.50 92.50 95.90 92.70 
     8 89.20 95.50 95.30 95.00 98.40 96.40 99.00 98.30 100.10 100.10 
     9 103.70 96.60 104.70 103.30 99.40 96.90 97.40 103.70 99.50 99.90 
   10 101.20 98.90 99.60 99.30 101.20 101.60 95.60 97.10 97.40 98.20 
   12 93.90 85.90 92.30 98.10 94.30 95.30 96.40 95.40 96.20 97.00 
     14* 93.60 95.30 94.00 98.80 98.40 91.20 99.40 93.10 103.90 89.70 
    15* 89.50 97.30 84.50 86.00 81.50 84.90 95.20 88.20 92.50 86.30 
    16* 101.50 100.40 105.30 92.80 95.70 94.80 92.50 98.50 100.00 92.80 
102 87.60 89.30 92.70 94.00 96.00 88.50 94.20 92.20 96.80 93.60 
111 97.70 97.60 92.80 94.30 95.90 98.00 92.90 103.10 96.50 97.50 
112 103.80 100.60 92.10 102.40 97.70 104.10 100.90 105.30 104.40 102.30 
  114* 97.40 93.00 96.40 102.10 92.00 96.20 96.00 88.90 99.20 98.10 
206 96.00 94.50 94.50 96.10 -- 98.00 95.20 102.20 96.40 100.50 
  213* -- -- 101.40 98.10 -- 101.80 104.70 98.00 104.60 97.30 
Mean 95.51 94.58 96.68 95.84 96.39 96.58 96.72 97.12 99.08 96.32 
St. Dev. 5.40 4.47 5.16 5.27 4.82 5.01 3.14 4.86 3.65 4.14 
           
*Minority Subjects 
(--) Accuracy not obtained 
  
Table E6.  Accuracy (msec) to 8 degree targets for young men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 98.30 100.00 99.10 97.90 96.60 101.00 98.80 97.30 99.40 97.40 
  34 90.60 90.90 95.70 99.30 91.40 97.00 93.10 95.80 92.10 102.70 
  35 86.50 98.30 92.20 100.40 99.70 98.90 95.40 100.60 95.50 98.80 
  36 95.90 93.00 96.60 93.10 93.00 95.10 95.10 94.30 96.40 94.10 
  37 99.50 100.00 98.00 94.40 97.70 103.20 100.10 91.70 97.10 102.80 
  38 90.80 98.10 98.00 95.80 96.70 96.70 97.50 96.20 98.30 92.40 
  39 96.50 93.80 104.60 93.80 89.70 95.40 96.60 93.80 102.60 102.00 
  41 93.40 93.10 96.70 97.70 98.10 99.50 103.80 94.50 102.40 102.80 
  42 93.30 95.60 90.80 100.10 93.50 96.80 90.90 90.60 95.70 97.00 
  43 96.10 97.00 98.90 97.00 102.70 96.70 96.10 96.10 95.00 98.20 
  44 92.10 90.20 95.80 95.80 96.50 94.60 93.50 92.50 96.50 94.60 
     47* 102.00 101.20 103.50 98.90 100.90 100.00 107.50 104.50 97.70 103.70 
     48* 88.20 93.30 83.50 92.00 97.60 92.30 100.00 100.00 97.20 95.90 
 140 83.50 83.50 86.10 84.50 85.20 88.40 85.70 91.60 91.50 87.10 
  146* 89.70 86.20 92.40 97.00 94.30 89.00 88.60 93.90 90.70 89.40 
  245* 90.60 98.90 97.00 99.10 93.50 100.60 92.80 97.30 95.60 95.50 
Mean 92.94 94.57 95.56 96.05 95.44 96.58 95.97 95.67 96.48 97.15 
St. Dev. 4.94 5.08 5.56 3.98 4.40 4.13 5.47 3.69 3.35 4.96 
           
*Minority Subjects 
  
Table E7.  Accuracy (msec) to 8 degree targets for older women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 98.40 94.50 89.00 94.80 81.10 96.40 93.30 86.30 88.80 88.90 
    18 84.50 95.20 99.00 108.00 94.80 102.20 91.20 87.20 93.90 95.30 
    19 94.80 94.60 93.20 94.20 91.90 93.30 96.90 85.80 95.90 92.60 
      20* 83.30 84.50 84.50 86.70 88.10 94.30 97.00 94.30 81.60 87.10 
   21 94.60 94.70 96.10 98.30 95.90 95.40 98.40 94.00 95.20 99.60 
   22 94.80 89.80 94.20 92.30 93.70 99.10 91.80 98.10 93.50 98.30 
   23 91.20 92.10 98.20 90.90 92.20 102.00 98.70 91.90 93.10 93.50 
   24 92.70 94.10 94.00 90.70 96.60 95.20 102.90 92.60 93.60 91.10 
   25 100.30 95.20 109.90 108.90 101.00 101.80 97.70 98.60 90.70 102.70 
   26 81.10 77.30 90.70 86.20 80.90 78.20 83.10 88.40 93.40 81.80 
   27 -- 101.00 100.80 90.90 96.20 87.50 94.20 97.00 91.10 87.20 
   28 105.20 99.40 96.00 98.10 95.40 101.50 94.80 94.70 99.10 108.30 
     29* 90.90 83.10 94.80 89.80 93.10 100.20 100.00 101.90 98.10 94.40 
     30* 95.70 94.70 107.20 101.40 92.50 100.70 97.90 99.30 100.30 102.50 
     31* -- -- -- 92.20 -- -- -- 80.70 -- 87.40 
120 103.70 92.50 100.60 101.90 98.60 95.30 93.50 101.60 96.10 100.70 
Mean 93.66 92.18 96.55 95.33 92.80 96.21 95.43 93.28 93.63 94.46 
St. Dev. 7.19 6.24 6.54 6.88 5.67 6.48 4.67 6.19 4.56 7.16 
           
*Minority Subjects 
(--) Accuracy not obtained 
  
Table E8.  Accuracy (msec) to 8 degree targets for older men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 82.80 85.30 85.70 91.10 91.50 82.60 83.20 89.10 90.00 85.10 
  51 88.10 94.60 91.40 94.20 90.20 93.90 99.40 89.10 92.40 87.60 
  52 98.00 91.70 97.70 87.80 96.10 95.10 94.10 90.80 89.20 84.80 
  53 100.00 95.10 96.20 100.20 93.40 101.30 102.80 90.50 88.50 94.10 
  54 88.70 92.50 91.10 91.80 95.50 93.60 90.40 91.40 90.40 91.40 
  55 92.10 92.20 90.50 90.40 93.60 91.90 96.00 90.40 96.90 86.10 
  56 96.90 93.80 103.30 95.30 98.70 100.80 102.30 101.00 95.80 95.70 
  57 97.00 90.90 107.50 97.00 96.20 98.80 98.20 100.10 105.30 99.80 
  58 85.20 95.40 92.70 90.10 95.90 93.20 93.10 92.50 92.70 89.00 
  59 72.90 84.30 72.80 81.70 92.80 88.30 88.60 73.40 79.60 69.80 
     61* 68.70 76.90 83.10 76.30 91.90 80.10 94.20 86.00 89.30 90.20 
149 96.00 94.30 89.70 87.30 87.80 99.50 94.60 93.20 92.50 92.00 
160 105.50 95.90 96.40 94.80 91.00 98.80 90.40 92.60 93.70 93.10 
Mean 90.15 90.99 92.16 90.62 93.43 93.68 94.41 90.78 92.02 89.13 
St. Dev. 10.67 5.57 8.82 6.39 2.99 6.69 5.54 6.67 5.82 7.26 
           
*Minority Subjects 
  
Table E9.  Accuracy (msec) to 8 degree targets for young women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 102.80 87.20 72.80 68.60 79.70 88.30 85.80 86.70 92.40 95.00 
     3 87.40 89.30 66.30 66.90 59.50 81.80 76.70 86.40 92.90 102.30 
     4 98.40 99.30 87.30 72.00 88.20 74.60 93.40 95.50 100.10 88.90 
     5 96.70 92.90 63.70 91.90 82.80 87.50 107.90 91.50 101.90 96.80 
     7 83.10 87.40 91.80 95.30 113.90 98.30 92.60 90.60 96.00 99.20 
     8 89.80 99.20 61.20 79.10 52.20 87.30 88.70 89.30 88.80 99.20 
     9 94.70 95.30 96.70 85.50 83.20 101.70 105.10 105.20 107.40 111.70 
   10 94.00 95.70 97.60 92.70 105.90 97.50 103.30 95.30 93.30 95.60 
   11 97.60 96.70 102.90 65.70 82.00 91.00 95.70 103.80 101.30 100.70 
   12 96.80 97.80 90.90 79.10 90.10 82.30 80.30 91.70 88.70 98.40 
     14* 98.10 101.20 94.50 68.70 78.50 75.40 93.90 97.00 87.30 103.20 
    15* 89.90 93.30 72.00 70.20 85.50 83.40 84.40 94.90 95.10 91.40 
    16* 97.30 89.90 96.80 95.50 102.40 112.20 101.40 96.90 96.40 95.80 
102 89.00 93.70 79.40 82.20 86.70 90.30 92.30 95.60 86.60 95.80 
111 91.60 101.70 90.50 74.80 85.80 90.70 95.70 96.80 92.90 100.60 
112 105.80 97.40 76.60 75.60 76.40 89.60 82.90 86.00 95.60 93.40 
  114* 90.30 90.50 81.20 92.90 88.50 90.40 94.60 87.70 91.70 89.00 
206 99.30 98.90 79.30 60.50 72.70 74.90 82.60 82.80 94.10 95.50 
  213* 93.10 96.30 82.20 88.20 82.50 90.90 95.10 89.70 97.60 96.50 
Mean 94.51 94.93 83.35 79.23 84.03 88.85 92.23 92.81 94.74 97.32 
St. Dev. 5.57 4.47 12.37 11.20 14.25 9.42 8.62 5.92 5.34 5.29 
           
*Minority Subjects 
  
Table E10.  Accuracy (msec) to 8 degree targets for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 94.60 99.70 76.50 77.40 84.60 84.30 88.60 92.70 100.80 95.20 
  34 94.10 90.70 66.00 93.80 109.30 91.10 92.60 81.70 97.30 93.00 
  35 87.90 97.00 -- 79.60 86.10 93.40 89.10 93.20 99.60 94.60 
  36 94.10 94.40 83.30 78.40 79.90 84.10 92.10 92.80 92.10 94.10 
  37 96.30 97.00 85.40 74.20 84.00 96.90 99.90 100.50 102.40 101.10 
  38 99.00 106.80 76.20 81.00 86.10 84.70 91.50 89.90 90.90 87.60 
  39 94.60 98.10 56.70 56.90 68.60 68.00 82.50 95.10 97.40 98.40 
  41 98.00 101.10 98.50 98.00 100.90 105.30 102.20 99.10 101.20 98.30 
  42 -- 93.30 70.80 67.40 71.10 68.60 81.90 87.50 88.10 88.30 
  43 97.60 94.30 90.00 83.50 86.30 84.00 92.30 95.20 95.10 92.10 
  44 92.40 89.60 81.80 76.80 80.30 81.40 -- 82.70 89.70 91.90 
     47* 100.90 98.20 69.50 78.50 84.70 78.10 81.80 103.70 95.00 87.00 
     48* 96.70 90.70 49.50 -- 73.50 83.20 85.50 92.60 91.40 93.10 
 140 85.90 87.30 43.10 72.30 76.00 80.30 88.20 89.70 85.60 89.10 
  146* 93.20 94.60 78.00 85.00 83.30 90.40 85.10 88.80 93.80 92.40 
  245* 89.90 97.40 -- -- -- 81.90 84.20 83.30 100.30 92.30 
Mean 94.35 95.64 73.24 78.77 83.65 84.73 89.17 91.78 95.04 93.03 
St. Dev. 4.11 4.86 15.45 10.15 10.51 9.47 6.14 6.27 5.10 3.97 
           
*Minority Subjects 
(--) Accuracy not obtained 
  
Table E11.  Accuracy (msec) to 8 degree targets for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 83.90 90.10 85.60 75.90 84.70 96.40 103.10 90.10 91.80 99.10 
    18 97.30 97.90 55.10 66.20 51.50 79.00 70.50 79.10 86.90 78.70 
    19 92.60 99.10 -- -- 75.60 -- 64.60 59.30 80.40 78.60 
      20* 92.90 89.20 83.00 65.00 56.70 73.20 70.30 75.50 86.10 78.40 
   21 93.70 93.80 -- 71.30 72.50 84.80 94.10 88.50 88.80 94.20 
   22 85.50 93.50 88.40 50.80 74.80 58.20 59.60 66.90 79.20 76.50 
   23 -- 93.30 -- 96.50 88.40 71.60 78.30 85.30 90.10 80.00 
   24 98.00 99.20 74.00 72.50 75.10 81.50 85.40 86.10 95.70 -- 
   25 101.40 111.10 83.60 80.60 80.00 92.40 84.60 85.60 85.10 93.60 
   26 93.90 88.20 -- -- 47.30 49.60 48.00 56.70 55.80 57.90 
   27 96.50 101.70 -- -- -- -- -- -- 90.70 91.40 
   28 103.00 98.50 -- 64.20 44.50 -- -- 81.50 92.90 83.50 
     29* 80.70 100.20 -- 50.20 74.50 55.30 63.10 81.70 70.40 62.20 
     30* 94.30 104.80 -- -- 100.20 75.50 100.70 93.10 112.80 105.90 
     31* 100.00 86.40 -- -- -- -- -- -- 67.40 78.60 
120 111.80 96.20 -- -- -- -- 84.50 94.00 97.00 95.60 
Mean 95.03 96.45 78.28 69.32 71.22 74.32 77.45 80.24 85.69 83.61 
St. Dev. 7.84 6.50 12.35 13.69 16.68 14.97 16.58 11.79 13.27 13.20 
           
*Minority Subjects 
(--) Accuracy not obtained 
  
Table E12.  Accuracy (msec) to 8 degree targets for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 81.70 86.60 52.70 50.40 58.50 61.40 55.80 71.70 69.80 83.10 
  51 98.40 93.70 43.80 60.70 54.20 67.30 71.90 69.70 80.90 82.40 
  52 94.00 82.50 -- -- -- -- 72.40 64.90 83.00 75.90 
  53 102.30 103.70 61.70 61.00 78.00 59.50 74.50 92.70 99.90 88.90 
  54 88.20 95.40 71.40 73.20 74.10 68.80 95.70 79.40 90.30 90.20 
  55 92.40 86.60 86.60 72.80 89.30 81.80 87.70 91.70 87.60 96.90 
  56 110.20 97.00 -- 70.60 75.20 70.10 82.70 91.60 100.60 82.40 
  57 96.90 96.20 54.90 60.90 45.50 66.60 86.30 83.20 94.10 96.60 
  58 91.20 93.50 82.90 87.50 85.20 89.90 90.70 84.90 89.20 97.90 
  59 75.70 82.30 -- 58.70 60.70 74.70 73.60 73.50 76.10 63.60 
     61* 90.00 96.50 43.90 59.60 69.50 82.40 85.30 88.10 100.70 99.10 
149 93.70 -- 71.00 72.70 74.40 73.70 82.50 82.70 86.20 78.70 
160 91.30 96.60 -- -- -- 82.20 82.20 71.80 90.20 82.90 
Mean 92.77 92.55 63.21 66.19 69.51 73.20 80.10 80.45 88.35 86.05 
St. Dev. 8.63 6.58 15.79 10.21 13.41 9.32 10.35 9.35 9.40 10.29 
           
*Minority Subjects 
(--) Accuracy not obtained 
  
Table E13.  Accuracy (msec) to 8 degree targets for young women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 101.90 89.00 67.80 84.60 82.20 88.90 88.40 89.00 94.20 96.00 
     3 97.20 101.00 80.40 66.20 86.40 84.30 92.90 100.30 94.10 99.10 
     4 103.80 96.30 81.80 68.70 70.00 71.80 96.30 102.60 95.10 98.80 
     5 99.90 95.20 65.00 84.20 70.00 89.20 96.50 97.20 100.60 102.90 
     7 89.00 92.20 96.00 98.40 92.60 103.70 93.50 92.30 97.70 92.90 
     8 104.50 97.40 88.60 74.40 71.90 79.00 72.10 86.80 88.10 95.50 
     9 106.00 99.70 97.00 98.10 93.80 108.20 98.60 96.00 106.30 107.90 
   10 97.30 98.70 92.30 97.00 90.10 94.60 95.60 94.90 102.70 98.20 
   11 101.20 94.70 86.00 87.50 84.10 90.50 103.90 89.50 97.00 102.70 
   12 92.70 95.20 77.20 94.10 89.30 82.50 85.30 90.20 87.60 87.20 
     14* 102.50 99.50 97.20 106.70 96.80 104.80 94.30 99.50 111.00 97.00 
    15* 85.90 92.70 63.80 61.00 65.40 81.30 82.40 88.50 93.30 87.90 
    16* 95.80 97.10 103.30 99.40 103.70 97.00 100.30 98.90 100.00 92.80 
102 93.00 90.40 83.70 84.80 83.90 99.50 93.40 82.30 90.50 87.30 
111 91.10 89.20 77.80 71.00 90.80 84.00 85.20 93.20 95.20 87.90 
112 90.80 95.10 57.60 84.20 73.10 81.40 86.30 84.80 95.20 95.60 
  114* 94.90 95.10 97.60 92.90 88.60 91.70 98.90 94.30 95.00 91.10 
206 98.70 104.10 83.00 -- 70.50 78.40 76.80 86.70 93.10 94.10 
  213* 89.10 95.30 79.80 90.20 83.00 100.20 91.00 94.40 96.90 89.80 
Mean 96.59 95.68 82.94 85.74 83.48 90.05 91.14 92.71 96.51 94.98 
St. Dev. 5.90 3.96 12.84 12.94 10.66 10.19 8.19 5.63 5.78 5.81 
           
*Minority Subjects 
(--) Accuracy not obtained 
  
Table E14.  Accuracy (msec) to 8 degree targets for young men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 99.80 98.40 80.70 78.90 72.20 90.00 94.00 100.80 99.00 99.00 
  34 99.80 94.60 66.40 87.30 91.80 86.70 96.00 90.90 92.00 96.50 
  35 90.30 91.80 81.20 74.20 80.60 79.00 80.90 82.70 96.50 97.80 
  36 95.70 96.10 75.40 75.90 82.60 87.10 87.40 89.30 100.80 92.90 
  37 98.10 93.40 77.00 87.10 92.90 92.30 98.50 98.60 99.30 100.70 
  38 92.60 95.00 78.20 74.70 81.80 89.20 85.80 84.80 92.10 95.20 
  39 91.90 94.80 46.70 57.30 63.20 77.10 85.00 90.00 84.40 100.40 
  41 -- 98.70 85.70 99.10 100.00 98.70 103.90 105.40 102.60 95.60 
  42 89.10 91.30 75.00 73.40 69.10 72.00 88.70 90.50 92.70 93.00 
  43 100.30 99.40 79.50 84.30 92.80 95.60 93.60 96.70 93.90 100.80 
  44 95.70 95.90 78.60 76.50 78.40 74.10 87.70 88.00 89.50 93.60 
     47* 98.20 102.40 71.80 80.80 81.90 80.80 92.30 100.70 101.70 92.30 
     48* 96.40 91.30 87.80 93.20 66.90 75.00 87.10 85.80 94.50 91.80 
 140 85.60 90.20 82.60 107.70 68.80 80.60 84.80 93.90 91.30 91.40 
  146* 89.30 96.70 92.30 83.00 87.70 91.70 98.30 97.00 100.10 101.30 
  245* 89.30 93.00 -- -- -- 86.40 81.90 89.70 92.60 92.60 
Mean 94.14 95.19 77.26 82.23 80.71 84.77 90.37 92.80 95.19 95.93 
St. Dev. 4.72 3.38 10.56 12.00 11.01 8.05 6.55 6.48 5.06 3.60 
           
*Minority Subjects 
(--) Accuracy not obtained 
  
Table E15.  Accuracy (msec) to 8 degree targets for older women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 101.30 90.00 -- -- -- -- 96.40 93.60 100.80 74.50 
    18 90.10 98.50 52.80 64.70 62.70 70.40 60.90 70.20 87.40 81.60 
    19 93.60 91.00 -- -- -- -- 61.80 74.70 68.00 73.90 
      20* 91.30 88.40 53.40 46.20 58.40 56.70 58.80 83.10 65.70 83.30 
   21 98.10 93.00 71.10 67.10 76.70 86.40 88.80 88.90 95.70 87.20 
   22 88.90 88.90 52.00 65.60 64.00 66.50 64.50 75.10 78.80 88.00 
   23 85.50 93.20 -- 32.60 68.30 85.60 88.10 82.60 92.60 91.50 
   24 95.90 99.90 69.20 79.20 60.10 73.70 86.90 92.50 84.60 92.40 
   25 107.20 100.30 79.10 71.70 72.60 75.20 77.50 80.80 92.20 87.90 
   26 83.10 83.40 -- -- -- 42.00 63.70 46.40 69.30 76.50 
   27 96.90 97.10 -- -- -- -- -- 83.90 92.70 87.20 
   28 103.90 101.90 53.10 -- 67.70 -- 90.50 96.40 -- 101.70 
     29* 91.50 95.50 -- -- -- -- -- -- 90.70 85.40 
     30* 92.60 104.20 -- 78.60 93.30 94.40 67.20 89.70 92.20 94.50 
     31* 91.80 96.20 -- -- -- -- -- 71.60 91.70 87.30 
120 103.40 97.60 -- -- -- 81.50 79.00 86.90 92.80 97.00 
Mean 94.69 94.94 61.53 63.21 69.31 73.24 75.70 81.09 86.35 86.87 
St. Dev. 6.77 5.62 11.28 16.10 10.73 15.45 13.39 12.52 10.85 7.78 
           
*Minority Subjects 
(--) Accuracy not obtained 
  
Table E16.  Accuracy (msec) to 8 degree targets for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 85.70 87.00 -- -- -- -- 72.40 70.70 72.90 74.70 
  51 91.20 95.30 -- -- -- -- 69.60 79.40 78.60 69.40 
  52 86.70 90.10 -- -- 71.60 44.20 38.10 57.60 68.00 54.50 
  53 92.30 67.30 92.70 65.00 59.40 65.50 76.80 82.80 68.20 80.80 
  54 84.50 91.40 66.10 60.60 77.50 65.40 95.80 90.80 92.50 87.10 
  55 88.80 94.20 74.70 82.70 84.10 77.50 77.10 86.90 80.50 82.60 
  56 100.50 103.00 72.90 72.50 75.20 87.10 55.10 75.30 91.60 85.50 
  57 101.20 95.80 51.30 54.30 73.50 79.40 78.50 87.00 97.50 91.20 
  58 87.80 92.30 52.60 75.00 82.70 83.80 84.20 94.90 97.10 89.20 
  59 77.10 77.40 -- 57.80 45.00 68.70 70.60 71.50 78.60 56.70 
     61* 89.20 81.50 70.30 77.30  80.60 82.20 79.10 88.40 94.30 
149 91.10 91.70 -- 68.80 68.50 68.40 70.80 84.90 88.70 91.50 
160 97.00 91.60 -- -- -- -- 76.70 77.20 69.70 71.90 
Mean 90.24 89.12 68.66 68.22 70.83 72.06 72.92 79.85 82.48 79.18 
St. Dev. 6.61 9.16 14.15 9.54 12.20 12.51 14.04 9.83 10.80 12.99 
           
*Minority Subjects 
(--) Accuracy not obtained 
 
  
Table E17.  Accuracy (msec) to 16 degree targets for young women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 96.30 92.30 95.10 94.70 95.40 95.30 89.70 93.20 97.30 96.70 
     3 97.40 92.80 93.40 94.40 97.70 99.60 97.60 98.10 95.70 96.80 
     4 98.40 94.80 92.60 103.50 88.10 95.80 102.10 93.70 100.00 98.30 
     5 82.20 90.60 91.60 88.80 93.70 91.70 91.80 87.60 91.30 93.10 
     7 93.40 92.20 93.60 90.70 93.20 96.90 92.10 93.30 92.10 91.30 
     8 90.60 92.70 98.70 96.40 92.60 90.80 93.30 98.30 96.00 92.60 
     9 92.20 92.00 93.10 96.10 100.60 91.40 97.70 97.10 91.90 96.50 
   10 96.00 100.10 98.20 94.50 95.30 96.30 95.00 96.80 93.60 96.60 
   12 88.40 91.80 83.00 92.50 96.20 90.50 97.60 97.50 90.10 89.60 
     14* 84.70 88.80 87.80 94.00 92.90 91.50 92.70 81.10 95.30 91.80 
    15* 81.20 81.70 88.70 91.90 88.90 83.80 85.80 87.60 92.10 91.90 
    16* 90.00 90.40 96.40 91.00 91.10 91.80 93.60 91.00 95.60 92.20 
102 85.80 92.60 89.70 91.50 93.70 98.50 85.00 88.80 89.50 91.40 
111 92.60 104.80 94.20 96.90 94.10 96.10 98.50 90.10 97.60 93.40 
112 90.10 90.10 90.10 91.60 88.90 93.00 90.30 96.20 92.90 91.00 
  114* 95.30 93.40 97.00 99.00 95.50 94.00 99.50 95.00 101.40 99.20 
206 91.30 90.80 89.30 93.40 87.90 92.00 94.60 89.90 89.80 93.10 
  213* 90.10 91.90 94.40 92.10 94.70 95.30 91.70 91.90 99.60 94.80 
Mean 90.89 92.43 92.61 94.06 93.36 93.57 93.81 92.62 94.54 93.91 
St. Dev. 5.01 4.62 4.01 3.47 3.41 3.66 4.56 4.59 3.64 2.80 
           
*Minority Subjects 
  
Table E18.  Accuracy (msec) to 16 degree targets for young men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 95.60 92.00 95.70 93.70 93.60 94.00 95.50 95.30 89.10 92.40 
  34 86.70 82.10 88.20 82.80 87.90 88.50 88.80 90.20 89.10 82.00 
  35 96.70 94.90 91.40 92.50 95.80 92.60 93.60 89.20 89.10 92.50 
  36 87.40 86.70 87.20 86.80 90.10 88.10 90.40 91.10 90.50 88.80 
  37 92.80 88.50 95.30 100.30 91.70 105.20 90.50 96.20 92.40 97.00 
  38 87.60 86.80 90.20 87.20 85.60 92.00 87.90 90.50 90.90 90.60 
  39 85.10 87.00 81.00 89.20 85.10 84.40 84.00 85.00 85.30 85.30 
  41 100.60 101.80 103.90 93.90 99.70 99.00 98.00 94.30 100.00 92.40 
  42 82.70 84.90 84.70 86.90 86.00 84.10 94.80 94.90 95.60 91.10 
  43 92.40 93.60 91.30 91.90 88.00 86.00 92.00 92.10 94.00 91.60 
  44 82.60 82.60 88.60 91.70 88.80 89.90 90.20 90.80 92.10 90.70 
     47* 96.40 94.30 89.20 93.00 91.20 88.10 87.50 90.40 91.70 94.80 
     48* 93.10 94.00 97.90 89.30 101.00 90.60 97.40 98.00 85.80 103.10 
 140 75.50 79.50 69.90 80.00 78.40 84.80 85.50 80.30 82.50 82.00 
  146* 83.40 84.40 93.50 83.90 92.30 91.40 92.90 89.70 88.20 85.00 
  245* 84.20 84.00 85.90 89.50 94.20 87.80 93.20 89.50 90.80 87.30 
Mean 88.93 88.57 89.62 89.54 90.59 90.41 91.39 91.09 90.44 90.41 
St. Dev. 6.72 5.97 7.63 4.98 5.70 5.55 4.05 4.33 4.17 5.46 
           
*Minority Subjects 
  
Table E19.  Accuracy (msec) to 16 degree targets for older women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 88.10 101.20 88.20 93.10 92.10 95.80 96.70 90.90 93.30 90.10 
    18 92.00 79.80 81.50 94.40 89.60 80.30 91.90 90.30 91.50 97.30 
    19 82.60 105.70 81.00 87.20 87.00 88.00 84.40 89.40 83.00 96.80 
      20* 84.80 92.60 82.40 89.80 97.80 92.00 96.30 96.60 91.60 91.60 
   21 94.50 98.10 93.40 88.10 87.60 93.00 95.40 93.20 94.20 94.10 
   22 94.20 88.80 89.70 89.40 91.30 93.00 93.40 92.60 87.20 91.40 
   23 92.60 95.00 93.60 103.20 91.40 93.20 96.10 95.40 97.30 84.60 
   24 91.10 99.50 82.00 103.00 61.10 88.90 86.20 83.10 83.10 93.40 
   25 93.00 88.10 92.30 101.60 98.80 91.80 99.70 99.10 96.90 100.30 
   26 90.90 91.50 92.60 95.90 90.70 95.40 94.80 90.80 91.80 90.70 
   27 85.90 98.80 86.10 87.60 92.10 90.20 94.30 90.70 93.30 93.20 
   28 103.50 87.10 91.40 88.00 93.30 88.30 92.10 94.50 91.90 95.30 
     29* 71.00 87.00 85.00 77.70 -- 83.80 85.80 70.00 78.60 102.80 
     30* 79.80 80.20 93.70 90.90 92.40 99.30 80.60 91.40 86.10 92.80 
     31* -- 90.20 90.70 92.70 82.80 94.10 90.60 -- 95.20 76.70 
120 100.10 95.30 94.80 94.40 92.90 94.60 95.80 92.90 89.80 96.90 
Mean 89.61 92.43 88.65 92.31 89.39 91.36 92.13 90.73 90.30 93.00 
St. Dev. 8.06 7.28 4.93 6.62 8.75 4.72 5.29 6.79 5.34 6.10 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table E20.  Accuracy (msec) to 16 degree targets for older men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 83.10 103.00 80.60 90.80 90.30 88.50 82.20 -- 92.90 90.50 
  51 90.50 84.30 87.90 91.00 85.30 83.90 83.30 84.20 85.20 82.50 
  52 82.30 91.00 101.30 91.90 87.80 79.10 90.30 90.40 88.70 86.60 
  53 99.20 92.00 97.30 86.20 90.60 94.70 90.90 92.90 88.30 84.80 
  54 92.20 98.10 86.80 90.50 90.60 93.40 94.80 87.70 87.80 96.60 
  55 80.50 90.50 89.80 89.30 91.30 88.00 87.40 87.70 85.90 90.50 
  56 100.00 98.10 108.50 95.80 97.80 100.00 100.30 101.00 95.20 95.10 
  57 80.70 89.30 86.10 87.20 83.30 83.30 80.60 84.00 81.70 80.70 
  58 91.40 87.50 87.60 87.40 83.10 87.80 85.90 85.90 84.30 84.30 
  59 87.60 78.00 78.20 56.10 80.20 72.60 74.20 76.70 75.90 74.20 
     61* -- 90.50 89.00 84.10 93.90 87.60 92.50 92.40 88.30 89.60 
149 93.50 91.80 91.80 90.90 93.70 88.60 97.20 91.70 90.60 92.90 
160 89.90 87.50 85.90 90.10 87.20 85.10 82.40 89.10 84.00 90.80 
Mean 89.24 90.89 90.06 87.02 88.85 87.12 87.85 88.64 86.83 87.62 
St. Dev. 6.65 6.38 8.20 9.74 4.99 6.91 7.38 5.96 4.95 6.25 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table E21.  Accuracy (msec) to 16 degree targets for young women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 84.70 83.40 91.20 88.30 105.30 92.80 91.20 93.10 93.90 91.20 
     3 92.00 97.70 97.20 98.00 97.50 95.40 98.50 97.00 98.10 98.10 
     4 94.90 99.40 93.10 93.80 98.10 100.80 97.60 93.40 94.80 96.50 
     5 89.90 77.40 87.70 89.70 86.30 93.00 86.80 83.70 97.60 88.10 
     7 91.30 92.80 91.70 88.50 95.60 94.40 94.80 91.30 92.50 90.90 
     8 95.90 94.50 94.40 98.00 94.80 95.20 96.20 97.60 98.30 97.20 
     9 98.70 94.30 95.10 98.60 95.00 96.80 95.80 102.60 93.90 93.60 
   10 94.60 99.60 96.30 95.60 97.90 99.30 96.70 98.60 96.30 97.40 
   12 81.60 86.20 94.90 92.70 88.90 90.40 94.50 88.50 92.30 93.20 
     14* 84.80 85.80 84.40 87.30 85.00 87.60 89.80 89.60 94.00 92.40 
    15* 81.40 91.80 87.10 83.80 90.40 87.30 95.20 94.20 95.10 89.80 
    16* 86.00 88.50 89.00 77.80 85.60 90.40 88.20 87.40 94.00 87.30 
102 85.20 83.80 87.10 74.60 96.60 95.40 90.50 83.60 84.60 92.50 
111 97.30 95.20 89.40 88.60 96.10 94.90 91.00 94.40 94.90 93.40 
112 93.30 89.50 91.80 96.80 86.80 94.00 93.70 96.30 96.70 89.30 
  114* 88.90 91.10 96.20 93.00 95.70 92.00 92.60 92.80 101.80 99.50 
206 92.40 92.60 89.30 93.40 -- 91.60 92.20 94.10 90.80 91.60 
  213* -- -- 84.00 78.70 -- 91.00 89.80 93.00 89.40 86.80 
Mean 90.17 90.80 91.11 89.84 93.48 93.46 93.06 92.84 94.39 92.71 
St. Dev. 5.42 6.07 4.10 7.23 5.70 3.57 3.34 4.95 3.81 3.80 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table E22.  Accuracy (msec) to 16 degree targets for young men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 93.30 89.90 94.90 93.30 88.90 90.80 96.60 94.70 92.80 90.80 
  34 86.40 86.90 90.10 91.90 91.10 91.90 91.50 96.30 93.90 83.10 
  35 85.30 93.50 90.30 90.90 95.60 92.70 88.90 88.20 88.90 89.70 
  36 90.50 88.60 90.80 92.50 86.50 89.80 90.20 88.40 90.60 90.20 
  37 95.90 93.30 93.20 95.40 92.50 95.30 93.50 92.00 94.90 91.90 
  38 90.70 88.80 88.00 88.90 94.50 94.50 89.50 89.80 91.00 92.30 
  39 85.60 79.30 87.20 87.00 88.90 86.70 80.60 84.80 89.60 91.20 
  41 94.60 91.80 96.80 93.90 99.10 98.00 98.40 101.40 97.50 99.20 
  42 90.30 95.90 82.20 94.90 89.30 90.20 98.60 87.90 87.30 89.30 
  43 90.40 90.40 90.80 89.20 93.70 91.70 95.60 92.50 92.00 89.70 
  44 86.70 86.80 87.70 90.20 87.40 90.70 90.90 90.80 89.00 88.00 
     47* 93.80 94.00 91.10 93.20 92.10 96.30 94.90 93.10 88.60 91.20 
     48* 86.70 94.10 96.20 94.20 93.50 95.60 99.30 95.40 99.10 91.70 
 140 70.90 78.20 78.90 80.40 76.10 77.60 85.00 74.90 78.50 68.60 
  146* 82.80 87.30 87.10 98.00 88.20 86.60 90.00 85.30 85.20 89.50 
  245* 88.20 92.90 91.90 94.70 90.80 91.90 86.20 89.50 86.30 92.50 
Mean 88.26 89.48 89.83 91.79 90.51 91.27 91.86 90.31 90.33 89.31 
St. Dev. 5.94 5.05 4.72 4.13 5.08 4.85 5.29 5.93 4.97 6.37 




TableE23.  Accuracy (msec) to 16 degree targets for older women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 94.00 90.00 95.10 90.00 85.00 93.60 93.90 90.20 90.00 91.00 
    18 77.90 92.50 90.20 99.10 88.60 88.10 88.80 86.20 85.30 90.30 
    19 81.80 89.70 81.20 89.10 90.10 82.00 80.50 87.50 86.20 88.60 
      20* 93.60 85.90 99.10 98.40 87.90 97.00 92.90 91.10 87.60 90.60 
   21 94.80 95.60 91.90 95.20 97.00 98.00 97.20 98.50 96.20 91.70 
   22 95.70 90.50 95.10 92.60 94.10 92.60 93.10 92.40 93.00 94.70 
   23 89.60 98.00 95.00 95.30 95.00 97.10 99.60 99.90 97.80 91.30 
   24 88.80 87.30 89.00 92.70 84.00 89.50 109.20 81.10 95.10 83.70 
   25 97.70 93.40 101.30 98.00 93.10 93.90 88.60 91.50 91.00 93.60 
   26 93.50 86.60 91.00 97.70 94.50 98.10 92.10 89.70 91.10 90.10 
   27 -- 92.10 92.40 86.30 90.80 89.00 95.20 85.50 82.80 82.40 
   28 94.30 96.60 100.60 91.40 93.10 98.10 96.10 90.10 93.40 95.30 
     29* 78.50 80.20 68.10 87.10 92.40 79.50 95.40 75.80 76.40 83.10 
     30* 83.80 95.50 93.60 94.10 99.50 89.40 92.40 90.90 92.00 90.20 
     31* -- -- -- 87.10 -- -- -- 90.80 -- 68.80 
120 91.00 87.70 94.60 101.20 94.80 94.30 95.60 94.40 94.40 93.20 
Mean 89.64 90.77 91.88 93.46 91.99 92.01 94.04 89.73 90.15 88.66 
St. Dev. 6.56 4.78 8.24 4.69 4.29 5.77 6.15 5.89 5.67 6.57 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table E24.  Accuracy (msec) to 16 degree targets for older men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 82.90 83.00 89.80 88.60 89.20 94.80 86.60 91.40 81.50 91.00 
  51 88.40 86.40 82.50 81.40 90.60 77.10 88.60 87.10 90.10 94.50 
  52 90.90 83.80 103.00 92.80 89.20 92.20 93.50 87.10 86.70 88.10 
  53 91.20 97.30 90.50 93.40 90.70 99.80 93.50 97.70 93.50 82.80 
  54 87.00 91.50 91.60 90.90 88.90 96.80 89.30 89.70 88.40 89.80 
  55 85.70 91.60 87.90 90.00 85.10 88.00 91.20 89.90 92.40 89.20 
  56 100.30 99.50 88.40 91.90 94.70 98.00 95.10 100.70 96.50 96.30 
  57 79.90 86.30 87.50 89.60 85.00 85.70 86.60 83.70 86.80 86.00 
  58 87.00 92.00 89.70 89.20 92.90 90.10 89.80 87.30 86.90 86.70 
  59 64.60 72.10 89.30 80.20 68.00 73.30 76.80 63.50 67.20 72.90 
     61* 81.10 77.40 72.00 83.80 85.70 90.10 86.30 92.00 87.30 91.70 
149 89.90 87.70 91.90 92.30 85.70 98.50 94.70 90.10 89.60 91.30 
160 92.80 89.70 96.90 101.40 91.10 95.40 85.30 90.40 87.70 90.60 
Mean 86.28 87.56 89.31 89.65 87.45 90.75 89.02 88.51 87.28 88.53 
St. Dev. 8.43 7.49 7.13 5.54 6.58 8.14 4.98 8.74 7.08 5.87 




Table E25.  Accuracy (msec) to 16 degree targets for young women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 90.60 97.60 75.60 59.30 71.20 70.50 76.40 89.00 91.20 94.00 
     3 91.50 93.90 78.70 86.40 86.10 91.90 93.20 95.20 94.10 100.70 
     4 99.50 94.40 100.20 73.90 87.90 94.00 99.30 102.20 97.60 96.80 
     5 86.60 89.40 65.70 79.30 74.00 80.90 105.60 91.60 95.60 96.90 
     7 84.00 87.20 89.70 99.20 105.30 93.60 91.90 94.80 98.20 93.90 
     8 87.70 95.80 84.50 78.80 72.50 90.00 91.70 89.60 95.60 96.20 
     9 93.90 94.80 93.90 89.00 89.70 101.40 105.20 101.40 102.00 91.70 
   10 97.80 97.30 95.20 90.00 96.20 98.00 101.90 92.10 95.60 92.00 
   11 91.80 93.60 93.40 101.40 81.40 90.20 103.30 94.00 94.00 92.00 
   12 94.30 90.80 89.10 81.40 88.10 91.80 93.00 89.00 90.00 95.80 
     14* 92.80 101.00 84.20 76.10 82.40 84.00 86.70 89.50 101.00 104.30 
    15* 85.60 86.50 64.80 66.10 70.00 83.30 77.80 88.90 92.50 85.90 
    16* 90.40 97.30 93.00 80.30 109.00 92.60 107.30 94.90 90.80 93.20 
102 83.90 93.40 80.50 78.30 86.00 86.40 94.50 93.30 91.00 91.90 
111 89.60 89.60 91.50 87.80 83.60 95.30 97.20 94.50 94.60 97.30 
112 97.70 95.00 79.80 85.90 88.00 88.60 85.40 86.00 92.70 94.50 
  114* 90.10 94.10 86.60 90.60 100.70 97.30 95.80 91.00 92.50 92.00 
206 94.40 93.00 77.60 72.10 55.00 83.60 76.10 82.30 89.00 88.70 
  213* 85.80 88.90 82.60 89.10 85.00 92.10 91.10 89.90 88.90 86.90 
Mean 90.95 93.35 84.56 82.37 84.85 89.76 93.34 92.06 94.05 93.93 
St. Dev. 4.64 3.81 9.56 10.48 12.96 7.15 9.60 4.75 3.74 4.43 
           
*Minority Subjects 
  
Table E26.  Accuracy (msec) to 16 degree targets for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 95.00 94.80 86.70 85.10 87.00 95.70 100.70 96.20 94.10 95.00 
  34 87.50 89.60 64.40 85.80 91.30 100.10 98.10 86.00 88.70 91.50 
  35 81.00 91.40 -- 68.50 75.30 85.00 83.30 89.50 95.80 93.40 
  36 89.80 89.40 82.90 78.30 83.50 84.90 94.70 92.30 85.80 89.20 
  37 93.30 91.90 88.80 86.50 92.50 98.50 94.70 98.00 97.30 100.60 
  38 91.40 95.40 81.20 82.00 89.70 93.10 90.10 86.30 86.90 84.80 
  39 84.70 89.70 77.10 79.20 75.20 84.70 79.60 90.10 92.20 90.00 
  41 100.50 96.60 97.80 100.00 101.00 100.40 96.50 95.40 95.40 97.90 
  42 -- 91.40 80.30 70.90 81.50 91.10 85.10 92.60 84.00 88.30 
  43 89.50 90.40 86.70 95.80 106.80 92.30 96.70 90.20 93.70 93.80 
  44 89.40 86.10 80.30 79.60 81.50 89.60 -- 91.80 89.20 90.60 
     47* 83.20 87.20 79.60 89.50 81.40 84.30 94.60 99.10 88.50 89.00 
     48* 94.60 84.10 80.80 -- 90.20 87.00 97.90 84.40 89.10 94.50 
 140 72.70 82.00 57.20 93.40 76.90 79.10 73.20 81.00 87.80 83.10 
  146* 88.40 89.40 78.90 86.90 88.60 88.90 89.50 88.30 88.60 94.60 
  245* 83.40 90.30 -- -- -- 78.70 84.20 85.10 89.10 90.30 
Mean 88.29 89.98 80.19 84.39 86.83 89.59 90.59 90.39 90.39 91.66 
St. Dev. 6.73 3.88 9.87 8.86 9.02 6.82 7.94 5.14 3.88 4.51 
           
*Minority Subjects 
(--) Latency not obtained 
  
TableE27.  Accuracy (msec) to 16 degree targets for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 91.00 90.30 88.90 79.00 86.10 96.70 96.90 84.60 95.20 89.60 
    18 90.00 86.90 66.40 74.10 80.20 100.30 92.80 94.80 90.40 90.80 
    19 84.80 90.60 -- -- 72.50 -- 66.40 62.60 75.40 77.20 
      20* 92.90 90.90 88.50 74.30 62.10 71.00 75.70 70.90 103.70 94.80 
   21 97.30 94.50 -- 69.30 68.30 89.60 91.60 92.70 91.40 90.10 
   22 92.30 91.10 51.00 54.20 68.00 76.80 77.60 79.90 91.50 86.50 
   23 -- 97.80 -- 72.70 69.90 85.10 88.20 92.10 83.50 79.80 
   24 89.70 88.00 68.70 73.40 71.90 75.60 80.60 88.90 85.60 89.90 
   25 101.00 108.00 75.30 66.60 77.90 85.90 84.20 84.30 82.80 86.70 
   26 95.80 90.00 -- -- 80.50 75.70 71.90 70.10 81.40 87.40 
   27 93.70 93.20 -- -- -- -- -- -- 89.80 92.60 
   28 95.50 89.30 -- 75.30 73.90 -- -- 92.80 89.00 87.40 
     29* 74.70 87.60 -- 62.60 72.00 82.60 74.40 86.60 80.30 81.00 
     30* 92.30 94.00 -- -- 90.20 82.30 82.80 90.30 94.60 98.20 
     31* 91.90 86.00 -- -- -- -- -- -- 93.30 94.90 
120 98.30 93.60 -- -- -- -- 94.50 102.00 91.10 92.90 
Mean 92.08 91.99 73.13 70.15 74.88 83.78 82.89 85.19 88.69 88.74 
St. Dev. 6.21 5.29 14.45 7.30 7.81 9.10 9.51 10.92 6.93 5.72 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table E28.  Accuracy (msec) to 16 degree targets for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 86.30 87.60 56.00 60.80 75.50 75.40 81.60 80.20 83.50 86.70 
  51 92.60 89.80 63.40 67.20 64.50 75.70 71.50 77.80 76.70 82.40 
  52 92.30 84.50 -- -- -- -- 82.80 84.90 84.80 89.80 
  53 96.00 92.90 77.20 81.10 82.50 76.60 87.20 88.10 94.00 90.90 
  54 99.30 94.10 81.70 80.50 90.20 77.50 62.60 92.00 96.40 96.60 
  55 99.70 83.80 83.80 73.80 84.60 86.70 86.80 95.00 86.70 97.50 
  56 103.20 93.00 -- 59.70 68.70 73.90 80.80 83.00 95.50 97.20 
  57 87.20 85.50 46.40 56.40 42.30 62.80 73.70 74.20 87.20 84.20 
  58 89.20 85.60 70.70 77.80 78.60 80.80 84.10 83.00 88.50 85.60 
  59 67.40 69.30 -- 64.20 61.10 74.10 63.60 87.00 61.40 71.10 
     61* 92.20 98.30 54.00 71.10 78.90 83.70 92.40 90.10 91.00 88.50 
149 88.20 -- 65.50 71.60 68.20 80.80 89.10 94.00 92.10 83.80 
160 88.00 88.00 -- -- -- 82.00 81.00 80.10 83.30 86.90 
Mean 90.89 87.70 66.52 69.47 72.28 77.50 79.78 85.34 86.24 87.78 
St. Dev. 8.84 7.30 12.96 8.52 13.36 6.14 9.34 6.40 9.30 7.18 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table E29.  Accuracy (msec) to 16 degree targets for young women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
     1 94.80 92.40 78.40 76.40 77.30 74.50 89.10 88.90 94.00 95.30 
     3 96.00 93.20 95.70 76.40 74.20 89.50 94.30 94.60 98.00 99.30 
     4 98.40 96.40 88.90 86.70 84.80 87.50 93.90 95.50 93.90 93.30 
     5 92.30 93.20 76.90 81.80 85.10 94.00 91.10 92.50 94.10 95.20 
     7 93.30 91.90 98.70 98.60 106.10 102.10 106.10 95.60 95.80 95.10 
     8 72.90 94.70 76.70 79.80 76.70 80.60 88.00 93.30 94.00 94.90 
     9 99.20 94.90 92.00 97.60 102.10 103.50 107.10 90.90 102.00 96.10 
   10 93.70 98.20 107.00 92.40 85.90 92.80 94.60 99.50 100.50 94.70 
   11 97.10 94.40 85.20 83.60 98.50 94.70 98.90 92.00 96.70 103.60 
   12 84.70 84.90 79.30 88.20 89.60 91.40 84.20 83.40 94.50 88.90 
     14* 93.00 92.80 96.50 92.60 101.70 89.80 92.80 97.50 108.70 90.40 
    15* 91.90 89.20 59.10 57.70 74.70 73.90 80.10 91.60 87.40 90.60 
    16* 90.80 92.20 106.10 101.20 95.40 94.90 98.50 96.50 94.80 93.90 
102 87.60 89.80 83.50 81.60 87.10 85.90 86.90 92.90 86.60 88.30 
111 88.00 92.10 86.50 97.90 92.40 89.70 94.00 92.10 95.80 91.20 
112 88.00 89.60 75.00 78.80 79.30 88.90 91.50 91.70 93.80 94.00 
  114* 90.70 94.50 105.20 88.50 93.30 92.00 94.90 90.20 89.70 85.00 
206 93.70 94.20 82.20 -- 74.50 86.80 75.90 84.90 83.80 93.80 
  213* 84.40 91.60 73.80 104.50 89.40 97.20 89.50 90.10 90.30 88.70 
Mean 91.08 92.64 86.67 86.91 87.79 89.98 92.18 92.30 94.44 93.28 
St. Dev. 6.08 2.94 12.70 11.40 10.06 7.74 7.69 3.96 5.70 4.22 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table E30.  Accuracy (msec) to 16 degree targets for young men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  33 94.10 94.90 85.90 88.10 81.20 91.80 93.60 91.70 94.30 94.40 
  34 91.50 95.10 60.20 93.90 98.10 91.30 101.40 88.90 89.70 91.00 
  35 86.00 88.60 81.30 80.40 89.10 90.10 90.10 88.10 95.60 92.30 
  36 84.60 89.50 81.50 80.70 84.70 85.90 89.50 89.70 92.90 85.60 
  37 90.50 90.10 84.60 87.00 94.70 94.40 93.50 94.10 96.90 99.70 
  38 89.30 92.40 78.90 88.30 90.70 88.50 95.40 87.20 97.00 89.90 
  39 87.10 88.10 46.00 65.30 68.00 79.70 88.20 87.40 89.90 90.10 
  41 -- 97.20 95.80 100.70 99.00 99.80 104.50 101.00 101.10 97.50 
  42 87.60 92.50 82.40 80.70 85.10 82.10 92.70 91.70 87.90 95.20 
  43 92.70 91.40 84.80 98.90 100.30 97.30 92.50 93.60 96.60 92.60 
  44 91.60 87.80 81.90 83.20 84.40 81.20 84.40 91.00 89.10 87.30 
     47* 86.50 83.50 69.90 81.30 84.10 85.10 86.80 93.10 98.50 87.90 
     48* 93.70 85.30 85.10 87.30 66.70 88.50 91.20 90.50 91.60 94.30 
 140 79.80 82.30 92.40 69.90 75.70 83.00 90.20 85.50 85.60 81.00 
  146* 85.10 90.60 92.60 86.30 91.90 96.90 94.20 94.80 89.70 94.30 
  245* 87.30 91.50 -- -- -- 77.70 82.80 84.60 92.30 87.80 
Mean 88.49 90.05 80.22 84.80 86.25 88.33 91.94 90.81 93.04 91.31 
St. Dev. 3.93 4.10 12.90 9.41 10.34 6.67 5.56 4.07 4.31 4.74 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table E31.  Accuracy (msec) to 16 degree targets for older women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    17 91.70 98.50 -- -- -- -- 94.60 95.60 98.40 89.20 
    18 90.90 95.80 73.80 71.00 83.10 80.80 90.60 89.50 97.00 93.10 
    19 88.20 85.10 -- -- -- -- 79.70 72.90 85.00 85.50 
      20* 98.40 88.90 65.30 65.80 48.80 57.70 61.90 79.10 83.30 78.60 
   21 93.00 93.90 67.70 70.80 78.70 82.50 92.80 88.10 86.90 92.60 
   22 92.60 89.20 48.60 73.10 59.90 80.30 82.30 88.40 98.10 90.40 
   23 100.10 99.40 -- 40.80 91.90 84.30 83.90 95.40 95.10 97.00 
   24 95.40 89.90 65.30 70.10 61.60 77.80 85.70 90.10 83.70 82.60 
   25 100.60 108.20 73.10 61.30 71.40 76.30 72.80 80.90 92.30 80.30 
   26 92.50 86.30 -- -- -- 45.80 76.90 85.60 80.60 82.90 
   27 100.20 101.20 -- -- -- -- -- 93.20 90.20 93.80 
   28 86.40 96.60 79.40 -- 101.90 -- 94.30 99.20 -- 89.20 
     29* 90.80 86.70 -- -- -- -- -- -- 88.00 75.90 
     30* 93.40 97.70 -- 71.40 95.10 99.00 78.10 80.50 92.50 85.80 
     31* 95.00 86.30 -- -- -- -- -- 69.70 95.90 103.40 
120 94.90 96.00 -- -- -- 87.00 88.60 105.10 101.70 94.40 
Mean 94.01 93.73 67.60 65.54 76.93 77.15 83.25 87.55 91.25 88.42 
St. Dev. 4.20 6.56 9.83 10.69 17.91 15.05 9.47 9.69 6.45 7.33 
           
*Minority Subjects 
(--) Latency not obtained 
  
Table E32.  Accuracy (msec) to 16 degree targets for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
  50 85.30 89.20 -- -- -- -- 80.60 87.30 85.30 88.00 
  51 87.70 88.30 -- -- -- -- 75.90 85.30 78.10 78.90 
  52 90.20 92.10 -- -- 76.80 65.60 51.50 77.70 78.80 67.60 
  53 93.40 60.30 94.10 64.10 92.90 70.20 74.90 80.10 82.70 88.90 
  54 91.50 92.00 75.60 86.60 76.00 83.00 96.70 92.00 90.10 94.60 
  55 89.30 85.80 74.80 83.40 79.90 81.80 86.00 85.10 87.90 84.90 
  56 101.30 94.20 68.50 68.80 78.00 86.40 87.30 82.90 87.70 93.20 
  57 89.50 87.40 50.80 52.90 55.60 67.80 67.30 73.30 82.10 76.20 
  58 85.40 87.50 50.40 68.60 80.80 82.00 84.30 86.60 86.80 86.60 
  59 74.00 77.60 -- 48.00 70.20 76.90 52.00 72.00 77.10 68.80 
     61* 88.10 90.50 63.20 85.90 -- 79.30 93.60 92.90 91.00 91.10 
149 86.10 91.30 -- 80.50 79.10 88.20 94.60 82.10 91.90 90.80 
160 90.20 94.90 -- -- -- -- 71.30 71.20 87.30 69.70 
Mean 88.62 87.01 68.20 70.98 76.59 78.12 78.15 82.19 85.14 83.02 
St. Dev. 6.06 9.15 15.35 14.25 9.90 7.83 14.77 7.09 4.97 9.66 
           
*Minority Subjects 
(--) Latency not obtained 
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Table F1.  DSST scores for young women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
   1 55 56 52 51 57 51 60 62 55 60 
   2 64 76 77 73 81 79 72 77 80 74 
   3 87 90 82 96 91 90 93 90 91 94 
   4 71 77 86 68 83 78 92 88 76 86 
   5 80 82 77 86 71 77 81 79 80 85 
   6 -- -- -- -- -- -- -- -- -- -- 
   7 71 67 71 71 69 70 70 69 69 71 
   8 49 52 62 66 72 70 61 73 57 63 
   9 90 94 90 95 97 95 87 95 82 80 
 10 73 80 73 62 74 72 69 73 71 71 
 11 78 67 67 74 72 76 67 81 74 77 
 12 63 60 57 56 59 69 61 65 67 74 
  13 63 64 64 64 62 59 62 43 65 58 
    14* 60 61 66 60 61 63 60 58 58 60 
    15* 67 64 72 79 77 68 79 74 75 76 
    16* 76 83 90 89 74 83 91 86 90 91 
  66 73 75 74 69 69 74 72 71 69 73 
102 87 108 103 98 97 96 100 106 100 88 
106 91 80 85 90 93 82 98 88 97 91 
111 73 81 84 88 84 75 75 77 79 75 
112 84 75 97 93 89 94 96 90 92 99 
113 65 51 68 63 65 59 62 69 64 64 
   114* 71 89 88 80 83 82 82 75 77 79 
 206 75 75 76 74 81 75 81 70 75 64 
  4 
   213* 73 61 69 66 64 65 73 68 72 77 
Mean 72.46 73.67 76.25 75.46 76.04 75.08 76.83 76.13 75.63 76.25 
St. Dev. 10.77 13.96 12.53 13.68 11.94 11.60 13.17 13.27 12.13 11.45 
           
*Minority Subjects 
(--) DSST score not obtained 
  5 
Table F2.  DSST scores for young men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 33 81 87 88 87 88 91 70 90 87 80 
 34 68 68 66 71 69 70 70 69 68 73 
 35 65 52 62 68 59 63 66 68 65 68 
 36 63 71 70 69 69 71 65 72 76 74 
 37 66 67 68 65 63 66 65 73 66 72 
 38 78 74 75 73 75 77 80 75 76 81 
 39 75 81 76 84 86 81 66 83 81 75 
 40 66 64 61 63 60 61 73 61 66 67 
 41 76 76 85 85 82 75 82 79 83 83 
 42 73 61 66 72 68 68 73 64 72 72 
 43 68 69 77 72 73 71 70 83 80 71 
 44 60 59 53 60 59 61 66 58 59 63 
 45 53 58 71 60 61 59 66 63 64 66 
 46 62 68 69 67 68 69 60 70 69 67 
    47* 79 76 68 74 69 76 80 76 70 69 
    48* 82 84 89 92 88 79 86 82 91 89 
140 79 89 84 97 90 94 90 88 82 85 
145 42 48 45 39 44 37 35 47 43 45 
   146* 67 65 73 70 77 69 66 66 65 72 
   245* 49 53 59 54 55 45 48 60 58 55 
Mean 67.60 68.50 70.25 71.10 70.15 69.15 68.85 71.35 71.05 71.35 
St. Dev. 10.87 11.55 11.35 13.45 12.39 13.35 12.42 10.97 11.32 10.11 
           
*Minority Subjects 
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Table F3.  DSST scores for older women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 17 38 35 43 39 43 45 39 40 41 39 
 18 52 53 50 51 51 52 51 52 46 54 
 19 44 43 45 47 48 49 45 44 49 47 
    20* 29 32 34 29 32 32 37 32 35 36 
 21 47 51 45 50 49 47 44 45 48 50 
 22 43 39 43 40 43 40 40 42 43 40 
 23 53 58 55 48 57 53 59 57 58 58 
 24 62 60 64 57 65 65 68 62 62 71 
 25 45 46 45 47 42 45 49 43 49 48 
 26 37 42 43 45 40 43 40 40 42 41 
 27 51 48 49 51 43 47 42 49 45 48 
 28 47 46 45 40 40 43 48 48 40 44 
    29* 59 46 53 43 48 51 53 46 47 43 
    30* 45 47 32 47 48 50 47 50 54 48 
    31* 46 42 45 42 46 45 44 48 52 52 
120 43 34 42 36 34 34 34 24 31 29 
Mean 46.31 45.13 45.81 44.50 45.56 46.31 46.25 45.13 46.38 46.75 
St. Dev. 8.14 7.99 7.60 6.80 8.08 7.72 8.61 9.00 7.97 9.66 
           
*Minority Subjects 
  7 
Table F4.  DSST scores for older men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 49 -- -- -- -- -- -- -- -- -- -- 
 50 32 35 29 34 33 30 35 32 32 31 
 51 45 44 45 46 43 49 47 43 44 46 
 52 34 32 35 33 35 39 37 35 35 33 
 53 42 43 45 49 45 48 46 48 43 46 
 54 45 48 49 43 48 48 51 49 45 47 
 55 41 39 40 41 41 40 40 35 41 40 
 56 45 46 46 44 45 44 45 45 49 47 
 57 57 54 61 60 55 60 61 54 60 58 
 58 61 61 63 67 67 61 59 70 61 67 
 59 47 50 49 46 45 49 49 53 44 54 
 60 54 32 32 29 36 31 35 36 38 40 
   61* 33 44 37 45 42 39 42 37 37 40 
149 45 42 48 47 50 44 46 46 47 48 
160 41 39 37 36 40 40 40 36 35 36 
Mean 44.43 43.50 44 44.29 44.64 44.43 45.21 44.21 43.64 45.21 
St. Dev. 8.57 8.16 9.95 10.18 8.75 9.08 8.00 10.33 8.68 9.80 
           
*Minority Subjects 
(--) DSST score not obtained 
  8 
Table F5.  DSST scores for young women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
   1 70 42 31 32 34 43 35 47 55 54 
   2 -- -- -- -- -- -- -- -- -- -- 
   3 95 98 64 52 63 60 71 58 91 88 
   4 86 72 75 38 46 38 45 65 58 60 
   5 77 91 28 51 34 66 68 81 80 84 
   6 -- -- -- -- -- -- -- -- -- -- 
   7 76 70 77 49 57 52 50 70 64 71 
   8 77 64 63 47 53 53 28 47 52 44 
   9 90 90 100 80 76 85 70 75 83 97 
 10 93 94 42 26 33 65 86 70 60 85 
 11 77 76 7 44 21 57 48 44 64 71 
 12 69 62 50 41 42 38 45 64 60 62 
  13 -- -- -- -- -- -- -- -- -- -- 
    14* 70 68 60 62 62 57 63 62 65 62 
    15* 81 83 40 28 28 37 47 61 72 75 
    16* 93 94 28 46 61 68 67 80 90 81 
  66 73 72 26 33 36 39 44 46 59 51 
102 107 110 108 83 84 66 88 84 106 109 
106 -- -- -- -- -- -- -- -- -- -- 
111 85 86 75 60 53 69 62 64 77 79 
112 92 86 45 66 60 67 68 60 82 76 
113 71 72 56 43 34 44 49 56 47 58 
   114* 94 85 80 59 72 74 89 84 86 88 
 206 84 83 73 26 40 56 43 63 70 69 
  9 
   213* 78 78 45 43 53 60 56 61 77 79 
Mean 82.76 79.81 55.86 48.05 49.62 56.86 58.19 63.90 71.33 73.48 
St. Dev. 10.36 14.88 25.52 16.01 16.85 13.29 17.08 12.21 15.02 15.93 
           
*Minority Subjects 
(--) DSST Score not obtained 
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Table F6.  DSST scores for young men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 33 66 66 73 75 83 75 76 70 83 80 
 34 74 71 74 73 70 73 72 69 71 71 
 35 58 53 47 60 56 62 64 62 52 65 
 36 73 74 71 79 78 75 79 72 81 78 
 37 71 70 69 70 68 74 75 73 72 74 
 38 78 79 81 85 84 82 81 81 89 86 
 39 67 63 72 67 72 64 78 78 79 77 
 40 59 63 69 61 67 61 62 58 63 69 
 41 75 72 69 69 75 76 81 78 79 73 
 42 49 53 58 60 65 67 57 62 68 67 
 43 75 78 73 80 85 79 60 82 75 75 
 44 56 57 68 72 57 60 69 60 65 66 
 45 69 73 73 72 69 72 73 75 76 75 
 46 61 58 65 58 60 62 61 66 64 65 
    47* 72 74 81 77 80 84 80 80 78 84 
    48* 75 80 77 80 83 81 82 82 84 79 
140 77 85 90 78 84 88 81 92 83 84 
145 41 46 48 45 46 46 47 44 46 48 
   146* 57 67 70 58 59 63 65 74 63 66 
   245* 50 55 50 55 59 57 52 56 56 59 
Mean 65.15 66.85 68.90 68.70 70 70.05 69.75 70.70 71.35 72.05 
St. Dev. 10.68 10.59 11.01 10.40 11.40 10.59 10.65 11.30 11.54 9.26 
           
*Minority Subjects 
  11 
Table F7.  DSST scores for older women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 17 46 40 41 45 42 42 43 40 44 40 
 18 47 39 45 45 43 45 44 44 44 46 
 19 35 42 41 39 43 38 41 44 45 44 
    20* 37 40 38 42 40 45 27 40 32 33 
 21 47 47 53 49 57 53 51 40 51 53 
 22 43 42 40 39 40 41 39 39 39 40 
 23 56 50 59 57 59 58 58 51 58 56 
 24 57 44 53 58 54 53 54 55 56 54 
 25 49 54 52 50 44 52 49 48 48 48 
 26 37 30 34 35 36 39 38 37 38 33 
 27 48 41 47 43 44 44 44 44 44 44 
 28 51 45 49 48 41 50 48 48 54 52 
    29* 53 49 52 50 58 48 50 54 49 54 
    30* 60 57 57 57 58 55 55 53 54 63 
    31* 45 44 37 46 43 43 43 44 42 43 
120 45 46 44 48 40 42 40 45 44 41 
Mean 47.25 44.38 46.38 46.94 46.38 46.75 45.25 45.38 46.38 46.50 
St. Dev. 7.19 6.39 7.52 6.67 7.85 6.08 7.72 5.63 7.07 8.38 
           
*Minority Subjects 
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Table F8.  DSST scores for older men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 49 45 36 43 44 35 39 26 37 46 48 
 50 32 28 30 30 30 29 29 28 31 27 
 51 51 47 47 50 48 50 48 46 45 39 
 52 42 39 42 36 30 38 35 37 40 35 
 53 42 44 45 42 42 37 45 46 41 46 
 54 52 49 47 52 48 50 47 48 54 54 
 55 40 40 41 35 39 32 42 39 38 37 
 56 46 48 50 48 50 50 52 48 48 48 
 57 50 62 58 58 57 57 60 53 54 61 
 58 53 53 54 57 57 61 60 60 62 61 
 59 60 52 56 63 48 55 49 50 45 57 
 60 43 41 45 38 45 45 41 42 39 46 
   61* 35 29 33 35 35 35 34 33 33 32 
149 46 42 52 44 40 41 46 41 45 43 
160 43 41 46 42 40 44 41 44 38 44 
Mean 45.33 43.40 45.93 44.93 42.93 44.20 43.67 43.47 43.93 45.20 
St. Dev. 7.17 8.95 7.74 9.62 8.54 9.47 9.93 8.11 8.28 10.19 
           
*Minority Subjects 
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Table F9.  DSST scores for young women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
   1 58 49 30 33 33 43 32 30 38 37 
   2 -- -- -- -- -- -- -- -- -- -- 
   3 87 91 41 51 62 65 66 79 84 87 
   4 78 76 64 35 48 47 37 66 56 73 
   5 92 87 35 25 36 45 54 79 87 85 
   6 -- -- -- -- -- -- -- -- -- -- 
   7 76 76 68 49 48 51 58 64 71 71 
   8 72 66 60 26 33 35 23 49 51 68 
   9 84 90 88 67 64 70 59 59 77 91 
 10 90 82 77 22 40 47 55 51 54 70 
 11 60 67 51 11 22 49 40 46 64 75 
 12 64 65 63 56 45 46 42 52 63 53 
  13 -- -- -- -- -- -- -- -- -- -- 
    14* 60 60 56 40 36 44 42 56 56 57 
    15* 87 82 40 32 26 66 64 74 70 79 
    16* 95 84 52 60 47 28 47 83 90 88 
  66 71 69 53 54 58 52 51 58 68 59 
102 113 119 98 42 76 76 86 90 104 110 
106 -- -- -- -- -- -- -- -- -- -- 
111 77 82 83 36 43 51 70 65 75 76 
112 90 96 32 29 53 53 44 60 83 80 
113 67 59 63 38 44 42 53 40 55 58 
   114* 93 97 45 64 66 78 65 87 85 79 
 206 88 79 77 38 43 58 58 62 65 66 
  14 
   213* 81 86 31 41 63 65 66 66 73 75 
Mean 80.14 79.14 57.48 40.43 46.95 52.90 52.95 62.67 69.95 73.19 
St. Dev. 13.94 15.70 19.55 14.54 14.01 13.01 14.49 15.53 15.64 15.58 
           
*Minority Subjects 
(--) DSST score not obtained 
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Table F10.  DSST scores for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 33 80 92 37 38 36 53 31 45 77 82 
 34 73 48 5 26 39 43 45 46 74 71 
 35 62 74 23 26 38 38 35 42 43 57 
 36 84 75 57 56 61 55 57 66 74 76 
 37 70 73 65 50 60 60 74 70 69 73 
 38 86 91 67 41 67 65 65 78 80 83 
 39 73 83 71 22 46 37 65 65 70 48 
 40 -- -- -- -- -- -- -- -- -- -- 
 41 88 84 70 67 77 71 78 74 85 79 
 42 68 73 23 17 36 74 60 58 44 60 
 43 72 64 24 9 40 41 65 75 75 76 
 44 58 64 22 15 37 45 46 53 52 54 
 45 81 84 11 53 68 51 78 76 79 79 
 46 66 69 29 42 31 53 51 47 58 60 
    47* 83 84 41 54 64 56 62 61 73 57 
    48* 90 95 7 15 24 53 59 72 75 76 
140 89 89 44 32 50 80 22 83 90 94 
145 45 49 14 6 26 22 43 31 47 48 
   146* 79 74 54 56 41 49 60 70 80 75 
   245* 60 49 42 42 30 48 45 46 58 52 
Mean 74.05 74.42 37.16 35.11 45.84 52.32 54.79 60.95 68.58 68.42 
St. Dev. 12.18 14.55 21.97 18.17 15.75 13.92 15.53 14.76 14.05 13.40 
           
*Minority Subjects 
(--) DSST score not obtained 
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Table F11.  DSST scores for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 17 51 45 11 22 20 24 32 25 13 37 
 18 58 54 14 40 37 46 43 46 53 52 
 19 48 42 5 13 12 -- 30 14 40 30 
    20* 32 36 34 22 11 24 26 16 33 16 
 21 58 54 -- 19 31 27 39 36 48 32 
 22 41 45 21 25 26 27 24 26 35 32 
 23 63 56 32 8 16 25 22 25 40 47 
 24 68 63 4 17 45 45 41 51 65 64 
 25 48 49 49 25 34 37 33 39 43 34 
 26 44 42 2 9 14 22 24 25 27 33 
 27 54 48 29 8 15 9 19 26 39 38 
 28 46 47 10 9 21 35 26 39 40 43 
    29* 59 60 -- 46 44 31 35 46 53 57 
    30* 57 55 32 -- 33 35 45 20 41 43 
    31* 51 39 -- 4 1 5 8 23 40 43 
120 58 52 10 25 24 21 23 33 45 43 
Mean 52.25 49.19 19.46 19.47 24.00 27.53 29.38 30.63 40.94 40.25 
St. Dev. 9.01 7.59 14.51 11.95 12.53 11.39 9.83 11.14 11.61 11.53 
           
*Minority Subjects 
(--) DSST score not obtained 
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Table F12.  DSST scores for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 49 -- -- -- -- -- -- -- -- -- -- 
 50 36 31 14 16 24 21 21 21 29 22 
 51 52 49 32 32 31 29 38 38 42 42 
 52 47 45 -- 3 22 19 32 19 37 37 
 53 51 47 46 42 41 41 43 36 45 45 
 54 47 49 22 26 34 33 24 40 45 43 
 55 39 43 19 18 25 33 25 27 37 33 
 56 41 46 12 24 24 33 39 30 43 37 
 57 57 56 23 16 30 34 50 40 45 57 
 58 67 69 25 47 52 55 62 56 55 54 
 59 60 60 7 16 38 47 46 47 54 53 
 60 42 43 16 19 31 34 28 39 34 37 
   61* 43 45 15 26 24 27 21 35 37 37 
149 52 46 23 29 21 37 21 37 38 46 
160 50 48 -- 4 5 19 25 27 39 40 
Mean 48.86 48.36 21.17 22.71 28.71 33.00 33.93 35.14 41.43 41.64 
St. Dev. 8.58 8.84 10.28 12.47 10.98 10.19 12.75 9.88 7.18 9.20 
           
*Minority Subjects 
(--) DSST score not obtained 
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Table F13.  DSST scores for young women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
   1 70 42 31 32 34 43 35 47 55 54 
   2 -- -- -- -- -- -- -- -- -- -- 
   3 95 98 64 52 63 60 71 58 91 88 
   4 86 72 75 38 46 38 45 65 58 60 
   5 77 91 28 51 34 66 68 81 80 84 
   6 -- -- -- -- -- -- -- -- -- -- 
   7 76 70 77 49 57 52 50 70 64 71 
   8 77 64 63 47 53 53 28 47 52 44 
   9 90 90 100 80 76 85 70 75 83 97 
 10 93 94 42 26 33 65 86 70 60 85 
 11 77 76 7 44 21 57 48 44 64 71 
 12 69 62 50 41 42 38 45 64 60 62 
  13 -- -- -- -- -- -- -- -- -- -- 
    14* 70 68 60 62 62 57 63 62 65 62 
    15* 81 83 40 28 28 37 47 61 72 75 
    16* 93 94 28 46 61 68 67 80 90 81 
  66 73 72 26 33 36 39 44 46 59 51 
102 107 110 108 83 84 66 88 84 106 109 
106 -- -- -- -- -- -- -- -- -- -- 
111 85 86 75 60 53 69 62 64 77 79 
112 92 86 45 66 60 67 68 60 82 76 
113 71 72 56 43 34 44 49 56 47 58 
   114* 94 85 80 59 72 74 89 84 86 88 
 206 84 83 73 26 40 56 43 63 70 69 
  19 
   213* 78 78 45 43 53 60 56 61 77 79 
Mean 82.76 79.81 55.86 48.05 49.62 56.86 58.19 63.90 71.33 73.48 
St. Dev. 10.36 14.88 25.52 16.01 16.85 13.29 17.08 12.21 15.02 15.93 
           
*Minority Subjects 
(--) DSST Score not obtained 
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Table F14.  DSST scores for young men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 33 77 79 25 29 39 45 58 80 48 88 
 34 70 72 3 38 55 53 29 72 72 76 
 35 52 46 30 37 39 33 24 40 52 54 
 36 76 78 40 46 53 54 70 66 73 68 
 37 79 75 68 56 68 33 23 -- 74 73 
 38 84 83 67 52 72 68 65 68 82 80 
 39 79 77 20 3 26 33 23 41 54 44 
 40 -- -- -- -- -- -- -- -- -- -- 
 41 84 91 58 74 67 71 65 83 81 81 
 42 77 59 51 43 29 45 74 51 52 74 
 43 80 79 31 17 31 53 62 78 77 88 
 44 70 62 22 37 38 44 44 43 51 59 
 45 73 69 72 59 64 49 67 68 81 71 
 46 61 67 32 50 52 51 56 58 60 68 
    47* 82 87 48 63 65 61 57 63 82 76 
    48* 92 83 68 39 18 35 39 56 86 74 
140 87 91 57 50 73 81 86 88 90 89 
145 51 52 23 6 13 23 37 32 44 35 
   146* 72 81 84 66 61 76 76 79 79 83 
   245* 53 59 44 33 26 40 41 51 43 49 
Mean 73.63 73.16 44.37 42.00 46.79 49.89 52.42 62.06 67.42 70.00 
St. Dev. 11.84 12.82 21.81 19.06 19.36 15.93 19.51 16.55 15.76 15.35 
           
*Minority Subjects 
(--) DSST Score not obtained 
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Table F15.  DSST scores for older women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 17 54 48 18 18 23 25 41 44 48 45 
 18 55 46 23 17 39 36 43 40 46 52 
 19 51 48 19 7 -- -- 27 33 40 43 
    20* 40 32 24 17 11 22 9 15 28 14 
 21 53 48 10 17 31 29 38 39 32 32 
 22 40 40 25 28 26 30 32 27 31 34 
 23 62 55 11 13 31 32 34 36 51 46 
 24 68 72 14 39 15 41 50 50 52 61 
 25 46 50 16 10 21 39 28 24 38 38 
 26 48 45 4 5 9 22 26 25 15 25 
 27 50 50 30 9 8 23 16 31 41 43 
 28 50 60 25 16 20 31 39 28 34 23 
    29* 63 60 35 5 19 40 57 50 57 47 
    30* 48 58 -- 33 39 34 43 34 43 45 
    31* 46 39 -- 5 33 31 32 31 39 40 
120 53 49 23 25 22 30 26 34 41 43 
Mean 51.69 50.00 19.79 16.50 23.13 31.00 33.81 33.81 39.75 39.44 
St. Dev. 7.71 9.56 8.33 10.28 10.03 6.26 12.13 9.39 10.39 11.65 
           
*Minority Subjects 
(--) DSST score not obtained 
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Table F16.  DSST scores for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 49 -- -- -- -- -- -- -- -- -- -- 
 50 37 38 14 12 24 22 32 30 31 35 
 51 55 52 16 28 34 34 43 45 47 42 
 52 40 41 5 5 18 21 13 12 30 14 
 53 51 46 25 41 42 41 36 40 45 41 
 54 50 49 25 15 33 31 31 31 41 44 
 55 44 44 35 34 31 32 25 29 28 38 
 56 46 49 22 22 32 26 27 26 40 45 
 57 53 62 2 19 41 40 44 52 63 43 
 58 70 60 62 34 41 54 56 54 61 59 
 59 63 65 -- 42 46 45 51 46 54 52 
 60 50 44 8 22 28 24 35 33 37 39 
   61* 41 45 13 28 23 28 24 26 37 37 
149 51 48 6 27 31 31 37 36 43 41 
160 45 44 -- 6 10 20 13 22 34 34 
Mean 49.71 49.07 19.42 23.93 31.00 32.07 33.36 34.43 42.21 40.29 
St. Dev. 8.90 8.04 16.59 11.76 9.97 9.94 12.67 11.88 10.96 10.04 
           
*Minority Subjects 
(--) DSST score not obtained 
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Table F17.  Card Sorting scores for young women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
   1 1.49 0.98 1.27 1.33 1.49 1.44 1.41 1.18 1.41 1.49 
   2 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   3 1.58 1.58 1.53 1.49 1.44 1.53 1.44 1.63 1.37 1.58 
   4 1.32 1.63 1.58 1.63 1.55 1.37 1.43 1.63 1.53 1.49 
   5 1.27 1.27 1.27 1.30 1.27 1.18 1.37 1.27 1.33 1.27 
   6 1.68 1.68 1.73 1.68 1.79 1.79 1.79 1.49 1.58 1.68 
   7 0.98 1.30 1.33 1.27 1.41 1.27 1.44 1.41 1.41 1.30 
   8 1.63 1.53 1.49 1.63 1.63 1.37 1.41 1.41 1.41 1.46 
   9 1.58 1.33 1.44 1.44 1.53 1.49 1.58 1.53 1.68 1.58 
 10 1.21 1.30 1.21 1.16 1.11 1.27 1.18 1.08 1.30 1.30 
 11 1.18 1.16 1.27 1.21 1.30 1.00 1.21 1.24 1.30 1.06 
 12 1.33 1.41 1.41 1.49 1.44 1.30 1.44 1.44 1.33 1.53 
  13 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
    14* 0.79 0.83 0.90 1.00 1.06 0.90 0.91 0.90 0.85 1.08 
    15* 1.16 1.11 1.11 1.18 0.98 1.13 1.11 1.13 1.13 1.24 
    16* 1.13 1.06 1.06 1.08 1.13 1.06 1.06 1.13 1.13 1.08 
  66 1.27 1.19 1.49 1.41 1.41 1.44 1.37 1.41 1.37 1.37 
102 1.24 1.44 1.44 1.37 1.44 1.33 1.49 1.41 1.44 1.58 
106 0.98 1.68 1.85 1.93 2.00 2.00 1.93 2.00 1.79 2.17 
111 1.37 1.30 1.21 1.27 1.24 1.21 1.30 1.30 1.27 1.18 
112 1.44 1.41 1.44 1.53 1.49 1.53 1.33 1.49 1.53 1.53 
113 1.08 0.90 0.95 1.11 1.00 1.04 1.04 1.04 0.96 1.02 
   114* 1.49 1.49 1.41 1.44 1.44 1.37 1.49 1.49 1.68 1.53 
 206 1.41 1.53 1.49 1.44 1.44 1.44 1.53 1.49 1.53 1.58 
  24 
   213* 1.49 1.41 1.49 1.49 1.49 1.44 1.44 1.53 1.49 1.49 
Mean 1.28 1.30 1.33 1.35 1.36 1.32 1.35 1.34 1.35 1.38 
St. Dev. 0.23 0.25 0.24 0.23 0.26 0.26 0.24 0.25 0.24 0.27 
           
*Minority Subjects 
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Table F18.  Card Sorting scores for young men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 33 1.79 2.08 1.93 2.08 1.59 1.86 1.53 2.08 2.08 1.93 
 34 1.41 1.41 1.18 1.30 1.41 1.27 1.49 1.18 1.18 1.41 
 35 1.41 1.18 1.18 1.27 1.24 1.27 1.41 1.16 1.33 1.41 
 36 1.44 1.58 1.63 1.63 1.53 1.49 1.63 1.58 1.63 1.63 
 37 1.27 1.27 1.24 1.27 1.21 1.18 1.33 1.41 1.37 1.41 
 38 1.68 1.63 1.68 1.53 1.44 1.44 1.44 1.41 1.63 1.00 
 39 1.41 1.58 1.38 1.53 1.53 1.53 1.37 1.44 1.53 1.49 
 40 1.18 1.27 1.21 1.24 1.24 1.18 1.30 1.30 1.41 1.41 
 41 1.44 1.53 1.49 1.49 1.53 1.49 1.41 1.41 1.49 1.53 
 42 1.63 1.33 1.41 1.58 1.58 1.58 1.63 1.79 1.86 1.53 
 43 1.53 1.41 1.44 1.49 1.44 1.27 1.37 1.27 1.33 1.41 
 44 1.44 1.37 1.49 1.33 1.58 1.49 1.53 1.41 1.49 1.49 
 45 1.30 1.44 1.24 1.73 1.53 1.41 1.53 1.73 1.49 1.68 
 46 1.63 1.73 1.68 1.58 1.58 1.65 1.63 1.73 1.73 1.63 
    47* 1.53 1.37 1.44 1.58 1.24 1.27 1.41 1.37 1.33 1.33 
    48* 1.30 1.24 1.33 1.24 1.28 1.21 1.27 1.06 1.41 1.49 
140 1.13 1.18 1.30 1.30 1.24 1.41 1.27 1.13 1.21 1.16 
145 0.81 1.00 0.95 0.96 0.95 1.06 1.13 1.16 1.11 1.06 
   146* 1.33 1.21 1.33 1.24 1.30 1.19 1.41 1.41 1.20 1.33 
   245* 0.72 0.62 0.63 0.85 0.70 0.68 0.81 0.87 0.78 0.84 
Mean 1.37 1.37 1.36 1.41 1.36 1.34 1.39 1.39 1.43 1.41 
St. Dev. 0.26 0.30 0.28 0.27 0.23 0.25 0.19 0.28 0.28 0.25 
           
*Minority Subjects 
  26 
Table F19.  Card Sorting scores for older women during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 17 1.11 1.02 1.02 1.02 0.98 1.00 0.84 0.91 1.04 0.84 
 18 1.30 1.13 1.08 1.11 1.13 1.04 1.13 1.24 1.08 1.30 
 19 1.02 0.88 1.02 0.90 1.02 1.00 0.93 0.91 0.91 0.98 
    20* 1.16 0.93 1.13 1.08 1.13 1.16 1.13 0.98 1.13 1.04 
 21 1.13 1.18 1.21 1.00 1.16 1.24 1.13 1.16 1.18 1.21 
 22 1.13 1.11 1.08 1.18 1.11 1.04 1.13 1.13 1.16 1.24 
 23 1.04 1.11 1.02 1.02 1.08 1.16 0.93 0.93 1.06 1.04 
 24 1.27 1.21 1.30 0.93 1.30 1.21 1.27 1.37 1.21 0.98 
 25 0.83 0.90 0.91 0.83 0.98 0.88 0.95 0.87 0.88 0.88 
 26 1.08 1.16 1.18 1.16 1.11 1.11 1.13 1.16 1.08 1.18 
 27 1.41 1.41 1.37 1.37 1.33 1.33 1.33 1.41 1.30 1.37 
 28 1.00 1.04 0.88 0.98 1.02 0.85 0.96 0.96 0.95 0.96 
    29* 1.44 1.24 1.41 1.37 1.18 1.58 1.53 1.30 1.27 1.33 
    30* 1.27 1.11 1.04 1.24 1.06 0.98 1.06 1.17 1.24 1.27 
    31* 1.06 0.96 0.81 0.96 0.96 1.06 0.90 0.93 1.18 0.95 
120 0.81 0.76 0.81 0.70 0.58 0.68 0.70 0.58 0.61 0.56 
Mean 1.13 1.07 1.08 1.05 1.07 1.08 1.07 1.06 1.08 1.07 
St. Dev. 0.18 0.16 0.18 0.18 0.17 0.21 0.20 0.22 0.18 0.22 
           
*Minority Subjects 
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Table F20.  Card Sorting scores for older men during Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 49 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 50 0.80 0.65 0.74 0.70 0.67 0.68 0.61 0.68 0.66 0.73 
 51 1.13 1.08 1.27 1.04 1.18 1.18 1.04 1.21 0.93 1.16 
 52 1.18 1.16 1.13 1.30 1.30 1.30 1.24 1.18 1.24 1.04 
 53 1.18 1.06 1.04 1.13 1.08 1.13 1.21 1.16 1.11 1.11 
 54 1.24 1.16 1.27 1.13 1.16 1.13 1.11 1.08 1.11 1.13 
 55 1.11 1.00 0.98 1.06 0.98 1.04 1.00 1.00 1.06 1.02 
 56 1.24 1.21 1.21 1.16 1.27 1.13 1.18 1.30 1.27 1.21 
 57 1.53 1.63 1.68 1.63 1.49 1.53 1.68 1.73 1.63 1.73 
 58 1.49 1.58 1.37 1.41 1.41 1.41 1.49 1.44 1.37 1.44 
 59 1.41 1.37 1.30 1.33 1.30 1.24 1.37 1.18 1.27 1.27 
 60 0.98 1.06 1.08 1.02 1.00 0.76 1.00 1.04 0.96 1.16 
   61* 1.30 1.30 1.13 1.04 1.08 1.06 1.21 1.13 1.18 1.21 
149 1.16 1.13 1.13 1.16 0.98 1.16 1.21 1.11 1.13 1.16 
160 0.71 0.93 0.90 0.87 1.04 0.95 0.81 0.95 0.93 0.83 
Mean 1.16 1.15 1.15 1.13 1.13 1.11 1.14 1.15 1.12 1.15 
St. Dev. 0.23 0.25 0.22 0.22 0.20 0.22 0.26 0.24 0.22 0.24 
           
*Minority Subjects 
  28 
Table F21.  Card Sorting scores for young women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
    1 1.27 1.33 0.98 1.18 1.30 1.24 1.13 1.33 1.27 1.44 
    2 1.37 1.44 1.41 1.53 1.16 1.53 1.49 1.37 1.63 1.27 
    3 1.63 1.58 1.53 1.63 1.49 1.73 1.58 1.58 1.49 1.79 
    4 1.33 1.49 1.53 1.44 1.73 1.30 1.73 1.67 1.73 1.68 
    5 1.16 1.27 1.21 1.13 1.27 1.24 1.27 1.21 0.62 1.33 
    6 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
    7 1.18 1.13 1.13 1.13 1.24 1.30 1.27 1.41 1.24 1.24 
    8 1.16 1.16 1.00 0.98 1.44 1.44 1.41 1.21 1.13 1.41 
    9 1.68 1.49 1.53 1.53 1.58 1.63 1.53 1.49 1.53 1.68 
  10 1.27 1.21 1.37 1.18 1.33 1.24 1.00 1.30 1.11 1.24 
  11 1.30 1.30 1.11 1.21 1.33 1.41 1.44 1.30 1.27 1.37 
  12 1.37 1.21 1.41 1.33 1.37 1.18 1.37 1.41 1.30 1.37 
  13 1.27 1.21 1.18 1.18 1.13 1.08 1.18 1.21 1.16 1.04 
  14 1.04 1.13 1.13 0.93 1.27 0.96 1.11 1.18 1.04 1.16 
  15 1.04 0.96 1.24 1.13 1.00 1.08 1.13 1.06 1.08 1.11 
  16 1.16 1.11 1.08 1.13 1.11 0.98 0.90 0.86 1.13 1.13 
  66 1.33 1.37 1.18 1.33 1.30 1.18 1.27 1.44 1.49 1.30 
102 1.30 1.44 1.41 1.41 1.41 1.33 1.53 1.44 1.41 1.49 
106 1.73 2.17 2.08 1.79 1.79 1.67 1.79 1.93 1.93 1.86 
111 1.41 1.16 1.33 1.24 1.30 1.37 1.37 1.33 1.44 1.33 
112 1.37 1.37 1.58 1.63 1.53 1.49 1.58 1.53 1.58 1.49 
113 1.06 0.96 1.08 1.02 0.96 0.95 1.00 1.00 1.04 1.11 
114 1.53 1.63 1.41 1.41 1.44 1.37 1.63 1.49 1.41 1.49 
206 1.63 1.73 1.68 1.68 1.63 1.73 1.86 1.79 1.79 1.93 
  29 
  213* 1.41 1.13 1.33 1.37 1.30 1.41 1.37 1.37 1.49 1.41 
Mean 1.32 1.32 1.32 1.30 1.34 1.31 1.36 1.36 1.33 1.39 
St. Dev. 0.20 0.27 0.25 0.24 0.22 0.23 0.26 0.24 0.29 0.25 
           
*Minority Subjects 
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Table F22.  Card Sorting scores for young men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 33 1.73 1.79 1.73 1.86 1.86 1.58 1.63 1.49 1.68 2.00 
 34 1.33 1.30 1.33 1.28 1.21 1.28 1.30 1.41 1.37 1.37 
 35 1.13 1.08 1.04 1.30 1.27 1.21 1.21 1.18 1.24 1.30 
 36 1.58 1.73 1.63 1.63 1.68 1.73 1.68 1.68 1.86 1.93 
 37 1.41 1.16 1.33 1.33 1.33 1.41 1.27 1.41 1.41 1.33 
 38 1.58 1.63 1.68 1.41 1.44 1.58 1.58 1.58 1.53 1.73 
 39 1.16 1.27 1.27 1.41 1.33 1.37 1.49 1.41 1.41 1.44 
 40 1.11 1.18 1.27 1.37 1.33 1.21 1.27 1.21 1.27 1.27 
 41 1.33 1.33 1.28 1.30 1.13 1.41 1.41 1.41 1.33 1.41 
 42 1.53 1.63 1.68 1.34 1.53 1.53 1.44 1.63 1.53 1.79 
 43 1.41 1.53 1.41 1.27 1.58 1.58 1.33 1.49 1.49 1.37 
 44 1.79 1.49 1.63 1.58 1.68 1.68 1.86 1.53 1.53 1.20 
 45 1.53 1.70 1.73 1.68 1.33 1.93 1.86 1.68 1.73 1.73 
 46 1.30 1.38 1.37 1.41 1.44 1.41 1.41 1.44 1.41 1.44 
    47* 1.49 1.37 1.27 1.30 1.41 1.30 1.33 1.30 1.44 1.33 
    48* 1.13 1.21 1.30 1.21 1.06 1.06 1.25 1.30 1.21 1.16 
140 1.13 1.13 1.27 1.27 1.33 1.37 1.41 1.18 1.33 1.27 
145 0.95 0.98 1.11 1.11 1.06 1.06 1.13 1.27 1.24 1.18 
   146* 1.27 1.30 1.33 1.33 1.49 1.41 1.44 1.33 1.37 1.37 
   245* 0.87 1.02 0.90 1.00 0.87 0.87 0.91 0.96 0.98 0.98 
Mean 1.34 1.36 1.38 1.37 1.37 1.40 1.41 1.39 1.42 1.43 
St. Dev. 0.25 0.24 0.23 0.19 0.24 0.25 0.23 0.18 0.20 0.27 
           
*Minority Subjects 
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Table F23.  Card Sorting scores for older women during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 17 1.13 1.11 1.18 1.08 0.95 0.98 0.87 0.88 0.91 0.91 
 18 1.08 0.95 1.06 1.02 0.98 1.06 1.08 1.04 0.98 1.08 
 19 1.08 1.04 0.93 0.84 0.87 0.72 0.76 0.86 0.84 0.83 
    20* 1.24 1.18 1.13 1.16 1.16 1.11 1.06 1.18 1.08 1.21 
 21 1.41 1.13 1.21 1.24 1.21 1.18 1.27 1.16 1.21 1.24 
 22 1.02 1.16 1.06 1.08 1.11 1.04 1.13 1.13 1.08 1.11 
 23 1.06 1.02 1.04 1.02 1.04 1.02 0.91 1.11 1.06 1.04 
 24 1.18 1.13 1.18 1.30 1.16 1.18 1.13 1.11 1.11 1.27 
 25 1.08 1.06 1.08 1.24 1.06 1.24 1.06 1.00 0.95 0.95 
 26 1.11 1.04 1.06 1.04 1.02 1.06 1.08 1.08 1.04 1.11 
 27 1.18 1.13 1.13 1.18 1.16 1.16 1.16 1.16 1.13 1.21 
 28 1.00 0.79 0.96 0.93 1.00 1.13 0.96 0.98 0.98 0.98 
    29* 1.37 1.44 1.49 1.41 1.41 1.38 1.11 1.21 1.24 1.11 
    30* 1.24 1.16 1.02 0.98 0.81 1.00 0.90 1.21 0.93 1.27 
    31* 0.91 0.91 0.95 0.76 0.81 0.87 0.78 0.85 0.88 1.06 
120 0.85 0.78 0.88 0.84 0.84 0.72 0.74 0.83 0.84 0.80 
Mean 1.12 1.06 1.09 1.07 1.04 1.05 1.00 1.05 1.02 1.07 
St. Dev. 0.15 0.16 0.14 0.18 0.16 0.17 0.16 0.13 0.12 0.15 
           
*Minority Subjects 
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Table F24.  Card Sorting scores for older men during DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 49 1.18 1.11 1.18 1.11 1.08 1.16 1.18 0.98 1.08 1.13 
 50 0.68 0.71 0.68 0.73 0.63 0.67 0.73 0.68 0.71 0.65 
 51 1.37 1.24 1.21 1.21 1.30 1.21 1.21 1.21 1.21 1.21 
 52 1.33 1.37 1.18 1.33 1.02 1.27 1.11 1.06 1.06 1.06 
 53 1.02 1.04 1.16 1.18 1.11 1.13 1.11 1.13 1.13 1.24 
 54 1.18 1.16 1.16 1.13 1.16 1.27 1.13 1.18 1.16 1.21 
 55 1.02 1.24 0.90 0.96 1.02 0.90 1.00 1.00 0.91 1.00 
 56 1.27 1.37 1.27 1.21 1.24 1.21 1.37 1.33 1.44 1.37 
 57 1.68 1.58 1.63 1.53 1.58 1.53 1.63 1.53 1.53 1.37 
 58 1.58 1.41 1.44 1.44 1.49 1.49 1.11 1.30 1.30 1.37 
 59 1.53 1.37 1.49 1.09 1.31 1.41 1.27 1.31 1.30 1.41 
 60 1.08 0.86 0.95 1.11 1.08 0.88 0.96 1.02 0.98 0.96 
   61* 1.16 1.04 1.30 1.11 1.16 1.21 1.16 1.18 1.02 1.06 
149 1.16 1.02 1.04 1.11 1.06 1.11 1.08 1.13 1.13 1.02 
160 0.88 0.96 0.88 0.93 0.88 0.88 0.84 0.93 1.02 0.95 
Mean 1.21 1.16 1.16 1.15 1.14 1.15 1.13 1.13 1.13 1.13 
St. Dev. 0.27 0.23 0.25 0.20 0.23 0.24 0.21 0.20 0.21 0.21 
           
*Minority Subjects 
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Table F25.  Card Sorting scores for young women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
   1 1.30 1.18 0.98 0.91 0.91 0.93 0.96 0.85 1.02 1.04 
   2 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   3 1.53 1.68 1.11 1.24 1.30 1.27 1.24 1.33 1.49 1.58 
   4 1.53 1.53 1.13 0.62 0.81 0.87 0.80 1.08 1.27 1.49 
   5 1.38 1.41 0.33 0.51 0.61 0.72 0.88 1.33 1.24 1.37 
   6 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   7 1.37 1.33 1.02 1.02 0.98 0.90 0.88 1.21 1.21 1.06 
   8 1.53 1.49 1.33 0.67 0.96 1.06 0.87 1.11 1.49 1.68 
   9 1.58 1.68 1.44 1.13 1.18 1.13 1.16 1.21 1.30 1.41 
 10 1.27 1.30 1.13 0.65 0.81 0.95 0.93 0.81 0.93 1.13 
 11 1.41 1.37 0.88 0.59 0.74 0.87 0.84 1.00 1.30 1.33 
 12 1.30 1.37 1.27 1.00 0.78 1.08 1.08 1.11 1.24 1.33 
  13 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
    14* 1.18 1.02 1.06 0.68 0.68 0.79 0.83 0.64 1.04 1.00 
    15* 1.24 1.11 0.68 0.67 0.75 0.64 0.87 0.96 0.98 0.98 
    16* 1.08 1.08 0.63 0.72 0.76 0.70 0.63 0.90 1.04 0.96 
  66 1.41 1.30 1.02 1.00 1.06 1.04 1.08 1.11 1.41 1.30 
102 1.44 1.86 1.30 0.91 1.16 1.08 1.16 1.33 1.41 1.58 
106 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
111 1.49 1.41 1.27 0.71 0.87 0.73 1.04 1.18 1.30 1.30 
112 1.27 1.53 0.47 0.49 0.76 0.68 0.65 0.83 1.16 1.24 
113 1.08 1.04 0.96 0.68 0.82 0.74 0.78 0.71 0.83 0.80 
   114* 1.63 1.68 1.00 0.79 0.74 0.96 1.33 1.49 1.30 1.27 
 206 1.53 1.73 1.53 0.88 0.88 1.13 1.21 1.27 1.58 1.49 
  34 
   213* 1.49 1.58 1.11 1.06 1.19 1.24 1.33 1.41 1.37 1.53 
Mean 1.32 1.35 1.03 0.84 0.91 0.94 0.98 1.07 1.19 1.23 
St. Dev. 0.20 0.27 0.28 0.21 0.17 0.17 0.19 0.22 0.20 0.24 
           
*Minority Subjects 
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Table F26.  Card Sorting scores for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 33 1.93 2.08 1.21 1.41 1.53 1.53 1.53 1.49 1.68 1.79 
 34 1.30 1.37 0.58 0.93 0.90 0.76 1.04 1.06 1.21 1.53 
 35 1.44 1.24 0.69 0.81 0.78 1.06 0.93 1.00 0.90 1.27 
 36 1.79 1.86 1.49 1.44 1.49 1.37 1.33 1.68 1.63 1.73 
 37 1.44 1.44 1.16 0.96 1.13 1.16 1.30 1.27 1.30 1.24 
 38 1.58 1.53 1.24 1.11 1.28 1.44 1.37 1.49 1.68 1.53 
 39 1.49 1.58 1.16 0.93 0.87 0.91 1.08 1.24 1.44 1.13 
 40 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 41 1.41 1.49 1.16 1.27 1.18 1.27 1.13 1.18 1.27 1.37 
 42 1.41 1.53 0.77 1.08 1.13 1.41 1.33 1.37 1.30 1.53 
 43 1.37 1.53 0.57 0.60 0.85 1.04 1.18 1.30 1.63 1.63 
 44 1.63 1.73 0.71 0.60 0.84 1.33 1.41 1.24 1.41 1.44 
 45 1.93 1.58 0.46 1.00 1.14 1.24 1.24 1.49 1.73 1.33 
 46 1.44 1.68 1.13 0.96 1.24 1.37 1.24 1.33 1.59 1.63 
    47* 1.58 1.41 0.91 0.93 1.13 1.08 1.16 1.11 1.41 1.24 
    48* 1.13 1.18 0.30 0.36 0.68 0.82 1.04 1.27 1.02 1.24 
140 1.41 1.41 0.75 0.58 0.90 1.13 0.76 1.21 1.30 1.41 
145 1.41 1.41 0.79 0.33 0.72 0.79 0.91 1.06 1.21 1.44 
   146* 1.22 1.49 1.08 1.18 1.16 1.16 1.30 1.33 1.37 1.53 
   245* 1.02 0.93 0.83 0.65 0.50 0.76 0.85 0.85 0.98 0.85 
Mean 1.45 1.47 0.90 0.91 1.02 1.13 1.16 1.25 1.35 1.39 
St. Dev. 0.25 0.27 0.30 0.31 0.26 0.24 0.20 0.20 0.25 0.24 
           
*Minority Subjects 
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Table F27.  Card Sorting scores for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 17 1.24 0.96 0.36 0.70 0.70 0.56 0.67 0.83 0.60 0.72 
 18 1.18 1.24 0.62 0.85 0.74 0.93 0.98 0.91 1.11 1.11 
 19 1.16 0.95 0.72 0.71 1.00 1.00 0.57 0.48 0.74 0.66 
    20* 1.21 1.13 0.91 0.64 0.39 0.71 0.64 0.63 1.00 0.65 
 21 1.41 1.24 0.15 0.44 0.62 0.79 0.93 0.84 1.00 1.04 
 22 1.13 1.13 0.44 0.63 0.72 0.71 0.75 0.74 0.93 0.83 
 23 1.13 1.06 0.62 0.28 0.49 0.57 0.56 0.57 0.76 0.87 
 24 1.27 1.18 0.88 0.93 0.87 1.00 0.90 1.08 1.16 1.30 
 25 1.27 1.24 1.06 0.41 0.67 0.84 0.90 0.75 0.95 0.79 
 26 1.21 1.21 0.13 0.22 0.35 0.50 0.68 0.91 0.80 0.87 
 27 1.44 1.49 1.02 0.81 0.72 0.47 0.93 0.87 1.21 1.02 
 28 1.06 1.02 0.29 0.18 0.54 0.71 0.74 0.76 0.90 0.78 
    29* 1.68 1.37 1.00 0.91 0.95 0.81 0.80 1.13 1.18 0.96 
    30* 1.18 1.06 0.65 1.00 0.69 0.63 0.63 0.61 0.95 0.95 
    31* 0.90 0.81 1.00 0.15 1.00 0.13 0.26 0.31 0.90 0.87 
120 0.96 0.98 0.08 0.32 0.37 0.42 0.40 0.50 0.73 0.75 
Mean 1.21 1.13 0.62 0.58 0.68 0.67 0.71 0.75 0.93 0.88 
St. Dev. 0.19 0.17 0.34 0.29 0.21 0.23 0.20 0.22 0.18 0.17 
           
*Minority Subjects 
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Table F28.  Card Sorting scores for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 49 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 50 0.74 0.68 0.33 0.38 0.34 0.53 0.50 0.50 0.56 0.51 
 51 1.41 1.24 0.80 0.70 0.78 0.88 0.85 0.98 1.08 0.96 
 52 1.27 1.33 1.00 0.34 1.00 0.68 0.93 0.62 1.16 1.13 
 53 1.16 1.16 0.63 0.95 0.93 0.95 1.04 1.00 1.08 1.04 
 54 1.16 1.24 0.70 0.78 0.90 0.79 0.78 0.91 0.95 0.91 
 55 1.11 1.04 0.87 0.65 0.68 0.82 0.76 0.69 0.90 0.91 
 56 1.27 1.18 0.49 0.53 0.68 0.71 0.93 0.68 0.95 0.90 
 57 1.68 1.58 0.58 0.69 0.83 0.94 0.98 1.08 1.16 1.24 
 58 1.58 1.68 0.95 1.11 1.06 1.21 1.18 1.08 1.04 1.21 
 59 1.53 1.53 0.27 0.65 0.81 1.06 1.11 1.04 1.33 1.22 
 60 1.11 1.16 0.46 0.70 0.65 0.76 0.62 0.80 0.75 0.90 
   61* 1.27 1.11 0.45 0.85 0.73 0.72 0.62 0.90 0.84 0.95 
149 1.27 1.11 0.65 0.63 0.71 0.76 0.73 0.90 1.02 1.00 
160 1.06 0.98 1.00 0.16 1.00 0.50 0.53 0.58 0.70 0.74 
Mean 1.24 1.20 0.68 0.67 0.81 0.82 0.84 0.85 0.97 0.97 
St. Dev. 0.24 0.25 0.25 0.25 0.19 0.19 0.21 0.19 0.20 0.19 
           
*Minority Subjects 
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Table F29.  Card Sorting scores for young women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
   1 1.37 1.44 0.96 0.96 1.08 1.16 1.13 1.11 1.37 1.58 
   2 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   3 1.53 1.49 1.24 1.11 1.30 1.21 1.21 1.04 1.53 1.73 
   4 1.49 1.58 1.49 0.72 0.79 0.74 0.80 1.28 1.16 1.53 
   5 1.37 1.53 0.42 0.80 0.57 0.95 1.00 1.13 1.04 1.30 
   6 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   7 1.37 1.33 1.24 0.78 0.98 0.91 0.98 1.13 1.30 1.41 
   8 1.68 1.37 1.27 1.08 0.96 1.13 1.00 0.98 1.16 1.44 
   9 1.63 1.44 1.73 1.27 1.24 1.21 1.27 1.18 1.44 1.68 
 10 1.30 1.41 0.78 0.55 0.57 1.16 1.24 1.21 1.24 1.37 
 11 1.24 1.33 0.90 0.87 0.94 1.00 0.98 1.11 1.18 1.16 
 12 1.08 1.44 0.98 0.88 0.93 0.96 1.02 1.30 1.18 1.30 
  13 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
    14* 1.11 1.21 0.95 1.27 1.11 1.13 1.00 1.02 1.18 1.11 
    15* 1.16 1.08 0.76 0.79 0.66 0.69 0.69 0.95 1.08 1.00 
    16* 1.16 1.06 0.41 0.71 0.71 0.76 0.78 0.93 0.98 1.02 
  66 1.44 1.44 0.65 0.69 0.63 0.58 0.95 0.87 1.13 1.13 
102 1.41 1.53 1.33 1.04 1.02 0.95 1.13 1.08 1.49 1.58 
106 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
111 1.33 1.37 1.04 0.95 0.88 0.96 0.94 1.04 1.30 1.24 
112 1.33 1.41 0.65 0.79 0.76 0.84 0.74 0.87 1.18 1.11 
113 1.06 1.02 0.78 0.71 0.66 0.67 0.72 0.85 0.84 0.95 
   114* 1.58 1.44 1.27 0.93 1.02 1.30 1.49 1.30 1.18 1.24 
 206 1.58 1.68 1.37 0.62 0.95 0.96 1.18 1.30 1.38 1.37 
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   213* 1.44 1.53 1.00 0.91 1.13 1.08 1.11 1.09 1.37 1.44 
Mean 1.31 1.33 1.01 0.90 0.92 0.97 1.01 1.07 1.19 1.27 
St. Dev. 0.21 0.21 0.31 0.18 0.20 0.18 0.18 0.14 0.18 0.24 
           
*Minority Subjects 
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Table F30.  Card Sorting scores for young men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 33 1.79 1.79 1.16 1.21 1.41 1.41 1.63 1.79 1.41 1.73 
 34 1.30 1.33 0.53 0.95 1.18 1.24 0.95 1.33 1.11 1.53 
 35 1.00 1.18 0.85 0.91 0.85 0.84 0.69 0.85 0.88 1.16 
 36 1.73 1.79 1.37 1.13 1.44 1.41 1.73 1.68 1.58 1.63 
 37 1.49 1.37 1.21 1.13 1.08 1.13 1.08 1.30 1.41 1.41 
 38 1.49 1.68 1.30 1.27 1.30 1.24 1.37 1.41 1.44 1.53 
 39 1.58 1.49 0.70 0.67 0.75 0.85 0.76 0.98 1.21 1.00 
 40 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 41 1.44 1.44 1.13 1.18 1.24 1.16 1.18 1.30 1.30 1.41 
 42 1.68 1.58 1.21 1.18 1.49 1.49 1.41 1.37 1.24 1.93 
 43 1.63 1.53 0.88 0.72 0.69 0.80 1.06 1.53 1.53 1.49 
 44 2.00 1.73 0.84 1.13 0.96 1.16 1.13 1.27 1.44 1.16 
 45 2.08 2.08 1.68 1.73 1.41 1.53 1.49 1.49 1.58 1.73 
 46 1.63 1.68 1.06 1.16 1.33 1.37 1.58 1.63 1.44 1.68 
    47* 1.68 1.53 1.11 1.16 1.18 1.21 1.30 1.33 1.41 1.49 
    48* 1.33 1.30 0.76 0.90 0.62 0.57 0.73 0.80 1.21 1.08 
140 1.37 1.49 0.93 0.78 1.06 1.21 1.18 1.30 1.19 1.37 
145 1.18 1.21 0.67 0.19 0.58 0.73 0.81 0.81 0.95 0.81 
   146* 1.44 1.58 1.27 1.30 1.27 1.44 1.44 1.41 1.58 1.53 
   245* 1.00 0.96 0.66 0.55 0.50 0.76 0.85 0.80 0.87 0.95 
Mean 1.49 1.49 1.02 1.01 1.07 1.13 1.17 1.27 1.29 1.38 
St. Dev. 0.31 0.28 0.29 0.33 0.31 0.28 0.32 0.30 0.23 0.31 
           
*Minority Subjects 
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Table F31.  Card Sorting scores for older women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 17 0.96 1.06 0.44 0.47 0.59 0.64 0.69 0.76 0.88 0.75 
 18 1.24 1.24 0.59 0.81 0.93 0.87 0.96 1.02 1.02 0.95 
 19 1.02 1.02 0.35 0.37 1.00 1.00 0.66 0.62 0.74 0.93 
    20* 1.08 0.95 0.63 0.65 0.71 0.61 0.54 0.66 0.84 0.58 
 21 1.24 1.16 0.40 0.51 0.54 0.69 0.83 0.79 0.90 0.70 
 22 1.13 1.13 0.66 0.73 0.80 0.78 0.83 0.90 1.04 1.04 
 23 1.13 1.04 0.44 0.29 0.70 0.63 0.69 0.67 0.88 0.74 
 24 1.21 1.11 0.40 0.87 0.93 0.96 1.02 1.04 1.02 1.13 
 25 1.13 1.21 0.43 0.28 0.51 0.63 0.63 0.69 0.76 0.72 
 26 1.21 1.18 0.32 0.20 0.26 0.24 0.79 0.70 0.74 0.74 
 27 1.33 1.41 0.95 0.75 0.42 0.72 0.64 0.85 1.30 1.18 
 28 1.04 1.13 0.51 0.54 0.46 0.66 0.83 0.71 0.79 0.74 
    29* 1.73 1.53 0.76 1.00 0.81 1.11 1.08 1.18 1.21 1.27 
    30* 0.98 1.18 1.00 0.35 0.68 0.71 0.58 0.80 0.75 1.08 
    31* 1.11 0.76 1.00 0.26 0.26 0.48 0.78 0.76 0.85 0.87 
120 0.91 0.84 0.28 0.33 0.38 0.51 0.45 0.43 0.69 0.59 
Mean 1.15 1.12 0.57 0.53 0.62 0.70 0.75 0.79 0.90 0.88 
St. Dev. 0.19 0.19 0.24 0.25 0.24 0.21 0.17 0.18 0.17 0.21 
           
*Minority Subjects 
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Table F32.  Card Sorting scores for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 2 3.5 4.5 5.5 7 8.5 10 11.5 12.5 
 49 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 50 0.70 0.74 0.37 0.35 0.39 0.47 0.53 0.27 0.54 0.56 
 51 1.44 1.21 0.74 0.68 0.85 0.85 0.88 0.91 1.13 1.08 
 52 1.33 1.18 1.00 0.33 0.54 0.65 0.60 0.67 1.06 0.98 
 53 1.16 1.13 0.67 0.81 0.87 0.96 0.93 1.02 1.11 1.11 
 54 1.27 1.16 0.70 0.78 0.76 0.84 0.81 0.90 1.00 1.04 
 55 1.13 1.08 0.76 0.81 0.96 0.63 0.82 0.88 0.81 0.79 
 56 1.30 1.30 0.64 0.68 0.83 0.72 0.67 0.80 0.96 1.08 
 57 1.58 1.53 0.28 0.88 1.18 1.16 1.24 1.24 1.46 1.73 
 58 1.49 1.68 1.44 0.96 1.13 1.06 1.06 1.16 1.37 0.93 
 59 1.68 1.49 1 0.85 0.90 1.11 1.33 1.28 1.44 1.41 
 60 1.24 1.04 0.30 0.39 0.70 0.79 0.72 0.68 0.83 0.67 
   61* 1.30 1.21 0.50 0.63 0.61 0.80 0.70 0.68 1.11 0.98 
149 1.21 1.16 0.26 0.59 0.62 0.75 0.83 0.83 0.91 0.96 
160 0.86 0.93 1.00 1.00 1.00 0.39 0.26 0.50 0.67 0.57 
Mean 1.25 1.19 0.71 0.72 0.82 0.81 0.83 0.85 1.03 0.99 
St. Dev. 0.26 0.24 0.34 0.22 0.22 0.22 0.27 0.27 0.26 0.30 









Table G1.  Alprazolam Concentrations (msec) for young women during Alprazolam/Placebo Treatment 
Time (h) 
Subject 0 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
     1 0.00 23.21 25.73 27.76 26.88 21.53 21.17 19.20 16.21 14.69 11.08 8.03 8.00 
     3 0.00 26.49 45.39 24.02 22.55 19.39 16.00 16.92 15.32 12.98 9.54 8.09 7.04 
     4 0.00 10.72 25.38 48.05 31.63 29.09 27.80 24.61 24.41 20.70 17.08 14.87 12.35 
     5 0.00 16.65 32.01 29.57 25.45 22.93 16.48 23.79 17.95 11.46 8.92 6.09 6.81 
     7 0.00 0.68 16.32 26.85 25.26 18.86 13.16 13.89 11.87 8.24 9.60 3.72 3.21 
     8 0.00 4.19 15.44 31.90 34.68 26.32 23.82 19.93 19.37 15.75 11.13 8.15 8.41 
     9 0.00 2.92 7.03 24.61 21.19 22.57 25.56 20.13 16.43 15.04 10.65 8.80 7.97 
   10 0.00 2.82 5.96 29.58 31.48 25.20 20.00 18.03 19.27 20.69 11.82 10.96 11.09 
   11 0.00 4.12 27.35 29.45 29.45 28.41 25.53 18.73 19.87 18.45 9.65 9.77 9.53 
   12 0.00 6.57 9.10 41.94 24.03 24.64 19.35 18.40 15.50 15.44 11.80 8.52 6.36 
     14* 0.00 0.29 1.20 32.44 40.66 32.10 26.26 26.39 22.92 21.20 15.23 11.84 13.23 
    15* 0.00 18.03 23.52 27.21 23.63 23.42 18.92 20.57 17.38 17.88 12.51 10.46 7.97 
    16* 0.00 19.74 24.89 23.81 22.82 22.18 19.99 19.30 16.59 14.16 13.02 11.62 10.10 
   66 0.00 4.89 29.39 30.74 22.42 21.57 20.50 18.53 16.33 15.70 16.56 12.34 13.32 
102 0.00 8.08 17.86 32.19 27.00 28.54 19.99 18.64 15.24 16.66 13.12 7.25 7.23 
111 0.00 3.79 6.06 31.37 24.10 22.47 20.26 20.01 15.93 14.54 11.94 10.41 10.36 
112 0.00 15.31 30.87 27.29 22.56 21.18 18.79 17.61 17.20 13.68 11.85 10.45 9.50 
113 0.00 3.93 10.76 29.10 33.27 26.97 25.76 25.74 19.93 19.25 13.45 13.21 11.84 
  114* 0.00 22.08 23.13 28.37 28.42 25.78 22.51 20.35 17.87 16.41 10.68 8.66 8.75 
206 0.00 1.47 11.49 26.72 35.80 33.20 27.88 27.08 25.46 24.96 19.70 16.30 14.03 
  213* 0.00 24.08 25.10 26.32 22.65 17.33 17.41 13.50 11.84 10.60 6.54 5.80 5.44 
Mean 0.00 10.48 19.71 29.97 27.42 24.46 21.29 20.06 17.76 16.12 12.18 9.78 9.17 
St. Dev. 0.00 8.83 10.98 5.69 5.35 4.20 4.06 3.66 3.48 3.91 3.02 3.02 2.80 
              
*Minority Subjects 
Table G2.  Alprazolam Concentrations (msec) for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
  33 0.00 10.43 25.26 31.12 24.14 21.34 22.01 18.76 16.27 15.23 11.26 9.19 8.54 
  34 0.00 25.21 21.40 20.03 18.52 16.46 14.66 14.69 12.44 12.24 9.51 7.32 6.36 
  35 0.00 27.98 26.24 22.34 21.69 23.30 17.93 16.37 16.65 14.74 13.31 10.66 9.12 
  36 0.00 11.03 18.57 32.46 30.97 26.35 20.87 18.27 18.23 17.87 13.68 11.46 6.90 
  37 0.00 10.16 19.80 26.26 24.47 20.36 19.38 18.69 16.37 14.80 9.19 7.64 7.48 
  38 0.00 26.14 23.79 31.17 31.01 22.47 20.76 18.21 18.53 14.47 8.50 7.27 8.10 
  39 0.00 11.06 27.05 27.81 28.93 26.87 22.84 22.90 22.28 21.40 16.55 15.79 12.94 
  41 0.00 21.04 30.66 34.61 26.63 25.78 24.53 22.32 16.62 16.06 11.41 8.59 8.69 
  42 0.00 23.25 23.78 33.30 26.14 24.85 20.19 15.48 14.91 13.57 9.61 7.52 7.45 
  43 0.00 16.08 18.10 23.80 29.41 21.68 20.97 19.78 18.25 14.91 11.62 9.83 9.43 
  44 0.00 24.57 27.20 26.94 24.73 22.70 20.99 19.64 18.26 17.16 16.75 13.08 10.56 
  45 0.00 36.36 26.64 20.70 17.09 16.05 14.84 13.92 11.38 11.04 9.05 7.09 7.31 
  46 0.00 32.98 33.46 45.68 29.14 24.27 25.33 22.28 22.70 19.91 15.91 15.49 14.36 
     47* 0.00 29.76 29.34 26.67 23.86 21.12 19.33 19.87 16.87 16.11 12.66 11.97 10.58 
     48* 0.00 17.89 24.85 27.98 27.56 22.87 21.58 20.51 20.21 17.83 16.10 12.39 11.09 
 140 0.00 2.15 30.89 26.25 22.57 23.44 22.95 17.01 16.86 18.19 12.39 9.54 8.71 
 145 0.00 11.55 13.35 20.33 15.32 13.83 12.72 12.25 12.15 11.81 11.02 8.10 7.42 
  146* 0.00 17.09 16.50 21.09 16.47 16.36 16.63 14.01 13.62 9.68 8.59 8.11 7.75 
  245* 0.00 3.79 11.31 12.42 14.25 12.53 11.91 10.60 10.35 10.31 8.33 6.50 5.99 
Mean 0.00 18.87 23.59 26.89 23.84 21.19 19.50 17.66 16.47 15.12 11.86 9.87 8.88 
St. Dev. 0.00 9.71 6.06 7.17 5.35 4.22 3.81 3.47 3.41 3.20 2.87 2.81 2.19 
              
*Minority Subjects 
 
Table G3.  Alprazolam Concentrations (msec) for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
    17 0.00 33.26 39.58 29.13 30.62 24.84 21.93 22.04 20.98 19.93 17.01 15.14 14.03 
    18 0.00 34.73 24.31 29.08 23.97 23.90 18.92 19.39 18.26 16.15 14.29 13.50 12.39 
    19 0.00 18.04 26.34 39.93 34.88 31.26 27.32 23.17 23.11 20.05 17.36 14.51 14.34 
      20* 0.00 9.16 11.20 25.64 25.67 25.23 23.07 21.35 21.21 20.35 19.11 17.02 15.92 
   21 0.00 55.50 42.11 23.92 23.04 21.69 18.87 19.07 17.93 17.98 14.30 13.62 13.28 
   22 0.00 45.38 37.37 33.39 30.30 22.96 19.56 20.05 19.79 19.43 15.61 15.13 12.45 
   23 0.00 7.63 45.63 56.29 39.73 29.12 26.55 24.92 23.80 21.07 16.50 15.18 13.95 
   24 0.00 30.83 36.42 35.05 26.67 23.11 24.07 22.17 19.56 17.87 13.35 13.06 11.60 
   25 0.00 13.08 23.66 43.44 36.41 30.46 28.13 26.63 25.32 25.07 19.80 16.95 18.12 
   26 0.00 61.43 35.79 44.54 35.48 31.44 29.88 28.35 27.41 25.92 19.92 18.92 18.12 
   27 0.00 1.37 15.72 21.97 24.70 20.07 17.67 15.91 14.11 14.47 11.30 10.02 10.40 
   28 0.00 40.55 34.75 31.13 23.13 22.68 22.43 21.64 19.27 18.40 18.14 18.30 17.78 
     29* 0.00 26.74 43.09 38.07 35.46 28.51 21.43 22.17 21.50 18.22 14.52 11.44 10.97 
     30* 0.00 15.60 32.40 28.99 24.46 18.60 17.05 15.30 14.82 13.30 11.20 9.24 9.85 
     31* 0.00 40.08 33.08 28.64 25.80 21.46 21.06 18.75 17.08 17.19 13.51 10.46 10.69 
120 0.00 50.58 34.51 34.33 28.36 23.38 21.72 21.08 16.53 17.14 12.67 9.68 7.97 
Mean 0.00 30.25 32.25 33.97 29.29 24.92 22.48 21.37 20.04 18.91 15.54 13.89 13.24 
St. Dev. 0.00 18.16 9.67 8.86 5.49 4.05 3.83 3.45 3.67 3.31 2.84 3.08 3.06 
              
*Minority Subjects 
Table G4.  Alprazolam Concentrations (msec) for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
  50 0.00 11.64 17.68 23.16 26.80 22.54 18.35 20.61 16.30 16.12 14.35 13.07 12.22 
  51 0.00 11.68 18.10 20.11 23.79 22.39 19.46 19.36 18.00 17.56 14.42 14.14 15.12 
  52 0.00 22.20 36.50 28.83 22.68 21.74 22.80 21.26 18.75 19.37 15.05 13.99 13.40 
  53 0.00 7.34 19.10 18.47 25.42 21.86 19.91 21.39 17.84 15.59 13.64 12.31 10.78 
  54 0.00 22.42 21.72 23.23 23.06 15.87 16.14 15.21 12.70 12.83 9.68 7.46 6.69 
  55 0.00 18.52 24.31 29.20 28.98 23.40 22.39 20.45 22.05 20.90 18.68 14.55 12.67 
  56 0.00 32.63 30.28 23.14 23.01 20.35 18.07 21.37 14.96 15.95 12.77 12.09 12.03 
  57 0.00 17.03 31.09 23.90 22.54 20.88 19.35 17.29 14.94 16.88 15.33 14.25 12.38 
  58 0.00 58.25 31.11 24.06 17.73 15.96 17.92 15.66 13.01 12.67 10.04 9.23 9.05 
  59 0.00 64.28 41.26 26.63 21.26 18.53 18.36 15.06 15.23 13.76 10.38 9.13 7.40 
  60 0.00 29.45 21.54 20.28 18.25 -- 12.84 14.56 12.94 12.84 6.78 7.66 6.04 
     61* 0.00 5.25 40.23 25.31 23.66 22.27 20.88 20.61 18.28 18.80 13.70 14.04 14.29 
149 0.00 25.55 20.17 25.43 19.01 18.98 17.73 17.48 14.81 13.78 11.90 9.96 9.79 
160 0.00 33.84 35.49 30.43 30.90 23.41 23.00 22.03 21.68 20.32 14.81 15.34 15.51 
Mean 0.00 25.72 27.76 24.44 23.36 20.63 19.09 18.74 16.54 16.24 12.97 11.94 11.24 
St. Dev. 0.00 17.49 8.40 3.52 3.79 2.57 2.73 2.75 3.02 2.85 2.99 2.72 3.06 
              
*Minority Subjects 
(--) Alprazolam concentration not obtained 
Table G5.  Alprazolam Concentrations (msec) for young women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
     1 0.00 28.74 25.45 27.21 28.37 21.74 21.40 16.98 15.79 14.10 11.02 8.92 8.20 
     3 0.00 19.77 15.95 26.43 20.31 19.39 18.28 14.07 12.18 12.28 8.13 6.91 5.23 
     4 0.00 4.78 14.71 32.83 34.37 31.12 23.76 22.94 21.79 21.73 15.04 14.67 12.73 
     5 0.00 40.10 29.31 30.87 24.29 22.93 18.28 16.06 16.58 13.03 9.16 7.13 8.48 
     7 0.00 3.59 7.46 29.36 18.17 16.74 17.27 12.19 10.50 11.44 6.43 4.64 4.07 
     8 0.00 9.56 22.63 30.22 28.96 23.96 25.54 21.02 16.42 15.48 11.00 9.16 8.10 
     9 0.00 0.90 3.77 17.06 18.15 21.44 21.49 18.08 14.77 13.53 10.95 8.25 7.14 
   10 0.00 35.45 27.98 28.74 21.26 23.42 21.07 20.05 19.85 12.82 10.36 9.50 8.58 
   11 0.00 7.90 30.56 31.29 34.36 41.06 38.56 23.79 23.39 18.33 15.78 9.54 4.71 
   12 0.00 16.93 20.31 29.65 29.06 26.18 20.39 19.08 16.42 13.00 10.50 11.40 9.36 
     14* 0.00 3.35 5.83 5.89 5.33 4.79 3.97 3.85 2.89 3.00 2.52 2.85 2.88 
    15* 0.00 18.17 25.66 31.51 29.70 19.38 18.91 18.23 14.45 15.09 12.52 10.89 11.24 
    16* 0.00 24.64 24.81 24.52 22.45 25.14 22.53 20.98 18.40 18.20 13.94 12.72 11.31 
   66 0.00 19.38 18.34 25.55 24.52 19.77 19.80 18.76 16.31 15.93 13.84 12.10 12.65 
102 0.00 1.02 19.03 22.72 23.67 26.64 21.94 17.96 18.23 14.37 10.60 7.55 6.04 
111 0.00 19.31 20.14 25.03 22.97 22.17 21.23 17.45 17.07 15.85 13.17 10.91 10.85 
112 0.00 0.69 39.48 23.48 19.24 18.02 15.55 14.76 13.74 12.55 12.26 10.12 7.66 
113 0.00 13.47 30.51 35.76 31.98 25.93 25.69 20.91 20.57 20.30 14.45 9.04 9.91 
  114* 0.00 1.05 5.72 25.61 24.01 20.88 19.72 18.10 15.81 13.38 10.09 8.58 7.62 
206 0.00 8.40 12.96 38.91 35.84 36.10 34.72 35.84 24.51 23.21 20.99 18.36 15.34 
  213* 0.00 18.83 32.22 24.27 22.52 19.55 15.91 15.16 14.76 11.18 8.20 5.83 4.67 
Mean 0.00 14.09 20.61 27.00 24.74 23.16 21.24 18.39 16.40 14.71 11.47 9.48 8.42 
St. Dev. 0.00 11.60 9.77 6.82 6.98 7.26 6.82 5.83 4.65 4.27 3.78 3.40 3.21 
              
*Minority Subjects 
Table G6.  Alprazolam Concentrations (msec) for young men during Alprazolam/ DHEA Treatment 
 
Time (h) 
Subject 0 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
  33 0.00 21.05 31.59 29.09 24.41 24.49 21.08 18.42 16.26 15.56 11.45 9.79 7.72 
  34 0.00 10.87 17.77 17.86 17.28 16.05 15.93 13.59 11.29 11.05 9.47 7.15 7.04 
  35 0.00 24.12 15.78 26.06 24.74 22.65 17.29 18.07 16.34 17.05 14.73 12.19 13.43 
  36 0.00 20.18 33.69 37.68 45.71 26.65 22.89 23.20 18.00 16.57 11.21 10.23 7.00 
  37 0.00 21.52 32.63 25.21 22.61 19.07 17.06 16.60 13.58 13.14 9.66 9.05 7.29 
  38 0.00 25.20 43.14 31.61 26.96 23.67 23.21 19.57 18.85 14.38 9.89 9.75 7.06 
  39 0.00 30.54 33.20 28.22 25.61 25.24 22.48 23.80 21.03 18.99 18.08 13.95 13.42 
  41 0.00 15.89 28.02 33.51 30.92 28.01 23.69 20.40 16.73 15.17 10.70 7.92 7.89 
  42 0.00 10.01 28.39 38.12 27.73 22.63 21.98 18.27 16.45 15.40 9.60 5.84 5.47 
  43 0.00 10.12 14.56 19.65 17.45 15.81 14.85 13.98 11.92 12.32 8.76 8.68 7.07 
  44 0.00 51.05 38.69 25.46 22.52 22.87 20.67 19.86 17.89 16.76 15.03 11.35 9.75 
  45 0.00 11.59 31.49 28.14 20.37 17.94 16.38 15.06 14.17 13.31 9.34 7.13 7.88 
  46 0.00 52.27 34.91 31.81 29.98 29.02 23.58 21.79 18.42 17.81 16.13 13.44 12.44 
     47* 0.00 42.68 28.47 27.08 20.71 20.59 19.11 19.03 16.89 16.24 13.23 11.35 9.91 
     48* 0.00 2.92 19.36 33.86 33.02 23.01 20.96 24.30 18.24 18.75 12.04 11.30 9.50 
 140 0.00 30.95 27.94 29.99 27.65 26.92 27.07 20.18 17.73 13.56 12.68 10.32 7.44 
 145 0.00 9.43 10.30 20.46 14.62 14.19 13.88 12.09 11.61 10.23 6.46 7.48 7.62 
  146* 0.00 2.05 4.81 18.44 21.22 18.40 15.23 15.58 11.66 11.58 10.67 8.20 7.24 
  245* 0.00 4.23 12.60 16.45 13.31 12.42 12.25 10.15 11.01 10.22 7.31 6.14 5.33 
Mean 0.00 20.88 25.65 27.30 24.57 21.56 19.45 18.10 15.69 14.63 11.39 9.54 8.45 
St. Dev. 0.00 15.14 10.51 6.49 7.44 4.81 4.05 3.95 3.03 2.75 3.00 2.34 2.39 
              
*Minority Subjects 
 
Table G7.  Alprazolam Concentrations (msec) for older women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
    17 0.00 28.13 25.75 22.94 18.73 19.36 18.37 18.32 18.77 15.62 13.91 12.47 12.88 
    18 0.00 29.39 19.46 25.04 23.44 23.03 18.73 17.79 17.51 15.75 13.84 12.19 11.65 
    19 0.00 17.59 27.15 33.79 33.21 28.51 24.09 23.94 19.48 19.73 15.76 13.45 11.43 
      20* 0.00 2.74 21.16 21.64 26.77 29.96 22.04 22.19 23.64 19.32 19.57 17.67 16.59 
   21 0.00 41.66 32.74 36.22 27.02 22.16 20.24 18.52 17.33 17.69 18.16 15.19 14.44 
   22 0.00 11.85 32.91 32.79 28.82 29.57 -999.00 22.12 22.03 22.52 16.24 15.19 15.38 
   23 0.00 59.47 38.14 41.52 35.60 29.82 27.17 24.47 23.44 19.79 16.72 14.13 14.17 
   24 0.00 29.01 34.60 32.15 26.35 24.12 24.12 21.15 18.36 16.52 12.12 11.15 11.45 
   25 0.00 33.19 28.35 40.29 29.35 28.42 29.38 29.08 28.35 25.48 25.26 21.76 15.71 
   26 0.00 26.35 40.93 42.05 35.84 31.57 29.74 27.78 26.73 24.47 20.61 19.43 18.54 
   27 0.00 8.13 14.17 25.40 27.02 20.59 18.37 18.05 16.59 13.76 11.24 9.00 8.88 
   28 0.00 27.93 31.31 27.10 21.74 21.33 21.06 19.66 18.04 18.25 17.23 15.58 17.22 
     29* 0.00 39.94 34.13 35.50 27.20 26.75 25.69 25.17 20.41 19.01 15.78 13.52 11.90 
     30* 0.00 60.24 40.11 26.08 24.01 19.73 20.34 16.71 14.71 13.44 10.37 10.03 8.92 
     31* 0.00 27.61 32.42 27.34 26.57 22.11 20.92 19.52 17.05 15.91 13.61 9.06 9.59 
120 0.00 32.75 35.97 31.55 27.23 23.68 22.10 19.36 17.04 13.99 12.09 9.84 9.35 
Mean 0.00 29.75 30.58 31.34 27.43 25.04 -41.04 21.49 19.97 18.20 15.78 13.73 13.01 
St. Dev. 0.00 15.85 7.52 6.58 4.58 4.12 255.48 3.70 3.86 3.64 3.88 3.69 3.10 
              
*Minority Subjects 
Table G8.  Alprazolam Concentrations (msec) for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
  50 0.00 27.53 29.34 24.70 23.59 21.35 21.57 21.40 19.49 16.62 13.95 11.61 11.10 
  51 0.00 23.92 27.43 20.69 22.48 22.56 20.73 19.74 20.22 17.30 14.00 14.98 14.29 
  52 0.00 49.86 31.85 27.13 24.71 23.27 19.56 19.99 17.49 16.01 15.26 13.61 14.95 
  53 0.00 33.19 25.26 22.92 20.92 20.84 18.74 19.49 15.61 14.82 11.97 11.72 10.02 
  54 0.00 27.58 21.31 22.48 20.18 20.45 18.09 16.48 13.90 14.20 9.48 7.66 5.46 
  55 0.00 9.36 18.40 16.88 14.79 23.88 27.90 16.54 22.38 19.80 18.41 13.52 15.08 
  56 0.00 23.48 23.28 28.13 23.64 21.65 20.33 18.92 17.37 15.88 14.35 13.86 11.24 
  57 0.00 39.82 30.73 23.70 21.79 18.74 18.06 17.52 16.04 14.74 13.01 12.65 10.24 
  58 0.00 0.23 50.54 25.19 20.62 18.25 16.71 15.62 13.77 13.26 10.53 9.92 8.57 
  59 0.00 60.13 24.83 20.72 19.24 17.59 18.90 16.68 15.08 14.02 11.14 9.18 8.93 
  60 0.00 30.33 24.24 20.42 18.08 19.08 15.04 13.10 14.30 13.41 9.22 8.89 7.04 
     61* 0.00 47.13 30.46 25.15 25.19 24.59 21.80 22.60 19.70 19.64 16.90 16.45 14.05 
149 0.00 36.60 25.08 23.44 21.96 18.09 18.41 15.22 13.74 13.39 11.66 10.08 9.22 
160 0.00 48.24 39.07 31.14 26.27 25.55 22.33 21.50 17.50 17.70 15.78 16.04 13.85 
Mean 0.00 32.67 28.70 23.76 21.68 21.13 19.87 18.20 16.90 15.77 13.26 12.15 11.00 
St. Dev. 0.00 16.13 8.10 3.61 3.05 2.58 3.07 2.75 2.74 2.20 2.76 2.75 3.06 














Table H1.  DHEA concentrations (ng/ml) for young women during Placebo Treatment 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
   1 10.66 6.22 6.85 15.38 16.15 11.34 13.17 10.70 12.28 12.98 10.28 11.36 7.74 10.42 9.36 
   3 13.87 6.59 6.45 7.26 6.60 6.48 7.53 8.47 5.96 7.80 5.51 4.79 4.63 11.09 10.47 
   4 19.43 12.73 13.43 14.51 10.46 8.04 11.44 10.73 9.21 7.50 8.85 8.32 7.88 8.79 16.60 
   5 20.71 8.61 8.34 7.66 10.60 9.35 11.39 8.49 7.07 10.82 6.19 6.41 4.83 18.11 22.51 
   7 12.99 4.13 4.21 6.26 5.95 7.80 4.99 5.19 3.98 2.52 3.85 2.76 2.21 7.71 8.14 
   8 19.98 10.62 14.74 8.13 7.65 7.84 10.14 6.91 8.64 5.64 9.70 5.21 5.54 4.77 14.28 
   9 12.67 9.56 7.29 6.77 6.92 6.39 6.07 6.05 6.67 8.54 5.78 5.05 3.15 2.98 12.11 
 10 19.06 11.73 12.48 13.76 12.48 15.06 12.31 12.26 11.65 10.23 8.78 8.78 8.72 8.79 19.16 
 11 13.46 7.81 14.52 15.52 15.97 14.33 14.13 15.72 12.24 15.85 13.57 11.98 9.51 10.19 17.36 
 12 15.52 8.27 10.29 10.98 15.69 18.15 14.93 10.40 14.76 16.83 12.14 8.26 8.66 5.94 10.24 
    14* 11.10 5.25 5.26 6.52 6.80 7.15 5.67 5.59 7.07 5.14 6.06 3.82 3.80 5.96 8.04 
    15* 2.60 1.07 1.27 1.32 1.44 1.25 1.11 1.76 1.11 1.10 0.93 1.09 0.91 1.25 1.77 
    16* 4.08 6.62 7.57 7.20 6.09 6.26 4.89 5.10 5.40 6.14 6.12 4.43 3.43 4.23 9.58 
  66 18.98 11.14 13.28 16.26 16.43 12.26 12.25 11.18 9.06 13.15 9.41 7.34 10.37 10.83 15.62 
102 17.62 8.37 10.71 10.75 13.85 12.48 10.68 10.56 9.41 8.65 8.38 7.46 6.78 5.32 14.50 
111 15.22 8.58 14.87 19.56 13.64 7.87 6.80 8.83 7.50 7.36 6.06 5.36 5.08 11.01 13.41 
112 9.31 13.57 8.31 5.94 8.02 6.71 6.92 5.99 10.01 8.67 4.63 6.88 4.75 2.33 14.03 
113 20.23 10.41 9.47 12.79 15.39 18.63 17.23 12.31 12.80 11.12 13.74 8.37 6.12 12.84 16.61 
   114* 8.52 4.99 4.72 4.25 5.72 5.64 5.92 5.32 5.50 4.88 3.66 3.52 2.94 4.91 9.63 
 206 8.04 5.74 7.02 5.79 4.62 3.83 4.90 3.48 2.83 3.90 3.77 3.93 2.80 4.17 4.03 
   213* 14.59 6.25 6.25 6.05 6.82 6.57 6.40 6.77 7.13 8.16 5.51 5.52 5.41 6.22 15.93 
Mean 13.74 8.01 8.92 9.65 9.87 9.21 8.99 8.18 8.11 8.43 7.28 6.22 5.49 7.52 12.54 
St. Dev. 5.26 3.07 3.85 4.74 4.55 4.51 4.14 3.41 3.46 4.08 3.38 2.72 2.58 4.06 4.98 
                
*Minority Subjects 
  
Table H2.  DHEA concentrations (ng/ml) for young men during Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 33 9.22 4.98 6.19 5.30 7.28 6.56 4.92 4.76 3.82 4.99 4.52 3.55 3.99 4.37 10.35 
 34 10.15 4.27 7.13 6.98 5.83 5.91 5.73 5.31 4.97 7.16 5.35 5.45 2.70 3.89 7.76 
 35 9.07 4.90 4.71 5.32 6.81 6.44 4.41 6.24 7.27 4.00 3.17 2.83 3.64 3.62 7.11 
 36 9.51 8.77 8.25 8.47 8.55 6.99 7.77 9.59 7.82 8.07 5.96 5.47 4.39 8.06 10.75 
 37 11.33 8.97 9.61 8.31 9.71 8.88 7.53 8.06 10.13 8.69 5.84 3.95 3.42 5.53 14.33 
 38 12.76 9.08 11.02 10.19 8.94 10.62 8.21 9.12 9.33 8.67 7.50 5.70 3.78 7.65 11.22 
 39 20.46 8.37 8.41 7.06 9.14 10.69 8.16 9.84 7.34 8.23 4.84 5.41 4.82 6.09 13.71 
 41 17.08 9.10 10.32 12.91 10.74 10.15 10.05 12.82 12.01 11.69 7.76 4.99 10.92 7.82 16.68 
 42 6.94 12.76 9.24 10.53 9.26 13.08 11.35 8.15 9.85 9.20 9.34 6.44 5.87 4.29 13.99 
 43 16.44 9.76 13.61 9.79 10.34 11.40 12.05 13.13 9.15 9.16 7.24 5.92 6.36 13.53 13.72 
 44 11.90 6.48 6.13 8.65 9.51 8.59 10.20 9.16 10.41 12.34 7.61 6.67 5.13 4.37 11.51 
 45 17.73 12.55 14.09 10.46 12.99 12.83 14.19 12.53 10.60 8.62 7.21 6.10 5.64 9.64 15.11 
 46 21.39 10.38 12.48 14.01 10.94 18.73 18.03 15.95 10.16 15.11 11.91 6.49 5.39 15.68 21.76 
    47* 16.05 5.41 5.70 6.32 9.87 7.40 6.44 4.95 13.43 5.92 4.35 4.00 3.94 7.63 14.29 
    48* 15.32 8.04 11.66 9.55 9.66 11.40 9.10 7.28 9.90 9.53 6.66 7.31 5.97 15.91 12.97 
140 6.16 5.77 8.77 11.13 8.54 9.06 6.92 10.36 7.81 7.01 7.65 5.60 3.99 2.30 7.36 
145 18.05 12.20 14.46 12.01 12.82 12.25 11.80 11.07 13.27 12.23 11.81 17.49 12.38 10.05 13.60 
   146* 15.05 7.10 8.09 7.00 9.10 9.67 7.18 8.14 7.10 6.42 5.97 5.17 5.31 9.02 15.68 
   245* 19.78 6.49 9.66 10.39 10.46 13.20 9.49 7.99 9.58 8.71 6.97 5.32 6.30 4.40 15.18 
Mean 13.92 8.18 9.45 9.18 9.50 10.20 9.13 9.18 9.16 8.72 6.93 5.99 5.47 7.57 13.00 
St. Dev. 4.65 2.61 2.88 2.46 1.78 3.11 3.34 2.99 2.48 2.70 2.28 3.00 2.43 4.00 3.53 
                
*Minority Subjects 
--Concentration not obtained 
  
Table H3.  DHEA concentrations (ng/ml) for older women during Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 17 4.23 1.91 2.06 0.86 1.98 1.71 2.28 1.56 4.08 1.35 1.23 1.25 1.00 1.99 10.60 
 18 4.26 2.10 2.15 1.80 2.04 2.95 1.63 2.61 1.93 2.07 1.58 1.78 1.05 1.84 2.24 
 19 9.78 4.06 3.81 5.48 6.20 4.84 3.80 6.24 4.43 3.45 3.46 2.95 2.13 2.41 6.37 
    20* 5.45 2.14 2.68 2.55 2.75 2.63 2.51 2.20 2.33 2.31 2.96 2.53 1.62 2.50 3.04 
 21 7.80 7.97 4.66 6.33 8.82 14.44 5.63 5.38 6.11 3.99 7.29 4.34 4.97 3.79 6.02 
 22 8.45 3.94 5.88 4.49 5.31 5.05 4.15 3.73 3.54 2.69 3.32 3.31 1.99 4.58 7.28 
 23 2.03 1.79 1.61 1.81 2.82 2.11 1.88 1.77 1.68 1.96 1.73 1.37 1.35 2.32 2.81 
 24 4.01 1.71 1.80 2.21 1.97 2.11 2.29 2.19 1.59 2.22 1.93 1.51 1.28 2.07 4.13 
 25 4.83 2.79 2.97 2.36 3.22 3.72 2.61 3.26 2.37 2.99 2.58 2.01 1.95 3.52 6.96 
 26 5.18 1.66 2.22 1.61 1.82 1.55 1.89 1.74 -- 1.88 1.52 1.34 1.22 3.20 2.77 
 27 2.92 1.50 1.20 1.21 1.16 1.30 1.26 1.43 1.40 1.38 -- 1.48 0.99 0.93 2.73 
 28 1.33 1.03 1.40 1.33 1.23 1.03 1.60 1.24 1.38 1.49 1.11 1.23 0.91 1.30 1.51 
    29* 1.33 1.02 0.98 1.01 1.48 1.43 1.33 1.07 1.27 1.02 0.91 1.07 0.78 1.86 2.22 
    30* 2.29 2.14 1.97 2.07 2.13 1.56 1.69 1.81 1.54 1.62 1.64 1.44 0.81 1.01 4.40 
    31* 0.63 1.33 1.45 0.89 0.89 0.88 1.39 0.75 0.86 0.96 0.78 0.74 1.00 0.72 1.32 
120 10.32 3.26 3.49 2.88 3.25 3.35 5.67 3.58 3.23 4.19 2.40 1.74 1.98 2.28 5.02 
Mean 4.68 2.52 2.52 2.43 2.94 3.17 2.60 2.54 2.52 2.22 2.30 1.88 1.56 2.27 4.34 
St. Dev. 3.03 1.72 1.35 1.64 2.13 3.27 1.44 1.55 1.47 1.00 1.62 0.95 1.02 1.08 2.55 
                
*Minority Subjects 
--Concentration not obtained 
  
Table H4.  DHEA concentrations (ng/ml) for older men during Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 50 4.48 3.37 5.26 4.14 3.88 3.39 3.70 2.59 2.75 3.64 2.66 2.35 2.20 3.64 6.94 
 51 4.12 2.42 2.48 2.28 2.49 2.77 2.35 2.10 2.43 2.32 1.72 2.00 3.49 4.28 2.71 
 52 6.76 2.17 3.17 2.10 2.33 2.41 2.10 2.31 2.15 1.99 1.97 1.77 1.74 5.51 7.73 
 53 4.07 3.12 7.58 4.77 3.71 3.04 3.26 3.76 4.09 3.50 3.01 2.88 2.91 2.92 7.59 
 54 5.12 3.28 4.89 3.53 3.22 4.15 3.20 4.46 3.79 2.99 3.06 2.50 1.93 2.52 3.99 
 55 4.65 3.24 4.24 3.63 3.56 3.97 3.35 2.65 2.22 3.03 2.20 2.71 1.36 6.91 4.01 
 56 3.36 2.41 2.80 2.33 2.63 2.54 2.46 2.86 2.52 2.61 1.92 1.99 1.63 1.90 3.16 
 57 4.44 2.46 3.61 3.53 2.40 2.37 2.07 2.52 2.97 3.42 1.89 2.16 1.88 4.31 4.86 
 58 1.53 1.37 1.46 1.42 1.57 1.87 1.45 1.55 1.29 1.20 1.48 1.04 1.27 1.03 2.02 
 59 7.49 4.79 6.01 6.30 5.42 7.06 4.97 6.18 4.76 8.13 4.69 3.91 2.65 3.44 10.61 
 60 5.73 4.44 4.07 3.55 3.93 3.31 3.17 4.37 3.45 3.15 2.85 3.03 2.41 2.43 3.87 
   61* 12.10 5.50 4.70 4.97 5.75 7.02 5.22 5.47 5.49 5.35 4.57 3.73 3.74 7.08 12.20 
149 4.18 3.06 3.05 2.92 3.47 3.37 3.14 2.88 2.48 2.79 2.58 2.39 2.20 3.37 4.65 
160 4.81 2.39 2.46 2.23 2.95 2.96 2.48 2.07 2.18 2.22 2.54 1.79 1.85 1.85 2.79 
Mean 5.20 3.14 3.98 3.41 3.38 3.59 3.07 3.27 3.04 3.31 2.65 2.45 2.23 3.66 5.51 
St. Dev. 2.44 1.12 1.62 1.33 1.16 1.59 1.06 1.38 1.15 1.68 0.97 0.77 0.74 1.82 3.08 
                
*Minority Subjects 
--Concentration not obtained 
  
Table H5.  DHEA concentrations (ng/ml) for young women during DHEA Treatment 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
   1 16.77 18.04 17.31 15.59 20.17 16.97 13.76 12.76 16.19 16.74 14.86 11.82 10.09 9.97 16.89 
   3 15.92 9.75 17.33 16.07 17.57 17.65 16.18 14.79 17.41 16.81 15.00 15.25 10.23 15.84 17.05 
   4 14.41 11.16 13.40 16.55 14.51 15.09 15.13 13.48 16.66 14.06 13.12 12.00 11.23 7.39 20.62 
   5 17.92 19.06 19.30 15.78 15.37 11.59 10.26 12.56 15.44 14.41 13.57 11.70 7.20 10.72 18.58 
   7 13.22 12.46 13.63 15.43 13.71 12.60 14.03 9.98 12.23 13.21 11.94 10.21 6.25 12.94 13.31 
   8 18.42 16.57 14.49 14.03 13.02 16.95 10.81 12.03 14.36 14.51 11.21 8.77 6.90 4.74 17.87 
   9 12.49 10.31 13.70 16.40 15.25 14.78 11.93 11.15 14.03 -- 18.14 11.79 11.98 11.38 14.26 
 10 21.35 15.59 16.21 15.68 14.63 14.35 16.32 21.49 17.12 14.37 13.51 13.00 10.67 11.28 24.43 
 11 14.44 7.50 9.93 15.05 15.95 17.53 15.24 16.28 17.59 15.48 12.94 13.00 11.93 10.11 13.10 
 12 18.19 13.92 17.18 19.77 20.04 19.34 23.70 16.63 22.41 22.36 19.78 16.95 13.13 9.85 8.02 
    14* 10.39 6.10 15.28 14.83 16.54 12.61 12.94 13.62 17.39 13.43 17.07 12.38 8.15 9.54 12.84 
    15* 1.70 1.74 13.92 13.07 11.33 8.25 7.60 8.71 11.28 11.83 10.28 10.37 9.67 9.40 9.98 
    16* 7.12 17.24 14.48 12.06 11.72 11.28 8.05 10.54 13.06 11.81 10.85 8.60 6.38 8.01 13.40 
  66 19.42 21.66 23.32 20.13 20.88 19.28 12.16 18.11 20.82 21.52 15.15 13.85 14.60 17.63 17.65 
102 14.91 15.94 16.14 15.34 17.70 17.48 14.28 13.20 12.35 13.77 15.78 12.94 10.76 9.48 18.57 
111 14.69 9.16 13.91 13.46 15.01 12.45 10.90 12.47 11.72 17.94 18.14 13.11 9.73 11.92 13.24 
112 14.25 10.14 16.44 11.59 11.14 9.86 9.63 9.67 11.82 13.02 8.92 8.88 8.10 8.42 8.75 
113 19.89 9.96 19.98 19.39 19.13 16.86 16.77 15.74 18.63 17.12 12.34 12.09 12.87 9.15 17.78 
   114* 8.21 12.65 12.88 12.81 11.42 9.12 11.04 15.45 13.63 10.90 9.40 6.97 6.76 8.75 11.07 
 206 8.02 10.23 15.99 15.12 11.73 14.67 13.18 13.78 16.81 16.11 16.94 15.17 13.61 13.56 12.67 
   213* 18.26 16.22 19.05 16.38 16.82 15.05 13.99 15.35 13.48 17.56 16.34 13.72 11.22 12.43 16.40 
Mean 14.29 12.64 15.90 15.45 15.41 14.46 13.23 13.70 15.45 15.35 14.06 12.03 10.07 10.60 15.07 
St. Dev. 4.92 4.78 2.94 2.29 3.08 3.26 3.54 3.04 3.06 3.01 3.04 2.44 2.51 2.86 4.06 
                
*Minority Subjects; (--) Concentration not obtained 
  
Table H6.  DHEA concentrations (ng/ml) for young men during DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 33 8.39 8.43 13.34 12.97 12.78 11.02 9.91 8.71 14.29 13.59 9.76 7.77 6.28 5.80 10.59 
 34 10.58 10.68 12.52 12.67 13.63 12.53 9.94 11.29 13.41 12.80 12.79 9.87 8.04 7.52 10.67 
 35 12.59 7.87 13.07 15.71 14.58 14.54 8.94 8.51 13.10 11.49 8.62 7.98 6.02 6.23 11.71 
 36 10.13 9.35 21.97 21.07 19.22 18.34 14.68 13.29 17.93 20.83 17.04 13.95 10.72 10.16 9.19 
 37 13.69 18.66 18.24 13.45 12.52 12.05 10.41 12.76 17.14 14.36 11.47 9.96 8.02 8.87 15.25 
 38 10.33 15.52 17.05 13.62 12.49 14.52 11.41 10.24 14.57 13.85 10.71 8.82 4.85 6.87 11.22 
 39 20.34 9.39 15.55 15.45 13.76 12.70 10.59 15.41 14.69 10.46 8.87 8.28 6.04 10.98 14.43 
 41 19.17 12.14 17.10 16.81 14.92 15.61 15.07 15.12 15.30 13.26 9.35 8.87 9.64 11.66 15.23 
 42 17.15 8.25 17.08 15.63 14.90 14.88 14.33 11.18 16.16 15.02 15.88 13.16 7.43 15.69 11.62 
 43 13.11 10.32 18.34 15.81 16.30 15.66 12.53 15.11 15.78 14.08 10.72 9.77 8.43 14.07 14.34 
 44 8.90 9.86 10.94 14.63 12.15 13.41 17.48 10.75 16.42 15.55 14.44 12.18 12.48 12.09 7.93 
 45 16.62 15.99 18.89 14.94 14.01 12.55 11.73 21.03 16.32 12.71 8.20 9.19 7.77 7.04 15.60 
 46 18.86 12.76 17.30 16.77 15.63 16.14 17.45 21.77 12.68 16.29 14.76 15.23 9.19 19.77 24.55 
    47* 15.55 13.38 13.57 12.86 11.90 12.82 10.56 8.30 13.06 13.74 12.21 9.31 6.90 8.57 11.93 
    48* 16.24 9.34 20.39 19.28 16.96 14.37 14.87 15.57 14.70 20.28 16.94 14.03 13.36 11.46 19.14 
140 17.71 8.32 16.11 17.77 15.53 14.55 14.78 15.32 15.12 17.97 14.95 11.05 7.60 4.69 13.91 
145 15.12 17.12 21.55 21.17 18.42 16.58 15.00 15.10 18.53 17.05 17.41 19.37 13.49 13.88 16.03 
   146* 15.31 17.91 15.87 13.84 13.19 13.67 12.44 11.80 11.63 14.05 12.99 10.53 7.47 13.38 15.80 
   245* 20.46 22.90 23.33 20.87 18.72 16.33 16.03 15.16 18.23 17.75 15.53 11.79 10.65 6.42 20.07 
Mean 14.75 12.54 16.96 16.07 14.82 14.33 13.06 13.50 15.21 15.01 12.77 11.11 8.65 10.27 14.17 
St. Dev. 3.82 4.33 3.38 2.81 2.26 1.84 2.66 3.75 1.95 2.76 3.08 2.97 2.50 3.95 4.03 




Table H7.  DHEA concentrations (ng/ml) for older women during DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 17 2.51 20.34 22.13 19.40 18.56 16.81 14.32 12.75 15.77 14.94 11.21 9.51 10.59 9.10 9.36 
 18 5.85 15.23 15.05 14.95 14.39 13.78 11.85 15.96 19.75 16.36 14.62 12.34 8.99 8.90 12.77 
 19 8.69 3.93 16.99 15.98 16.95 14.05 11.75 11.29 16.89 13.53 12.10 10.03 9.81 8.16 13.16 
    20* 4.66 1.25 4.07 13.16 11.80 16.77 15.30 12.23 13.53 12.37 13.31 13.53 9.83 9.48 10.63 
 21 11.82 17.99 19.90 15.59 14.96 16.62 10.23 9.35 9.13 16.61 12.98 13.87 8.85 11.57 10.83 
 22 6.92 3.34 10.21 13.37 13.81 12.34 10.82 11.81 15.08 13.80 12.44 11.81 8.81 7.66 12.41 
 23 4.73 16.13 14.10 12.05 11.55 11.47 9.92 11.52 12.73 18.12 14.54 12.79 9.44 8.25 11.64 
 24 2.33 18.07 18.65 12.38 11.27 11.12 9.17 16.50 14.76 12.36 10.86 8.10 5.45 7.12 6.10 
 25 3.76 3.00 12.10 13.61 12.62 12.23 9.29 12.62 16.32 17.97 16.07 13.06 12.55 11.65 11.39 
 26 3.82 17.04 22.74 20.05 18.82 15.54 15.37 19.88 23.44 20.12 14.82 12.63 11.07 9.87 11.54 
 27 2.98 2.28 12.21 14.50 14.54 13.11 11.27 9.69 10.46 16.62 15.25 15.38 9.55 9.18 9.48 
 28 1.56 2.37 13.47 11.38 10.99 9.12 6.49 6.25 11.94 14.31 11.92 11.09 6.91 6.35 7.90 
    29* 0.88 9.98 20.34 18.25 16.51 16.04 12.96 10.05 10.33 15.76 11.29 8.58 6.55 6.67 6.32 
    30* 2.84 3.88 11.80 9.33 8.94 8.00 7.83 7.52 8.41 12.97 11.16 10.93 7.75 6.52 10.17 
    31* 0.93 9.94 11.94 9.70 11.51 11.19 8.87 8.22 13.02 13.34 11.10 9.61 5.44 6.36 6.23 
120 11.64 3.59 12.25 12.74 12.24 12.62 11.90 9.87 14.11 12.72 10.75 10.54 9.32 16.11 14.25 
Mean 4.75 9.27 14.87 14.15 13.72 13.18 11.08 11.59 14.10 15.12 12.78 11.49 8.81 8.93 10.26 
St. Dev. 3.45 7.05 4.96 3.14 2.87 2.70 2.55 3.51 3.90 2.34 1.77 2.04 1.97 2.55 2.54 
                
*Minority Subjects 
  
Table H8.  DHEA concentrations (ng/ml) for older men during DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 49 23.09 21.11 22.56 20.81 17.52 14.49 17.35 14.26 12.87 12.08 12.24 11.44 10.29 15.95 16.11 
 50 3.75 23.95 23.94 19.67 18.88 15.77 14.71 11.08 12.36 15.10 11.34 10.61 8.58 9.08 8.27 
 51 2.51 19.92 22.17 20.77 18.54 17.91 16.72 14.54 13.70 14.41 14.21 12.42 9.85 9.06 9.63 
 52 6.15 2.31 7.11 10.18 11.79 7.34 5.96 6.08 9.18 10.62 13.25 11.77 6.24 6.56 9.46 
 53 4.06 10.50 14.88 13.35 11.32 9.55 9.20 9.26 13.31 11.59 9.85 8.61 7.11 8.80 9.14 
 54 3.48 9.69 13.73 10.85 10.81 10.28 6.94 4.96 4.91 12.32 4.67 6.87 4.53 2.54 3.87 
 55 7.12 3.74 4.82 7.90 10.80 9.86 8.83 8.71 7.67 9.72 9.43 10.01 6.10 5.41 5.82 
 56 3.13 3.00 16.66 18.16 15.12 12.55 10.72 14.63 16.53 14.43 10.42 9.61 8.01 6.83 7.66 
 57 5.02 2.70 4.63 6.10 6.08 6.08 5.18 5.74 6.95 8.53 5.67 5.24 4.50 3.97 8.66 
 58 1.66 2.46 8.77 13.36 14.80 11.82 9.30 13.29 16.28 12.89 9.21 7.92 5.26 3.96 6.08 
 59 11.10 13.25 13.58 12.42 12.33 11.47 3.89 4.00 8.52 13.36 11.23 9.57 5.91 7.87 9.45 
 60 4.82 11.57 11.60 8.65 8.40 8.31 6.68 8.36 10.24 10.02 8.11 6.61 5.79 6.37 7.46 
   61* 11.35 8.82 16.23 18.44 19.25 15.91 12.83 12.73 13.61 16.76 16.26 11.13 8.99 9.26 11.51 
149 4.40 2.66 12.64 10.80 10.36 9.53 7.66 8.04 11.94 10.44 9.18 7.77 6.92 6.93 9.21 
160 3.44 2.24 12.69 12.40 11.13 9.96 8.38 14.43 18.45 14.10 10.98 8.83 8.66 6.36 10.32 
Mean 6.34 9.19 13.73 13.59 13.14 11.39 9.62 10.01 11.77 12.42 10.40 9.23 7.12 7.26 8.84 
St. Dev. 5.43 7.53 6.02 4.84 4.02 3.38 4.10 3.81 3.83 2.30 3.01 2.08 1.86 3.15 2.79 







Table H9.  DHEA concentrations (ng/ml) for young women during Alprazolam/Placebo Treatment 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
   1 13.99 13.43 14.51 13.58 12.74 11.38 12.85 13.57 15.77 10.96 12.54 11.51 9.35 14.88 9.07 
   3 16.21 7.81 8.15 7.58 7.32 6.04 5.39 8.40 9.80 6.89 5.99 4.48 4.37 6.64 13.65 
   4 17.43 8.50 11.17 8.46 8.25 7.40 9.39 8.55 7.79 7.11 8.47 7.15 5.60 7.11 10.55 
   5 20.73 9.44 13.75 11.90 9.23 6.90 7.96 10.82 8.82 7.10 9.83 7.19 5.78 7.60 10.05 
   7 14.01 4.76 5.23 7.49 4.73 3.80 3.67 3.68 3.63 8.20 2.93 2.61 2.86 2.98 8.09 
   8 18.24 6.72 7.17 14.81 9.38 7.94 6.86 7.31 8.05 6.83 9.64 6.23 5.28 3.93 15.09 
   9 10.52 4.94 8.52 6.23 6.29 5.95 3.86 5.13 9.02 5.83 6.00 4.90 3.44 4.73 7.60 
 10 22.46 12.65 12.12 12.38 11.17 9.65 9.17 9.25 9.94 8.19 9.95 8.92 10.08 13.52 25.66 
 11 8.54 7.83 10.96 11.01 8.24 6.51 5.83 6.31 11.67 7.74 8.04 6.24 3.07 5.14 10.98 
 12 10.06 14.68 16.65 14.15 10.35 9.23 7.47 14.02 8.43 5.71 9.45 7.08 7.71 4.55 5.91 
    14* 15.72 6.59 6.65 9.20 8.81 6.30 6.18 6.16 5.56 5.98 7.24 5.49 4.55 5.80 10.88 
    15* 3.07 2.85 1.14 1.20 1.00 0.71 0.80 0.75 0.58 0.90 0.77 0.72 0.67 0.85 1.42 
    16* 3.34 4.34 4.58 4.41 3.53 2.80 2.53 5.32 3.76 4.65 3.12 2.38 2.38 2.75 3.59 
  66 15.87 15.40 15.01 11.17 10.69 9.94 9.97 9.30 9.24 12.58 16.19 10.43 7.50 9.97 15.19 
102 13.79 6.66 10.86 9.96 8.46 6.86 6.78 7.53 9.57 9.27 8.50 6.77 6.07 4.29 11.62 
111 17.15 9.23 8.53 11.25 9.21 7.34 6.13 7.53 9.52 8.17 6.53 5.72 4.51 7.80 16.97 
112 12.15 10.84 10.19 8.56 6.64 6.85 5.65 6.57 7.49 6.49 11.15 6.49 4.95 4.87 8.99 
113 18.88 8.60 8.63 12.81 10.50 7.98 7.20 16.03 10.78 8.56 8.42 7.27 5.34 11.28 12.16 
   114* 7.35 3.70 3.65 3.45 3.41 2.84 3.32 3.92 4.50 3.56 4.35 3.21 4.30 3.25 9.95 
 206 10.31 6.93 10.19 12.35 9.21 6.36 5.77 5.96 5.78 6.63 5.40 4.86 4.80 4.35 8.08 
   213* 10.49 6.65 7.88 8.00 8.30 7.12 7.33 6.75 14.48 7.22 7.48 8.26 6.10 7.75 19.66 
Mean 13.35 8.22 9.31 9.52 7.97 6.66 6.39 7.76 8.29 7.07 7.71 6.09 5.18 6.38 11.20 
St. Dev. 5.23 3.52 3.91 3.62 2.87 2.53 2.73 3.61 3.55 2.43 3.47 2.60 2.22 3.58 5.38 
                
*Minority subject 
  
Subjects Table H10.  DHEA concentrations (ng/ml) for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 33 6.34 7.12 7.44 6.58 5.77 5.47 5.40 7.84 5.43 5.52 5.65 4.74 4.64 5.79 7.70 
 34 9.34 7.39 7.88 5.50 5.53 4.97 5.06 7.10 5.02 5.82 4.75 3.75 3.09 3.07 4.87 
 35 11.86 3.56 11.53 5.46 4.45 3.72 3.24 5.63 4.43 3.93 3.35 3.25 5.29 2.97 6.36 
 36 9.28 8.52 9.12 7.90 7.38 5.77 4.40 5.63 5.83 7.21 5.45 4.89 3.88 5.35 9.69 
 37 10.38 10.85 10.90 11.08 8.83 6.57 6.23 6.70 6.62 8.03 5.70 4.09 3.40 4.50 14.98 
 38 12.72 9.98 11.21 8.76 7.61 7.35 6.59 6.33 6.86 8.25 8.90 6.00 5.38 4.74 13.98 
 39 22.21 9.16 11.56 8.75 8.03 9.13 6.31 12.94 8.00 7.31 6.72 5.44 4.48 11.48 12.37 
 41 19.12 8.74 13.39 14.92 10.48 7.53 6.10 7.73 11.92 7.34 8.21 5.97 7.32 6.48 15.87 
 42 11.31 7.68 8.35 10.23 7.80 5.91 4.77 5.56 5.06 6.16 5.61 4.06 4.89 5.09 5.96 
 43 15.78 9.98 10.51 10.74 10.14 8.63 8.57 7.11 9.33 12.38 7.37 6.80 5.56 5.61 10.24 
 44 12.33 7.56 7.20 7.44 6.21 5.90 6.71 12.73 9.06 10.46 10.37 8.78 5.79 15.00 6.31 
 45 17.83 6.83 8.60 9.69 8.33 7.69 6.57 7.62 10.52 6.75 5.61 5.36 6.85 5.84 6.04 
 46 23.12 8.65 16.05 10.67 9.54 7.80 9.64 14.17 7.86 10.51 5.42 5.48 5.83 16.33 22.76 
    47* 10.55 6.51 6.62 6.46 5.24 4.70 4.18 4.72 10.83 5.10 4.15 3.45 3.80 7.20 14.71 
    48* 15.51 8.70 9.67 11.08 8.33 7.09 7.58 8.69 9.38 11.53 8.56 7.71 5.95 17.46 12.61 
140 14.33 5.78 14.13 12.57 7.95 6.92 4.67 5.57 6.12 10.74 8.09 5.93 4.85 3.98 11.35 
145 14.99 13.69 14.08 12.66 12.38 12.12 11.35 12.15 12.74 11.35 10.69 14.22 8.65 8.30 12.70 
   146* 15.72 7.78 9.37 8.30 8.42 6.80 6.41 7.33 9.79 11.22 7.05 5.25 5.34 12.19 17.11 
   245* 18.37 11.14 13.56 12.49 10.44 11.23 9.00 9.70 11.23 12.39 10.27 7.63 6.10 4.87 4.75 
Mean 14.27 8.40 10.59 9.54 8.05 7.12 6.46 8.17 8.21 8.53 6.94 5.94 5.32 7.70 11.07 
St. Dev. 4.49 2.21 2.70 2.64 2.03 2.10 2.05 2.84 2.56 2.68 2.15 2.50 1.37 4.52 4.88 




Table H11.  DHEA concentrations (ng/ml) for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 17 3.88 3.44 3.98 2.66 2.38 2.52 2.16 1.96 2.43 2.66 2.22 2.36 4.00 6.37 6.10 
 18 4.91 2.04 1.98 1.73 1.64 1.73 2.06 2.22 1.46 1.73 1.38 1.47 2.94 1.00 3.94 
 19 10.90 2.71 2.61 2.23 2.37 2.10 1.95 0.99 4.67 2.09 2.00 1.89 1.58 2.78 4.97 
    20* 7.21 2.89 2.96 2.83 3.09 2.78 2.34 2.53 2.04 2.45 2.98 2.52 2.12 3.29 2.61 
 21 10.52 4.17 5.95 3.63 3.23 2.32 1.52 4.50 3.06 2.66 2.86 3.05 2.33 12.48 4.88 
 22 8.65 4.32 3.11 2.68 3.21 2.58 2.52 2.80 4.46 2.61 2.60 2.50 1.71 4.33 8.19 
 23 2.72 1.91 1.64 1.59 1.59 1.58 1.74 1.98 1.88 1.57 1.94 1.67 1.33 2.89 2.38 
 24 3.65 1.96 1.82 1.73 1.75 1.86 1.39 1.61 1.63 1.69 2.03 1.55 1.22 1.46 2.70 
 25 3.02 2.18 2.71 3.08 2.65 2.06 1.88 1.77 3.06 2.50 2.78 1.94 1.50 2.12 2.49 
 26 2.40 1.62 1.93 2.33 1.94 1.64 1.62 1.54 1.59 5.40 1.83 1.72 1.22 4.73 1.48 
 27 1.59 1.36 1.52 1.22 1.10 0.89 1.03 1.10 0.86 0.98 2.41 1.25 1.28 1.91 2.11 
 28 0.92 0.81 2.06 0.92 1.02 0.91 0.83 0.83 0.85 0.82 1.03 0.90 1.42 0.82 1.36 
    29* 2.09 0.98 0.91 1.01 0.78 0.78 0.85 0.78 1.02 0.74 0.89 0.73 0.62 0.75 0.73 
    30* 2.43 1.25 1.96 1.55 1.55 1.42 1.86 1.49 3.14 1.54 1.30 1.18 0.94 1.34 3.16 
    31* 0.85 1.00 1.15 0.85 0.78 0.70 0.61 0.73 0.74 0.72 0.74 0.78 0.63 0.96 0.89 
120 7.36 2.13 2.21 2.09 1.96 1.71 1.82 2.84 1.76 1.56 1.47 1.26 1.04 3.86 5.86 
Mean 4.57 2.17 2.41 2.01 1.94 1.72 1.64 1.85 2.17 1.98 1.90 1.67 1.62 3.19 3.37 
St. Dev. 3.32 1.08 1.22 0.82 0.82 0.66 0.56 0.99 1.22 1.15 0.72 0.67 0.88 2.96 2.12 
                
*Minority Subjects 
  
Table H12.  DHEA concentrations (ng/ml) for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 50 5.35 3.30 4.49 2.90 2.83 2.62 4.02 2.79 2.19 2.55 2.28 2.43 4.15 4.82 2.86 
 51 2.49 2.58 2.42 2.27 2.40 2.27 2.30 1.92 1.74 2.16 1.65 1.89 3.22 2.74 2.88 
 52 2.95 2.18 2.67 2.31 2.06 2.69 1.87 1.89 2.22 2.17 1.81 1.82 1.64 4.13 3.48 
 53 5.59 4.05 7.12 4.06 4.13 4.00 3.26 4.07 3.30 3.53 3.20 3.02 2.50 3.84 3.48 
 54 3.30 4.36 2.76 1.78 2.50 2.77 2.77 2.73 1.91 2.66 2.17 2.13 1.35 1.63 4.63 
 55 3.80 2.92 3.06 2.64 2.54 2.62 2.55 3.30 2.37 2.03 2.31 2.06 1.92 2.20 5.69 
 56 3.18 1.88 2.24 1.97 2.04 1.89 1.75 2.16 1.84 2.02 1.20 1.57 1.37 2.06 2.83 
 57 4.53 1.92 4.61 2.06 1.78 1.72 1.55 1.74 1.13 1.78 1.65 1.61 1.50 1.93 1.98 
 58 1.50 1.55 1.74 1.62 1.53 1.53 1.28 0.68 1.63 1.64 1.30 1.16 1.05 1.29 1.66 
 59 9.35 5.20 5.55 4.53 4.51 4.24 4.61 5.62 5.26 4.47 4.59 3.97 3.21 8.79 8.28 
 60 5.32 2.54 2.80 2.42 2.61 2.20 2.08 0.70 2.36 2.53 2.15 2.50 1.56 3.15 3.46 
   61* 10.81 5.97 5.48 4.49 3.73 4.45 4.15 4.29 4.77 4.78 4.21 3.60 2.96 4.88 7.54 
149 4.08 2.26 2.37 2.42 3.11 2.84 2.67 3.26 3.72 3.13 2.87 2.40 2.65 3.77 4.86 
160 6.38 2.02 2.35 2.90 2.34 2.59 2.54 2.64 2.72 2.69 2.32 1.92 1.78 1.95 3.36 
Mean 4.90 3.05 3.55 2.74 2.72 2.75 2.67 2.70 2.65 2.72 2.41 2.29 2.20 3.37 4.07 
St. Dev. 2.58 1.35 1.61 0.96 0.87 0.90 1.01 1.36 1.20 0.95 1.01 0.78 0.92 1.96 1.95 




Table H13.  DHEA concentrations (ng/ml) for young women during Alprazolam/DHEA Treatment 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
   1 13.32 17.79 16.43 17.39 14.90 14.22 13.36 19.85 18.39 16.45 14.23 12.79 11.70 9.08 8.82 
   3 12.78 9.01 16.42 16.53 15.14 13.50 12.11 14.75 17.88 19.98 16.16 14.95 11.52 10.39 16.46 
   4 19.04 7.47 16.49 16.17 15.05 15.31 13.66 14.42 12.35 17.58 18.59 15.00 9.76 14.51 12.43 
   5 19.99 22.46 21.53 17.04 14.10 12.33 10.63 13.27 12.25 23.33 18.18 14.95 10.35 10.80 13.72 
   7 12.63 12.33 13.51 12.56 9.28 8.85 6.59 6.64 13.52 11.62 7.48 6.04 4.28 5.79 10.83 
   8 16.26 11.99 16.09 19.52 13.54 12.54 10.11 12.97 12.34 17.00 13.34 11.04 4.68 5.50 16.05 
   9 10.92 6.13 19.69 19.24 19.50 16.25 17.20 13.36 14.92 16.38 18.65 17.77 13.22 12.95 16.54 
 10 13.71 11.44 16.08 15.74 14.69 13.67 13.41 13.42 16.99 15.63 14.56 9.58 10.16 9.55 17.06 
 11 15.70 8.76 18.07 14.77 12.51 11.35 11.15 11.55 16.68 15.52 14.65 13.04 9.56 11.79 11.26 
 12 11.79 11.22 18.15 24.12 18.47 14.59 14.10 19.92 16.68 22.06 14.83 15.45 11.15 10.37 10.39 
    14* 9.17 6.66 8.39 10.69 11.54 20.11 17.74 12.23 19.96 17.20 13.18 11.55 8.44 10.58 13.17 
    15* 2.95 8.60 12.39 10.44 9.73 7.55 7.12 6.01 8.42 13.36 11.46 9.90 8.35 8.01 8.20 
    16* 4.63 15.53 12.42 11.58 9.66 7.95 7.16 11.35 12.84 10.64 10.43 8.63 5.93 4.81 8.25 
  66 13.30 9.86 18.35 17.79 15.75 13.84 11.80 10.40 11.66 17.81 17.25 14.36 10.39 10.64 16.22 
102 15.59 16.83 14.42 16.49 17.02 14.44 14.96 14.58 14.27 17.53 20.71 17.60 13.34 15.75 18.06 
111 13.58 8.68 16.33 13.73 12.97 11.21 9.41 8.48 13.40 11.36 10.26 8.50 6.69 15.17 12.52 
112 5.15 1.72 7.11 4.22 9.78 11.32 12.04 10.41 10.63 9.74 9.74 9.29 7.99 6.32 8.92 
113 19.15 10.81 12.05 13.36 10.53 9.68 8.72 10.10 13.69 8.67 9.65 8.65 11.35 4.86 12.50 
   114* 7.02 4.60 12.44 12.44 10.75 9.20 7.46 12.21 16.17 13.13 10.32 7.52 6.26 5.89 7.10 
 206 9.43 10.69 14.86 15.95 14.89 13.60 13.27 13.91 16.13 14.52 13.37 12.23 11.62 10.60 11.98 
   213* 9.50 8.95 18.75 16.91 15.91 16.17 16.85 13.93 17.42 21.84 15.99 13.97 12.85 13.05 20.75 
Mean 12.17 10.55 15.24 15.08 13.61 12.75 11.85 12.56 14.60 15.78 13.95 12.04 9.50 9.83 12.92 
St. Dev. 4.74 4.68 3.58 4.09 2.97 3.08 3.36 3.45 2.88 4.06 3.56 3.34 2.72 3.39 3.73 
                
*Minority Subjects;  (--) Concentration not obtained 
  
Table H14.  DHEA concentrations (ng/ml) for young men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 33 12.55 6.02 9.93 18.42 18.09 18.55 14.88 12.09 15.67 17.55 14.35 12.05 7.65 5.97 11.82 
 34 7.40 12.76 11.91 11.13 10.80 8.97 8.19 9.99 10.95 14.27 10.39 8.73 6.60 6.46 9.41 
 35 8.09 15.10 13.74 11.53 10.54 8.13 7.23 7.53 8.61 8.90 11.03 8.77 7.76 6.59 7.42 
 36 7.44 22.49 20.21 19.61 16.62 15.49 14.35 12.64 16.44 13.93 18.12 15.87 10.72 9.57 11.07 
 37 11.43 8.44 19.73 14.95 12.68 10.25 8.28 10.50 9.63 12.96 11.94 9.90 6.09 7.33 10.79 
 38 15.22 20.88 18.94 14.75 14.12 11.92 9.30 11.61 15.76 14.88 13.51 11.08 8.09 13.66 13.97 
 39 18.77 17.47 15.71 11.97 12.19 9.96 7.90 9.33 11.11 13.76 10.33 8.87 6.91 10.72 18.81 
 41 15.97 18.62 18.62 18.28 15.65 12.79 11.22 10.50 14.76 20.09 15.13 10.03 10.97 7.96 15.88 
 42 16.10 14.89 16.92 19.95 16.59 14.38 12.72 10.10 11.01 10.66 19.81 18.34 5.93 8.77 7.55 
 43 13.95 8.80 16.58 17.17 17.78 11.82 10.87 10.02 12.99 16.88 14.58 9.42 10.96 11.89 13.28 
 44 10.63 15.46 13.71 15.41 14.04 12.15 11.74 15.89 15.55 16.96 15.21 12.29 14.80 9.39 8.13 
 45 22.36 17.26 20.63 15.44 13.93 11.71 12.14 13.52 12.09 15.34 13.14 11.74 10.24 16.58 15.35 
 46 22.66 10.18 20.16 13.07 12.78 12.66 12.23 19.52 16.07 18.54 15.49 12.69 11.31 16.12 19.71 
    47* 11.89 19.33 16.85 11.09 10.29 8.94 7.84 7.42 11.71 11.16 12.10 10.16 7.72 9.38 10.72 
    48* 13.81 18.85 18.57 15.44 13.21 12.36 12.45 12.06 18.02 17.06 14.61 13.07 8.90 8.01 15.76 
140 12.04 6.18 14.45 16.12 14.50 11.55 9.79 11.63 15.46 11.75 12.76 9.87 8.33 6.01 13.51 
145 17.42 18.77 20.04 17.13 17.28 16.57 26.47 15.45 21.79 18.31 17.75 22.14 14.69 13.40 15.55 
   146* 15.61 12.08 15.41 15.32 13.83 12.47 11.57 12.25 18.24 16.89 14.95 12.48 11.42 11.48 19.50 
   245* 8.06 10.59 16.15 16.20 15.54 14.75 15.63 18.31 22.54 19.08 16.12 13.10 10.38 8.47 12.07 
Mean 13.76 14.43 16.75 15.42 14.23 12.39 11.83 12.12 14.65 15.21 14.28 12.14 9.45 9.88 13.17 
St. Dev. 4.57 5.02 3.04 2.72 2.39 2.67 4.32 3.25 3.84 3.12 2.58 3.46 2.60 3.23 3.82 
                
*Minority Subjects 
  
Table H15.  DHEA concentrations (ng/ml) for older women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 17 3.18 13.90 13.31 9.04 8.79 7.90 6.70 12.30 17.35 16.69 16.27 11.78 8.57 9.74 9.84 
 18 4.22 16.20 16.87 13.73 12.65 11.07 10.24 12.96 16.59 16.75 14.95 12.59 8.21 8.79 8.41 
 19 4.20 7.88 15.29 12.51 11.32 10.25 9.82 9.15 14.18 17.22 11.81 11.19 8.66 9.98 8.69 
    20* 8.43 3.16 11.22 14.14 15.08 12.99 12.60 10.69 15.71 15.64 14.13 12.61 10.05 9.17 7.16 
 21 8.04 9.16 15.58 14.91 12.87 11.83 10.52 9.53 9.84 9.92 16.08 14.19 9.74 13.50 8.63 
 22 5.06 8.80 12.39 9.74 10.03 10.54 9.29 9.69 8.51 10.79 14.59 13.78 10.37 9.65 13.23 
 23 3.82 14.19 18.02 13.56 12.26 10.77 10.77 9.12 10.45 17.95 15.92 14.37 10.37 9.25 12.47 
 24 5.62 17.77 15.27 16.95 11.33 9.87 7.99 9.78 12.51 15.44 13.81 10.92 7.40 7.60 9.03 
 25 5.70 7.63 13.07 12.79 13.24 12.69 8.59 11.98 11.69 18.53 17.73 16.13 12.97 12.56 13.90 
 26 2.77 23.96 25.77 18.00 19.15 16.52 14.93 13.21 21.60 23.73 20.15 15.93 11.85 13.18 10.33 
 27 2.25 2.40 10.86 13.39 13.50 10.80 12.46 9.99 10.29 15.97 16.27 12.74 8.32 6.89 7.56 
 28 1.00 10.21 20.44 15.31 13.85 11.70 10.50 9.98 13.03 14.48 12.53 12.45 9.98 8.08 8.78 
    29* 1.03 11.44 10.95 8.86 8.06 8.52 6.35 7.57 14.14 15.35 12.52 11.53 7.92 6.80 7.64 
    30* 5.14 3.77 9.53 13.71 13.36 10.03 9.08 8.60 12.06 13.82 10.74 9.27 6.32 5.72 8.59 
    31* 1.23 6.31 11.90 11.80 10.99 9.17 8.98 7.37 8.49 11.60 11.24 8.42 5.27 3.95 4.40 
120 8.72 2.98 21.57 19.58 18.90 16.47 14.06 13.52 17.22 16.30 13.26 11.52 13.65 10.26 9.83 
Mean 4.40 9.99 15.13 13.63 12.84 11.32 10.18 10.34 13.35 15.64 14.50 12.46 9.35 9.07 9.28 
St. Dev. 2.51 6.04 4.49 3.00 3.04 2.44 2.41 1.93 3.64 3.28 2.52 2.11 2.25 2.61 2.38 
                
*Minority Subjects 
  
Table H16.  DHEA concentrations (ng/ml) for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 50 7.58 14.79 14.09 8.78 8.78 7.28 6.70 6.93 11.53 14.14 14.36 12.47 9.66 6.14 7.54 
 51 3.34 16.85 14.78 4.03 9.09 7.72 7.88 6.73 16.80 18.93 15.51 13.37 9.10 8.42 10.15 
 52 3.38 6.34 16.12 12.46 12.94 10.40 8.61 7.39 12.65 13.21 9.21 8.42 8.54 5.31 8.43 
 53 7.53 4.81 14.11 12.65 12.04 9.08 8.34 7.99 14.53 17.56 17.18 13.50 12.21 9.82 8.92 
 54 2.74 3.00 8.33 8.66 6.46 7.23 6.63 11.21 17.72 14.01 9.71 8.87 5.63 5.17 5.08 
 55 3.41 2.68 4.02 4.69 4.60 3.36 3.08 10.08 13.50 9.71 12.65 10.48 6.75 6.65 10.65 
 56 2.73 3.04 19.76 21.55 21.38 17.08 15.60 23.29 17.68 13.61 11.11 10.72 7.79 6.92 6.71 
 57 3.65 4.49 13.42 12.47 10.07 8.69 7.54 7.11 8.44 7.43 7.65 6.26 5.17 4.96 6.62 
 58 2.54 1.18 5.76 12.16 13.10 11.25 8.86 13.66 17.30 13.26 10.26 9.15 6.37 5.70 7.07 
 59 11.32 5.16 15.58 13.60 10.51 11.41 9.34 8.42 8.88 17.36 12.66 10.70 6.58 9.65 12.02 
 60 3.73 15.64 11.72 9.17 7.63 7.04 5.65 10.51 8.94 8.47 7.76 6.46 5.68 5.03 7.94 
   61* 12.33 5.56 14.46 17.87 17.00 14.72 14.27 12.30 12.78 20.13 15.45 13.30 10.10 10.09 15.09 
149 3.19 14.54 16.15 14.07 13.38 13.72 11.63 10.33 11.14 10.87 9.82 9.55 8.05 7.34 8.62 
160 6.15 2.84 21.88 18.83 14.23 16.11 13.93 12.45 20.48 17.56 14.26 11.60 8.69 8.05 11.53 
Mean 5.26 7.21 13.58 12.21 11.52 10.36 9.15 10.60 13.74 14.02 11.97 10.35 7.88 7.09 9.03 
St. Dev. 3.26 5.60 4.89 5.01 4.37 3.93 3.55 4.30 3.80 3.94 3.05 2.38 2.00 1.85 2.64 





Table H17.  DHEA-S concentrations (ng/ml) for young women during Placebo Treatment 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
   1 1490.02 1294.47 1256.30 1457.18 1480.47 1579.86 1703.86 1726.23 1962.53 1805.42 1976.28 1863.28 1592.50 1451.36 1437.34 
   3 1643.99 1420.17 1574.09 1566.95 1087.29 1421.57 1509.40 1722.64 1537.48 1670.93 1466.39 1309.39 1192.99 1425.93 1561.92 
   4 1498.55 1492.01 1516.08 1597.33 1561.17 1398.44 1538.00 1690.92 1674.83 1465.07 1295.29 1440.25 1348.11 1366.64 1890.04 
   5 2597.41 2396.45 2403.66 2512.26 2535.42 2563.34 2657.12 2539.23 2256.70 2309.55 2233.59 2112.37 1749.65 1999.18 2558.32 
   7 1232.84 1221.63 1280.26 1244.79 1289.78 1371.94 1463.50 1470.74 1479.29 1293.99 1292.53 1069.96 914.55 870.69 1117.60 
   8 848.42 897.96 1086.82 1278.49 1005.90 1004.76 1204.75 980.19 1391.90 988.04 1320.89 890.26 955.24 729.09 893.57 
   9 746.36 722.55 732.03 782.01 942.10 881.93 856.49 799.66 877.99 999.21 981.67 934.02 704.47 633.43 863.90 
 10 4544.52 4076.97 4199.58 4275.67 4380.48 4420.33 4313.63 4329.37 4152.53 4124.31 3893.13 4002.93 3791.39 3886.53 4264.83 
 11 1774.38 1914.49 2816.64 4506.64 4627.74 4781.73 4651.11 4687.84 4566.38 4918.96 5588.25 5362.43 4771.45 3964.80 4061.31 
 12 2678.15 2498.54 2293.29 2385.44 2575.06 2751.88 2966.02 2761.33 2802.25 3002.67 2970.00 2760.24 2427.49 1903.80 2358.88 
    14* 2609.74 2303.96 2155.51 2274.50 2353.58 2564.08 2430.64 2301.09 2459.31 2482.69 2593.67 1991.12 2000.91 2027.87 2391.31 
    15* 134.86 102.82 89.79 92.87 91.50 96.70 94.79 94.97 91.75 101.22 100.17 102.44 87.61 92.12 95.43 
    16* 716.30 969.09 1007.83 1131.16 1108.87 1139.44 1004.06 1084.31 1115.30 1172.99 1110.70 1075.69 812.63 818.13 901.77 
  66 2590.10 2565.06 2684.68 2760.38 2682.93 3257.49 2864.35 2650.99 2595.63 3163.46 2548.38 2484.91 2088.50 2118.28 2404.55 
102 1941.61 1861.06 1815.32 1836.74 1915.19 2067.94 2024.86 1999.03 1992.62 2015.52 2005.81 1905.62 1672.16 1444.85 1652.14 
111 1780.87 1765.16 1618.27 1756.64 1609.17 1650.61 1498.27 1438.22 1442.82 1524.96 1449.13 1336.58 1258.27 1486.21 1497.71 
112 1731.90 1894.04 2054.48 2093.98 2077.84 2194.48 2112.81 2216.88 2067.14 2340.32 2143.76 2445.41 1911.77 1520.88 1752.93 
113 2519.78 2143.29 2161.51 2306.27 2415.26 2396.22 2602.77 2778.62 2667.56 2570.61 2608.17 2468.59 1946.40 1862.29 1882.83 
   114* 838.72 613.99 734.22 674.69 828.04 838.20 876.48 837.92 874.38 882.50 802.36 866.56 710.16 770.00 851.66 
 206 929.40 791.21 1059.43 1055.91 1020.71 951.87 1037.06 950.71 817.44 902.45 1024.39 981.87 770.06 784.02 743.77 
   213* 1178.12 1023.51 1003.20 943.37 975.60 981.35 897.32 935.91 910.34 941.21 1014.56 991.03 924.28 803.42 1066.02 
Mean 1715.53 1617.54 1692.52 1834.92 1836.39 1919.72 1919.39 1904.61 1892.20 1936.96 1924.72 1828.33 1601.46 1521.88 1726.09 
St. Dev. 979.23 886.43 908.64 1084.38 1124.33 1181.56 1139.47 1137.38 1084.19 1164.58 1208.74 1188.02 1073.94 967.30 1035.01 
                
*Minority Subjects 
  
Table H18.  DHEA-S concentrations (ng/ml) for young men during Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
33 1365.47 1255.28 1400.18 1387.27 1525.45 1442.70 1362.57 1327.32 1323.46 1369.20 1635.51 1650.47 1501.86 1502.91 1834.16 
34 1574.88 1468.96 1598.89 1521.64 1532.22 1601.59 1687.54 1552.21 1687.07 1711.69 1738.93 1798.36 1615.89 1381.22 1627.23 
35 1352.48 1231.33 1222.44 1215.57 1422.59 1304.39 1209.96 1272.18 1284.80 1235.66 1049.81 1060.99 1031.35 1145.31 1245.95 
36 2105.21 2069.29 2210.97 2157.33 2153.80 2133.99 2169.43 2208.10 2041.79 2404.92 2262.58 2236.97 1996.88 1834.13 2256.46 
37 3099.37 3256.88 3069.96 3143.64 3256.88 3255.65 3341.13 3315.89 3179.08 3347.51 3184.28 3111.08 2782.35 2573.19 2992.17 
38 3684.17 3602.25 3802.85 3658.48 3483.47 3745.77 3911.37 3859.96 3755.34 3809.37 3678.93 3517.66 2690.05 2946.66 3742.49 
39 2438.81 2014.78 1852.42 1804.21 1873.20 1966.24 1727.58 1846.45 1727.30 1896.83 1824.06 1692.02 1507.39 1679.95 1861.75 
41 2667.19 2628.67 2609.08 2702.67 2595.18 2771.35 2644.44 2720.94 2791.54 2750.55 2773.60 2676.30 2306.64 2293.96 2750.37 
42 3645.66 3841.53 3761.86 3810.90 3904.59 3966.20 3916.79 4029.04 4081.52 4181.85 4157.74 4039.84 3725.98 3512.16 3877.20 
43 3171.28 3758.73 3482.93 3310.66 3310.66 3400.58 3543.05 3552.99 3430.34 3825.99 3383.46 3097.91 3111.86 3107.56 3441.27 
44 2655.65 2732.03 2650.11 2683.63 2677.27 2656.82 2730.15 2848.29 3001.83 3071.41 3111.38 3082.29 2998.72 2942.51 2712.97 
45 4075.88 4208.89 4072.41 4071.87 4333.88 4247.67 4134.90 4449.25 4365.15 4559.98 4433.32 4066.52 3986.20 3966.86 3845.71 
46 4746.73 4710.99 4823.80 4927.35 4896.57 4824.79 4960.35 4942.19 4881.17 4885.86 5069.86 4927.35 4730.17 4713.74 4994.12 
47* 2507.80 2252.28 2380.34 2230.78 2256.98 2412.33 2203.19 2167.39 2314.71 2570.99 2248.43 2165.11 1931.24 1931.64 2374.31 
48* 2426.03 2419.57 2740.15 2607.41 2613.32 2718.98 2691.00 2574.90 2797.99 2816.25 2811.82 2788.62 2927.16 4460.40 2549.39 
140 2230.69 2196.34 2287.22 2625.72 2487.07 2797.96 2588.15 2780.94 2752.48 2857.80 2852.00 2758.45 2433.74 2046.61 2281.80 
145 2793.46 2585.58 2686.84 2653.34 2718.71 2645.77 2614.92 2503.75 2384.78 2504.68 2714.53 2786.57 2602.68 2208.79 2282.37 
146* 2042.50 2004.54 2083.02 2021.61 2020.15 2100.24 1999.77 2127.41 2042.28 2071.26 2088.57 1901.56 1789.99 1908.65 2404.34 
245* 2736.30 2914.98 2836.43 2846.76 2731.13 2952.43 2941.01 2850.70 2898.80 2979.04 2784.13 2696.95 2579.33 2238.39 2405.22 
Mean 2701.03 2692.26 2714.31 2704.25 2725.95 2786.60 2756.70 2785.78 2775.86 2886.89 2831.73 2739.74 2539.45 2547.09 2709.44 
St. Dev. 894.08 988.17 949.00 963.10 951.92 954.05 1007.11 1029.95 1009.43 1027.91 1016.80 957.71 932.05 1025.20 920.47 




Table H19.  DHEA-S concentrations (ng/ml) for older women during Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 17 114.69 98.72 109.63 127.08 109.94 110.94 120.30 115.95 137.02 115.05 99.07 108.14 97.93 108.13 160.14 
 18 264.07 266.61 269.78 266.85 279.27 315.24 282.52 292.63 288.56 267.60 275.09 280.15 205.56 209.93 273.78 
 19 489.63 465.43 389.03 420.39 449.19 497.86 474.22 461.70 495.20 422.34 500.74 417.11 309.43 281.33 363.57 
    20* 95.67 87.31 80.79 73.61 66.81 89.75 89.17 84.53 84.28 76.95 96.99 98.52 71.78 77.35 80.26 
 21 231.90 310.20 346.14 292.63 307.79 447.56 394.81 332.70 390.13 363.90 457.88 394.52 404.99 408.70 593.59 
 22 397.02 489.16 542.79 587.90 583.76 542.51 712.45 620.06 675.68 421.24 645.99 514.14 360.08 376.00 440.41 
 23 236.05 268.25 320.76 228.53 244.37 240.47 397.54 263.26 270.76 277.07 285.85 239.12 176.66 159.55 247.33 
 24 119.98 123.55 120.36 134.06 138.98 138.37 128.74 131.41 133.43 128.32 140.87 131.39 105.54 97.93 125.78 
 25 159.44 174.62 153.64 147.72 150.33 185.05 183.23 176.35 146.32 169.06 170.52 173.36 127.34 94.39 143.49 
 26 117.62 114.23 126.43 126.52 132.74 126.17 111.78 104.81 -999.00 116.54 115.24 107.11 89.09 97.60 112.43 
 27 83.76 86.25 75.61 72.62 70.91 66.20 78.71 70.87 71.97 66.22 -999.00 89.27 54.43 61.86 75.74 
 28 66.21 64.96 61.58 54.84 70.59 67.61 76.20 69.18 65.39 72.57 68.78 75.22 64.28 57.76 54.01 
    29* 68.17 59.51 67.99 61.10 63.45 67.22 63.89 67.71 67.09 58.61 68.19 62.23 58.66 65.18 71.70 
    30* 139.42 156.42 150.20 139.68 150.17 162.24 152.93 148.77 150.69 155.03 155.64 152.44 120.48 111.99 138.01 
    31* 74.15 79.68 85.34 86.12 89.44 80.34 93.25 87.82 91.83 79.08 74.80 77.00 69.43 58.79 63.92 
120 327.09 321.84 361.49 287.19 306.79 319.07 373.59 340.42 347.09 350.04 332.39 279.95 243.78 195.89 283.49 
Mean 186.55 197.92 203.85 194.18 200.91 216.04 233.33 210.51 151.03 196.23 155.57 199.98 159.97 153.90 201.73 
St. Dev. 127.46 140.04 146.94 147.63 151.43 161.38 187.60 162.13 353.48 132.72 353.74 140.24 113.37 112.43 155.34 
                
*Minority Subjects 
  
Table H20.  DHEA-S concentrations (ng/ml) for older men during Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 50 502.78 578.52 575.88 653.35 587.54 580.89 609.78 568.40 539.18 577.25 641.52 500.48 453.81 490.84 594.65 
 51 202.10 226.33 237.42 254.67 210.91 237.64 246.08 269.59 257.97 254.73 227.44 233.52 208.59 249.07 265.70 
 52 715.71 630.14 716.15 702.92 607.99 729.79 704.29 714.64 707.08 705.15 707.37 659.16 584.43 677.34 679.08 
 53 680.73 472.68 612.25 627.68 640.61 561.97 469.36 555.22 670.90 736.35 492.65 471.11 492.72 427.24 775.20 
 54 904.55 846.21 875.18 904.55 843.22 949.03 965.25 926.54 863.14 898.22 996.27 895.52 621.83 661.19 517.08 
 55 2214.96 2170.90 2158.52 2130.84 2139.98 2378.40 2308.55 2095.57 2172.72 2295.55 1833.33 2129.05 1303.12 2112.61 1738.89 
 56 91.71 95.32 95.64 98.27 98.37 112.06 96.21 111.24 105.96 124.82 111.00 104.22 85.58 92.71 106.52 
 57 730.05 794.43 877.78 782.09 733.13 765.27 734.65 740.02 777.80 931.78 884.55 785.31 706.55 696.98 771.24 
 58 69.66 68.42 72.56 69.35 75.56 83.85 75.72 67.81 72.16 80.55 78.57 71.30 64.73 58.01 72.19 
 59 1460.38 1430.42 1621.57 1639.52 1695.15 1784.34 1658.24 1880.21 1769.78 1765.26 1669.76 1599.23 1198.45 1047.01 1494.10 
 60 1523.83 1571.09 1545.73 1581.66 1559.91 1533.02 1484.41 1584.12 1745.87 1888.97 1406.90 1487.36 1301.81 1241.16 1422.28 
   61* 440.46 473.74 524.14 526.40 550.90 510.55 516.07 540.02 533.06 529.61 518.49 494.61 436.87 413.31 610.73 
149 546.73 586.21 561.40 556.14 546.77 675.67 649.95 595.23 639.02 617.06 651.81 625.94 509.74 527.06 500.61 
160 466.36 464.61 517.70 463.43 466.92 498.85 492.58 471.67 544.33 552.12 572.62 577.30 502.99 470.23 529.33 
Mean 753.57 743.50 785.14 785.06 768.35 814.38 786.51 794.31 814.21 854.10 770.88 759.58 605.09 654.63 719.83 
St. Dev. 604.77 597.39 603.34 603.00 612.39 657.50 631.77 626.92 637.44 670.35 542.82 594.26 405.55 529.82 503.35 




Table H21.  DHEA-S concentrations (ng/ml) for young women during DHEA Treatment 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
   1 1995.54 4755.38 4647.65 4552.83 4551.84 4309.04 4153.11 3926.72 4823.88 5077.60 4619.37 4257.62 3728.81 3387.23 3434.20 
   3 1677.29 2060.64 3986.02 4463.88 4694.60 4985.65 4876.12 4735.27 5376.41 5515.81 5421.46 5527.85 4651.25 4697.41 4528.27 
   4 1733.89 1631.94 2928.39 4165.03 4178.51 4463.51 4623.37 4063.83 3947.17 4044.73 4021.29 3751.94 3692.68 2227.96 3956.45 
   5 2494.52 3801.04 5181.27 4896.66 4493.47 3946.67 3407.94 3494.97 4503.85 4903.84 4655.81 4364.35 3240.97 3157.77 3239.19 
   7 1515.79 3286.02 4294.20 4327.99 4415.89 4640.76 4159.50 3745.85 4400.21 4881.18 4406.97 4020.21 3177.37 2675.97 2717.33 
   8 642.52 4104.42 4366.30 3930.70 3719.18 3555.82 2885.36 2333.32 4418.87 4139.64 3508.02 2892.66 1632.30 1134.01 1484.24 
   9 734.85 2108.15 3891.10 4054.29 4180.21 4051.88 4055.30 3848.56 3880.18 -- 5116.86 5218.18 4618.73 4194.13 4096.27 
 10 4119.80 5257.33 5407.76 5216.59 5214.70 5446.20 5285.99 5844.76 5739.72 5431.75 5393.48 5156.89 4728.60 4732.02 4985.54 
 11 1944.65 2215.63 3194.49 4346.17 4464.78 4718.04 4735.89 4870.81 5797.37 5591.67 5633.11 5480.56 4929.68 4461.61 4163.38 
 12 2533.24 2601.76 3987.87 4086.39 4231.85 4395.06 4776.95 4663.03 4522.24 5343.03 5579.10 5340.24 4539.45 4018.83 3832.14 
    14* 3101.25 2704.99 4602.52 4901.16 5217.72 5106.43 5105.00 5049.23 5332.29 4865.89 4868.28 4928.97 3862.27 3626.31 3468.48 
    15* 107.52 129.38 3558.31 4275.50 4213.32 4186.45 4141.41 4162.61 4907.82 5330.61 5312.99 5214.74 5072.75 4355.70 4071.06 
    16* 930.50 4419.74 4561.42 4325.20 4127.33 3952.90 3517.41 3596.86 4680.60 4934.78 4464.60 4097.95 3378.09 2677.13 2683.87 
  66 2290.55 5019.73 5317.12 4927.87 4873.25 4748.01 4494.14 5051.12 5515.04 4807.01 4673.65 4288.24 4066.09 3554.94 3458.57 
102 1581.50 3521.80 4877.14 4697.03 4734.03 4718.28 4375.77 4006.64 4133.66 4539.39 5473.56 5329.75 4267.19 3681.68 3558.50 
111 2283.99 2292.69 3480.27 3647.82 4072.51 4164.85 3746.14 3306.67 3399.49 4564.82 4377.68 4026.10 3412.81 2982.39 2622.39 
112 2042.58 3087.98 4959.43 4856.03 4639.60 4522.55 4615.94 3334.69 4831.27 5698.02 5153.42 4854.71 4181.84 3780.55 3530.94 
113 2729.35 2504.68 5196.54 5326.63 5084.50 4695.06 4506.53 4330.41 5512.10 4817.24 4470.57 4267.24 3845.17 3366.72 3469.16 
   114* 1568.85 3275.34 4713.63 4355.74 4091.38 3567.78 3119.74 4358.75 4375.28 4066.09 3756.03 3351.55 2781.16 2241.67 1819.54 
 206 1181.56 2071.13 4630.84 5060.99 4955.54 5390.71 5336.65 5294.83 5676.97 5838.95 5984.60 5874.18 5323.22 4682.00 3647.27 
   213* 1169.85 2318.07 4191.16 4021.94 4363.63 4226.07 4126.70 4103.57 3857.18 4872.53 5084.50 4743.33 3796.69 3510.26 3458.34 
Mean 1827.60 3007.99 4379.69 4496.97 4500.85 4466.27 4287.86 4196.31 4744.36 4963.23 4855.97 4618.44 3948.91 3483.16 3439.29 
St. Dev. 911.35 1250.87 697.96 452.67 407.07 518.88 670.72 797.04 698.62 526.09 647.82 777.43 859.57 934.15 826.65 
                
*Minority Subjects; (--) Concentration not obtained 
  
Table H22.  DHEA-S concentrations (ng/ml) for young men during DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 33 1722.76 2168.21 4262.94 4750.70 4778.48 4496.02 4258.79 4114.99 4993.65 4966.87 4578.61 4080.87 3762.59 3378.96 3363.24 
 34 1825.37 2484.42 4377.42 4639.74 4531.68 4450.25 4197.25 4672.89 5484.09 5283.25 5186.68 5221.15 5019.19 4429.54 4329.29 
 35 1128.46 1980.45 4406.92 4827.07 4667.66 4927.35 4445.53 4461.02 5376.58 5405.53 5058.62 5144.56 4547.18 4129.49 4235.50 
 36 1760.77 2146.59 4076.10 4933.50 4778.48 4808.37 4415.13 4244.25 4694.76 5329.84 5034.01 4832.84 4083.04 3875.24 3579.87 
 37 2864.15 5162.16 5227.79 4964.76 5001.09 4971.21 4648.25 4667.09 5553.77 5477.73 5321.40 5205.06 4504.53 4158.84 4144.84 
 38 3381.27 4719.78 5480.26 5612.65 5431.54 5473.27 5263.56 4956.72 5572.91 5659.90 5617.97 5286.43 3816.46 3859.96 4622.75 
 39 1801.91 1722.96 3512.77 4093.43 3796.80 3327.08 2949.75 2919.52 4146.28 3711.09 3655.92 3611.47 3082.98 2758.80 2746.51 
 41 2002.99 2824.91 5079.71 4957.77 4652.08 4421.23 4414.25 4441.60 4991.54 4729.31 4489.00 4481.38 3982.44 3696.32 3514.18 
 42 3996.19 3920.89 5322.73 5647.14 5772.23 5929.21 5834.98 5854.90 5898.94 5938.59 6378.09 6237.26 5761.24 5287.61 5431.77 
 43 3361.53 3470.18 5905.56 6087.81 6096.44 5979.95 5704.27 5726.20 6377.39 6430.98 6056.73 6069.31 5383.28 5081.24 5115.08 
 44 2793.43 3265.67 4075.12 4631.29 4553.52 4773.39 4855.45 4500.81 5502.82 5331.78 5332.81 5179.48 5062.84 4578.43 4262.94 
 45 4339.05 5819.04 5964.15 5721.49 5947.06 6048.46 5565.20 5759.47 6041.77 5925.47 5611.21 5497.78 5360.30 5015.87 5086.90 
 46 4575.69 4545.89 5847.97 5954.06 5915.38 5887.14 5892.70 5722.64 6019.10 6369.10 6258.56 6138.53 5603.71 5553.64 5530.96 
    47* 1571.67 3300.52 4383.35 4426.06 4331.83 4533.75 4319.51 4061.66 4609.11 5116.98 5108.44 4851.21 4284.27 3818.97 3773.30 
    48* 2588.04 2788.91 5361.35 5873.36 5555.29 5575.98 5536.70 5291.73 5267.20 6248.91 6243.35 5696.21 5614.53 5276.04 5149.05 
140 2780.49 2540.38 3573.15 4329.30 4549.55 4783.19 4707.24 4637.28 4376.84 5040.10 5630.73 5388.79 4207.53 3348.26 3472.90 
145 2825.51 3093.88 4509.63 4899.86 4728.79 4771.30 4812.22 4532.53 5212.76 5278.65 5107.97 4957.18 4377.65 3951.25 3831.28 
   146* 1951.49 4236.30 4758.55 4341.87 4378.39 4335.60 3949.48 3890.45 4119.76 4596.09 4666.24 4363.06 3517.33 3472.96 3690.13 
   245* 2426.61 3717.40 4599.18 4661.56 4682.52 4515.95 4142.62 4196.52 4788.93 4814.82 4788.23 4434.04 4254.96 3618.20 3417.64 
Mean 2615.65 3363.61 4774.98 5018.60 4955.20 4947.83 4732.26 4665.91 5212.01 5350.26 5269.71 5088.24 4538.21 4173.14 4173.59 
St. Dev. 958.25 913.91 763.29 679.23 691.47 688.81 699.25 735.52 720.01 665.35 659.77 674.26 760.37 818.62 837.37 
                
*Minority Subjects 
  
Table H23.  DHEA-S concentrations (ng/ml) for older women during DHEA  Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 17 121.84 5792.48 6445.03 6166.27 5778.57 5715.85 5629.33 5271.49 5751.46 5644.49 5240.00 5018.57 4536.98 4033.42 3720.38 
 18 180.37 3043.01 4026.06 4298.86 4320.04 4286.80 4208.89 4697.58 5315.24 5292.53 5059.99 4949.81 4322.56 3824.71 4081.88 
 19 361.37 497.75 4574.12 5214.80 5140.44 4925.67 4657.31 4584.49 5699.35 5377.44 5042.21 4715.78 4240.10 3692.41 3614.26 
    20* 99.53 97.44 184.30 1863.00 2336.10 3659.94 3825.92 3067.18 3955.03 3966.02 3751.85 3643.15 2399.28 1951.82 1803.52 
 21 260.44 3223.54 4194.94 4059.93 3422.10 3307.58 3019.30 2654.22 2740.75 4234.94 3649.26 4000.12 2824.95 2240.26 2260.19 
 22 264.45 298.48 2327.44 4609.69 4832.20 4799.79 4606.77 4276.73 5580.10 5583.18 5268.23 4964.88 4104.40 3229.59 3135.66 
 23 343.43 4603.42 5609.99 5460.35 5480.19 5248.80 4968.73 5003.72 5527.68 6307.66 5932.45 5788.61 4946.71 4269.96 4439.95 
 24 112.28 2935.13 4309.74 3582.01 3483.33 3131.58 2961.77 3891.18 4512.49 4002.16 3770.29 3592.47 2818.21 2222.09 1922.62 
 25 140.81 260.76 4166.62 4387.47 4338.85 4471.34 4211.07 4687.98 5868.33 5909.52 5864.12 5815.66 5183.90 4672.92 4455.67 
 26 111.79 1954.40 4326.42 4251.75 4494.48 4186.94 3941.35 4149.64 4779.57 4642.48 3961.29 3497.52 3222.42 2637.76 2352.57 
 27 76.92 105.26 2384.53 3313.02 3145.41 3210.05 2956.66 2666.13 2719.65 4031.23 4258.12 3925.78 3284.62 2997.72 2638.98 
 28 65.11 145.14 3383.52 3719.99 3518.97 3297.81 2918.29 2666.44 3658.99 4684.30 4252.82 4019.79 3124.83 2686.68 2457.31 
    29* 58.13 2823.51 6571.84 6335.96 6247.64 5709.68 5622.24 5227.83 5235.92 6158.01 5450.42 5103.53 4037.47 3586.03 3391.04 
    30* 170.10 1012.90 4615.60 4078.22 4016.39 3872.49 3772.68 3372.82 4361.77 4995.75 4674.37 4611.32 3779.62 3072.95 3070.47 
    31* 66.87 1340.11 3175.10 5051.77 3447.75 3310.82 3102.13 3041.45 4186.57 5162.93 4980.18 4565.25 3420.87 2923.71 2509.30 
120 271.88 349.90 3023.80 3430.33 3558.06 3844.00 3515.19 3260.65 4534.18 4688.42 4370.71 4224.41 3614.95 2984.55 2730.11 
Mean 169.08 1780.20 3957.44 4363.96 4222.53 4186.20 3994.85 3907.47 4651.69 5042.57 4720.39 4527.29 3741.37 3189.16 3036.49 
St. Dev. 100.65 1779.27 1594.02 1126.80 1061.46 882.79 914.25 948.85 1013.36 764.74 743.31 727.70 793.48 773.93 845.04 
                
*Minority Subjects 
  
Table H24.  DHEA-S concentrations (ng/ml) for older men during DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 49 2011.37 2542.59 5681.88 5420.19 5418.96 5550.57 5243.27 5420.19 5336.52 5343.81 5423.28 5349.77 4728.20 4423.36 4237.24 
 50 480.16 4091.71 5812.83 5522.32 5290.99 4837.72 4713.69 4221.58 4499.53 4996.13 4645.99 4460.10 3625.65 3321.06 3071.82 
 51 274.16 3375.11 5167.89 5600.90 5460.99 5737.79 5676.99 5443.59 5133.49 5408.01 5287.63 4802.98 3948.40 3806.60 3905.13 
 52 652.00 693.80 2486.11 4587.60 4684.31 4261.42 4128.08 3887.39 4952.43 5349.83 5238.75 5009.05 4465.20 3982.26 4143.46 
 53 395.63 2766.99 4649.39 4938.00 4826.86 4339.43 4357.24 3820.34 5297.28 5214.97 4889.50 4517.82 4074.02 3561.17 3077.79 
 54 605.31 2028.68 4731.77 4691.29 4641.05 4126.89 4004.42 3084.44 3656.85 5447.80 4244.02 4609.26 3845.05 2757.20 2345.10 
 55 2896.76 1304.77 2423.53 4148.95 5386.44 5542.81 5552.54 5643.44 5831.56 6257.69 6396.14 6311.46 5663.26 4821.22 4190.19 
 56 79.55 84.00 2155.24 3810.92 3716.97 3577.63 3231.72 3453.85 4529.75 4191.25 3822.84 3482.40 2952.37 2249.37 1746.59 
 57 789.59 923.07 1291.20 2742.64 2928.54 3205.76 3238.72 3213.85 4175.34 4800.21 4527.95 4219.95 3825.99 3291.99 2766.10 
 58 38.42 55.08 455.14 2319.86 2905.20 2932.30 2523.18 2678.72 3911.44 3593.39 3104.44 2786.93 2066.65 1310.76 1488.69 
 59 1555.76 3199.95 4455.97 4510.03 4417.36 4429.31 4031.70 4189.93 4779.56 4810.34 4677.61 4620.79 3601.28 2835.51 2921.58 
 60 1546.76 3086.77 4742.69 4623.06 4770.82 4649.23 4417.02 4474.12 5298.64 5219.07 5148.68 5104.32 4368.90 4193.32 3999.71 
   61* 376.40 688.41 2121.32 3458.30 3393.55 3181.05 2950.24 2893.79 3509.85 4117.44 4414.19 4138.61 3807.03 3461.84 3230.89 
149 528.98 518.40 3952.07 4177.07 4242.80 4190.30 3992.87 3802.71 5022.39 5000.67 5065.28 4878.98 4009.79 3688.92 3593.81 
160 465.26 403.48 3668.11 4668.20 4893.71 4748.37 4782.47 5067.67 6355.67 6177.27 5924.54 5915.32 5508.65 4868.62 4972.39 
Mean 846.41 1717.52 3586.34 4347.96 4465.24 4354.04 4189.61 4086.37 4819.35 5061.86 4854.06 4680.52 4032.70 3504.88 3312.70 
St. Dev. 802.97 1358.60 1655.18 951.15 864.94 872.09 930.53 961.68 791.07 712.12 810.10 869.53 892.17 954.11 973.18 




Table H25.  DHEA-S concentrations (ng/ml) for young women during Alprazolam/Placebo Treatment 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
   1 2061.79 1995.15 2097.42 2246.69 2211.64 2252.65 2289.14 2288.40 2242.68 2241.68 2248.64 2228.25 1887.62 2007.39 1982.23 
   3 1714.60 1698.40 1677.88 1641.12 1643.03 1498.23 1404.60 1371.52 1527.86 1594.04 1529.16 1320.97 1069.87 1251.88 1497.81 
   4 1735.08 1802.31 1909.50 1833.37 1738.87 1634.57 1744.26 1692.47 1527.96 1629.14 1636.10 1468.93 1280.36 2336.05 1461.19 
   5 2459.01 2173.15 2133.87 2204.98 2025.91 1863.12 1679.36 1753.53 1692.02 1476.49 1834.57 1636.85 1643.61 1716.92 2300.18 
   7 1196.47 1130.03 1214.14 1254.50 1265.97 1076.50 990.87 944.37 924.08 1280.04 959.84 843.38 930.04 642.41 783.90 
   8 1159.47 1500.69 1122.34 1435.99 1224.71 1089.26 995.85 884.28 956.21 967.88 1216.37 1053.19 907.04 972.26 1049.40 
   9 1003.83 862.76 945.98 831.94 900.66 970.07 752.57 767.87 787.98 802.91 863.65 846.36 659.40 592.60 805.63 
 10 4277.36 4029.21 4149.68 4160.18 3993.99 3817.92 3765.67 3493.60 3462.40 3395.77 3701.24 3642.78 3294.25 3875.84 4035.03 
 11 1880.31 1993.89 2000.90 2182.16 2042.47 1976.43 1881.35 1859.98 1845.94 1949.76 2194.47 2172.47 1603.49 1659.64 1740.10 
 12 2337.87 2367.92 2483.60 2663.26 2678.41 2392.99 2067.44 2308.39 2253.34 2059.28 2182.87 2014.55 2049.45 1421.54 1555.03 
    14* 2376.78 2152.20 2005.96 2217.04 2212.34 2035.98 1921.01 1742.47 1727.90 1651.68 1934.58 1821.84 1560.61 1693.08 2268.42 
    15* 153.78 113.91 111.19 134.61 114.90 106.42 116.61 101.37 99.42 118.77 127.55 119.92 94.55 97.85 117.94 
    16* 725.89 872.50 893.03 885.76 836.52 828.96 731.65 793.86 783.57 779.54 853.64 831.33 582.60 557.72 565.21 
  66 2852.12 3158.47 3332.17 2836.84 2818.89 2698.87 2660.50 2516.73 2422.23 2594.06 2606.33 2479.57 2486.52 2261.29 2708.20 
102 1426.02 1430.33 1542.02 1609.33 1680.79 1539.73 1500.34 1339.28 1380.28 1491.11 1669.06 1426.00 1420.35 1120.78 1333.98 
111 2448.88 1940.51 1988.31 1906.03 1853.74 1797.95 1717.10 1577.43 1545.87 1472.83 1483.91 1366.92 1171.31 1468.64 1707.86 
112 1875.48 1939.43 1972.56 1853.47 1849.51 1962.16 1629.23 1738.47 1287.77 1767.40 2253.65 1849.12 1603.75 1480.82 1700.13 
113 2530.87 2347.99 1902.02 2022.59 2074.37 1916.20 1858.13 1867.60 1887.75 1824.05 1893.42 1934.04 1609.09 2180.01 2089.67 
   114* 729.63 730.01 727.71 635.55 648.49 596.43 612.03 603.21 667.93 593.99 644.45 518.60 553.49 451.92 614.41 
 206 1297.02 1329.54 1457.22 1420.80 1566.83 1416.95 1421.24 1239.43 1243.47 1213.34 1238.94 1194.21 1080.53 911.45 971.83 
   213* 1195.68 1112.82 1008.32 1070.96 1030.33 937.51 920.41 976.61 962.80 962.69 1104.27 1164.34 981.96 937.26 1260.86 
Mean 1782.76 1746.72 1746.47 1764.15 1733.92 1638.52 1555.21 1517.18 1487.12 1517.45 1627.46 1520.65 1355.71 1411.30 1549.95 
St. Dev. 908.78 862.02 889.61 871.25 844.68 808.50 796.34 762.62 738.07 724.99 785.63 769.98 712.49 844.19 863.72 
                
*Minority Subjects  
  
Table H26.  DHEA-S concentrations (ng/ml) for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 33 2418.52 2473.20 2680.57 2543.04 2560.54 2372.71 2288.74 2376.40 2327.23 2211.43 2359.67 2231.67 2166.72 2039.57 2274.81 
 34 1712.63 1701.09 1689.41 1631.01 1812.77 1634.61 1611.46 1583.63 1836.75 1614.12 1757.32 1874.42 1673.61 1467.13 1504.63 
 35 1008.89 958.90 926.08 1003.32 1074.02 908.38 902.11 783.30 769.12 815.90 877.03 851.98 956.37 743.04 829.25 
 36 1683.73 1684.28 1729.62 1809.43 1960.40 1642.18 1573.74 1538.54 1632.91 1589.51 1676.24 1659.78 1428.41 1415.78 1553.24 
 37 2905.07 3105.22 3166.98 3184.95 3163.66 2997.25 2913.66 2892.56 2834.24 2857.44 2912.20 2645.68 2492.74 2277.12 2812.71 
 38 4152.13 4233.57 4381.92 4313.47 4354.70 4105.48 4047.54 3916.93 3776.75 3832.21 4536.96 4128.74 3269.78 3123.25 3918.93 
 39 2179.60 2025.17 2040.69 1996.74 1957.29 1829.35 1934.48 1880.25 1781.89 1917.29 1988.04 1897.74 1697.12 1723.45 1842.73 
 41 1823.36 1831.00 1997.09 1981.50 1957.84 1802.58 1704.52 1690.68 1783.43 1809.09 1954.93 1832.22 1693.78 1703.43 1993.49 
 42 3629.84 3443.68 3634.16 3604.67 3656.67 3480.39 3249.80 3289.94 3306.30 3253.62 3554.38 3393.03 3313.34 3463.48 3414.36 
 43 2887.92 2811.66 2998.42 2982.81 2992.21 2714.60 2673.61 2638.71 2697.75 2960.72 3087.00 2786.20 2594.20 2345.56 2505.86 
 44 2670.21 2881.77 2681.67 2860.75 2633.58 2513.38 2619.58 2648.61 2614.41 2617.73 2868.11 2729.73 2620.27 2754.65 2640.50 
 45 3351.60 3339.31 3268.22 3271.80 3139.29 3282.84 3103.45 3742.80 3259.77 3237.64 3271.44 3237.05 3376.85 3005.05 2973.09 
 46 4553.63 4235.50 4430.57 4325.81 4386.16 4181.96 4263.53 4245.05 4191.39 4213.75 4194.03 4197.40 4045.83 4166.13 4406.23 
    47* 2188.92 2296.25 2086.18 1989.48 1971.91 1853.55 1763.56 1813.71 1879.16 1842.64 1919.60 1898.49 1811.06 1768.84 1904.45 
    48* 2992.93 3080.66 3026.37 3172.87 2911.82 2821.78 2828.17 2835.78 2835.78 2786.43 3100.01 2835.83 2506.13 1583.22 2694.04 
140 3037.02 2715.61 2782.87 2958.38 2693.29 2755.40 2477.34 2708.90 2558.15 2726.92 2715.41 2746.72 2365.73 2148.58 2284.29 
145 2914.49 2910.15 3229.85 2963.30 2999.75 2880.11 2850.94 3169.36 2775.52 2728.72 3059.51 3084.06 2923.26 2742.13 2934.38 
   146* 2123.10 1994.98 2116.37 2041.96 1994.98 1927.28 1735.02 1879.95 1809.12 1968.39 1972.14 1856.14 1796.54 2022.36 2478.20 
   245* 2603.68 2792.89 3015.54 2913.19 2872.91 2789.70 2677.63 2527.66 2565.29 2752.44 2916.03 2797.84 2567.61 2417.71 2261.13 
Mean 2675.65 2658.68 2730.66 2713.08 2689.15 2552.29 2485.20 2534.88 2486.05 2512.42 2669.48 2562.35 2384.18 2258.45 2485.60 
St. Dev. 873.55 850.80 899.35 879.48 859.06 860.73 857.36 901.23 822.74 832.97 906.19 850.83 780.74 814.74 847.33 
                
*Minority Subjects 
  
Table H27.  DHEA-S concentrations (ng/ml) for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 17 288.43 301.13 320.98 278.06 365.78 281.23 279.16 199.21 254.76 239.27 217.44 238.33 202.55 223.29 267.24 
 18 244.79 209.65 243.57 220.27 203.66 217.92 212.53 183.82 177.82 177.97 225.21 177.18 183.92 146.14 187.12 
 19 377.72 374.61 316.02 277.96 279.14 263.00 299.03 226.30 301.44 223.14 234.55 216.91 168.72 202.89 153.19 
    20* 90.55 102.33 128.99 90.13 82.26 70.48 72.96 70.38 70.45 76.28 88.28 74.33 64.18 64.30 71.91 
 21 573.04 558.60 565.30 597.22 540.31 459.15 335.26 463.73 407.35 398.02 489.43 470.61 406.76 459.59 549.42 
 22 307.62 408.47 1146.66 293.93 255.57 240.87 245.81 231.54 334.55 216.39 286.34 226.33 170.62 233.71 283.63 
 23 340.50 325.71 325.05 321.54 325.71 315.57 394.29 295.41 295.77 291.19 353.57 299.51 233.96 244.66 239.15 
 24 107.98 114.03 121.54 110.08 128.81 104.15 98.71 96.33 100.73 98.11 110.23 108.58 87.10 88.58 102.55 
 25 334.27 348.42 316.94 377.23 355.29 353.02 301.99 302.39 266.01 292.74 302.41 251.98 228.42 189.76 225.46 
 26 123.38 106.96 139.86 123.40 112.43 118.27 106.58 108.50 103.01 134.25 119.35 107.07 91.04 95.83 89.01 
 27 75.65 79.85 81.80 60.07 67.22 67.74 61.57 61.94 55.51 58.52 62.69 67.55 52.09 71.75 83.74 
 28 84.20 66.85 68.45 67.21 67.59 57.74 57.92 60.44 53.03 56.95 61.60 54.59 52.28 54.45 64.57 
    29* 62.92 60.57 70.18 71.25 74.70 67.13 69.22 56.34 55.24 60.32 63.29 64.75 58.54 63.88 57.23 
    30* 259.37 204.26 228.24 234.87 215.55 196.18 203.27 202.78 180.53 183.80 192.11 159.10 144.22 148.93 165.87 
    31* 66.46 67.35 75.09 69.02 70.50 67.17 67.71 62.31 65.97 69.52 73.11 68.63 65.46 66.94 72.20 
120 362.05 419.14 407.05 345.20 342.89 315.53 312.30 326.41 299.16 279.80 279.74 255.17 226.18 224.57 288.18 
Mean 231.18 234.25 284.73 221.09 217.96 199.70 194.89 184.24 188.83 178.52 197.46 177.54 152.25 161.20 181.28 
St. Dev. 149.66 158.06 270.34 150.01 141.96 125.31 117.21 120.32 119.46 104.95 124.79 113.28 96.27 106.07 128.65 
                
*Minority Subjects 
  
Table H28.  DHEA-S concentrations (ng/ml) for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 50 596.40 522.39 529.86 473.23 538.89 513.81 559.40 510.91 447.91 475.14 425.37 529.10 442.52 426.19 457.59 
 51 193.30 213.38 207.04 204.04 191.40 201.10 214.93 191.65 176.72 221.90 170.03 181.19 161.62 186.11 213.29 
 52 1138.96 843.95 1016.54 906.74 880.38 936.19 716.41 762.80 823.31 759.92 777.02 874.81 678.42 761.79 844.65 
 53 441.57 417.48 430.70 410.37 438.29 428.56 343.74 308.52 328.40 326.67 398.47 410.35 331.69 333.48 288.17 
 54 753.07 762.90 925.86 544.06 749.64 689.44 805.52 567.06 594.12 668.98 620.00 671.99 510.86 437.83 649.27 
 55 2065.51 2113.87 2031.03 1981.77 1844.30 2140.81 1914.21 1844.10 1952.32 1522.79 1904.24 1585.79 1438.94 1433.35 452.52 
 56 86.49 73.91 76.91 71.89 76.16 66.47 67.45 61.50 66.50 73.69 72.55 67.64 67.96 67.10 71.85 
 57 695.56 619.29 658.64 605.48 631.74 636.98 639.78 601.08 603.53 593.61 548.64 574.23 473.38 571.16 569.29 
 58 51.91 62.32 57.48 50.73 53.20 52.19 52.24 53.08 58.94 52.17 60.27 55.44 52.67 52.69 59.11 
 59 1513.46 1519.51 1559.71 1480.08 1107.75 1611.84 1422.77 1381.70 1348.29 1432.84 1404.69 1383.99 1062.81 1223.99 985.30 
 60 1765.57 1775.37 1880.96 1777.38 1687.65 1652.76 1499.59 -- 1551.04 1656.03 1589.07 1496.27 1297.25 1418.27 1663.45 
   61* 552.54 720.99 598.47 492.06 443.37 479.27 472.32 460.27 489.52 498.12 475.59 500.07 344.77 397.17 439.43 
149 658.79 612.54 559.65 584.49 571.56 588.17 540.28 572.81 575.88 529.33 523.78 561.23 447.40 462.31 495.42 
160 824.33 852.00 884.97 861.60 807.13 852.70 783.72 771.88 797.36 813.38 861.64 845.23 630.53 652.69 703.34 
Mean 809.82 793.56 815.56 745.99 715.82 775.02 716.60 622.10 700.99 687.47 702.24 695.52 567.20 601.72 563.76 
St. Dev. 611.31 614.80 625.19 603.75 536.50 623.82 550.05 506.51 561.97 515.52 563.65 497.02 427.89 457.89 414.35 
                
*Minority Subjects 
--Concentration not obtained 
  
Table H29.  DHEA-S concentrations (ng/ml) for young women during Alprazolam/DHEA Treatment 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
   1 1849.11 4508.51 4698.79 4494.31 4412.69 4142.40 3906.38 4185.75 4917.63 4939.01 4155.00 4180.90 3522.72 2806.55 2872.66 
   3 1767.33 2454.02 4274.01 5082.14 4762.40 4833.27 4587.02 4456.75 5142.16 5392.11 5546.11 5436.74 4588.70 4274.94 4139.58 
   4 1561.92 1473.73 2860.81 4104.10 4007.51 3998.25 4550.58 3827.10 3492.08 4227.93 4849.88 4501.96 3738.84 3481.74 2954.55 
   5 1711.65 4722.80 5093.87 4696.06 4121.97 3517.12 2994.00 2679.89 3068.38 4002.21 4266.44 3831.93 2733.98 2307.86 2286.57 
   7 1075.78 3340.35 4094.40 4258.60 3547.50 3446.84 2916.16 2757.93 4092.67 3845.90 3159.21 2895.40 2374.10 2075.20 2000.74 
   8 769.23 2526.09 4350.14 4362.63 3855.63 3393.41 3011.97 2410.38 2874.05 4147.04 3393.63 3033.11 1903.06 1434.61 1839.89 
   9 904.95 1027.18 4617.97 4977.52 4945.36 4749.60 4893.07 4728.45 4660.92 4565.59 5246.38 5698.49 5255.32 4841.65 4533.55 
 10 4008.76 3958.65 5311.60 5462.73 5306.43 5273.54 5089.13 4989.74 5672.88 5525.43 5786.43 5227.01 4854.09 4533.93 4392.35 
 11 2001.55 2184.68 4567.64 4732.02 4730.31 4734.41 4698.51 4489.55 5567.99 5508.71 5391.40 5450.72 4879.08 4385.02 3773.06 
 12 2571.61 3006.10 4458.17 5098.63 5155.81 5242.25 4752.94 5036.12 5370.93 6206.49 5953.11 5371.69 4867.89 4101.59 4144.60 
    14* 2810.67 2706.64 2821.90 3547.93 3899.51 5339.71 5249.21 4471.52 5562.17 4978.86 4980.12 4749.49 4424.02 4104.11 3896.04 
    15* 180.46 1610.95 4510.45 4728.54 4850.32 4528.78 4129.81 4388.97 4264.04 5504.86 5275.39 5386.40 4795.91 4103.56 3893.10 
    16* 645.06 4106.54 4093.57 3720.96 3509.24 3143.18 2868.17 3021.78 4160.24 3982.83 3598.89 3290.70 2285.29 1849.01 1962.45 
  66 2250.83 2536.42 4975.98 4877.61 4766.36 4665.22 4384.77 4054.00 4245.06 5030.28 5229.43 5163.72 4438.25 4015.27 4114.68 
102 1653.13 1899.55 3406.84 4091.10 4531.64 4442.24 4431.83 4015.63 4042.48 4492.10 5856.18 5743.49 4626.42 3982.84 3594.13 
111 2123.64 2106.77 3758.91 4199.77 4046.28 3924.71 3488.79 3236.54 4138.35 3996.87 3731.02 3492.14 2701.17 2327.90 2198.87 
112 1650.43 1830.28 4311.88 4721.53 4551.18 4650.94 5112.03 4523.66 4401.44 4293.32 4988.54 4803.28 4443.16 3982.33 3475.07 
113 2543.77 2591.22 2664.21 2686.49 2507.97 2468.04 2249.88 1992.92 2151.41 1913.35 2306.94 2151.47 2357.32 1497.46 2129.09 
   114* 714.54 1341.41 4507.49 4462.97 4234.96 4051.93 3392.56 3647.56 5066.06 4671.20 4294.42 3821.06 3032.97 2419.61 1792.59 
 206 1796.83 2777.41 5130.89 5107.78 5288.11 5190.88 5036.27 5287.30 5742.59 5544.76 5228.66 5221.05 4696.64 4365.40 3923.89 
   213* 1273.51 995.73 4302.21 4456.20 4516.65 4286.45 4265.84 4037.13 4048.91 5359.09 4990.14 4875.90 4316.99 4049.22 4062.73 
Mean 1707.85 2557.38 4229.13 4469.98 4359.42 4286.82 4095.66 3916.13 4413.45 4672.76 4677.49 4491.75 3849.33 3378.09 3237.15 
St. Dev. 869.80 1081.43 750.00 625.92 674.77 770.92 892.56 915.50 972.19 918.01 983.28 1044.56 1074.27 1102.02 962.46 
                
*Minority Subjects 
  
Table H30.  DHEA-S concentrations (ng/ml) for young men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 33 2363.78 2345.92 3035.41 5976.87 5916.99 5985.98 5572.36 5083.77 5547.19 5677.28 5488.53 5176.80 4409.48 3842.71 3790.25 
 34 1418.08 4057.43 4545.44 4482.29 4414.56 4286.92 4163.08 4192.94 5098.23 5527.90 5422.83 5468.92 4988.38 4533.11 4376.16 
 35 1022.55 3938.98 4607.71 4189.08 4312.21 4211.70 3963.06 3646.65 3867.27 4224.58 5235.42 4855.65 4216.14 4456.32 3575.64 
 36 2231.81 3910.91 4708.02 4866.70 4936.17 4612.36 4498.26 4198.48 4530.07 4711.95 5308.62 5088.51 4499.28 4123.35 3932.68 
 37 3334.14 3346.81 4987.07 5036.73 4954.57 4657.61 4398.68 4248.32 4081.67 5123.48 4919.30 4844.02 4023.00 3666.63 3660.34 
 38 4334.59 5633.15 6023.85 5774.49 5639.31 5425.41 5331.32 4717.89 5142.02 5517.13 5353.52 5224.95 4467.39 4548.88 4560.50 
 39 2587.39 4534.00 4272.02 3593.60 3372.55 3190.79 2907.48 2616.47 3168.18 4097.69 3856.90 3689.13 2972.96 2732.29 2947.75 
 41 1921.08 4137.05 4684.20 4585.02 4466.72 4160.50 3921.55 3542.75 4417.48 4547.40 4215.57 4318.64 3565.76 3084.55 3021.37 
 42 3698.25 4498.39 5458.07 5734.97 5763.50 5906.96 5434.11 5221.47 5379.26 5247.99 6378.17 6390.84 5515.96 5527.57 5284.23 
 43 3474.75 3682.57 5135.82 6029.57 5405.48 5638.38 5682.41 5364.14 6146.18 6603.58 6319.66 6166.83 5740.28 5837.35 5696.18 
 44 2934.23 4213.53 5102.37 5298.89 5260.74 5137.73 4963.34 4973.64 5316.04 5454.39 5548.16 5561.51 5316.48 4763.98 4579.95 
 45 3783.99 5121.92 5537.92 5628.92 5431.84 5300.85 5359.85 5176.47 5075.71 5743.59 5745.34 5515.40 4875.30 4611.07 4769.72 
 46 4772.28 4869.20 5647.01 5958.38 5758.98 5903.47 5751.18 5640.88 6034.09 6386.97 6313.49 6332.80 5840.33 5682.69 5577.57 
    47* 1949.34 3969.28 4995.24 4605.97 4528.32 4195.39 4102.09 3959.06 4599.80 4749.29 5204.51 5110.97 4628.55 4138.90 4091.19 
    48* 2853.42 5630.77 5898.57 5705.66 5269.54 5270.50 5196.71 4859.99 5623.15 5775.59 5669.35 5566.64 4872.08 4594.29 4665.75 
140 2756.01 2559.13 3876.56 4781.08 4855.35 4777.48 4695.12 4790.17 5255.46 5016.32 5259.18 5027.49 4736.26 3879.70 3813.04 
145 3198.21 3556.30 4159.40 4630.28 4357.05 4718.00 4818.44 4754.10 5176.65 5974.87 5522.63 5303.87 4453.06 4921.56 4795.35 
   146* 2572.82 3123.64 4763.67 4926.06 4807.81 4506.93 4093.26 4130.24 4997.53 5250.46 4991.72 5074.34 4384.11 4066.65 4209.13 
   245* 2864.20 3044.26 3249.88 4061.65 4224.88 4341.30 4527.14 4584.21 5209.11 5009.58 4990.35 4707.77 4468.23 4077.36 3837.22 
Mean 2845.84 4009.12 4773.06 5045.59 4930.35 4854.12 4704.18 4510.61 4982.37 5296.84 5354.91 5232.90 4630.16 4373.10 4272.84 
St. Dev. 945.20 918.06 811.26 720.22 660.70 738.11 748.01 737.58 733.59 668.46 636.00 653.09 700.81 798.94 766.79 




Table H31.  DHEA-S concentrations (ng/ml) for older women during Alprazolam/DHEA  Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 17 126.08 4001.71 4269.73 3847.82 3553.04 3331.16 3094.83 3129.08 5272.24 5303.00 5209.36 5114.00 4031.84 3329.80 3330.90 
 18 164.10 3256.60 4154.01 3706.55 3526.67 3371.84 3225.81 3602.45 4880.76 5241.22 5069.73 4746.28 4119.74 3383.34 3101.57 
 19 485.52 1998.09 5191.76 5043.49 4822.85 4833.08 4533.61 3905.58 4382.54 5184.07 4655.14 4838.09 4053.58 3365.55 2937.60 
    20* 118.88 104.32 1382.54 2988.24 2814.38 2566.29 3009.07 2442.66 4087.98 3169.61 3019.54 2743.87 1876.11 1336.33 1027.06 
 21 375.72 997.83 3084.20 3820.35 3785.73 3755.88 3820.03 3301.74 3411.54 3729.55 5119.39 4949.43 4319.65 3612.41 3320.56 
 22 213.81 1573.75 4130.98 4220.13 4256.60 4206.41 3788.87 3412.77 3172.20 3714.36 5544.36 5553.85 4589.77 3690.77 3675.22 
 23 307.48 3278.51 5589.77 5370.30 5107.75 4903.21 4769.59 4448.61 4747.81 5969.67 5743.74 5556.71 4947.55 4275.10 4331.78 
 24 144.98 4450.12 4150.64 3828.89 3493.98 3340.16 2991.54 2839.50 3857.56 4909.95 4469.25 4441.00 3282.74 2707.01 2428.25 
 25 284.38 1425.43 4023.74 4158.65 4327.90 4512.08 3932.13 4278.01 4050.48 5238.50 5761.93 5561.09 5088.83 4561.18 4619.17 
 26 110.27 3924.43 4683.17 4133.05 4090.94 3879.83 3642.89 3142.42 4325.52 5447.59 5008.39 4681.78 3808.81 3174.43 2825.04 
 27 69.53 85.85 1144.55 2552.75 2576.75 2384.89 2581.29 2267.10 2479.13 3921.22 4040.95 3622.09 2466.31 1591.83 1387.41 
 28 61.34 1574.65 5006.92 5188.36 5059.03 4914.92 4534.18 4194.21 4699.11 5147.99 5080.85 4887.88 4265.20 3664.77 3479.14 
    29* 64.29 3994.32 4850.49 4414.23 4193.54 4023.07 4054.76 3571.68 6001.51 6004.13 5652.72 5474.23 4508.45 3795.87 3551.96 
    30* 218.24 654.43 2849.39 4318.94 4301.55 4089.09 3711.97 3572.27 4633.71 5218.42 4821.43 4640.91 3852.07 3176.42 3635.17 
    31* 81.59 627.98 3273.55 3531.38 3233.76 2784.05 2937.28 2710.72 3397.29 3932.16 4427.73 3928.86 3254.90 2203.91 2177.69 
120 407.34 566.29 5581.93 5469.96 5226.17 4957.35 4763.21 4418.69 5369.80 5035.29 4958.39 4626.10 4370.40 3711.05 3244.06 
Mean 202.10 2032.14 3960.46 4162.07 4023.17 3865.83 3711.94 3452.34 4298.07 4822.92 4911.43 4710.39 3927.25 3223.74 3067.04 
St. Dev. 133.57 1540.37 1328.18 816.19 798.95 847.85 696.28 682.63 905.37 851.98 702.56 763.84 853.39 880.02 949.73 
                
*Minority Subjects 
  
Table H32.  DHEA-S concentrations (ng/ml) for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 50 600.26 4061.12 4153.25 3600.69 3468.52 3321.51 3211.98 2794.80 4082.65 4589.17 4971.06 4735.60 3996.25 3410.76 3278.10 
 51 280.86 3207.69 3813.86 3670.39 3470.44 3318.37 3342.24 3033.03 4497.65 5394.65 5385.25 5089.26 4260.98 4092.43 3790.16 
 52 687.66 1592.45 5710.69 6274.65 6068.48 5816.81 5388.38 5195.45 5585.10 5653.74 5564.20 5280.81 4932.78 4439.62 4721.78 
 53 674.58 958.97 4413.86 4619.33 4357.51 4208.54 3951.38 3699.62 5507.96 5768.47 5905.14 5546.40 5016.40 4640.19 4149.60 
 54 667.93 7939.09 2583.90 3988.58 3493.26 3532.31 3684.14 4016.10 6278.35 5495.00 5269.10 5463.49 4813.95 3729.25 3049.80 
 55 3068.34 1929.34 2049.34 2235.07 2130.79 2147.84 2294.64 3896.15 5351.07 5159.54 5716.57 5582.09 5131.98 4700.21 4646.31 
 56 76.78 93.76 2432.50 5685.07 5177.27 5022.18 4506.73 4265.28 4354.13 4029.34 3932.69 3628.64 3465.27 2518.65 1917.27 
 57 706.03 907.66 4192.73 5478.72 5192.48 5110.34 4847.70 4528.61 5231.50 4877.08 5178.19 4978.46 4177.62 3673.21 3509.27 
 58 70.67 57.82 166.44 2679.40 3389.83 3335.02 3026.30 3134.76 4785.63 4259.72 3758.26 3551.22 2763.83 2371.93 2227.32 
 59 1330.87 1339.15 3886.55 3929.28 3453.99 3689.39 3414.51 3082.57 3459.38 4619.62 4535.13 4320.94 3099.55 2603.82 2630.01 
 60 1577.76 4345.71 4828.27 4660.86 4545.86 4543.04 4283.90 5218.11 5181.34 5046.30 4937.16 4695.26 4306.81 4067.80 3880.64 
   61* 492.88 473.83 1566.61 2788.59 2967.69 3045.88 3151.99 2920.25 3058.73 4333.29 4247.73 4307.81 3784.99 3338.14 3321.30 
149 455.68 3488.71 5392.25 5377.87 5353.98 5124.63 5567.08 5563.70 5509.06 5320.94 4923.93 4786.89 4616.17 4173.98 3963.35 
160 437.50 499.80 6474.90 6732.84 6535.70 6442.93 6155.17 6031.27 6443.78 6699.77 6441.00 6361.08 5716.30 5320.63 5296.84 
Mean 794.84 2206.79 3690.37 4408.67 4257.56 4189.91 4059.01 4098.55 4951.88 5089.05 5054.67 4880.57 4291.63 3791.47 3598.70 
St. Dev. 774.35 2200.87 1743.08 1376.98 1267.84 1198.33 1113.18 1072.13 978.80 712.03 755.08 770.63 824.93 878.45 957.98 
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Table H33.  Cortisol concentrations (ng/ml) for young women during Placebo Treatment 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
   1 12.27 3.03 1.86 13.22 16.86 12.52 10.54 5.98 9.37 8.50 6.98 8.73 1.14 4.37 2.60 
   3 22.29 10.70 7.44 7.72 4.95 4.72 6.68 9.83 4.38 2.16 2.57 1.51 1.87 16.10 17.37 
   4 21.84 9.93 10.17 9.91 5.47 4.66 10.93 10.35 5.30 1.71 2.91 2.68 6.49 8.74 20.63 
   5 22.97 10.13 5.84 3.78 5.20 5.81 8.25 4.36 2.70 6.77 2.94 1.96 1.88 15.12 23.64 
   7 39.24 27.03 18.87 23.21 20.88 25.24 18.36 19.50 24.00 12.06 14.23 7.19 4.40 22.08 23.63 
   8 20.63 10.63 19.22 13.31 8.16 5.11 8.74 5.85 8.63 2.20 12.08 4.09 3.44 1.40 10.51 
   9 31.54 20.51 12.56 11.62 8.76 11.56 10.17 5.49 7.52 14.47 5.48 3.24 0.94 2.80 30.35 
 10 21.15 4.43 4.56 7.37 5.24 9.62 5.33 3.93 5.01 1.69 2.70 1.18 3.14 6.27 22.79 
 11 20.94 16.75 22.56 22.11 17.63 16.33 19.00 18.82 12.90 12.13 15.15 9.37 3.80 1.66 22.97 
 12 18.40 4.81 2.94 4.24 8.94 17.64 18.34 4.92 14.14 12.97 13.60 5.49 1.99 0.80 3.44 
    14* 24.51 9.97 6.46 7.92 9.65 10.86 6.17 5.18 3.99 2.39 15.17 6.36 4.28 8.32 14.95 
    15* 20.36 12.86 8.08 6.82 4.51 3.82 5.86 12.18 6.27 3.02 2.89 4.68 2.62 8.69 15.23 
    16* 1.50 8.87 10.09 10.54 6.25 7.13 4.26 4.00 5.53 9.15 10.12 3.95 0.97 2.89 12.06 
  66 32.67 17.73 14.30 16.62 16.40 13.10 14.95 9.57 7.75 15.21 6.32 6.25 7.96 9.69 27.40 
102 22.44 7.52 4.76 8.62 10.54 6.61 8.45 4.26 7.82 3.95 2.38 1.18 4.30 1.40 14.75 
111 19.44 7.94 10.19 26.17 25.97 19.95 4.40 4.07 3.96 10.07 3.81 1.79 3.03 15.66 17.33 
112 12.30 23.85 27.76 21.61 21.92 20.16 16.20 16.81 18.24 22.49 13.41 14.09 3.27 1.62 21.27 
113 24.55 12.62 5.22 6.85 9.30 13.40 15.36 7.36 6.21 5.80 18.75 9.13 1.43 13.77 20.05 
   114* 11.12 5.81 4.73 2.76 6.26 4.17 6.62 5.30 6.77 3.53 3.15 3.05 3.25 8.26 12.62 
 206 32.31 32.77 37.89 39.61 42.91 36.96 37.12 33.13 28.97 35.85 35.34 35.96 17.78 16.91 25.09 
   213* 20.86 8.01 4.67 3.40 3.59 4.97 3.67 2.23 5.55 4.75 7.79 3.03 4.41 7.10 26.25 
Mean 21.59 12.66 11.44 12.73 12.35 12.11 11.40 9.20 9.29 9.09 9.42 6.42 3.92 8.27 18.33 
St. Dev. 8.29 7.82 9.19 9.25 9.56 8.40 7.73 7.44 6.85 8.29 7.94 7.54 3.63 6.24 7.37 
                
*Minority Subjects 
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Table H34.  Cortisol concentrations (ng/ml) for young men during Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 33 15.41 8.03 9.14 6.95 10.24 6.14 6.07 3.04 2.42 3.77 5.28 2.66 1.56 2.36 18.39 
 34 27.02 11.17 17.17 16.72 11.76 11.65 11.40 10.44 7.51 9.99 10.48 8.39 2.44 4.25 19.00 
 35 14.48 5.78 3.46 4.77 7.35 5.56 2.77 3.51 7.24 2.97 3.21 1.68 1.48 4.20 10.14 
 36 26.75 21.62 17.57 16.25 18.17 11.63 11.88 15.57 12.20 10.71 13.35 8.97 2.41 9.81 21.71 
 37 16.69 15.04 19.36 14.75 18.39 14.53 14.32 11.15 12.05 13.49 14.96 9.30 1.81 1.48 32.13 
 38 29.59 19.70 23.04 19.68 16.84 23.01 19.46 13.01 19.48 14.14 8.23 5.74 4.07 18.39 32.05 
 39 43.80 22.35 11.75 6.71 9.49 10.62 12.28 10.40 9.51 10.13 7.81 3.68 2.84 6.47 15.08 
 41 30.77 11.66 8.86 17.16 10.34 12.09 12.21 11.13 18.04 14.92 12.84 6.29 14.20 8.35 31.86 
 42 3.87 21.04 10.63 17.77 11.70 17.61 11.48 6.15 8.33 6.50 22.17 13.14 3.03 1.93 22.13 
 43 24.56 12.64 15.18 11.02 6.97 9.90 12.79 13.50 5.70 3.02 2.77 1.24 1.39 15.67 16.23 
 44 9.69 4.32 1.88 13.19 12.55 8.32 14.32 8.18 12.28 9.64 5.53 3.65 2.48 0.78 6.56 
 45 24.10 18.99 20.27 11.66 12.07 13.77 16.94 14.01 10.51 5.45 4.08 3.04 1.06 5.34 20.50 
 46 24.76 10.64 9.66 11.36 8.12 11.08 18.67 14.21 8.57 11.76 14.82 9.11 2.57 15.02 24.72 
    47* 28.74 5.81 4.12 6.31 14.20 10.04 10.79 4.88 22.94 8.31 2.71 2.03 0.98 12.85 25.16 
    48* 23.46 10.07 16.73 11.94 9.95 15.30 11.68 4.97 12.61 8.44 6.57 4.85 1.89 10.81 17.94 
140 3.82 7.34 13.73 19.76 13.37 13.61 7.67 15.81 9.16 4.96 16.42 7.54 1.50 0.64 6.14 
145 26.17 10.39 9.81 8.14 7.03 6.88 5.00 4.18 4.76 8.22 10.86 22.80 8.00 7.43 16.15 
   146* 21.61 7.54 5.82 4.05 7.78 6.42 4.05 3.45 2.78 1.63 2.67 1.46 0.69 7.56 42.91 
   245* 31.07 16.20 9.74 8.96 5.73 16.17 10.31 7.17 4.06 4.07 5.92 3.37 6.62 0.80 14.51 
Mean 22.44 12.65 12.00 11.96 11.16 11.81 11.27 9.20 10.01 8.01 8.98 6.26 3.21 7.06 20.70 
St. Dev. 9.88 5.83 6.00 5.03 3.77 4.41 4.61 4.44 5.55 4.02 5.56 5.20 3.25 5.49 9.33 
                
*Minority Subjects 
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Table H35.  Cortisol concentrations (ng/ml) for older women during Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 17 24.03 8.92 8.23 12.84 9.03 4.91 9.55 6.92 19.57 4.85 2.75 2.07 1.60 11.94 34.42 
 18 19.67 9.27 10.56 8.26 9.50 15.13 7.01 13.52 10.16 5.95 5.08 4.62 2.44 14.28 11.20 
 19 27.77 18.71 12.91 15.87 18.55 19.33 11.20 15.66 12.92 6.85 15.33 7.93 3.13 6.52 26.39 
    20* 21.18 10.59 6.44 6.14 5.20 5.30 9.07 3.66 3.45 2.80 14.35 7.50 2.73 6.86 16.21 
 21 19.35 16.40 8.68 9.50 18.16 31.60 15.61 8.90 11.59 4.24 19.82 10.64 4.77 5.67 12.64 
 22 22.12 9.45 10.74 6.62 6.63 7.99 9.16 6.13 7.92 3.98 6.31 10.97 1.07 10.72 21.65 
 23 24.61 13.06 9.64 8.99 7.68 9.41 12.77 6.43 6.12 7.08 5.34 3.15 2.01 16.96 28.59 
 24 25.19 10.47 7.41 7.83 7.34 7.15 11.21 7.06 7.80 7.61 10.05 4.31 2.03 8.37 22.12 
 25 17.90 11.20 13.97 4.97 7.72 10.77 8.24 7.88 6.15 6.38 12.33 6.38 1.52 8.42 28.84 
 26 23.46 18.28 15.28 11.86 14.35 9.30 13.14 15.78 -- 10.15 9.84 8.49 2.28 13.63 14.38 
 27 27.13 21.89 17.71 13.04 9.95 9.16 13.66 8.86 22.86 14.82 -- 13.24 3.79 9.05 27.31 
 28 19.94 14.13 12.04 14.11 11.02 8.86 15.90 10.98 13.64 14.13 17.96 7.54 9.96 30.07 15.02 
    29* 16.78 12.27 8.68 9.41 15.28 14.50 13.91 9.19 9.66 6.31 7.67 5.14 8.03 28.80 27.02 
    30* 13.33 13.33 12.47 13.86 10.93 5.50 6.12 6.13 5.66 5.25 4.07 3.01 1.44 6.89 24.51 
    31* 7.10 25.30 28.94 19.69 18.57 8.52 29.58 12.09 9.14 7.16 6.23 5.20 16.88 3.42 15.82 
120 31.82 22.51 16.15 11.51 11.27 10.03 26.15 12.15 11.38 11.28 9.14 3.83 3.55 3.73 26.80 
Mean 21.34 14.74 12.49 10.91 11.32 11.09 13.27 9.46 10.53 7.43 9.75 6.50 4.20 11.58 22.06 
St. Dev. 5.95 5.20 5.45 3.92 4.39 6.67 6.42 3.58 5.21 3.48 5.21 3.19 4.17 7.91 6.97 
                
*Minority Subjects 
--Concentrations not obtained 
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Table H36.  Cortisol concentrations (ng/ml) for older men during Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 50 12.85 8.91 11.63 10.20 9.31 6.91 10.72 4.29 4.21 10.05 3.69 2.45 3.22 11.30 19.35 
 51 26.86 8.90 9.08 12.82 7.35 12.40 11.33 9.79 10.88 3.96 2.76 2.87 21.82 22.93 16.89 
 52 20.04 4.82 10.33 5.64 4.30 4.23 3.72 2.73 3.39 1.42 1.10 0.83 2.12 19.05 23.52 
 53 16.67 3.98 24.17 20.08 13.13 7.27 7.72 8.77 13.71 8.90 10.76 6.27 1.90 14.18 27.40 
 54 30.23 12.57 23.44 13.75 10.53 16.34 9.58 20.27 18.35 11.41 7.81 4.12 1.11 12.03 24.56 
 55 16.20 10.73 11.21 8.59 7.10 12.15 11.34 7.38 3.70 4.96 3.90 6.53 1.03 20.25 14.41 
 56 21.73 13.69 13.65 12.04 8.63 9.14 8.79 14.44 8.54 7.64 4.27 2.59 1.08 7.16 18.96 
 57 20.83 13.28 12.61 12.79 10.55 12.57 7.58 9.00 15.24 15.17 12.62 5.10 2.38 16.05 22.13 
 58 14.16 11.47 8.84 11.38 9.84 14.53 10.47 4.62 7.29 5.84 5.51 3.13 2.38 1.29 27.35 
 59 21.88 20.20 17.61 17.72 13.41 18.80 12.20 13.91 10.59 14.39 9.85 5.34 1.89 5.13 29.10 
 60 24.27 19.00 15.10 10.65 9.45 9.14 8.46 15.86 13.86 4.93 2.78 3.80 3.85 6.05 20.65 
   61* 25.16 19.93 13.24 9.70 10.33 12.62 7.60 6.65 7.95 5.63 10.08 6.49 3.04 17.21 27.68 
149 21.04 16.91 10.32 7.49 6.50 6.57 8.08 7.37 8.96 5.42 14.66 7.77 4.52 16.36 27.14 
160 19.95 7.50 8.13 6.31 7.74 7.30 10.99 3.69 3.12 5.17 8.83 5.59 4.09 9.77 10.98 
Mean 20.85 12.28 13.53 11.37 9.16 10.71 9.18 9.20 9.27 7.49 7.04 4.49 3.89 12.77 22.15 
St. Dev. 4.85 5.29 5.05 4.04 2.48 4.17 2.23 5.17 4.79 4.01 4.18 1.97 5.28 6.34 5.54 
                
*Minority Subjects 
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Table H37.  Cortisol concentrations (ng/ml) for young women during DHEA Treatment 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
   1 16.50 4.19 1.76 1.85 13.79 16.07 7.36 3.47 4.25 5.39 10.13 3.80 0.77 1.38 13.09 
   3 23.45 7.51 4.35 5.00 5.67 8.60 8.24 3.57 4.53 3.99 2.15 1.31 0.73 9.02 20.82 
   4 15.02 6.57 5.32 8.01 4.79 3.07 5.73 5.29 9.34 2.48 3.46 2.42 1.16 5.82 17.11 
   5 20.72 11.45 6.79 5.95 3.82 2.51 5.26 7.06 6.16 1.98 2.86 1.97 1.74 4.85 20.22 
   7 29.50 13.97 9.28 22.10 17.08 10.04 21.42 8.78 10.26 6.16 10.13 8.52 1.93 17.41 23.02 
   8 18.99 12.29 7.32 10.37 8.31 13.11 7.39 5.70 6.38 6.39 9.13 4.06 2.95 0.68 16.92 
   9 26.18 12.63 6.98 12.99 14.00 8.74 8.15 4.22 12.47  21.94 10.53 1.17 0.87 19.08 
 10 27.58 4.21 3.27 3.27 2.10 3.18 7.80 17.53 16.72 5.62 2.67 1.88 1.72 8.65 25.91 
 11 14.22 15.29 11.75 14.68 17.66 20.96 18.70 17.73 24.54 7.66 6.10 4.25 2.93 1.05 7.51 
 12 13.14 5.63 4.49 11.22 10.41 11.98 23.60 11.72 13.97 18.09 15.48 6.86 4.04 1.03 0.70 
    14* 24.72 10.07 13.27 18.41 14.03 6.94 7.27 6.48 6.18 3.61 18.80 11.74 2.38 13.49 21.75 
    15* 18.70 10.05 7.54 7.82 6.55 6.07 3.27 14.21 5.53 5.17 4.30 3.46 3.31 11.01 20.27 
    16* 14.04 6.27 6.67 7.51 11.36 12.67 11.51 6.13 7.10 6.47 5.34 2.71 2.04 3.92 18.11 
  66 30.03 15.79 18.77 12.43 13.44 15.03 14.58 11.06 20.35 30.39 15.13 6.56 6.71 19.90 22.63 
102 24.05 12.30 9.51 4.27 11.39 18.11 10.45 3.78 4.15 5.35 8.51 2.03 1.48 0.55 13.78 
111 18.21 5.07 4.73 6.04 8.23 3.68 2.39 4.21 6.16 10.06 18.22 13.26 1.47 13.82 18.30 
112 31.44 17.81 30.80 24.90 22.12 13.29 16.57 15.48 15.78 15.79 8.20 6.93 5.08 10.29 9.76 
113 31.18 12.84 8.94 11.77 12.93 10.97 13.35 5.49 12.64 5.45 3.92 2.41 6.03 2.24 14.48 
   114* 12.78 7.88 5.66 4.48 3.56 2.66 5.70 4.51 2.78 5.75 6.26 3.15 1.76 16.48 18.06 
 206 21.44 34.63 32.93 38.92 24.94 24.21 23.84 17.00 23.99 36.20 22.68 11.22 11.27 16.37 24.70 
   213* 25.10 7.18 5.64 2.38 4.63 4.48 3.10 4.58 6.02 8.39 5.99 5.37 3.64 7.95 22.78 
Mean 21.76 11.13 9.80 11.16 10.99 10.30 10.75 8.48 10.44 9.52 9.59 5.45 3.06 7.94 17.57 
St. Dev. 6.19 6.71 8.24 8.93 6.18 6.26 6.68 5.08 6.59 9.08 6.53 3.67 2.51 6.39 6.08 
                
*Minority Subjects 
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Table H38.  Cortisol concentrations (ng/ml) for young men during DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 33 24.27 12.17 11.03 13.06 10.14 9.33 7.56 5.38 8.63 6.29 6.63 2.91 1.06 1.57 18.98 
 34 23.94 19.73 16.94 17.64 13.39 7.42 7.33 5.87 7.45 11.82 22.21 11.10 4.44 4.38 20.57 
 35 21.48 5.28 4.82 22.94 22.39 22.36 12.94 5.41 3.60 4.79 4.63 2.96 2.36 5.70 18.28 
 36 24.75 16.00 12.59 16.03 15.37 14.12 13.92 7.45 7.82 10.32 6.25 3.65 1.59 3.05 14.56 
 37 26.88 12.29 14.74 10.14 8.87 9.03 8.49 7.21 8.20 6.38 11.43 6.47 1.30 8.56 24.35 
 38 31.05 20.51 23.16 14.96 13.96 17.31 18.99 9.42 18.49 15.85 8.16 6.05 2.02 11.92 30.75 
 39 41.83 27.30 17.23 12.02 7.75 7.83 11.16 20.35 10.88 5.29 8.80 4.30 2.55 15.27 24.52 
 41 28.08 12.05 12.17 13.90 9.71 17.35 19.70 11.22 10.49 9.86 3.34 2.27 7.52 17.79 22.14 
 42 33.75 47.13 11.17 5.88 5.21 3.98 6.64 4.31 9.73 4.70 7.72 3.85 2.06 23.73 10.57 
 43 20.28 12.68 15.37 7.96 7.72 11.82 7.88 10.39 7.52 4.25 5.05 2.83 1.13 9.42 20.14 
 44 2.22 4.82 2.45 12.06 8.46 13.53 24.05 8.99 6.77 9.67 12.28 8.03 12.69 7.03 1.06 
 45 20.80 7.65 13.11 10.18 7.01 5.86 5.68 18.18 8.63 2.92 1.72 2.40 0.70 0.85 20.37 
 46 23.08 27.63 7.58 9.13 7.46 9.67 17.45 16.48 11.36 7.94 8.67 5.77 2.30 16.54 29.91 
    47* 26.48 10.03 6.34 4.18 5.20 15.21 9.09 7.87 13.62 3.72 7.40 3.23 0.98 9.42 16.42 
    48* 27.25 9.19 17.56 12.95 9.10 5.88 10.52 9.71 9.07 10.09 5.23 2.46 4.66 1.70 26.38 
140 23.59 6.36 19.13 22.27 16.06 7.83 11.58 12.49 10.16 19.42 13.14 5.46 0.79 0.93 11.26 
145 10.51 12.36 14.44 14.31 8.06 3.61 3.70 4.19 4.94 13.39 15.70 18.50 8.69 11.30 10.61 
   146* 21.50 10.57 6.66 4.76 3.16 6.12 8.04 4.89 2.93 1.78 2.94 1.97 1.42 15.41 22.05 
   245* 25.09 20.85 17.24 15.46 15.16 11.96 11.42 11.08 6.13 3.23 17.31 6.87 10.17 2.43 18.43 
Mean 24.04 15.51 12.83 12.62 10.22 10.54 11.38 9.52 8.76 7.98 8.87 5.32 3.60 8.79 19.02 
St. Dev. 8.17 10.19 5.39 5.16 4.71 5.07 5.35 4.67 3.54 4.75 5.33 3.97 3.56 6.67 7.25 
                
*Minority Subjects 
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Table H39.  Cortisol concentrations (ng/ml) for older women during DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 17 20.20 10.16 6.12 6.01 6.38 6.28 5.87 6.14 11.39 3.38 2.19 2.80 2.30 19.11 19.07 
 18 25.52 12.98 8.57 9.60 11.47 11.40 8.84 8.93 8.42 4.40 2.88 2.16 2.60 15.52 24.63 
 19 26.25 16.99 15.19 15.87 18.71 16.42 18.46 12.73 11.28 9.84 12.82 7.04 10.17 3.73 29.58 
    20* 21.04 10.97 7.10 6.02 4.36 4.80 6.44 4.75 2.76 2.51 4.78 5.46 3.30 8.59 21.13 
 21 26.42 7.14 6.77 14.77 13.75 25.98 10.55 3.96 2.54 6.33 3.97 7.09 3.07 16.94 20.57 
 22 22.89 12.26 10.39 9.36 6.53 7.58 9.30 7.47 11.42 6.15 8.54 3.87 1.50 7.15 22.70 
 23 33.85 19.17 10.30 7.76 8.76 5.46 8.25 15.90 11.71 11.06 6.52 4.49 0.96 2.79 26.19 
 24 9.36 12.80 10.12 8.80 5.54 6.34 6.78 8.96 9.05 6.24 8.77 3.34 1.96 11.18 14.38 
 25 11.52 9.98 6.54 5.31 8.32 11.73 7.26 4.91 4.74 9.25 21.94 10.06 2.27 4.46 13.60 
 26 25.73 16.04 12.07 11.97 14.63 11.17 10.45 11.03 17.15 8.25 5.46 12.78 3.72 16.73 28.89 
 27 40.18 21.66 16.38 14.78 11.85 9.53 10.16 10.43 11.72 5.80 12.73 35.41 30.18 19.49 29.78 
 28 25.17 13.15 11.72 9.81 9.84 8.72 8.32 12.92 9.60 10.22 13.05 9.14 2.91 18.06 32.04 
    29* 16.98 9.76 8.27 6.48 10.62 13.64 10.29 8.88 8.74 8.54 10.21 6.43 4.75 6.81 18.99 
    30* 16.51 9.13 9.05 5.77 6.00 5.02 8.22 9.08 5.77 5.45 8.12 3.61 3.96 7.46 24.37 
    31* 11.80 17.22 46.60 26.29 20.49 13.79 9.81 17.18 12.16 8.74 4.87 3.03 1.33 8.79 23.84 
120 34.17 24.71 16.60 10.50 7.67 6.81 17.75 10.47 7.70 5.27 10.12 5.65 6.43 33.65 31.94 
Mean 22.97 14.01 12.61 10.57 10.31 10.29 9.80 9.61 9.13 6.96 8.56 7.65 5.09 12.53 23.86 
St. Dev. 8.61 4.89 9.66 5.39 4.68 5.46 3.56 3.80 3.82 2.52 5.00 7.96 7.06 8.04 5.73 
                
*Minority Subjects 
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Table H40.  Cortisol concentrations (ng/ml) for older men during DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 50 16.32 8.54 12.60 7.21 5.69 9.90 12.22 4.27 4.74 3.21 2.00 3.15 8.45 19.27 15.82 
 51 16.53 11.43 8.82 8.17 10.02 15.77 7.83 7.98 6.99 4.82 5.34 3.13 13.88 16.47 26.95 
 52 20.04 4.86 3.09 2.47 3.01 2.92 2.12 2.72 1.96 7.39 1.59 1.07 2.32 9.18 20.49 
 53 8.49 9.80 24.00 22.97 15.34 8.95 14.63 12.51 6.31 8.75 11.13 6.24 1.15 21.59 21.55 
 54 24.60 22.11 15.31 13.73 11.21 15.06 13.42 6.11 10.69 6.92 1.88 3.88 1.12 6.40 14.01 
 55 23.25 15.47 11.90 13.79 14.10 13.61 11.98 7.40 9.99 3.05 2.14 1.54 4.46 6.70 8.63 
 56 16.96 12.52 16.25 11.83 11.05 11.02 8.39 16.65 12.10 5.49 5.28 2.99 1.63 7.98 22.82 
 57 32.69 12.38 18.94 17.86 12.39 17.39 11.22 17.03 16.90 16.26 10.36 4.57 3.47 4.91 31.73 
 58 25.24 11.63 16.47 10.70 11.15 12.01 11.96 9.75 10.59 8.60 19.12 9.24 1.76 10.39 32.29 
 59 25.30 18.80 13.76 11.59 15.76 15.25 9.04 14.22 13.10 12.05 10.86 6.41 5.12 13.99 18.36 
 60 28.22 13.98 16.93 12.16 12.81 19.86 11.29 12.61 11.85 11.15 5.43 4.59 3.22 13.05 22.22 
   61* 23.54 23.75 16.46 13.45 12.58 12.71 11.56 14.17 7.51 3.18 7.40 3.38 2.92 11.99 18.34 
149 23.94 17.26 13.72 6.98 9.67 8.47 11.16 9.92 5.66 13.01 14.55 7.82 5.93 10.34 25.32 
160 16.11 6.04 7.32 8.30 6.44 5.03 4.69 3.52 8.40 2.86 3.68 4.10 5.09 1.79 19.25 
Mean 21.52 13.47 13.97 11.52 10.80 12.00 10.11 9.92 9.06 7.62 7.20 4.44 4.32 11.00 21.27 
St. Dev. 6.17 5.58 5.18 5.03 3.66 4.69 3.41 4.77 3.88 4.24 5.34 2.29 3.44 5.54 6.49 
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Table H41.  Cortisol concentrations (ng/ml) for young women during Alprazolam/Placebo Treatment 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
   1 9.35 6.28 9.85 14.05 9.81 3.77 6.07 7.03 8.16 2.39 4.05 2.61 0.77 12.48 1.66 
   3 21.12 8.40 6.92 5.20 3.61 1.40 0.92 4.01 4.12 2.53 4.04 1.18 0.56 9.29 18.16 
   4 21.63 7.33 6.33 4.91 2.63 1.13 5.37 4.80 2.81 1.42 7.98 3.35 0.94 2.98 4.51 
   5 20.84 6.83 5.76 10.48 7.61 4.01 2.81 7.58 5.02 2.69 7.42 3.59 1.29 4.00 10.12 
   7 30.52 15.02 11.32 18.89 11.76 6.03 3.69 3.03 5.62 19.97 4.91 2.68 5.60 5.00 19.13 
   8 23.85 11.23 5.57 18.88 12.56 7.83 5.25 2.53 3.26 1.81 11.55 5.05 3.17 0.57 17.27 
   9 25.14 11.27 17.80 12.77 11.62 4.54 2.10 2.02 9.55 3.63 5.52 2.83 0.94 5.21 17.59 
 10 30.68 4.04 9.81 3.64 2.99 1.21 1.51 2.03 2.08 1.02 4.36 1.79 1.33 18.79 28.47 
 11 7.05 13.68 21.41 25.53 20.72 14.32 9.71 5.60 9.32 6.54 16.32 11.99 2.21 1.07 9.94 
 12 2.29 6.10 8.69 14.71 9.94 4.75 3.93 11.66 11.79 5.05 10.24 4.93 3.41 0.74 1.85 
    14* 26.81 12.37 6.64 8.96 9.57 3.95 2.42 1.61 1.42 1.14 14.53 7.24 3.01 9.33 22.90 
    15* 25.47 12.06 8.23 5.51 4.24 2.74 2.35 3.31 2.46 3.75 4.02 2.00 1.05 6.99 15.28 
    16* 1.77 6.60 6.47 6.00 3.71 1.64 1.16 7.18 4.10 3.90 5.70 2.12 0.68 2.65 5.11 
  66 28.52 28.33 26.83 11.44 8.76 4.28 3.96 1.96 3.89 11.87 14.91 8.20 3.13 9.84 16.71 
102 19.14 8.57 12.18 9.14 6.34 2.53 1.99 1.22 3.83 2.76 11.37 13.14 2.03 1.12 8.07 
111 16.60 7.93 5.18 10.58 7.24 4.41 2.28 3.12 5.86 3.29 5.71 1.77 2.15 9.26 16.06 
112 18.47 16.91 17.92 13.27 9.52 4.77 3.76 4.35 5.45 3.54 15.71 6.35 1.02 2.78 6.90 
113 22.19 7.24 3.95 7.44 4.57 2.39 1.75 7.60 4.35 2.40 3.50 2.46 0.68 16.21 9.13 
   114* 20.21 10.88 6.98 5.29 4.37 2.62 2.86 2.64 5.58 1.69 3.86 1.56 4.02 2.38 15.01 
 206 26.85 27.78 26.67 36.16 34.46 25.40 22.72 11.96 11.19 5.76 14.35 8.69 4.45 2.37 13.01 
   213* 20.26 7.38 3.74 7.73 6.11 2.80 2.14 5.16 8.58 2.41 6.45 3.77 6.42 7.86 29.19 
Mean 19.94 11.25 10.87 11.93 9.15 5.07 4.23 4.78 5.64 4.26 8.40 4.63 2.33 6.23 13.62 
St. Dev. 8.41 6.47 7.08 7.83 7.18 5.47 4.69 3.09 3.00 4.32 4.54 3.43 1.71 5.14 7.77 
                
*Minority Subjects 
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Table H42.  Cortisol concentrations (ng/ml) for young men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 33 6.84 10.84 12.54 9.78 7.55 3.36 3.57 5.06 2.21 2.54 3.20 1.21 0.72 6.02 13.86 
 34 18.86 16.24 20.96 11.34 9.80 5.23 4.14 8.21 2.04 4.29 6.61 2.95 3.08 0.83 8.06 
 35 19.68 5.40 17.56 12.94 7.04 3.58 2.02 1.50 2.31 1.24 2.29 1.38 5.84 1.40 10.48 
 36 21.50 17.38 19.37 16.79 15.53 7.32 4.17 2.87 4.16 5.71 5.29 3.55 1.05 6.02 19.77 
 37 21.27 19.05 15.10 15.64 12.58 6.76 6.93 3.26 5.90 7.10 5.57 1.97 1.08 1.38 27.02 
 38 38.05 27.46 30.61 23.43 20.06 14.79 10.84 6.37 6.53 7.88 15.87 8.98 7.16 15.76 37.29 
 39 43.97 19.28 14.18 10.50 7.43 3.92 7.44 13.06 10.81 4.86 13.82 6.96 1.62 18.75 14.10 
 41 30.60 15.21 15.51 19.15 13.07 9.44 4.50 4.27 13.05 5.19 11.00 4.98 5.69 9.38 28.45 
 42 22.77 9.77 12.11 25.98 14.83 12.41 5.85 2.04 2.01 4.13 15.43 7.70 2.82 3.64 3.16 
 43 20.06 13.68 16.00 14.48 5.67 4.23 2.71 3.14 2.82 15.10 9.09 3.53 7.57 17.12 19.16 
 44 7.97 3.67 2.46 2.07 1.60 0.80 2.05 13.01 10.38 12.50 15.98 8.37 1.21 15.40 2.32 
 45 26.51 9.21 4.51 6.98 3.85 3.68 2.21 3.37 2.51 0.97 0.84 1.24 5.26 2.41 3.24 
 46 29.14 7.83 13.76 8.27 6.07 4.51 7.32 6.45 5.68 3.18 4.37 2.70 1.96 19.24 26.47 
    47* 18.46 9.10 9.16 7.16 3.78 2.08 1.95 2.38 9.57 1.61 4.43 1.86 0.98 9.99 23.32 
    48* 24.68 12.13 10.71 18.39 10.46 4.92 3.28 2.80 5.09 8.21 9.75 4.61 1.01 21.10 16.86 
140 19.87 6.84 21.73 22.70 14.10 7.00 3.84 3.63 3.21 9.65 8.67 3.97 1.62 1.31 15.00 
145 10.98 10.88 13.07 8.01 5.36 3.30 6.20 3.96 2.08 4.41 5.77 16.48 3.76 2.25 9.25 
   146* 24.12 4.10 7.21 3.87 2.96 1.40 1.50 2.04 3.38 8.11 4.75 2.44 1.40 14.16 20.51 
   245* 15.73 12.86 16.20 23.99 11.96 7.15 4.19 1.93 2.43 8.36 15.03 8.55 3.33 2.32 2.51 
Mean 22.16 12.15 14.36 13.76 9.14 5.57 4.46 4.70 5.06 6.05 8.30 4.92 3.01 8.87 15.83 
St. Dev. 9.19 5.99 6.44 7.12 5.01 3.59 2.43 3.41 3.47 3.77 4.94 3.84 2.24 7.26 9.95 
                
*Minority Subjects 
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Table H43.  Cortisol concentrations (ng/ml) for older women during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 17 18.89 7.72 13.33 6.26 5.16 3.61 2.16 3.31 5.86 3.97 2.82 6.39 18.50 24.64 26.78 
 18 28.26 19.60 11.37 8.28 4.90 4.54 7.55 9.37 4.20 4.84 4.62 4.05 14.79 2.70 20.09 
 19 34.80 21.23 17.01 10.16 8.19 4.40 3.20 1.91 13.77 4.91 4.98 3.07 1.22 7.83 18.14 
    20* 7.59 21.40 11.15 5.20 5.93 2.80 2.20 2.66 2.45 2.32 8.53 3.29 2.74 7.83 10.45 
 21 28.63 3.54 9.83 8.77 4.89 1.61 0.90 8.38 2.60 1.78 3.92 5.17 3.12 22.24 9.53 
 22 22.83 10.42 5.23 3.41 2.95 2.11 3.90 3.68 9.95 3.67 2.86 1.71 0.88 11.71 21.94 
 23 17.54 19.04 13.78 6.60 5.60 2.80 3.95 2.82 5.24 3.03 11.82 5.39 2.52 16.44 19.50 
 24 16.97 9.71 6.32 3.61 2.25 1.39 1.41 1.98 2.17 2.48 8.88 3.81 2.71 5.96 7.10 
 25 17.82 9.81 8.10 13.79 9.49 6.60 4.01 4.84 2.13 2.29 12.98 6.76 3.45 8.94 10.44 
 26 17.80 16.09 18.50 23.45 20.05 12.95 17.44 14.45 8.43 27.82 19.34 14.79 5.37 31.41 10.89 
 27 23.17 18.90 18.70 9.81 10.11 6.35 6.53 3.72 2.80 2.13 11.16 11.65 6.34 12.24 20.18 
 28 18.47 7.43 17.89 14.60 11.72 7.50 6.51 5.96 3.55 6.41 7.54 4.27 24.01 13.72 23.19 
    29* 29.52 5.51 14.68 18.84 13.12 5.55 3.99 5.03 10.09 4.23 13.84 9.29 7.64 13.01 9.70 
    30* 19.36 8.76 11.86 6.77 9.07 6.85 6.00 8.62 10.79 3.72 5.57 2.37 3.67 13.46 23.74 
    31* 19.04 23.73 31.47 22.84 18.81 12.87 7.95 9.07 10.10 6.39 3.75 3.43 3.92 11.35 12.77 
120 24.08 17.38 11.55 7.46 5.40 3.46 3.91 7.38 3.30 1.97 3.25 2.39 1.79 8.91 29.71 
Mean 21.55 13.77 13.80 10.62 8.60 5.34 5.10 5.82 6.09 5.12 7.87 5.49 6.42 13.27 17.13 
St. Dev. 6.49 6.52 6.25 6.36 5.21 3.51 3.91 3.47 3.82 6.23 4.83 3.62 6.75 7.39 7.03 
                
*Minority Subjects 
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Table H44.  Cortisol concentrations (ng/ml) for older men during Alprazolam/Placebo Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 50 18.76 8.80 11.95 5.73 3.71 2.41 11.80 4.66 2.36 2.13 2.35 2.11 12.84 16.41 4.87 
 51 19.44 11.05 14.65 12.56 8.73 7.30 12.49 6.29 9.75 4.61 2.41 2.04 22.70 18.51 20.78 
 52 5.65 3.65 3.54 3.58 2.28 3.10 1.56 0.94 1.28 1.36 1.16 0.93 1.77 14.03 8.50 
 53 16.22 11.49 25.43 17.50 12.07 6.30 4.90 4.27 2.31 2.38 7.76 3.64 1.17 4.73 10.31 
 54 23.53 23.28 12.66 4.81 5.00 3.36 3.10 7.12 5.22 3.34 1.76 1.27 0.70 9.57 38.44 
 55 16.34 15.58 11.12 9.24 7.51 4.89 4.87 8.64 3.39 1.57 2.34 1.36 1.20 4.21 12.21 
 56 24.47 16.06 17.29 12.26 11.65 4.62 4.56 3.00 3.89 4.12 7.82 2.55 1.68 16.01 17.01 
 57 31.15 9.30 22.59 10.16 7.99 4.77 3.14 6.99 3.07 1.69 5.24 2.93 1.64 20.49 20.93 
 58 17.85 13.87 16.75 11.77 8.06 4.45 3.97 2.84 2.51 5.47 5.77 3.14 1.35 17.54 17.31 
 59 20.14 16.29 15.73 7.04 7.29 5.17 6.31 6.93 5.06 4.83 4.97 3.79 1.55 21.25 16.74 
 60 25.93 13.37 14.66 8.24 5.97 3.41 2.63 0.39 4.49 2.61 2.18 2.63 2.11 16.51 20.51 
   61* 25.81 21.66 17.87 8.77 5.57 4.27 4.25 3.91 5.55 3.04 4.05 2.63 1.54 4.41 14.21 
149 30.60 18.16 11.26 9.10 9.39 6.20 6.23 9.24 12.13 6.37 12.52 8.50 7.39 14.95 26.36 
160 25.19 12.37 7.22 8.74 5.63 2.56 8.05 6.32 3.33 4.34 10.05 6.48 0.83 6.03 15.35 
Mean 21.51 13.92 14.48 9.25 7.20 4.49 5.56 5.11 4.60 3.42 5.03 3.14 4.18 13.19 17.40 
St. Dev. 6.64 5.18 5.65 3.57 2.77 1.45 3.24 2.70 2.99 1.57 3.43 2.06 6.29 6.15 8.25 
                
*Minority Subjects 
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Table H45.  Cortisol concentrations (ng/ml) for young women during Alprazolam/DHEA Treatment 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
   1 8.06 4.60 2.61 8.79 5.32 3.87 4.69 10.78 4.45 2.64 8.47 3.26 3.37 1.02 1.03 
   3 22.48 10.98 7.91 5.81 4.04 2.26 1.06 5.91 4.09 3.56 5.99 2.69 0.76 2.69 18.15 
   4 20.15 4.89 5.80 3.76 2.99 1.60 1.62 4.69 1.54 1.46 4.67 1.89 0.55 10.90 7.65 
   5 22.27 8.53 7.81 6.09 4.65 2.81 1.99 3.34 4.76 7.84 9.12 4.82 1.76 7.97 12.17 
   7 23.88 15.68 9.14 11.57 7.06 3.17 1.77 3.22 6.54 6.68 6.49 2.51 1.42 8.79 22.55 
   8 13.48 9.53 6.75 14.43 9.34 4.59 2.19 4.22 3.01 2.45 5.27 3.36 1.11 0.59 20.15 
   9 26.94 9.91 12.92 15.35 9.63 4.28 3.27 1.41 1.90 4.60 9.95 4.41 0.84 6.19 18.69 
 10 16.24 5.01 2.77 3.03 2.64 0.99 0.72 1.97 1.81 2.31 7.25 3.42 0.58 5.97 17.10 
 11 15.34 17.62 16.73 14.69 11.32 8.15 5.23 3.74 7.55 4.79 13.90 8.95 2.16 2.11 12.73 
 12 0.19 5.39 7.00 17.27 11.52 6.16 4.10 12.41 13.39 5.16 12.04 6.42 1.18 1.33 1.39 
    14* 23.28 13.46 9.54 6.76 4.83 14.14 15.83 5.70 3.22 4.16 10.07 5.15 3.17 13.41 16.58 
    15* 20.51 14.80 7.96 6.97 5.59 2.79 2.16 1.68 2.35 3.74 7.52 3.74 1.31 15.23 18.96 
    16* 4.76 5.45 6.53 4.99 2.93 1.40 1.74 7.97 2.09 10.26 9.38 3.49 1.22 2.26 13.87 
  66 22.38 12.25 10.53 10.48 6.72 3.89 3.09 2.11 2.28 6.24 8.11 5.20 1.67 9.11 17.96 
102 21.13 14.20 10.04 8.36 6.43 2.75 3.22 3.27 5.05 2.36 10.20 3.23 0.98 4.92 18.58 
111 19.57 6.57 6.69 11.11 5.83 2.33 1.63 0.85 1.57 2.58 4.80 1.31 2.00 17.84 6.32 
112 29.29 25.30 24.93 24.85 21.44 14.67 9.42 5.42 5.19 6.81 11.36 7.48 2.47 0.96 9.52 
113 22.22 17.70 6.48 7.65 4.10 2.93 2.34 1.88 4.62 1.03 6.52 3.46 5.54 1.20 17.72 
   114* 15.00 10.20 4.67 3.68 2.82 2.58 1.54 1.98 1.27 1.29 4.38 1.77 0.71 2.71 4.11 
 206 38.65 37.61 36.50 40.46 32.78 28.05 24.42 22.61 12.16 7.82 6.19 8.99 7.08 5.55 12.22 
   213* 21.00 5.13 4.80 4.60 4.03 1.84 5.14 2.17 3.99 5.50 7.25 3.60 1.39 8.09 21.31 
Mean 19.37 12.13 9.91 10.99 7.91 5.49 4.63 5.11 4.42 4.44 8.04 4.25 1.97 6.14 13.75 
St. Dev. 8.35 7.97 7.84 8.66 7.14 6.37 5.67 5.03 3.27 2.49 2.59 2.16 1.66 5.03 6.50 
                
*Minority Subjects 
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Table H46.  Cortisol concentrations (ng/ml) for young men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 33 24.21 9.44 11.69 9.49 7.92 3.98 3.44 3.31 1.83 9.85 3.91 2.82 1.58 1.06 17.30 
 34 14.19 17.32 12.46 12.59 9.34 5.31 3.77 9.62 6.77 7.84 9.38 7.30 2.67 2.70 14.89 
 35 13.36 10.01 8.43 8.33 5.89 3.10 1.98 1.99 3.19 1.46 5.77 2.92 2.58 3.58 10.43 
 36 16.95 16.54 16.97 19.12 15.17 9.70 7.12 3.26 5.57 3.33 6.96 4.43 0.90 1.47 15.80 
 37 33.80 14.11 23.70 16.98 15.54 9.39 4.22 5.81 5.95 4.44 11.57 4.96 1.26 9.81 23.72 
 38 39.13 27.82 26.74 23.12 20.74 12.53 7.79 12.96 10.12 7.92 16.54 12.11 11.86 22.48 32.15 
 39 40.88 14.56 10.40 14.23 10.63 6.35 5.40 13.55 10.57 6.87 11.90 5.67 3.10 10.64 27.88 
 41 23.59 14.43 13.62 14.40 9.74 5.49 4.58 2.59 4.10 12.78 12.54 6.24 8.19 3.62 20.88 
 42 35.06 17.94 11.08 30.29 20.17 10.17 6.98 2.51 1.55 2.12 16.48 4.65 1.11 9.93 4.55 
 43 19.79 12.74 13.83 12.09 6.02 3.88 2.97 2.93 3.21 13.46 6.87 2.61 7.57 18.82 18.97 
 44 11.12 6.78 3.48 13.67 8.36 3.96 4.16 5.34 4.29 7.47 9.95 4.05 10.61 1.35 0.70 
 45 27.44 8.23 8.85 5.85 3.67 1.91 1.76 3.57 3.46 1.18 0.69 0.66 1.69 15.30 13.46 
 46 26.26 9.87 15.61 7.74 6.62 4.10 4.41 9.75 5.75 5.53 7.36 3.94 1.52 7.60 14.32 
    47* 28.41 10.08 14.86 6.34 3.96 2.13 2.53 3.39 4.98 2.90 3.96 2.13 1.31 7.86 10.79 
    48* 21.62 10.77 12.31 15.00 7.66 5.10 4.16 3.56 7.87 5.06 9.75 5.24 0.81 2.23 19.42 
140 15.50 5.87 16.00 22.42 10.81 8.20 5.12 4.91 10.84 3.48 13.86 5.52 3.51 1.02 17.44 
145 23.21 22.32 14.26 6.21 3.82 4.42 30.14 6.36 15.48 4.51 10.39 24.87 4.93 4.94 9.19 
   146* 22.35 9.70 5.88 6.45 3.36 2.17 2.94 2.76 1.69 1.39 8.13 2.51 0.82 1.43 20.98 
   245* 18.13 15.30 30.15 14.01 12.57 9.09 7.78 2.69 2.88 3.51 15.63 10.09 4.53 1.45 4.31 
Mean 23.95 13.36 14.23 13.60 9.58 5.84 5.86 5.31 5.79 5.53 9.56 5.93 3.71 6.70 15.64 
St. Dev. 8.59 5.47 6.66 6.64 5.25 3.11 6.16 3.57 3.73 3.63 4.40 5.34 3.42 6.42 7.99 
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Table H47.  Cortisol concentrations (ng/ml) for older women during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 17 22.00 11.23 14.01 8.68 6.77 3.74 5.14 4.80 6.01 7.13 4.72 3.48 3.75 19.47 29.03 
 18 21.85 15.24 9.05 6.16 3.76 3.92 3.47 6.41 5.76 5.29 5.55 2.50 1.23 14.20 7.84 
 19 21.31 15.94 17.71 12.45 7.87 5.73 2.87 2.82 1.70 5.16 8.55 7.08 1.75 11.82 16.81 
    20* 24.13 10.10 7.08 4.38 3.39 2.33 2.67 1.48 2.06 1.62 11.09 13.45 11.74 10.63 7.96 
 21 20.57 5.09 4.99 7.65 4.87 1.94 1.78 5.79 5.82 2.05 1.88 1.14 3.45 20.95 11.80 
 22 14.95 9.50 5.63 6.15 4.45 3.38 7.36 4.56 6.80 4.72 4.17 3.75 1.57 7.98 23.06 
 23 31.86 15.38 11.07 8.23 4.95 2.97 3.51 1.50 3.20 3.24 8.73 4.11 1.00 3.80 32.15 
 24 28.89 8.68 4.77 2.90 2.56 1.34 1.43 2.00 4.43 1.86 5.78 3.12 1.43 11.36 12.85 
 25 21.49 12.33 7.40 4.69 3.79 2.57 11.50 6.04 6.23 6.91 12.89 11.39 2.22 5.92 9.99 
 26 27.10 16.33 17.64 14.95 12.45 9.73 22.46 12.57 10.79 6.04 5.27 4.45 3.89 24.80 10.78 
 27 31.16 25.83 22.13 14.46 11.03 7.98 6.88 4.74 3.97 2.81 12.47 9.09 5.40 14.62 32.09 
 28 15.10 11.45 18.34 15.84 14.05 9.34 5.94 6.94 5.02 4.45 10.65 5.67 13.87 20.29 13.17 
    29* 20.95 13.12 13.90 9.61 6.30 5.74 5.40 10.17 15.09 13.20 18.76 11.15 13.01 15.78 16.67 
    30* 25.18 13.43 8.99 8.10 6.86 5.61 3.43 3.87 4.25 5.18 4.40 2.80 0.80 6.06 21.61 
    31* 25.09 13.98 26.95 18.55 13.41 8.50 8.68 2.87 5.54 10.76 8.38 3.49 2.23 6.88 4.61 
120 41.05 21.90 16.94 10.58 8.60 4.69 3.57 7.05 4.45 3.09 10.64 4.46 20.51 13.04 21.67 
Mean 24.54 13.72 12.91 9.59 7.19 4.97 6.01 5.23 5.70 5.22 8.37 5.70 5.49 12.98 17.01 
St. Dev. 6.53 5.00 6.61 4.54 3.73 2.70 5.14 3.05 3.27 3.17 4.29 3.66 5.94 6.13 8.75 
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Table H48.  Cortisol concentrations (ng/ml) for older men during Alprazolam/DHEA Treatment 
 
Time (h) 
Subject 0 1 2 3 3.5 4.5 5.5 7 8.5 10 11.5 12.5 16 20 23 
 50 27.67 7.97 10.05 4.27 3.49 1.90 5.69 4.92 3.33 1.78 2.23 5.20 17.45 7.66 14.09 
 51 26.62 18.53 12.30 11.66 8.73 8.39 9.75 6.21 3.87 5.79 4.80 4.02 15.22 15.44 17.08 
 52 9.36 3.62 5.98 3.18 2.33 1.72 2.32 1.66 1.61 1.28 0.67 0.56 12.29 0.90 17.79 
 53 25.70 11.02 19.94 15.01 10.36 5.00 4.00 3.59 3.53 4.08 9.81 4.25 20.41 13.86 15.89 
 54 20.50 8.22 14.72 6.79 3.17 2.23 2.14 17.18 7.33 4.34 2.92 2.16 1.37 11.71 19.25 
 55 8.83 10.24 11.97 8.89 8.43 3.24 1.72 5.45 3.04 2.10 3.42 1.50 2.33 7.20 18.93 
 56 24.16 18.28 17.56 11.79 9.60 7.32 3.97 3.31 2.19 2.20 5.11 1.79 1.48 8.31 26.38 
 57 25.54 19.83 21.77 15.71 11.13 6.48 3.31 4.00 2.27 4.84 9.40 4.14 8.46 14.19 22.95 
 58 34.79 12.05 10.29 11.82 8.67 4.13 3.19 7.49 8.83 3.46 10.43 4.76 1.31 5.36 29.91 
 59 27.76 15.25 13.49 12.65 7.30 7.74 5.18 5.05 2.91 9.46 5.99 3.33 0.98 18.12 23.03 
 60 23.02 16.40 16.62 10.68 7.68 5.13 3.24 3.95 14.59 4.56 3.43 2.64 4.07 8.81 24.75 
   61* 31.42 14.72 12.59 11.30 8.70 5.24 4.10 3.11 4.18 5.58 4.33 2.34 1.26 11.60 28.67 
149 16.73 19.85 19.10 15.37 10.82 6.95 7.16 4.05 7.06 7.97 5.34 4.62 7.83 13.84 25.29 
160 22.45 8.52 6.76 3.64 3.41 2.22 9.21 2.46 1.50 2.09 8.21 4.24 1.47 4.48 18.28 
Mean 23.18 13.18 13.80 10.20 7.42 4.84 4.64 5.17 4.73 4.25 5.44 3.25 6.85 10.11 21.59 
St. Dev. 7.42 5.11 4.78 4.26 3.04 2.32 2.51 3.77 3.61 2.40 3.00 1.42 6.86 4.81 4.94 










Figures for Chapter 7 
 
Latency, Duration, Accuracy, DSST and CS versus time 
 
  

















































































Figure I.1.  Scatter plots of percent change in performance from baseline at the 12.5 h time point for the young 
women (panels A and B), and young men (panels C and D). The SEM variables, VEL (velocity), LAT (latency), 
DUR (duration), and ACC (accuracy) are from saccades to the 8 degree target.  DSST= digit symbol substitution 
test and CS = card sorting.  The horizontal line indicates the 10% threshold.  Values are considered to be 
equivalent to baseline if they are ≤ 10% of baseline values.  Hollow symbols indicate PL/ALP treatment, filled 




















































































Figure I.2.  Scatter plots of percent change in performance from baseline at the 12.5 h time point for the young 
women (panels A and B), and young men (panels C and D). The SEM variables, VEL (velocity), LAT (latency), 
DUR (duration), and ACC (accuracy) are from saccades to the 8 degree target.  DSST= digit symbol substitution 
test and CS = card sorting.  The horizontal line indicates the 10% threshold.  Values are considered to be 
equivalent to baseline if they are ≤ 10% of baseline values.  Hollow symbols indicate PL/ALP treatment, filled 
































































Figure I.3.  Line plots of change in velocity between the two treatments (DHEA/Alp – PL/Alp)  for the 8 degree 
saccades for young women (?), young men (?) older women (?), older men.  Points above the horizontal line 
less impairment during the DHEA/Alp treatment.  Points below the horizontal line indicate more impairment 
during the the DHEA/Alp treatment. 
  
 
Figure I.4.  Line plots of latency vs. time for the 8-degree saccades for the young subjects.  Individual latency 
data from the PL/ALP treatment are in panels A, young women (?), and B, young men (?).  Individual latency 
data from the DH/ALP treatment are in panels C, young women (?), and D, young men (?).  The mean data 
with standard deviations are in panels E (young women) and F (young men).  


































































































































Figure I.5.  Line plots of latency vs. time for the 8-degree saccades for the older subjects.  Individual latency 
data from the PL/Alp treatment are in panels A, older women (?), and B, older men (?).  Individual latency 
data from the DHEA/Alp treatment are in panels C, older women (?), and D, older men (?).  The mean data 
with standard deviations are in panels E (older women) and F (older men). 
 
 

































































































































Figure I.6.  Line plots of duration vs. time for the 8-degree saccades for the young subjects.  Individual duration 
data from the PL/ALP treatment are in panels A, young women (?), and B, young men (?).  Individual duration 
data from the DH/ALP treatment are in panels C, young women (?), and D, young men (?).  The mean data 
with standard deviations are in panels E (young women) and F (young men).  












































































































Figure I.7.  Line plots of duration vs. time for the 8-degree saccades for the older subjects.  Individual duration 
data from the PL/Alp treatment are in panels A, older women (?), and B, older men (?).  Individual duration 
data from the DHEA/Alp treatment are in panels C, older women (?), and D, older men (?).  The mean data 
with standard deviations are in panels E (older women) and F (older men). 









































































































Figure I.8.  Line plots of accuracy vs. time for the 8-degree saccades for the young subjects.  Individual 
accuracy data from the PL/ALP treatment are in panels A, young women (?), and B, young men (?).  Individual 
accuracy data from the DH/ALP treatment are in panels C, young women (?), and D, young men (?).  The 
mean data with standard deviations are in panels E (young women) and F (young men).  






















































































































































Figure I.9.  Line plots of accuracy vs. time for the 8-degree saccades for the older subjects.  Individual accuracy 
data from the PL/Alp treatment are in panels A, older women (?), and B, older men (?).  Individual accuracy 
data from the DHEA/Alp treatment are in panels C, older women (?), and D, older men (?).  The mean data 
with standard deviations are in panels E (older women) and F (older men). 
 




















































































































































Figure I.10.  Line plots of DSST score vs. time for the young subjects.  Individual DSST scores from the PL/ALP 
treatment are in panels A, young women (?), and B, young men (?).  Individual DSST scores from the DH/ALP 
treatment are in panels C, young women (?), and D, young men (?).  The mean data with standard deviations 
are in panels E (young women) and F (young men). 































































































Figure I.11.  Line plots of DSST score vs. time for the older subjects.  Individual DSST scores from the PL/Alp 
treatment are in panels A, older women (?), and B, older men (?).  Individual DSST scores from the DHEA/Alp 
treatment are in panels C, older women (?), and D, older men (?).  The mean data with standard deviations 
are in panels E (older women) and F (older men). 
 































































































Figure I.12.  Line plots of Card Sorting vs. time for the young subjects.  Individual Card Sorting data from the 
PL/ALP treatment are in panels A, young women (?), and B, young men (?).  Individual Card Sorting data from 
the DH/ALP treatment are in panels C, young women (?), and D, young men (?).  The mean data with standard 
deviations are in panels E (young women) and F (young men). 


































































































































































Figure I.13.  Line plots of Card Sorting data vs. time for the older subjects.  Individual Card Sorting data from 
the PL/Alp treatment are in panels A, older women (?), and B, older men (?).  Individual Card Sorting data 
from the DHEA/Alp treatment are in panels C, older women (?), and D, older men (?).  The mean data with 
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